CA2156594A1 - Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors - Google Patents

Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors

Info

Publication number
CA2156594A1
CA2156594A1 CA 2156594 CA2156594A CA2156594A1 CA 2156594 A1 CA2156594 A1 CA 2156594A1 CA 2156594 CA2156594 CA 2156594 CA 2156594 A CA2156594 A CA 2156594A CA 2156594 A1 CA2156594 A1 CA 2156594A1
Authority
CA
Canada
Prior art keywords
substituted
benzyl
alkyl
nr13r14
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2156594
Other languages
French (fr)
Inventor
Patrick Yuk-Sun Lam
Prabhakar Kondaji Jadhav
Charles Joseph Eyermann
Carl Nicholas Hodge
George Vincent De Lucca
James David Rodgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2156594A1 publication Critical patent/CA2156594A1/en
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to substituted cyclic carbonyls and derivatives thereof useful as Human Immnunodifiency Virus (HIV) protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating HIV infection.

Description

DEMANDES OU BREVETS VOLUMINEUX

LA PRÉSENTE PARTIE DE CE:I IE DEIVIANDE OU CE 8REVEl COMPREND PLUS D'UN TOME.

CECI EST L,E TOME I DE ;2 NO~E: Pou~ les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONSIPATENTS

THIS SECTION OF THE APPLICATION/PATENT CClNTAlNS MORE
THAN ONE VOLUME

THIS lS VOLUME -L_ OF ~

NOTE: For additi~nal volumes please c~ntact the Canadian Patent Office l094/19329 21~6~9~ PCT~S94/01609 ~ ITT.FI
Substituted Cyclic Carbonyls and Derivatives Thereof Useful as Retroviral Protease Inhibitors FIF.T.~ OF THF. INV~NTION

This invention relates to substituted cy^lic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral infection.

RACKGROUND OF THF. INVFNTION
Current treatments for viral diseases usually involve administration of compounds that inhibit viral DNA synthesis. Current treatments for ~IDS (Dagani, Chem. Eng. News, November 23, 1987 pp. 41-49) involve administration of compounds such as 2',3'-dideoxycytidine, trisodium phosphonoformate, ammonium 21-tungsto-9-antimoniate, 1-b-D-ribofuranoxyl-1,2,4-triazole-3-carboxamide, 3'-azido-3'-deoxythymidine (AZT), and adriamycin that inhibit viral DNA synthesis;
compounds such as AL-721 and polymannoacetate which may prevent HIV from penetrating the host cell; and compounds which treat the opportunistic infections caused by the immunosuppression resulting from HIV
infection. None of the current AIDS treatments have proven to be totally effective in treating and/or reversing the disease. In addition, many of the compounds currently used to treat AIDS cause adverse side effects including low platelet count, renal toxicity, and bone marrow cytopenia.
The genomes of retroviruses encode a protease that is responsible for the proteolytic processing of one or WO94/19329 215 6 r 9 4 -2- PCT~S94/01609 more polyprotein precursors such as the pol and gag gene products. See Wellink, Arch. Virol. 98 1 (1988).
Retroviral proteases most commonly process the gag precursor into the core proteins, and also process the pol precursor into reverse transcriptase and retroviral protease.
The correct processing of the precursor polyproteins by the retroviral protease is necessary for the assembly of the infectious virions. It has been shown that in vitro mutagenesis that produces protease-defective virus leads to the production of immature core forms which lack infectivity. See Crawford et al., J.
Virol. ~ 899 (1985); Katoh et al., Virology 145 280 (1985). Therefore, retroviral protease inhibition provides an attractive target for antiviral therapy.
See Mitsuya, Nature ~2~ 775 (1987).
Moore, Biochem. Biophys. Res. Commun., 159 420 (1989) discloses peptidyl inhibitors of HIV protease.
Erickson, European Patent Application No. WO 89/10752 discloses derivatives of peptides which are inhibitors of HIV protease.
U.S. Patent No. 4,652,552 discloses methyl ketone derivatives of tetrapeptides as inhibitors of viral proteases. U.S. Patent No. 4,644,055 discloses halomethyl derivatives of peptides as inhibitors of viral proteases. European Patent Application No. WO
87/07836 discloses L-glutamic acid gamma-monohydroxamate as an antiviral agent. PCT Patent Application Publication No. WO 93/07128, the disclosure of which is hereby incorporated herein by reference, discloses synthetic procedures for preparing HIV protease inhibitors.
The ability to inhibit a viral protease provides a method for blocking viral replication and therefore a treatment for viral diseases, such as AIDS, that may have fewer side effects, be more efficacious, and be _ ~094/19329 21 S6 5 ~ ~ PCT~S94/01609 less prone to drug resistance when compared to current treatments.
The present invention concerns novel substituted cyclic carbonyls and derivatives thereof, which compounds are capable of inhibiting viral protease and which compounds are believed to serve as a means of combating viral diseases, such as AIDS. The substituted cyclic carbonyls and derivatives thereof of this invention provide significant improvements over protease inhibitors that are known in the art. The substituted cyclic carbonyls and derivatives of the invention are particularly useful as inhibitors of HIV protease and similar retroviral proteases.
The compounds of the invention are of low molecular weight and may, therefore, have good oral absorption properties in mammals.

SUM~qARY OF T}~F INVFNTION

This invention provides novel substituted cyclic carbonyl compounds and derivatives thereof, of formula (I) (described below) which are useful as inhibitors of Human Immunodeficiency Virus (HIV). The compounds of the present invention inhibit the HIV protease and thereby inhibit HIV replication. The present invention also includes pharmaceutical compositions containing such compounds of formula I, and methods of using such compounds for the inhibition of HIV in a sample containing HIV, and methods of using such compounds for the treatment of HIV infection in a patient.

The present invention also includes methods of inhibiting HIV or treating HIV infection by administering a compound of formula (I) in combination with one or more second therapeutic agents selected from WO94/19329 215 6 5 9 4 PCT~S94/01609 other inhibitors of HIV and/or therapeutic agents for the treatment of HIV-mediated disease conditions.
Also included in the present invention are pharmaceutical kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of formula I, for the treatment of HIV
infection.

DFTAIT,F.~ DF.SCRIPTION OF THF. INVFNTION
This invention provides novel substituted cyclic carbonyl compounds and derivatives thereof, of formula (I) (described below) which are useful as inhibitors of Human Immunodeficiency Virus (HIV). The compounds of the present invention inhibit the HIV protease and thereby inhibit HIV replication. The present invention also includes pharmaceutical compositions containing such compounds of formula I, and methods of using such compounds for the inhibition of HIV in a sample containing HIV, and methods of using such compounds for the treatment of HIV infection in a patient.

[l] ~here is provided by this invention a compound of the formula (I):

R ~7A

~ R6a R5 F 5a ~R6 ~ n (I) or a pharmaceutically acceptable salt form thereof whereln:

~O 94/19329 21 â~& ~94 PCT/US94/01609 R4 and R7 are independently selected from the following groups:
hydrogen;
C1-Cg alkyl substituted with 0-3 Rll;
C2-Cg alkenyl substituted with 0-3 R11;
C2-Cg alkynyl substituted with 0~3 R11;
a C3-C14 carbocyclic ring system substituted with 0-3 Rll or 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;
_oRl 3; --SRl 3; CO2R1 3;

R4~ and R7A are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-oR13; -SR13; Co2Rl3;
R9 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;
.

R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;

R5 is seiected from H; halogen; C1-C6 alkyl substituted with 0-3 R11, -N (R20)2, -SR20, -oR20, or -N3;
2 1~ 6 5 9`'I~ 6- PCT~S94/01609 R6 is independently selected from: hydrogen, halogen, Cl-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR21, or -N3;

R5 and R6 can alternatively join to fcrm an epoxide or aziridine ring; -OCH2SCH2O-; -OC(=O)O-; -OCH2O-;
-OC(=S)O-; -OC(=O)C(=O)O-; -OC(CH3)2O-;
-OC((CH2)3NH2)(CH3)O-; -OC(OCH3)(CH2CH2CH3)O-;
-OS(=O)O-; -NHC(=O)NH-; -OC(=O)NH-; -NHC(=O)O-;
-NHCH2O-; -OCH2NH-; -NHC(=S)O-; -OS(=O)NH-;
-NHC(=O)C(=O)O-; -OC(=O)C(=O)NH-; -NHC(=O)C(=O)NH-;
-NHC(CH3)2O-; -OC(CH3)2NH- or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl or diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20, or -oR20;

R6a is selected from: hydrogen, halogen, Cl-C6 alkyl, -N~R20)2, -SR20 or _oR21;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;
R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 ~re independently selected from:
hydrogen;
Cl-C6 alkyl substituted with 0-3 Rll;
C3-C6 alkoxyalkyl substituted with 0-3 R11;
C1-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 R11;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;

_ 094/19329 21 S 6 ~9~ PCT~S94/01609 benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;
.

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3~ -OC (=O) R13, -oRl3, -s (O) mR13, -NHC(=NH~NHR13, -C(=NH)NHR13, -C(=o)NR13R14, -NR14C (=O) R13, =NoR14, -NR14C (=O) oRl4 -OC ~=O)NR13R14, _NR13C (=O)NR13R14 --NR14So2NRl3Rl4, --NR14So2Rl3, --So2NRl3Rl4, -0P(o)(oRl3)2~ C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or _c(Rl4)=N(oRl4);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C1o cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0--2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 Rl2;
C1-C4 alkylcarbonyloxy substituted with 0-2 Rl2;
C6-Clo arylcarbonyloxy substituted with 0-2 R12i WO94/19329 215 6 ~ 9 4 PCT~S94/01609 a Cs-C14 carbocyclic residue substituted with 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:
H, keto, halogen, cyano, -CH2N(R13B)(R14B), N(R13B)tRl4B)~ -C02H, -OC(=O)(Cl-C3 alkyl)~
-OH, C2-C6 alkoxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-Clo cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-Clo arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, Cl-C~ alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, Cl-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(Cl-C3 alkyl), a Cs-C14 carbocyclic residue;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-10 94119319 2I $6 ' `

C1o arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, Cl-C4 alkyl substitu~ed with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, ~S(o)mRl3~ -So2NRl3Rl4 -NHSo2R14, -0CH2Co2Rl3~
2-(1-morpholino)ethoxy, -C(R14)=N(oRl4); or a 5- or 6-membere~ heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;
R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, Cl-c4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=r~(oRl4~;

WO94/19329 2 ~5 6 S 9 ~ PCT~S94/01609 R12A, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, Cl-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, Cl-C4 alkyl substituted with -NH2, -NH2r -NHMe, C2-c6 alkoxyalkyl optionally substituted with -Si(CH3)3, Cl-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, Cl-C4 alkoxycarbonyl, Cl-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mMe, -SO2NH2, -NHSO2Me, -ocH2co2Rl3~ 2-(1-morpholino)ethoxy, -C(=NOH)NH2; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, Cl-C4 alkyl, C1-C4 alkoxy, hydroxy,-NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;
R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, _ VO94/19329 ~ ~ ~1 PCT~S94/01609 -NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, Cl-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2i s R13 is selected from:
H;
phenyl substituted with 0-3 RllA;
benzyl substituted with 0-3 RllA;
C1-C6 alkyl substituted with 0-3 R11A;
C2-C4 alkenyl substituted with 0-3 RllA;
C1-C6 alkylcarbonyl substituted with 0-3 RllA;
Cl-C6 alkoxycarbonyl substituted with 0-3 R11A;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, CF3, Cl-C6 alkyl substituted with 0-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), Cl-c6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecling group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;
R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)s-, -cH2cH2N(R-5)cH2cH2-~ or -cH2cH2ocH2cH2-;

R13B and R14B are independently selected from H or C1-C6 alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -CH2CH20CH2CH2-;

R15 is H or CH3;

m is 0, 1 or 2;

WO 94/19329 215 6 S 9 4 PCT~S94/01609 W is selected from:
-N(R22)C(=S)C(=S)N(R23)-;
-N(R22)c(=NR24)c(=NR24)N(R23)-;
-N(R22)s(=z~)N(R23)_;
-N(R22)s(=z~)2N(R23)_;
-N(R22)p(=o)(R24a)N(R23)-;
--C ~R25) (R26) S (=Z' ) C (R27) (R28) _;
-C (R25) (R26) S (=Z' ) 2C (R27) (R28)-;
-C(R25) (R26)P(=O) (R24a)C(R27) (R28)_;
-C(R25)(R26)s(=z~)N(R23)_;
-C (R25) (R26) S (=Z' ) 2N (R23) -;
-c(R25)(R26)s(=o)2o-;
_c(R25)(R26)p(=o)(R24a)N(R23)-;
-c(R25)(R26)p(--o)(R24a)o-;
-C(R25)C(F2)C(=o)N(R23)-;
-C (R25) C (F2) S (=0) 2N (R23) -;
--SC (=Z)--;
-C(R25)(R26)c(R34)(R35)c(R27)(R28)-;
-N(R22)c(R34)(R35)N(R23)-;
-N=C(R36)N(R23~-;
-N+(R22)=C(R36)N(R23)-;
-N(R22)p(R24a)N(R23)-;
--C (=Z)--;
-p(=o)(R24a)-;
--S (=Z' )--;
-S(=Z )2-;
-N(R22)c(=c(R36a)(R36b))N(R23) -N(R22)c(=z)N(R23)c(=z) wherein:

Z is O, S, NR24;

Z' is O or NR24;

~094/19329 2t3 6 5~ ~ PCT~594/0160s R22 and R23 are independently selected from the following:
hydrogen;
Cl-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR22a; -N ~R22a) (R22b);
R22a and R22b are independently selected from the following:
hydrogen;
Cl-Cg alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R24 is selected from: hydrogen; hydroxy; amino; C1-C4 alkyl; C1-C4 alkoxy; mono- or di-(Cl-C6 alkyl)amino; cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally substituted with (C1-C6)alkyl;
-WO94119329 215 6 5 9 4 PCT~S94/01609 R24a is selected from: hydroxy; amino; C1-C4 alkyl;
C1-C4 alkoxy; mono- or di-(C1-C6 alkyl)amino;
cyano; nitro; benzyloxy; or phenoxy;

R25 and R27 are independently selected from the following:
hydrogen;
C1-Cg alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0_5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR13; -SR13;

R26 and R28 are independently selected from:
hydrogen;
halogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13;

R29 is selected from:
hydrogen;
C1-C4 alkyl substituted wiih 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;

'094/19329 21 ~ 6 ~3 ~ PCT~S94/01609 alternatively, R22, R25, or R26, independently, can join with R4 or R4A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R23, R27, or R28, independently, can join with R7 or R7A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R22, R25, R26, R23, R27, R28, R39, or R35 can join with R5 or R6 to form a 0- to 7-membered bridge tG form a carbocyclic or heterocyclic ring, said bridge being substituted with 0-2 R12 and said bridge containing 0-3 heteroatoms independently selected from N, S, or O (i.e., a 0-membered bridge is formed when R22, R25, R26, R23, R27, R28, R34, or R35 are taken together with R5 or R6 to form a direct bond);

alternatively R28 or R23 can join with R7A to form a direct bond;

alternatively R26 or R22 can join with R4A to form a direct bond;
R31 is selected from one or more of the following:

keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3, -C ~=0) Rll~ -OC (=O) R13, -oRl3, c2-c6 alkoxyalkyl, ~S(o)mRl3r -NHC(=NH)NHR13, WO94/19329 PCT~S94/01609 -C(=NH)NHR13, _C(=o)N~13R14, _NR14C(=o)R13, =NoR14, _NR14C (=O) oRl4, -oC (=O) NR13R14, ~, _NR13C (=O) NR13R14, --NR13C (=S) NR13R14, C~a _NR14SC2NR13R14, _NRl4so2Rl3~ -so2NRl3Rl4~ Cl-C4 alkyl, C2-Cq alkenyl, C3-Clo cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, Cl-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-Cg alkylcarbonyl, C1-C4 alkylcarbonylamino, -0CH2Co2Rl3~ 2-(1-morpholino)ethoxy, azido, _C(Rl4)=N(oRl4); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
a Cs-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
phenethyl, phenoxy, C3-C1o cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-Cg alkylcarbonyloxy, -NHSo2Rl4~ benzyloxy, halogen, 2-(1-morpholino)ethoxy, -Co2R13, ~094/19329 2 1 ~ ~ S g 4 PCT~S94/01609 hydroxamic acid, -CoNR13NR13Rlg, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, -_NRl3R14, -C (Rl4) =N (oRl4), -N02, -ORl3, -NR9OR41, -SomRl3~ -somNRl3Rl4~ -C(=o)NR13R14, --OC (=o) NR13R14, --C (=O) Rl 1, --OC (=O) Rl 1, -oCo2Rl3~ phenyl, -C(=o)NR13-(C1-C4 alkyl)-NR13R14, _c(=o)NR4oR4l~ C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, Cl-C4 haloalkynyl, -C (=O) NR13C (Rll ) 2NR13R14;
-C (=O) NR13C (Rll) 2NR13Co2Rl3;
-C(=o)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C (=O)N (R13)-(Cl-C~ alkyl)-Rll;
-C (=O) C ~Rll) 2NR13R14;
-c~=o)c~Rll)2NRl3co2Rl3; -C~=O)-~C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2Rl3; or Cl-C4 alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, --CozR13, _C(=o~NR13Rl4~ _NR13Rl4 or OH;
Cl-C4 alkyl substituted with 0-4 groups selected from Rll, =NRl4, =NNRl3c~=o)NRl3Rl4 =NNR13C ~=O) oR13, or _NR13R14;
C2-C4 alkenyl substituted with 0-4 Rll;
C2-C4 alkynyl substituted with 0-4 Rll;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;

or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, Cl-C4 alkoxy, hydrcxy, -NR13R14; or, WQ94/19329 PCT~S94/01609 when R32 is attached to a saturated carbon , it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, Cl-Cg alkoxy, C1-C4 alkyl, C3-c6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, Cl-C4 alkoxycarbonyl, -CO2H, Cl-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C (R14 ) =N tOR14 );

15 R34 is selected from:
hydrogen;
oR13;
SRl 3;
halogen;
N (R38) (R39) C1-C6 alkyl substituted with 0-3 Rll;
C1-C6 alkoxy substituted with 0-3 Rll;
C1-C6 thioalkyl substituted with 0-3 R11;

25 R35 is selected from:
hydrogen;
oR13;
sRl 3;
halogen;
N (R38) (R39) C1-Cb alkyl substituted with 0-3 R11;
C1-C6 alkoxy substituted with 0-3 R11;
C1-C6 thioalkyl substituted with 0-3 Rll;

~O 94/19329 21 S 6 ~ 9 1 PCT/US94/01609 R34 and R35 can be taken together to form a ketal ring, a 3- to 8-membered carbocyclic ring, or a 5- or `
6-membered heterocyclic ring containing 1-3 heteroatoms independently selected from the group O, N, or S, said ring substituted with 0-5 R

R36 is selected from:
H

C1-C6 alkyl substituted with 0-3 Rl1;
-CoR37;
-NR38R39;
-CN;

lS R37 is selected from:
hydrogen;
Cl-C6 alkyl substituted with 0-3 Rll;
hydroxyl;
Cl-C6 alkoxy substituted with 0-3 Rl1;
-NR38R39;

R38 and R39 are independently selected from:
hydrogen;
Cl-C6 alkyl substituted with 0-3 R11; or an amine protecting group;

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C(=o)NR13Rl9;
--C(=O)NR13NR13R14;
-C (=O) C (Rll) ~NR13R14;
-C (=O) C (Rll) 2NR13NR13R14;
-C (=O) C (Rll) 2NR13C02R13;

-C(=O)H;

WO94/19329 PCT~S94/01609 9~
_C(=O)Rll; -20--C(=O)-(C1-C4 alkyl)-NR13R14;
-C ~=0)- (Cl-C4 alkyl)-NR13C02R13;
1-3 amino acids linked together via amide bonds, S and linked to the N atom via the carboxylate terminus;

provided that:

R4, R4A, R7 and R7A are not all hydrogen;

when W is -OC(=Z)O-, -SC(=Z)-, -C(=Z)-, -P(=o)(R24a)-, -S(=Z')- or -S(=Z') 2-, R4 and R7 are not hydrogen.
[la] Preferred compounds include those compounds described above wherein:

W is -C(=Z)-;
_p(=o)(R24 a)_;
--S (=z~ ) _;
-S(=Z')2-; and n is l or 2.
[lb] Preferred compounds of this invention are those compounds described above with the proviso that when:
W is -c(R25)(R26)s(=z~)c(R27)(R28)-; and n = O; and Z' is O;
then R25, R26, R27, and R28 are not all H.

[lc] Preferred compounds of this invention are those compounds described above with the proviso that when:
W is -C (R2 5)(R26)S(=Z')2C(R27)(R28)-; and r. = O; and 21565~

Z' is O or NH;
then R25, R26, R27, and R28 are not all H.

[ld] Preferred compounds of this invention are those 5 compounds described above with the proviso that when:
W is -S(=O)- or -S(=O)2-; and n = l;
then R6 and R6a are not both H.

10 [le] Preferred compounds of this invention are those compounds described above with the proviso that when:

W is -C(R25) (R26)C(R39) (R35)C(R27) (R28)-; and n = 0; and R34 or R35 are N (R38) (R39);
then R25, R26, R27, and R28 are not all H.

[2] Further preferred compounds of the invention of formula (I) are compounds of formula (II):

R4 ~>--R7 (II) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-3 R11;
C3-C4 alkenyl substituted with 0-3 R11;

WO94/19329 215 6 5 9 4 PCT~S94/01609 R5 is -oR20;

R6 is hydrogen or -OR21;

R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:
H, keto, halogen, -CH2NR13R14, -NR13R14, -oR13, C2-C4 alkoxyalkyl, C2-C4 alkenyl, ;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substituted with 0-2 Ri2;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, C1-C4 alkyl, C7-C1o arylalkyl, C1-C4 alkoxy, 2-~1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(oR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, Cl-C4 alkyl substituted with _NR13R14, _NR13R14, methylenedioxy~ C1-C4 haloalkyl, Cl-c4 alkylcarbonyl, C1-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independentiy selected from oxygen, nitrogen or sulfur;

21~ili$9i ~094/19329 PCT~S94/01609 R12, when a substituent on nitrogen, is selected from benzyl or methyl;

R13 is H, C1-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R14 is OH, H, CF3, Cl-C4 alkyl, Cl-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;
R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2NtR15)CH2CH2-, or -cH2cH2ocH2cH2-;

R15 is H or CH3;
W is selected from:
-N(R22)c(=z)o-;
-N(R22)C(=o)c(=o)N(R23)-;
-C (R25) (R26) C (=Z) S-;
-N(R22)S(=Z~)N(R23)-;
-N(R22)S(=Z' )2N(R23)-;
N(R22)p(=o)(R24a)(~(R23)-;
-C (R25) (R26) S (=Z' ) C (R27) (R28) _;
-C(R25)(R25)S(=Z~)2C(R27)(R28)-;
-c(R25)(R26)p(=o)(R24a)c(R27)(R28)-;
-C(R25)(R26)S(=Z~)N(R23)-;
-C (R25) (R~6) S (=Z' ) 2N (R23)--;
-C(R25)C(F2)C(=o)N(R23)-;
-C(R25)C(F2)S(=o)2N(R23)-;
-C(=Z)-;
-p(=o)(R24a)-;
- --S (=Z ) -S(=Z )2-;

wherein:

WO94/19329 PCT~S94/01609 2ls65~ 4 -24-Z is O, S, or N-CN;

Z ' is O;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-2 R31;
C2-C6 alkenyl substituted with 0-1 R31;
C2-C4 alkynyl substituted with 0-1 R31;

R24a is selected from -OH, C1-C4 alkoxy, mono- or di-(Cl-C6 alkyl) amino;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C4 alkyl substituted with 0-3 R31;
C2-C4 alkenyl substituted with 0-3 R31;
R2 6 and R2 8 are hydrogen or halogen;

R31 iS selected from one or more of the following:
keto, halogen, -cH2NRl3Rl4~ _NR13R14, -oR13 C2-C4 alkoxyalkyl, Cl-C4 alkyl, C2-C4 alkenyl, C3-C1o cycloalkyl, -C(Rl4)=N(oRl4), -Co2Rl3r ~S (o)mRl3;
aryl substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:

~094/19329 2 1 5 ~ 9 ~1 PCT~S94/01609 phenethyl, phenoxy, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSo2Rl4~
benzyloxy, halogen, 2-(1-morpholino)ethoxy, -Co2Rl3~ hydroxamic acid, -CoNR13NR13R14, cyano, boronic acid, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C~Rl4)=NtoR14), NO2, -oR13, _NR40R41, _somRl3, -somNRl3Rl4~
-C (=o) NR13R14, -OC (=O) NR13R14, -C (=O) Rll, -OC(=O)R11, -0Co2Rl3~ phenyl, -C(=o)NRl3-(Cl-C4 alkyl)-NR13R~-4, -c(=o)NR4oR4l~ C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C2-C4 haloalkynyl, or -C (=O) C (Rll) 2NR13R14; -C (=O) C (Rll) 2NR13Co2Rl3;
-C(=O)-(C1-C4 alkyl)-NR13Rl4;
-C(=O)-(Cl-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-3 groups selected from: Rl1, C3-C6 cycloalkyl, -Co2Rl3 _C(=o~NR13R14~ _NR13R14 or OH;
Cl-C4 alkyl substituted with 0-3 groups selected from Rll, =NR14, =NNRl3c(=o)NRl3Rl4 or _NR13R14;
C2-C4 alkenyl substituted with 0-3 Rll;
C2-C4 alkynyl substituted with 0-3 Rll;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-3 R12;

R32, when a substituent on nitrogen, is selected from benzyl or methyl;
5 m is 0, 1, or 2;

WO94/19329 . PCT~S94/01609 ~S~-~9 -26-R34 is selected from:
hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;

R35 is selected from:
hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;
R34 and R35 can be taken together to form a ketal ring, a 3- to 8-membered carbocyclic ring, or a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms independently selected from the group O, N, or S;

R36 is selected from: Ci-C2 alkyl; CoR37; NR38R39; CN;
CCl3;
0 R37 is selected from:
hydrogen; C1-C2 alkyl substituted with 0-1 R11,~
hydroxyl; C1-C2 alkoxy substituted with 0-1 R11;
NR38R39;
5 R38 and R39 are independently selected from:
hydrogen; C1-C2 alkyl substituted with 0-3 R11; or an amine protecting group;

R40 is selected from: H, C1-C3 alkyl;
R41 is seiected from:
_c(=o)NRl3Rl4;
-c(=o)NRl3NRl4;
--C (=O) C (Rll) 2NR13R14;
-C(=o)ctRll)2NRl3NRl4;

~094/19329 ~6.~ 9~ PCT~S94/01609 , /

-C (=O) C (Rl~ ) 2NR13Co2Rl3;
-C(=O)H;
-C(=o)Rll;
-C (=O) - ~Cl-C4 alkyl)-NR13R14;
-C(=O)-(Cl-C4 alkyl)-NR13CO2Rl3;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the czrboxylate terminus;

provided that:

R4 and R7 are not both hydrogen;

when W is -C(=Z)-, -P(=o)(R24a)-~ -S(=Z')- or -S(=Z')2-, R4 and R7 are not hydrogen;

when R4 is hydrogen, at least one of the following is not hydrogen: R22, R25, R26 and R28.
[3] Preferred compounds of the present invention are compounds of formula (II) described above, wherein:

R4 and R7 are selected from benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R5 is -OH;

R6 is hydrogen or -OH;

Rl3 is H, C1-C4 alkyl, C2-Cq alkenyl, or benzyl;

Rl4 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

WO94/19329 PCT~S94/01609 ~6~ 4 -28-R13 and R14 can alternatively join to form -tCH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -cH2cH2ocH2cH2-;

W is selected from:
-N(R22)S(=o)2N(R23)_;
--C (=0)--;
-C(=N-CN)-;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-2 R31;
C2-C6 alkenyl substituted with 0-2 R31;
C2-C4 alkynyl substituted with 0-2 R31;

R31 is selected from one or more of the following:
halogen, -oR13, C1-C4 alkyl, C3-C1o cycloalkyl, _c(Rl4)=N(oRl4)~ -Co2Rl3~ ~S(O)mR13;
aryl substituted with 0-5 R32; or a heterocyclic ring system chosen from pyridyl, - pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, benzimidazolyl, benzotriazolyl, indazolyl, benzoxazolinyl, benzoxazolyl, said heterocyclic ring being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
-CONH2, -CO2H, -CHO, -CH2NHOH, -CH2NR13R14, -NR13R14, hydroxy, hydroxymethyl, -C(R14)=N(oRl4), halogen, methoxy, methyl, nitro, cyano, allylo~y, -CO2CH3, -NHCHO, -NHCOCH3, -OCO2CH3, -CH=NCH2CH2OH, ~l~6~9~
1094/19329 PCT~S94/01609 -OCONHCH2C6Hs, -OCONHCH3, oxazolidinyl, -C=C-CH2OH, -COCH3, hydroxyethyl, C1-C3 alkyl (said alkyl substituted with 0-4 halogen, or OH), tetrazolyl, -OCH2CONH2, -CONHNH2, -CH=NNHCONH2, -CONHOCH3, -CH2CH(OH)CH2OH, adamantamido, hydroxyethoxy, dihydroxyethyl, -C(NH2)=NH, -CONHCH3, -B(OH)2, benzyloxy, -CONHCH2CH3, -CON(CH2CH3)2, methylthio, -SO2CH3, -NHCONH2, -NHCONHCH3, -NHCOCH2N(CH3)2, -NHCOCH2NHCH3, --NHCOCH2NHC02CH2C6H5, --NHCOCH2NH2, -NHCOCH(CH3)NHCO2CH2C6Hs, -NHCOCH(CH2C6Hs)NHCO2CH2C6Hs, -NHCOCH(CH3)NH2, -NHCOCH(CH2C6Hs)NH2, -CO2CH2CH3, -CONHCH2CH2CH3, -CONHCH(CH3)2, -CH2-imidazole, -COC(CH3)3, -CH(OH)CF3, -CO-imidazole, -CO-pyrazolyl, oxadiazolidinonyl, -COCF3, -COCH2CH3, -COCH2CH2CH3, pyrazolyl, -SO2NH2 -C(CH2CH3)=N(OH) or -C(CF3)=N(OH), phenyl, acetoxy, hydroxyamino, -N(CH3)(CHO), cyclopropylmethoxy, -CoNRl3R14, -CONHOH, (diethylaminoethyl)aminocarbonyl, (N-ethyl,N-methylaminoethyl)aminocarbonyl, (4-methylpiperazinylethyl)aminocarbonyl, (pyrrolidinylethyl)aminocarbonyl, (piperidinylethyl)aminocarbonyl, -NHCOCH2NHCH3, N-(2-(4-morpholino)ethyl)aminocarbonyl, or N-(2-(N,N-dimethylamino)ethyl)aminocarbonyl;
R32, when a substituent on nitrogen, is methyl.
[4] Also preferred are compounds of formula (IId):

WQ94/19329 ~S659 PCT~S94/01609 ~ S /

R22~ R23 R4 ~`\ /-~R7 ~"'~
HO OH

(IId) or a pharmaceutically acceptable salt form thereof, wherein:

R4 and R7 are independently selected from: benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R22 and R23 are independently selected from the group consisting of:
hydrogen, allyl, methyl, ethyl, propyl, cyclopropylmethyl, n-butyl, i-butyl, CH2CH=C(CH3)2, pyridinylmethyl, methallyl, n-pentyl, i-pentyl, hexyl, benzyl, isoprenyl, propargyl, picolinyl, methoxyethyl, cyclohexylmethyl, dimethyl-butyl, ethoxyethyl, methyl-oxazolinylmethyl, naphthylmethyl, methyloxazolinylmethyl, vinyloxyethyl, pentafluorobenzyl, quinolinylmethyl, carboxybenzyl, chloro-thienyl, benzyloxybenzyl, phenylbenzyl, adamantylethyl, cyclopropylmethoxybenzyl, methoxybenzyl, methylbenzyl, ethoxybenzyl, hydroxybenzyl, hydroxymethylbenzyl, aminobenzyl, formylbenzyl, cyanobenzyl, cinnamyl, VO94/19329 ~6~9 PCT~S94/01609 allyloxybenzyl, fluorobenzyl, difluorobenzyl, chlorobenzyl, chloromethylbenzyl, fluoromethylbenzyl, iodobenzyl, bromobenzyl, cyclobutylmethyl, formaldoximebenzyl, cyclopentylmethyl, nitrobenzyl, (H2NC(=O))-benzyl, carbomethoxybenzyl, carboethoxybenzyl, tetrazolylbenzyl, and dimethylallyl, aminomethylbenzyl, ~O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2CO)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, N-methylaminobenzyl, N-ethylaminobenzyl, N-ethylaminomethylbenzyl, acetylbenzyl, acetoxybenzyl, N-hydroxylaminobenzyl, phenylmethyl-boronic acid, N-hydroxylaminomethylbenzyl, (hydroxyl)ethylbenzyl, (CH3C(=NOH))-benzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH30NHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl (oxazolidinyl)-benzyl, (hydroxyl)hexyl, hexenyl, (hydroxy)octyl, (hydroxyl)pentyl, (carboxy)pentyl, (carbomethoxy)pentyl, (methylthio)benzyl, (methylsulfonyl)benzyl, N,N-dimethylaminomethylbenzyl, N-methylaminomethylbenzyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethGxycarbonyl)alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, 2~s~9~
WO94/19329 PCT~S94/01609 N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, M-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, (oxadiazolidinonyl)benzyl, trifluoroacetylbenzyl, (pyrazolyl)benzyl, (H2NSO2)-benzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, methoxypentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (CH3CH2C(=NCH))-benzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)a.ninocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl, benzimidazolylmethyl, benzotriazolylmethyl, indazolylmethyl, benzoxazolinylmethyl, benzisoxazolylmethyl, thienylmethyl, furylmethyl.

~094/19329 ~6~9~ PCT~S94/01609
[5] Specifically preferred are compounds of formula (IId):

0~ //o - R22 ~p23 Ph / " Ph HO OH

(IId) or a pharmaceutically acceptable salt form thereof, selected from the group consisting of:

the compound of formula ~IId) wherein R22 is 4-hydroxymethylbenzyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (IId) wherein R22 is 3-hydroxybenzyl and R23 is 3-hydroxybenzyl;
the compound of formula (IId) wherein R22 is cyclopropylmethyl and R23 is cyclopropylmethyl;
the compound of formula (IId) wherein R22 is 2-naphthylmethyl and R23 is 2-naphthylmethyl;
the compound of formula (IId) wherein R22 is 4-hydroxybenzyl and R23 is 4-hydroxybenzyl;
the compound of formula (IId) wherein R22 is 3-aminobenzyl and R23 is 3-aminobenzyl;
the compound of formula (IId) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-hydroxymethylbenzyl;
the compound of formula (IId) wherein R22 is 3-(Me2NCH2C~=O)NH)-benzyl and R23 is 3-(Me2NCH~C(=O)NH)-benzyl;

WO94/19329 215 6 5 9 l PCT~S94/01609 the compound of f~rmula ~IId) wherein R22 is 3-formaldoximebenzyl and R23 is 3-formaldoximebenzyl;
the compound of formula (IId) wherein R22 is 3-(CH3C(=N-OH))-benzyl and R23 is 3-(CH3C(=N-OH))-benzyl;
the compound of formula (IId) wherein R22 is 3-(2-amino-4-thienyl)benzyl and R23 is 3-(2-amino-4-thienyl)benzyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 5-hydroxypentyl;
the compound of formula tIId) wherein R22 is 6-hydroxypentyl and R23 is 6-hydroxypentyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 2-naphthylmethyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 3-hydroxymethylbenzyl.
[6] A second embodiment of this invention is a compound of the formula (I):

P ~ ;R7 R6a ~ n (I) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
C1-Cg alkyl substituted with 1-3 Rl1B;
C2-Cg alkenyl substituted with 1-3 RllB;
C2-Cg alkynyl substituted with 1-3 RllB;
-oR13; -SR13; Co2Rl3;

R4A and R7A are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-oR13; -SR13; Co2Rl3;

R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;
R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;
R5 iS selected from H; halogen; C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -oR20, or -N3;

R6 is independently selected from: hydrogen, halogen, C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR21, or -N3;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -OCH2SCH2O-; -OC(=O)O-; -OCH2O-;
-OC(=S)O-; -OC(=O)C(=O)O-; -GC(CH3)2O-;
-OC((CH2)3NH2) (CH3)O-; -OC(OCH3) (CH2CH2CH3)O-;

W094/19329 PCT~S94/01609 2156~

-OS(=O)O-; -NHC(=O)NH-; -OC~=O)NH-; -NHC(=O)O-;
-NHCH2O-; -OCH2NH-; -NHC(=S)O-; -OS(=O)NH-;
-NHC(=O)C(=O)O-; -OC(=O)C(=O)NH-; -~HC(=O)C(=O)NH-;
-NHC(CH3)2O-; -OC(CH3)2NH- or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl or diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, Cl-C6 alkyl, -N(R20)2, -SR20, or -oR20;

R6a is selected from: hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20 or _oR21;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;
R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 R11;
C3-C6 alkoxyalkyl substituted with 0-3 R11;
Cl-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 Rll;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;

R11 is selected from one or more of the following:

~094/19329 21 ~ ~ ~ 9~ PCT~S94/01609 H, keto, halogen, cyano, -CH~NR13R14, -NR13R14, _C02R13, -OC ~=0) R13, -oRl3, -s ~0) mR13~
-NHC(=NH)NHR13, -C(=NH)NHR13, -C(=o)NR13R14, -NR14C (=O) R13, zNOR14, -NR14C (=O) oRl4, -oC(=o)NRl3Rl4~ _NRl3c(=o)NRl3Rl4 - -NR14So2NRl3Rl4~ -NR14So2R13, -So2NRl3Rl4~
-op(o)(oRl3)2~ Cl-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, Cl-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, Cl-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, Cl-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(oRl4);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C1o cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(Cl-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12;
C6-Clo arylcarbonyloxy substituted with 0-2 R12;
a Cs-C14 carbocyclic residue substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

WO94/19329 ~ ~S 6~ 9 PCT~S94/01609 R11A is selected from cne or more of the following:
H, keto, halogen, cyano, -CH2NR13BR19B, -NR13BR14B, -CO2H, -OC(=O)(C1-C3 alkyl), -OH, C2-C6 alkoxyalkyl, -c(=o)NH2~ -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C1o cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, Cl-C4 alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(C1-C3 alkyl), a Cs-C14 carbocyclic residue; a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R11B is selected from one or more of the following:
_CH2NRl3ARl4, _NR13AR14, -co2Rl3A~ -oC(=o)R13A, -oR13A, ~S(o)mRl3A~ -NHC(=NH)NHR13A, -C(=NH)NHR13A, -c(=o)NRl3ARl4~ _NRl4c(=o)Rl3A~
--OC (=o) NR13AR14, --NR13AC (=O) NR13AR14 _NRl4so2NRl3ARl4, --NR14So2R13A, --So2NRl3ARl4 _CH2NRl3Rl4A, -NR13R14A, -c(=o)NRl3Rl4A~
_NR14AC (=O) R13, =NoRl4A~ -NR14C (=O) oRl4A, -OC (=O) NR13R14A, -NR13C (=O) NR13R14A, _NR14ASo2NRl3Rl4A~ _NR14ASo2R13, -So2NR13R14A, nitro, hydrazide, boronic acid, formyl, C3-C6 3~ cycloalkoxy, C2-C4 alkyl substituted with .'094/19329 ~6~9~ PCT~Sg4/01609 -NR13Rl4, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, pyridylcarbonyloxy, C1-C4 alkylcarbonylr -ocH2co2H~
2-(1-morpholino)ethoxy, azido, -C(Rl4)=N(oRi4), -oP(o)(oR13)2;
C7-ClO cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 1-2 Ri2;
aryl(C1-C3 alkyl) substituted with 1-2 R12;
C2-C6 alkoxyalkyl, substituted with 1-2 R12;
C1-C4 alkylcarbonyloxy substituted with 1-2 Rl2;
C6-C1o arylcarbonyloxy substituted with 1-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-Cg alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, Cl-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(o)mRl3~ -So2NRl3Rl4 -NHS02R1 4, -0CH2 C02R13 , 2-(1-morpholino)ethoxy, -C(R14)=N(oR14);
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused WO94/19329 PCT~S94/01609 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-c6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(Rl4)=N~oR14);

R12A, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, Cl-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, C1-C4 alkyl substituted with -NH2~ -NH2~ -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, Cl-c4 alkoxycarbonyl, Cl-C4 alkylcarbonyloxy, Cl-C4 alkylcarbonvl, C1-C4 alkylcarbonylamino, -S(O)mMe, -SO2NH2, -NHSO2Me, -ocH2co2Rl3~ 2-(1-morphGlino)ethoxy, -C(=NOH)NH2;

WO94/19329 ~1 S~$9~ PCT~S94/01609 a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, -NH2, C2-C6 alkoxyalkyl, C1-C9 haloalkyl, Cl-Cg alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2;

R13 is selected from:
H;
phenyl substituted with 0-3 Rl1A;
benzyl substituted with 0-3 R11A;
C1-C6 alkyl substituted with 0-3 R11A;
C2-C4 alkenyl substituted with 0-3 R11A;
C1-C6 alkylcarbonyl substituted with 0-3 R11A;
C1-C6 alkoxycarbonyl substituted with 0-3 R11A;
C1-C6 alkylaminocarbonyl substituted with 0-3 Rl1A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

WO94/19329 ~ ~ 6 ~ ~ ~ PCT~S94/01609 R13A is selected from:
phenyl substituted with 1-3 R11;
benzyl substituted with 1-3 R11;
C1-C6 alkyl substituted with 1-3 Rll;
C2-C4 alkenyl substituted with 1-3 R11;
C1-C6 alkylcarbonyl substituted with 1-3 R11;
C1-C6 alkoxycarbonyl substituted with 1-3 R11;
C1-C6 alkylaminocarbonyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R11;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, CF3, C1-C6 alkyl substituted with 0-3 groups selected from OH, Cl-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), Cl-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when Rl4 is bonded to O;

R14A is C1-C6 alkyl substituted with 1-3 groups selected from OH, Cl-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when Rl4 is bonded to N, a hydroxy protecting group when Rl4 is bonded to O;
R13 and R19 can alternatively join to form -(CH2)4-, -(CH2)s-, -cH2cH2N(Rl5)cH2cH2-~ or -cH2cH2ocH2cH2-;

R13B and R14B are independently selected from H or C1-Cs alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2cH2-;

R15 is H or CH3;

~094/19329 21 S 6 ~9 ~ PCT~S94/01609 m is 0, 1 or 2;

W is selected from:
-N(R22)C(=Z)N(R23)--OC(=Z)O-, -N(R22)C(=Z)O-~
--C (R25) (R26) C (=Z) C (R27) (R28)--, -N(R22)c(=z)c(R27)(R28)_ --C(R25)(R26)c(=
-N(R22)C(=o)c(=o)N(R23)--C (R25) (R26) C (F2) C (R27) (R28) -, -c(R25)(R26)N(cH3)(o)c(R27)(R28) -C(R25) (R''6)N(oR29)C(R27) (R28)---C (R25) (R26) C (=Z) S--, -N(R22)S(=o)N(R23~_;
wherein:

Z is O, S, NR24;

R22 and R23 are independently selected from the following:
hydrogen;
C1-Cg alkyl substituted with 0-3 R31;
C2-Cg alkenyl substituted with 0-3 R31;
C2-Cg alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR22 a; -N(R22 a ) ( R22b);

R22a and R22b are independently selected from the followlng:

WO94/19329 2 ~ ~ 6 5 ~ 4 PCT~S94/01609 hydrogen;
C1-Cg alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R24 is selected from: hydrogen; hydroxy; amino; Cl-C4 alkyl; Cl-Cg alkoxy; mono- or di-(Cl-C6 alkyl)amino; cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally substituted with (C1-C6)alkyl;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0_5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, r.itrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR13; -SR13;

R26 and R28 are independently selected from:
hydrogen;
halogen;

~094/19329 1~94 PCT~S94/01609 C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
5-oR13; -SR13;

R29 is selected from:
hydrogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 10C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;

alternatively, R22, R25, or R26, independently, can join with R9 or R4A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R23, R27, or R28, independently, can join with R7 or R7A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R22, R25, R26, R23, R27, R28 R34 or R3s can join with R5 or R6 to form a 0- to 7-membered bridge to form a carbocyclic or heterocyclic ring, said bridge being substituted with 0-2 R12 and said bridge containing 0-3 heteroatoms independently selected from N, S, or O (i.e., a 0-membered bridge is formed when R22, R25, R26, R23, R27, R28 R34 or R35 are taken together with R5 or R6 to form a direct bond);

WO94/19329 PCT~S94/01609 S6' 94 -46-alternatively R28 or R23 can join with R7A to form a direct bond;

alternatively R26 or R22 can join with R4A to form a direct bond;

R31 is selected from one or more of the following:
keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3~ -C(=O)R11, -oC(=o)R13, -oR13, C2-C6 alkoxyalkyl, ~S(o)mRl3~ -NHC(=NH)NHR13, _C(=NH)NHR13, -C(=o)NR13R14~ -NR14C(=o)R13 =NoR14, -NR14C (=O) oRl4, -oc (=0) NR13R14, _NR13C (=O) NR13R14, --NR13C (=S) NR13R14, -NR14So2NRl3Rl4~ -NR14So2Rl3~ -So2NRl3Rl4~ C1-C4 alkyl, C2-C4 alkenyl, C3-C1o cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -ocH2co2Rl3l 2-(1-mcrpholino)ethoxy, azido, -C(R19)=N(oR14); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
a Cs-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said WO94/19329 ~9~ PCT~S94/01609 heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one ~ 5 or more of the following:
phenethyl, phenoxy, C3-Clo cycloalkyl, C3-C6 - cycloalkylmethyl, C7-Clo arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, Cl-C4 alkylcarbonyloxy, -NHSO2Rlg, benzyloxy, halogen, 2-(1-morpholino)ethoxy, -Co2Rl3 hydroxamic acid, -CoNR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, _NR13R14, _c(Rl4)=N(oRl4)~ -NO2, ~R13 _NR40R41, _somRl3~ -SomNR13R14, -C(=o)NRl3Rl4 -OC (=o) NR13R14, -C (=O) Rll ~ -OC (=O) Rll r -oCo2Rl3~ phenyl, -C(=o)NR13-(Cl-C4 alkyl)-NR13R14, _c(=o)NR4oR4l~ Cl-C4 haloalkyl, Cl-C4 haloalkoxy, C2-C4 haloalkenyl, Cl-C4 haloalkynyl;
-C (=O) NR13C (Rll) 2NR13R14;
-C (=O) NR13C (Rll) 2NR13Co2Rl3;
-C(=o)NRl3-(Cl-C4 alkyl)-NR13CO2R13;
-C~=o)N~R13)-(Cl-C4 alkyl)-Rll; or -C~=o)c(Rll)2NRl3Rl4;
-C (=O) C (Rll) 2NR13Co2Rl3;
-C (=O) - (Cl-C4 alkyl)--NR13R14;
-C(=O)-(Cl-C4 alkyl)-NR13CO2R13;
Cl-C4 alkoxy substituted with 0-4 groups selected from: Rll, C3-C6 cycloalkyl, -Co2Rl3 _C(=o~NR13R14, _NR13R14 or OH;
Cl-C4 alkyl substituted with 0-4 groups selected from Rll, =NR14, =NNRl3c(=o)NRl3Rl4 - =NNRl3c(=o)oRl3~ or _NR13R14;
C2-C4 alkenyl substituted with 0-4 Rll;
C2-C4 alkynyl substituted with 0-4 Rll;

WO94/19329 ~ ~S 6S 9 ~ PCT~S94/01609 a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-~ R12;
or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, Cl-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R32 is attached to a saturated carbon , it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, Cl-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, Cl-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, Cl-C4 alkylcarbonyl, _c(Rl4)=N(oRl4);

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
_c(=o)NRl3Rl4;
-C(=~)NR13NR14;
-C(=o)c(Rll)2NRl3Rl4;
--C (=O) C (Rll) 2NR13NR14;
--C (=O) C (Rll) 2NR13C02R13;
-C(=O)H;
_C(=O)Rll;
-C(=O)-(C1-C4 alkyl)-NR13Rl4;
-C (=O) - (Cl-C4 alkyl)-NR13C02R13;

WO94/19329 S 6 ~9~ PCT~S94/01609 1-3 amino aclds linked together via amide bonds, and linked to the N atom via the carboxylate terminus.
[7] Preferred compounds of this second embodiment are compounds of formula (II):
R4 ~ R7 Rs R6 (II) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are lndependently selected from the followlng groups:
hydrogen;
C1-C4 alkyl substltuted wlth 1-3 R11;
C3-C4 alkenyl substltuted wlth 1-3 R11;
R5 ls selected from -oR20;

R6 ls hydrogen or -OR21;

R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3, -OC (=O) R13, -oRl3, -s (O) mR13 ~ C2-C4 alkenyl, C3-C6 cycloalkylmethyl, nitro, hydrazlde, boronlc acld, formyl, C3-C6 WO94/19329 ~S6S~ 4 PCT~S94/01609 cycloalkoxy, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, Cl-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, -C(Rl4)=N(oRl4);
C3-C10 cycloalkyl substituted with 0-2 R12;
Cl-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12, C6-C1o arylcarbonyloxy substituted with 0-2 R12, aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

R11B is selected from one or more of the following:
_CH2NRl3ARl~, -NR13AR14, -co2Rl3A~ -oC(=o)R13A, _oR13A, -S (O) mR13A, --CH2NRl3~,14A, --NR13R14A, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, C1-C4 hydroxyalkyl, methylenedioxy, et~ylenedioxy, C1-C4 haloalkyl, Cl-C4 haloalkoxy, Cl-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, -C(R14)=N(oR14);
C7-C1o cycloalkyl substituted with 0-2 R12;
Cl-C4 alkyl substitued with 1-2 R12;
aryl(C1-C3 alkyl) substituted with 1-2 R12;
C2-C6 alkoxyalkyl, substituted with 1-2 R12;
C1-C4 alkylcarbonyloxy substituted with 1-2 R12;
C6-C1o arylcarbonyloxy substituted with 1-2 R12;

WO94/19329 21 ~ C ~ 3 4 i PCT~S94/01609 R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, C1-C4 alkyl, C7-C1o arylalkyl, C1-C4 alkoxy, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C~R14)=N(oR14), cyano, boronic acid, sulfor.amide, formyl, C3-C6 cycloalkoxy, -oR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, methylenedioxy, Cl-C4 haloalkyl, Cl-Cg alkylcarbonyl, Cl-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
R12, when a substituent on nitrogen, is selected from benzyl or methyl;

R13 is H, Cl-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R13A is selected from:
phenyl substituted with 1-3 Rll;
benzyl substituted with 1-3 Rll;
C1-C6 alkyl substituted with 1-3 Rll;
C2-C4 alkenyl substituted with 1-3 Rl1;
C3-C6 alkoxyalkyl substituted with 1-3 Rll;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;
R14 is OH, H, CF3, Cl-C4 alkyl, C1-C4 alkoxy, NH2, C2-~4 alkenyl, or benzyl;

- R14A is C1-C6 alkyl substituted with 1-3 groups selected from OH, C1-C4 alkoxy, halosen, NH2, -NH(Cl-C4 WO94/19329 ~ PCT~S94/01609 alkyl), Cl-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -~CH2)s-, -CH2CH2N(R15)CH2CH2-, or -cH2cH2ocH2cH2-;

R15 is H or CH3;

W is selected from:
-N(R22)c~=z)N(R23)_;
-N(R22)c(=z)o-;
-N(R22)c(=z)c(R27)(R28)_;
-N(R22)c(=o)c(=o)N(R23~-;
wherein:

Z is O, S, N-CN

R22 and R23 are independently selected from the following:
hydrogen;
Cl-C8 alkyl substituted with 0-2 R31;
C2-C6 alkenyl substituted with 0-1 R31;
C2-C4 alkynyl substituted with 0-1 R31;

R27 is selected from the following:
hydrogen;
C1-Cg alkyl substituted with 0-3 R31;
C2-Cg alkenyl substituted with 0-3 R31;
C3-Cg alkynyl substituted with 0-3 R31;

R28 is hydrogen or halogen;

R31 is selected from one or more of the following:

WO94119329 ~ 9 ~ PCT~S94/01609 keto, halogen, cyano, -CH2NR13R14, -NR13R14, --Co2Rl3, --C (=O) Rll, -OC (=O) R13, --oRl3, C2-C6 alkoxyalkyl, ~S(o)mRl3~ -NHC(=NH)NHR13, -C(=NH)NHR13, _C(=o)NR13R14, _NR14C(=o)R13, =NoR14, -NR19C(=o)oR14, -oC(=o)NR13R14, _NR13C (=O) NR13R14, -NR13C (=S) NR13R14, -NR14So2NR13R14, -NR14So2R13, -So2NRl3Rl4~ Cl-C4 alkyl, C2-C4 alkenyl, C3-C1o cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-Clo arYlalkY
hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -ocH2co2Rl3~ 2-(1-morpholino)ethoxy, azido, _C(Rl4)=N(oRl4); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
a Cs-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
R32, when a substituent on carbon, is selected from one or more of the following:
phenethyl, phenoxy, C3-clo cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, WO94/19329 PCT~S94/01609 hylenedioxy, ethylenedioxy, C1-Cg alkylcarbonyloxy, -NHSo2Rl4~ benzyloxy, halogen, 2-(1-morpholino)ethoxy, -Co2Rl3 hydroxamic acid, -CoNR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, _NR13R14, -C (R14)=N (oR14), -N02, -oRl3, -NR OR41, ~SomRl3~ ~SomNR13R14 -C (=O) NR13R14 -OC (=O) NR13R14, --C (=O! Rll, --OC (zO) Rll, -oco2Rl3~ phenyl, -C(=o)NR13-(C1-C4 alkyl)-NR13R14, _c(=o)NR4oR4l~ C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl, -C (=O) NR13C (Rll ) 2NR13R14;
-C (=O) NR13C (Rll) 2NR13ro2Rl3;
-C(=o)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C (=O) N (R13 ) - (Cl-C4 alkyl)-Rll; or -C (=O) C (Rll) 2NR13R14;
-c (=O) c (Rll) 2NR13Co2Rl3;
-C (=0)- (Cl-C4 alkyl)--NR13R14;
-C!=O)-(C1-C4 alkyl)-NR13CO2R13;
C1-Cg alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, -Co2Rl3 _C(=o~NR13R14~ _NR13R14 or OH;
C1-C4 alkyl substituted with 0-4 groups selected from R11, =NR14, =NNR13c(=o)NRl3Rl4 =NNR13C (=O) oR13 , or _NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 Rl1;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;
or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the 21 ~}~9 /
WO94/19329 PCT~S94/01609 ._ aliphatic carbons with halogen, Cl-C4 alkyl, Cl-C4 alkoxy, hydroxy, -NR13R14; or, when R32 is attached to a saturated carbon , it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-c6 cycloalkyl, C3-C 6 cycloalkylmethyl, _CH2NR13R14, _NR13R14, C2-C6 alkoxyalkyl~ Cl-C4 haloalkyl, Cl-C4 alkoxycarbonyl, -CO2H, Cl-C4 alkylcarbonyloxy, Cl-C4 alkylcarbonyl, -C(Rl4)=N(oRl4);

m is 0, l, or 2;

R40 is selected from: H, C1-C3 alkyl;

R4l is selected from:
-C (=O) NR13R14;
-c(=o)NRl3NRl4;
--C (=O) C (Rll) 2NR13R14;
-c(=o)c(Rll)2NRl3NRl4;
-C (=O) C (Rll) 2NR13C02R13;
-C(=O)H;
_C(=O)Rll;
-C(=O)-(Cl-C4 alkyl)-NR13R14;
-C(=O)-(Cl-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and lin}ed to the N atom via the carboxylate terminus.

WO94/19329 215 6 5 ~ 4 PCT~S94/01609
[8] A third embodiment of this invention is a compound of the formula (I):

Y~
Rs~RSR6a ~ n (I) or a pharmaceutically acceptable salt form thereof wherein:
R4 and R7 are independently selected from the following groups:
hydrogen;
Cl-Cg alkyl substituted with 0-3 Rll;
C2-C8 alkenyl substituted with 0-3 Rll;
C2-C8 alkynyl substituted with 0-3 Rll;
a C3-Cl4 carbocyclic ring system substituted with 0-3 Rll or 0-3 R12;
a 5- to lO-membered heterocyclic ring system containing l to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;
--oR13; -SR13; Co2Rl3;
R4A and R 7A are independently selected from the following groups:
hydrogen;
Cl-C4 alkyl substituted with 0-6 halogen or 0-3 Cl-C2 alkoxyi benzyl substituted with 0-6 halogen or 0-3 Cl-C2 alkoxy;
9 olS - PCT/US94/01609 - 57 ~9~
--oR13; --SR13; C02R13;

R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;
R5 is selected from H; halogen; Cl-C6 alkyl substituted with 0-3 Rll, -N (R20)2, -SR20, -oR20, or -N3;

R6 is independently selected from: hydrogen, halogen, Cl-C6 alkyl substituted with 0-3 Rll, -N (R20)2, -SR20, -OR21, or -N3;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -0CH2SCH20-; -0C(=0) G-; -OCH2o-;
-OC(=S)0-; -OC(=0)C(=0)0-; -OC(CH3)20-;
-OC((CH2)3NH2) (CH3)0-; -OC(OCH3) (CH2CH2CH3)0-;
-OS(=0)0-; -NHC(=O)NH-; --OC(=O)NH-;--NHC(=0)0--;
-NHCH20-; -OCH2NH-; -NHC (=S)0-; --OS(=O)NH-;
-NHC(=O)C(=0)0-; -OC(=O)C(=O)NH-; -NHC(=0) C(=O)NH-;
-NHC(CH3)20-; -OC(CH3)2NH- or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl or diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, Cl-C6 alkyl, -N (R'0)2, -SR2o~ or _o~20;

R6a is selected from: hydrogen, halogen, Cl-C6 alkyl, -N (R20)2, -SR20 or _oR21;

WO94/19329 21~ 6 5 9 ll PCT~S94/01609 R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 Rl1;
C3-C6 alkoxyalkyl substituted with 0-3 Rll;
Cl-C6 alkylcarbonyl substituted with 0-3 Rl1;
Cl-C6 alkoxycarbonyl substituted with 0-3 Rll;
C1-C6 alkylaminocarbonyl substituted with 0-3 Rll;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;
Rll is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3, -OC ~=0) R13, -oRl3, -s (O) mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C~=o)NR13R14, -NRl4c(=o)Rl3/ =NoRl4~ _NRl4c(=o)oRl4 -OC (=O) NR13Ri4, _NR13C (=O) NR13R14 -NR14So2NRl3Rl4~ -NR14so2Rl3~ -So2NRl3Rl4r -op(o)(oRl3)2/ Cl-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, ni~ro, C7-Clo arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, Cl-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 ~094/19329 2 I S 6 ~ 9 ~ PCT~S94/01609 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, -C~R14)=N(o~l4);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C10 cycloalkyl substituted with 0-2 R12;
Cl-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12;
C6-Clo arylcarbonyloxy substituted with 0-2 R12;
a Cs-C14 carbocyclic residue substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:
H, keto, halogen, cyano, _CH2NRl3BRl4B, _NR13BR14B, -CO2H, -OC(=O)(Cl-C3 alkyl), -OH, C2-C6 alkGxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C1o cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, Cl-C4 alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, Cl-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 W094/1932g 21~ CT~S94tO1609 alkylcarbonylamino, -OCH2C02H, 2-(1-morpholino)ethoxy, azido, aryl(Cl-C3 alkyl), a Cs-C14 carbocyclic residue;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, Cl-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, C1-C4 alkoxy, -C02H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, Cl-Cg alkyl substituted with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si~CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, Cl-C4 alkylcarbonylamino, -S(o)mRl3~ -So2NRl3Rl4 -NHSo2R14, -0CH2Co2Rl3~
2-(1-morpholino)ethoxy, -C(R14)=N(oR14); or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur; or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14; or, ~094tl9329 21S6~q PCT~S94/01609 when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, Cl-C4 hydroxyalkyl, Cl-C4 alkoxy, Cl-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, Cl-C4 haloalkyl, Cl-C4 alkoxycarbonyl, -CO2H, Cl-C4 alkylcarbonyloxy, Cl-C4 alkylcarbonyl, -C(R14)=N(oR14);

R12A, when a substituent on carbon! is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-Clo arylalkyl, Cl-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, Cl-C4 alkyl substituted with -NH2, -NH2, -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, Cl-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, Cl-C4 haloalkyl, Cl-C4 haloalkoxy, Cl-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, Cl-C4 alkylcarbonyl, Cl-C4 alkylcarbonylamino, ~s(o)mMe/ -SO2NH2~
-NHSO2Me, -ocH2co2Rl3/ 2-(1-morpholino)ethoxy, -C(=NOH)NH2; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfuri or WO94/19329 ~ ~ Cs~ -62- PCT~S94/01609 R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, Cl-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;
R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, Cl-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2~
-NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, Cl-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH
R13 is selected from:
H;
phenyl substituted with 0-3 R1lA;
benzyl substituted with 0-3 R11A;
C1-C6 alkyl substituted with 0-3 RllA;
C2-Cg alkenyl substituted with 0-3 Rl1A;
C1-C6 alkylcarbonyl substituted with 0-3 Rl1A;
C1-C6 alkoxycarbonyl substituted with 0-3 RllA;
C1-C6 alXylaminocarbonyl substituted with 0-3 R11A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting gxoup when R13 is bonded to O;

R13A is selected from:
phenyl substituted with 1-3 R11;

~094/19329 21 S ~ ~ - 9 ~ PCT~S94/01609 benzyl substituted with 1-3 Rll;
C1-C~ alkyl substituted with 1-3 Rll;
C2-C4 alkenyl substituted with 1-3 Rll;
Cl-C6 alkylcarbonyl substituted with 1-3 Rll;
Cl-C6 alkoxycarbonyl substituted with 1-3 Rll;
Cl-C6 alkylaminocarbonyl substituted with 1-3 Rll;
C3-C6 alkoxyalkyl substituted with 1-3 Rll;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;
R14 is hydrogen, hydroxy, Cl-C6 alkyl substituted with 0-3 groups selected from OH, Cl-C4 alkoxy, halogen, NH2, -NH (C1-C4 alkyl), Cl-C6 alkoxy, C2-C6 alkenyl, phenyl, henzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R19A is C1-C6 alkyl substituted with 1-3 groups selected from OH, Cl-C4 alkoxy, halogen, NH2, -NH(Cl-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -~CH2)5-, -cH2cH2N~Rl5)cH2cH2-l or -cH2cH2ocH2cH2-;

R13B and R14B are independently selected from H or Cl-C6 alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -~CH2)5-, -CH2CH2N~R15)CH2CH2-, or -CH2CH2OCH2cH2-;

R15 is H or CH3;

m is 0, 1 or 2;
W is selected from:

2l5659~

-N(R22)c(=z)N(R23)_ --OC (=Z) O--, -N(R22)C(=Z)O---N(R22)C(=Z)C(R27) (R28)_, --N(R22)C(=o)c(=o)N(R23) --N(R22)S(=o)N(R23)_;

wherein: -Z is O, S, NR24;

R22 and R23 are independently selected from the following:
Cl-C8 alkyl substituted with 1-3 R31;
C2-Cg alkenyl substituted with 1-3 R31;
C2-C8 alkynyl substituted with 1-3 R31;
a C3-C14 carbocyclic ring system substituted with 1-5 R31 or 1-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;
--OR22 a ; --N(R22 a ) ( R22b);
R22a and R22b are independently selected from the following:
hydrogen;
Cl-Cg alkyl substituted with 0-3 R31;
C2-Cg alkenyl substituted with 0-3 R31;
C2-Cg alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0_5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently WO94/19329 21 ~6 ~CT~S94/01609 selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R24 is selected from: hydrogen; hydroxy; amino; Cl-C4 alkyl; C1-C4 alkoxy; mono- or di-(Cl-C6 alkyl)amino; cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally substituted with (C1-C6)alkyl;
R31 is selected from one or more of the following:
_CH2NR13AR14, _NR13AR14, --co2Rl3A, --OC (=O) R13A~
-oR13A, -S(o)mRl3A~ -NHC(=NH3NHR13A, -C(=NH)NHR13A, -C(=o)NR13AR14~ -NR14C(=o)R13 oC(=o)NRl3ARl4~ _NRl3Ac(=o)NRl3ARl4 _NRl4so2NRl3ARl4~ -NRl4so2Rl3A~ -So2NRl3ARl4 _CH2NR13R14A, _NR13R14A, --C (=O) NR13R14A, --NR14AC (=O) R13, =NoRl4A~ --NR14C (=O) oRl4A, --OC (=O) NR13R14A, --NR13C (=O) NR13R14A
_NRl4Aso2NRl3Rl4A~ -NRl4Aso2Rl3~ -So2NRl3Rl4 nitro, hydrazide, boronlc acid, formyl, C3-C6 cycloalkoxy, C2-C4 alkyl substituted with -NR13R14, Cl-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, Cl-C4 haloalkyl, Cl-C4 haloalkoxy, C1-C4 alkylcarbonyl, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or -C(Rl4)=N(oRl4A);
aryl substituted with 1-5 R32; or a 5- to 10-membered heterocyclic rlng system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:

WQ g4/lg32g 215 6 S 9 ~ PCT/US94/01609 C7-Clo cycloalkyl, NHRSo2Rl4A, _c02Rl3A~ NR13AR14 NR13R14A, --C(R14)=N(oRl4A)~ --CoNR13NR13R14 -NR4OR41, -SomRl3A~ -C(=o)NR13R14, -OC (=O) NR13R14, -C (=O) Rll, -OC (=O) Rll, -0Co2Rl3~ -C(=o)NR13-(Cl-C4 alkyl)-NR13R14, oRl3A~ -C(=o)NR40R41, C2-C4 haloalkenyl~ Cl-C4 haloalkynyl, or -C(=O)NR13C(Rll)2NR13R14;
-C (=O) NR13C (Rll ) 2NR13Co2Rl3;
-C(=o)NR13- (Cl-C4 alkyl)-NR13CO2R13;
-C(=o)N~R13)-(Cl-C4 alkyl)-Rll; or -C (=O) C (Rll) 2NR13R14;
-c(=o)c(Rll)2NRl3co2Rl3; --C(=O)--(Cl--C4 alkyl)--NR13R14; -C(=O)-(Cl-C4 alkyl)-NR13CO2R13; or Cl-C4 alkoxy substituted with 1-4 groups selected from: Rll, C3-C6 cycloalkyl, -Co2Rl3 _C(=o)NR13R14~ _NR13R14 or OH;
Cl-C4 alkyl substituted with 1-4 groups selected from Rll, =NR14, =NNRl3c(=o)NRl3Rl4 =NNR13C (=o)OR13, or _NR13R14;
C2-C4 alkenyl substituted with 0-4 Rll;
C2-C4 alkynyl substituted with 0-4 Rll; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 1-2 R12; when R32 is attached to a saturated carbon, it may be =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrosen, is selected from one or more of the following:
_CH2NR13AR14, _NR13AR14, -CH2NR13R14 --NRl3Rl4A~-c(Rl4)=N (OR14A);

R40 is selected from: H, C1-C3 alkyl;

W094/19329 2t ~ 6 59~ PCT~S94/01609 R41 is selected from:
-C (=O) NR13R14;
-C(=o)NRl3NRl3Rl4;
5 _c(=o)c(Rll)2NRl3Rl4;
-C (=O) C (Rll) 2NR13NR13R14;
-C (=O) C (Rll) 2NR13Co2Rl3;
-C(=O)H;
_C(=O)Rll;
-C(=O)-(Cl-C4 alkyl)-NR13R14;
-C(=O)-(Cl-C4 alkyl)- NR13C02R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;
provided that:

R4, R4A, R7 and R7A are not all hydrogen.

[9] Preferred compounds of this third embodiment are compounds of the formula (I~ wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
Cl-C4 alkyl substituted with 0-3 Rll;
C3-C4 alkenyl substituted with 0-3 Rll;
C3-C4 alkynyl substituted with 0-3 Rll;

R4A and R7A are hydrogen;

~ n is 0, 1, or 2;

- R5 is selected from fluoro or -oR20;

WO94/19329 21 S ~ PCT~S94/01609 R6 is independently selected from: hydrogen, fluoro or -OR21;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -OCH2SCH2O-; -OS(=O)O-; -OC(=O)O-;
-OCH2O-; -OC(=S)O-; -OC(=O)C(=O)O-; -OC(CH3)2O-;
-OC(OCH3)(CH2CH2CH3)O-; or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl;
R5a is selected from hydrogen or fluoro;

R6a is selected from: hydrogen or fluoro;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternativelv join to orm =O, =S, or a ketal ring;
R20 and R21 are independently selected from:

hydrogen;
C1-C6 alkylcarbonyl;
C1-C6 alkoxycarbonyl;
benzoyl; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -co2Rl3~ -oC(=o)R13~ -oR13, ~S!o)mRl3~ C2-C4 alkenyl, C3-C6 cycloalkylmethyl, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, methylenedioxy, ethylenedioxy, VO94/19329 1 ~ 6 ~94 PCT~S94/01609 Cl-C4 haloalkyl, C1-C4 haloalkoxy, Cl-C4 alkoxycarbonyl, Cl-C4 alkylcarbonyl, Cl-C4 alkylcarbonylamino, -OCH2CO2H, -C(R14)=N(oRl4);
C3-C10 cycloalkyl substituted with 0-2 R12;
Cl-C4 alkyl substitued with 0-2 R12;
- aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12, C6-C1o arylcarbonyloxy substituted with 0-2 R12, aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, Cl-C4 alkyl, C7-Clo arylalkyl, C1-C4 alkoxy, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(oR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, C1-C4 alkyl substituted with _NR13R14, _NR13R14, methylenediOXY~ Cl-C4 haloalkyl, Cl-C4 alkylcarbonyl, Cl-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

R12, when a substituent on nitrogen, is selected from ben-yl or methyl;

wo 94~19329 2~5~S ~ 4 PCT~S94/01609 R13 is H, Cl-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R13A is selected from:
phenyl substituted with 1-3 R11;
benzyl substituted with 1-3 R11;
C1-C6 alkyl substituted with 1-3 R11;
C2-C4 alkenyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R11;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is OH, H, Cl-C4 alkyl, Cl-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl R14A is Cl-C6 alkyl substituted with 1-3 groups selected from OH, Cl-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), Cl-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)s-, -cH2cH2N(Rl5)cH2cH2-~ or -cH2cH2ocH2cH2 R15 is H or CH3i W is selected from:
-N(R22)c(=z)N(R23)_;
-N(R22)c(=z)o-;
-N(R22)C(=Z)C(R27)(R28)-;
-N(R22)C(=o)c(=o)N(R23)-;

wherein:

Z is O, S, N-CN, N-OH, N-OCH3;

WO94/19329 ~1~6~ 9 I PcT~s94lol6o9 R22 and R23 are independently selected from the following:
hydrogen;
Cl-Cg alkyl substituted with 1-2 R31;
C2-C6 alkenyl substituted with one R31;
C2-C4 alkynyl substituted with one R31;

R27 is selected from the following:
hydrogen;
Cl-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C3-Cg alkynyl substituted with 0-3 R31;

R28 is hydrogen or halogen;

R31 is selected from one or more of the following:
_CH2NR13AR14, _NR13AR14, --co2Rl3A, --OC(=O)R13A, -oR13A, ~S(o)mRl3A~ -NHC(=NH)NHR13A, -C(=NH)NHR13A, -C(=o)NR13AR14~ -NR14C(=o)R13A
-OC (=o) NR13AR14, -NR13AC (=O) NR13AR14 _NR14So2NRl3ARl4, --NR14So2R13A, --So2NR13AR14 _CH2NR13R14A, _NR13R14A, -C(=O)NR13R14A, _NR14AC (=O) R13, =NoR14A, -NR14C (=O) oRl4A, -oC(=o)NRl3Rl4A~ -NRl3c(=o)NRl3Rl4A
_NRl4Aso2NRl3Rl4A~ -NRl4Aso2Rl3~ -So2NRl3Rl4 nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, C2-C4 alkyl substituted with -NR13R14, Cl-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, Cl-C4 haloalkyl, Cl-C4 haloalkoxy, Cl-c4 alkylcarbonyl, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or -C(R14)=N(oRl4A);
- aryl substituted with 1-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently WO94/19329 ~ ~S ~ 72- PCT~S94/01609 selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
C7-C1o cycloalkyl, NHRSo2Rl4A~ -C02R13A~ NR13AR14, NR13R14A, -C(Rl4)=N(oRl4A~ _coNRl3NRl3Rl4 -NR4 OR41~ _SOmR13A~ _C(=O)NR13R14, --OC (=o) NR13R14, --C (=O) Rll, --OC (=O) Rll~
-oco2Rl3~ -C(=o)NR13-(C1-C4 alkyl)-NR13R14, oR13A, --C (=o)NR40R41, C2--C4 haloalkenyl~ Cl--C4 haloalkynyl, or _C(=O)NR13C(R11)2NR13R14;
-c(=o)NRl3c(Rll)2NRl3co2Rl3;
-C(=o)NRl3-(Cl-C4 alkyl)-NRl3CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl) -R11; or --C (=O) C (Rll) 2NR13R14;
-C(=3)C(R1l)2NRl3Co2Rl3; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O) -(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 1-4 groups selected from: Rll, C3-C6 cycloalkyl, -Co2Rl3 _C(=o~NR13R14~ _NR13R14 or OH;
Cl-C4 alkyl substituted with 1-4 groups selected 2 5 from R11 =NR14, =NNR13C(=O)NR13R1 4, =NNR13C(=O)OR13, or _NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 1-2 R12; when R32 is attached to a saturated carbon, it may be =NOH; or when R32 attached to sulfur it may be =O;
m is 0, 1, or 2;

~094/19329 2-1 S~ ~ PCT~S94/01609 R40 is selected from: H, Cl-C3 alkyl;

R4l is selected from:
-c(=o)NRl3Rl9;
-C(=o)NRl3NRl4;
--C (=O) C (Rll) 2NR13R14;
-C (=O) C (Rll) 2NR13NR14;
-C (=O) C (Rll) 2NR13Co2Rl3;
-C(=O)H;
_c(=O)Rll;
-C(=O)-(Cl-C4 alkyl)-NRl3Rl4;
-C (=O) - (Cl-C4 alkyl)-NR13C02R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4 and R7 are not both hydrogen;

when R4 is hydrogen, at least one of the following is not hydrogen: R22 and R28.

~lO] Further preferred compounds of this third embodiment of formula (I) are compounds of formula (II):
R4 ~ R7 Rs R6 (II) or a pharmaceutically acceptable salt form thereof wherein:

WO94/19329 2 ~S 6~ 9 4 PCT~S94/01609 R9 and R7 are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-3 Rl1;
C3-C4 alkenyl substituted with 0-3 Rll;

R5 is selected from -oR20;

R6 is hydrogen or -OR21;
R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

Rl1 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3, -OC (=O) R13, -oRl3, -s (O) mR13 ~ C2-C4 alkenyl, C3-C6 cycloalkylmethyl, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, _c(Rl4)=N(oRl4);
C3-C1o cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12, C6-C1o arylcarbonyloxy substituted with 0-2 Rl2, aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 Rl2;

WO94/19329 1S6Sg j PCT~S94/01609 R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, ~ 5 halogen, Cl-C4 alkyl, C7-Clo arylalkyl, Cl-C4 alkoxy, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(oR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, methylenedioxy, C1-C4 haloalkyl, C1-C4 alkylcarbonyl, Cl-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

R12, when a substituent on nitrogen, is selected from benzyl or methyl;

R13 is H, C1-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R13A is selected from:
phenyl substituted with 1-3 R11;
benzyl substituted with 1-3 R11;
C1-C6 alkyl substituted with 1-3 R11;
C2-C4 alkenyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R1l;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is OH, H, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

Rl4A is C1-C6 alkyl substituted with 1-3 groups selected from OH, Cl-C4 alkoxy, halogen, NH2, -NH(C1-C4 WO94/19329 ~ 1~ 6 S 9'~ PCT~S94/01609 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -cH2cH2ocH2cH2-;

R15 is H or CH3;

W is selected from:
-N(R22)c(=z)N(R23)-;
--N~R22)c(=z)o-;
-N(R22)C(=Z)C(R27)(R28)-;
-N(R22)C(=o)c(=o)N(R23)-;
wherein:

Z is O, S, N-CN

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 1-2 R31;
C2-C6 alkenyl substituted with one R31;
C2-C4 alkynyl substituted with one R31;

R27 is selected from the following:
hydrogen;
C1-Cg alkyl substituted with 0-3 R31;
C2-Cg alkenyl substituted with 0-3 R31;
C3-Cg alkynyl substituted with 0-3 R31;

R28 is hydrogen or halogen;

R31 is selected from one or more of the following:

VO94/19329 1 ~ 6 ~ ~ PCT~S94/01609 _CH2NR13AR14, _NR13ARl9, -C02R13A, -oRl3A, _s(o)mRl3A~ -CH2NR13R14A, -NR13R14A, or -C(R14)=N(oR14);
aryl substituted with 1-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;
R32, when a substituent on carbon, is selected from one or more of the following:
C7-clo cycloalkyl, NHRSo2R14A, -C02R13A, NR13AR14 NR13R14A, _C(R14)=N(oRl4A), -coNRl3NRl3Rl4 -NR40R41, _somRl3A~ -C(=o)NRl3Rl4~
-OC ~=o) NR13R14, -C (=O) Rll, -Oc (=O) Rll, -oco2Rl3~ -C(=o)NR13-(C1-C4 alkyl)-NR13R14, oR13A, -C(=O)NR40R4l~ C2-C4 haloalkenyl~ C1-C4 haloalkynyl, or -C(=O)NR13C(Rl1)2NR13R14;
--C (=O) NR13C ~Rll) 2NR13Co2Rl3;
-C(=o)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=o)N(R13)-(Cl-C4 alkyl)-R1l; or -C (=O) C (Rll) 2NR13R14;
-C(=o)c(Rll)2NRl3co2Rl3; -C(=O)-(Cl-C4 alkyl)-NRl3Rl4; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 1-4 groups selected from: R11, C3-C6 cycloalkyl, -Co2Rl3 _C(=o)NR13R14~ _NR13R14 or OH;
C1-C4 alkyl substituted with 1-4 groups selected from Rll, =NR14, =NNR13C (=O) NR13R14 =NNR13C (=O) oR13, or _NR13R14;
C2-C4 alkenyl substituted with 0-4 Rll;
C2-C4 alkynyl substituted with 0-4 R11; or WO94/19329 PCT~S94/01609 21~5g~

a 5- or 6-membered heterocyclic ring containing from l to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 1-2 Rl2; when R32 is attached to a saturated carbon, it may be =NOH; or when R32 attached to sulfur it may be =O;

m is 0, l, or 2;

R40 is selected from: H, Cl-C3 alkyl;

R4l is selected from:
-c(=o)NRl3Rl4;
_c(=o)NRl3NRl4;
-C(=o)c(Rll)2NRl3Rl4;
--C (=O) C (Rll) 2NR13NRl9, -C (=O) C (Rll) 2NR13Co2Rl3;
-C(=O)H;
-C (=O) Rll;
-C(=O)-(Cl-C4 alkyl)-NRl3Rl4;
-C(=O)-(Cl-C4 alkyl)-NRl3CO2Rl3;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;
provided that:

R4 and R7 are not both hydrogen;

when R4 is hydrogen, at least one of the following is not hydrogen: R22 and R28.

[ll] Preferred compounds of this third embodiment are compounds of formula (II) described above, wherein:

~094/19329 ~659~ PCT~S94/01609 R4 and R7 are selected from benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R5 is -OH;

R6 is hydrogen or -OH;

R13 is H, C1-C4 alkyl, C2-C4 alkenyl, or benzyl;

R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -cH2cH2ocH2cH2-;

W is selected from:
-N(R22)C(=o)N(R23)-;
-N(R22)C(=N-CN)N(R23)-;
-N(R22)C(=S)N(R23)-;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 1-2 R31;
C2-C6 alkenyl substituted with 1-2 R31;
C2-C4 alkynyl substituted with 1-2 R31;

R31 is selected from one or more of the following:
halogen, -oR13A~ -C(R14)=N(oR14) -Co2Rl3A
--S (O) mR13A;
aryl substituted with 1-5 R32; or a heterocyclic ring system chosen from pyridyl, pyrimidinyl, triazinyl; furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, WO94/19329 2 1~ 6 S 9 PCT~S94/01609 benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, said heterocyclic ring being substituted with 1-2 R32, or benzimidazolyl, benzotriazolyl, indazolyl, benzoxazolinyl, benzoxazolyl, optionally substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
_CH2NR13AR14, _NR13AR14, -CH2NR13R14A, -NR13R14A, -C(R14)=N(oR14A), allyloxy, -CO2CH3, -NHCHO, -OC02CH3, -CH=NCH2CH20H, -OCONHCH2C6H5, -OCONHCH3, -C=C-CH2OH, -OCH2CONH2, -CH=NNHCONH2, -CONHOCH3, -CH2CH(OH)CH2OH, adamantamido, hydroxyethoxy, dihydroxyethyl, -C(NH2)=NH, -CONHCH3, -CONHCH2CH3, -CON(CH2CH3)2, -NHCONH2, -NHCONHCH3, -NHCOCH2N(CH3)2, -NHCOCH2NHCH3, --NHCOCH2NHC02CH2C6H5, --NHCOCH2NH2, -NHCOCH(CH3)NHCO2CH2C6Hs, -NHCOCH(CH2C6Hs)NHCO2CH2C6Hs, -NHCOCH(CH3)NH2, -NHCOCH(CH2C6Hs)NH2, -CO2CH2CH3, -CONHCH2CH2CH3, -CONHCH(CH3)2, -CH2-imidazole, -COC(CH3)3, -CH(OH)CF3, -CO-imidazole, -CO-pyrazolyl, -COCF3, -C(CF3)=N(OH), acetoxy, -N(CH3)(CHO), -CoNRl3R19, -CONHOH, (diethylaminoethyl)aminocarbonyl, (N-ethyl,N-methylaminoethyl)aminocarbonyl, (4-methylpiperazinylethyl)aminocarbonyl, (pyrrolidinylethyl)aminocarbonyl, (piperidinylethyl)aminocarbonyl, -NHCOCH2NHCH3, N-(2-(4-morpholino)ethyl)aminocarbonyl, or N-(2-(N,N-dimethylamino)ethyl)aminocarbonyl.

W094/19329 1 S 659 ~ PCT~S94/01609 [12] Also preferred in the present invention are compounds, or a pharmaceutically acceptable salt form thereof, of the formula:

~W~_ ;~ ' HO - OH

wherein:

W is -N(R22)c(=o)N(R23)-;
-N(R22)C(=S)N(R23)-i -N(R22)C(=N-CN)N(R23)-;

R4 and R7 are independently selected from: benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R22 and R23 are independently selected from the group consisting of:
(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH302CO)-benzyl, 2 5 (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH30NHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH20)-benzyl, hydroxyethoxybenzyl, (carbomethoxy)pentyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, wo ~,lg32g ~ 3 ~ PCT~S94/01609 alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, ~MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.

[13] Also preferred are compounds of formula (IIa):

_,~Q ~/19329 2 1 ~ 6 ~ 9 ~ PCT~S94/01609 R ~ ~R23 - Ph ~ Ph ~'~, HO -OH

(IIa) or a pharmaceutically acceptable salt form thereof, wherein:

R22 and R23 are independently selected from the group consisting of:
(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2C-O)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH30NHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl, (carbomethoxy)pentyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, WO94/19329 2 ~ ~ 5 ~ ~ PCT~S94/01609 -~4-(pyridylmethylaminocarbonyl)benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-l-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, ~NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.

[14] Specifically preferred are compounds of formula (IIa):

RZ~ R23 Ph~ Ph HO OH
(IIa) or a ph.~rmaceutically acceptable salt form thereof, selected from the group consisting of:

N094/19329 6 St~4 . PCT~S94/01609 the compound of formula (IIa) wherein R22 is 1-cinnamyl and R23 is 1-cinnamyl;
the compound of formula (IIa) wherein R22 is vinylbenzyl and R23 is vinylbenzyl;
the compound of formula !IIa) wherein R22 is 3-(NHCHO)benzyl and R23 is 3-(NHCHO)benzyl;
the compound of formula (IIa) wherein R22 is 3-(NHCOCH3)benzyl and R23 is 3-(NHCOCH3)benzyl;
the compound of formula (IIa) wherein R22 is 3-formaldoximebenzyl and R23 is 3-(N-hydroxy)aminomethylbenzyl;
the compound of formula (IIa) wherein R22 is 3-(CH30C(=0)0-)benzyl and R23 is 3-(CH30C(=0)0-)benzyl;
the compound of formula (IIa) wherein R22 is 3-(HOCH2CH2N=CH)benzyl and R23 is 3-(HOCH2CH2N=CH)benzyl;
the compound of formula (IIa) wherein R22 is 3-(HOCH2CH2N=CH)benzyl and R23 is 3-(2-oxazolidinyl)benzyl;
the compcund of formula (IIa) wherein R22 is 3-(C6HsCH2NHC(=O)O)benzyl and R23 is 3-(C6HsCH2NHC(=O)O)benzyl;
the compound of formula (IIa) wherein R22 is 3-(CH3NHC(=O)O)benzyl and R23 is 3-(CH3NHC(=O)O)benzyl;
the compound of formula (IIa) wherein R22 is 3-(HOCH2CC)benzyl and R23 is 3-bromobenzyl;
the compound of formula (IIa) wherein R22 is 3-aminocarbonylbenzyl and R23 is 3-aminocarbonylbenzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NCOCH20)benzyl and R23 is 3-(H2NCOCH20)benzyl;

WO94/19329 215 6 ~ 9 -1 PCT~S94/01609 the compound of formula (IIa) wherein R22 is 3-(H2NNHC(=O))-benzyl and R23 is 3-(H2NNHC(=O))-benzyl;
the compound of formula (IIa) wherein R22 is 4-~H2NNHC~=O))-benzyl and R23 is 4-~H2NNHC~=O))-benzyl;
the compound of formula ~IIa) wherein R22 is 3-~H2NC~=O)NHN=CH)-benzyl and R23 is 3-(H2NC(=O)NHN=CH)-benzyl;
the compound of formula (IIa) wherein R22 is 3-[(N-methoxy)aminocarbonyl]-benzyl and R23 is 3-[(N-methoxy~aminocarbonyl]-benzyl;
the compound of formula (IIa) wherein R22 is 4-[(N-methoxy)aminocarbonyl]-benzyl and R23 is 4-[(N-methoxy)aminocarbonyl]-benzyl;
the compound of formula (IIa) wherein R22 is 3-~HOCH2CH(OH)CH2O)benzyl and R23 is 3-(HOCH2CH(OH)CH2O)benzyl;
the compound of formula (IIa) wherein R22 is 3-~2-hydroxyethoxy)benzyl and R23 is 3-~2-hydroxyethoxy)benzyl;
the compound of formula (IIa) wherein R22 is 3-(l,2-dihydroxyethyl)benzyl and R23 is 4-(l,2-dihydroxyethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-aminocarbonylbenzyl and R23 is 3-(H2NC(=NH))benzyl;
the compound of formula ~IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-~N-methylaminocarbonyl)benzyl;
the compound of formula ~IIa) wherein R22 is 3-(l,2-dihydroxyethyl)benzyl and R23 is 3-(l,2-dihydroxyethyl)benzyl;

NO94/19329 ~ S~ ~ PCT~S94/01609 the compound of formula ~IIa) wherein R22 is 4-(l,2-dihydroxyethyl)benzyl and R23 is 4-(l,2-dihydroxyethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N-methylaminocarbonyl)benzyl;
the compound of formula ~IIa) wherein R22 is 3-(N-ethylaminocarbonyl)benzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
(H2NC(=O)NH)benzyl and R23 is 3-(H2NC(=O)NH)benzyl;
the compound of formula (IIa) wherein R22 is 3-aminobenzyl and R23 is 3-(CH3NHC(=O)NH)benzyl;
the compound of formula (IIa) wherein R22 is 3-(CH3NHC(=O)NH)benzyl and R23 is 3-(CH3NHC(=O)NH)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N,N-dimethylaminoglycyl)amino)benzyl and R23 is 3-((N,N-dimethylaminoglycyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N-methylaminoglycyl)amino)benzyl and R23 is 3-((N-methylaminoglycyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N,N-dimethylaminoglycyl)amino)benzyl and R23 is 4-hydroxymethyibenzyl;
the compound of formula (IIa) wherein R22 is 3-((N-phenylmethoxycarbonylaminoglycyl)amino)benzyl and R23 is 3-((N-phenylmethoxycarbonylaminoglycyl)amino)benzyl;

WO94/19329 PCT~S94/01609 2J~,~G~

the compound of formula (IIa) wherein R22 is 3-(glycylamino)benzyl and R23 is 3-(glycylamino)benzyl;
the compound of formula (IIa) wherein R22 is 3-(glycylamino)benzyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (IIa) wherein R22 is 3-((N-phenylmethoxycarbonylamino-L-alanyl)amino)benzyl and R23 is 3-((N-phenylmethoxycarbonylamino-L-alanyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N-phenylmethoxycarbonylamino-L-phenylalanyl)amino)benzyl and R23 is 3-((N-phenylmethoxycarbonylamino-L-phenylalanyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-(L-alanyl)amino)benzyl and R23 is 3-(L-alanyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-(L-phenylalanyl)amino)benzyl and R23 is 3-(L-phenylalanyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 5-hvdroxy-l-pentyl and R23 is 3-carboethoxybenzyli the compound of formula (IIa) wherein R22 is 4-oxime-l-hexyl and R23 is 4-oxime-l-hexyl;
the compound of formula (IIa) wherein R22 is 3-(N,N-diethylaminocarbonyl)benzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;

~094/19329 Zl ~ 6 5 9 4 PCT~Sg4/01609 the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-~N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(N-propylaminocarbonyl)benzyl and R23 is 3-(N-propylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(H02C)benzyl and R23 is 3-(N-isopropylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(H02C)benzyl and R23 is 3-(N-propylaminocarbonyl)benzyl;
hydroxymethylbenzyl and R23 is 3-aminocarbonylbenzyl;
the compound of formula (IIa) wherein R22 is cyclopropylmethyl and R23 is 3-aminocarbonylbenzyl;
the compound of formula (IIa) wherein R22 is 3-aminocarbonylbenzyl and R23 is hydrogen;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(N-imidazolylmethyl)benzyl and R23 is 3-(N-imidazolylmethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2,2-dimethyl-l-propionyl)benzyl and R23 is 3-~ ~2,2-dimethyl-l-propionyl)ber.zyl;

WO94/19329 2 ~ ~ 6 ~ 9 A PCT~S94/01609 the compound cf formula (IIa) wherein R22 is 3-(2,2,2-trifluoro-l-hydroxyethyl)benzyl and R23 is 3-(2,2,2-trifluoro-1-hydroxyethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2-imidazolyl-C(=O))benzyl and R23 is 3-(2-imidazolyl-C(=O))benzyl;
the compound of formula (IIa) wherein R22 is 3-(3-hydroxy-l-propyn-l-yl)benzyl and R23 is 3-(3-hydroxy-l-propyn-l-yl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2,2,2-trifluoroacetyl)benzyl and R23 is 3-(2,2,2-trifluoroacetyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-propionylbenzyl and R23 is 3-propionylbenzyl;
the compound of formula (IIa) wherein R22 is 3-(CH3CH2C(=N-OH))benzyl and R23 is 3-(CH3CH2C(zN-OH))benzyl;
the compound of formula (IIa) wherein R22 is 3-(CF3CH2C(=N-OH))benzyl and R23 is 3-(CF3CH2C(=N-OH))benzyl;
the compound of formula (IIa) wherein R22 is 3-(5-methyl-1,2,3-oxadiazolyl)benzyl and R23 is 3-(5-methyl-l,2,3-oxadiazolyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NC(=NOH)benzyl and R23 is 3-(H2NC(=NOH)benzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NC(=NOH)-4-fluorobenzyl and R23 is 3-(H2NC(=NOH)-4-fluorobenzyl;
the compound of formula (IIa) wherein R22 is 3-chloro-5-indazolylmethyl and R23 is 3-chloro-5-indazolylmethyl;
the compound of formula (IIa) wherein R22 is 3-methylamino-5-indazolylmethyl and R23 is 3-methylamino-5-inda-olylmethyl;

~094/19329 1 S 6 ~g q PCT~S94/01609 the compound of formula (IIa) wherein R22 is 3-ethylamino-5-indazolylmethyl and R23 is 3-ethylamino-5-indazolylmethyl;
the compound of formula (IIa) wherein R22 is 3-5amino-5-benzisoxazolylmethyl and R23 is 3-amino-5-benzisoxazolylmethyl.

[15] Also preferred are compour.ds of formula (IIaa):
,~
RZN ~ R23 R4 ~ R7 H OH
(IIaa) or a pharmaceutically acceptable salt form thereof wherein:
R4 and R7 are independently selected from: benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl aminobenzyl, hydroxybenzyl, 4-pyridylmethyl, or thienylmethyl;
R22 and R23 are independently selected from:
(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH30~CO)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonyibenzyl, (H2NNHC(=O))-- benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH30NHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH20)-benzyl, hydroxyethoxybenzyl, WO94/19329 IS G ~ 9 ~ PCT~S94/01609 (carbomethoxy)pentyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylber.zyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.

WO94/19329 21 ~ ~ ~9 ~: ! PCT~S94/01609 [16] Speclfically preferred are compounds of formula (IIaa):
~I~
RZ~ 1~ R23 R4 ~ R7 HO OH
(IIaa) or a pharmaceutically acceptable salt form thereof, selected from the group consisting of:
the compound of formula (IIaa) wherein R4 and R7 are isobutyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are isobutyl, R22 and R23 are allyl;
the compound of formula (IIaa) wherein R4 is 4-nitrobenzyl, R7 is 2-nitrobenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-nitrobenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 is 4-nltrobenzyl, R7 is 2-nltrobenzyl, R22 and R23 are n-butyl;
the compound of formula (IIaa) wherein R4 is 4-aminobenzyl, R7 is 2-aminobenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-hydroxybenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are cyclopropylmethyl;

WO94/19329 2~59 PCT~S94/01609 the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 4-hydroxymethylbenzyl;
the compound of formula ~IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-aminocarbonylbenzyl;
the compound of formula ~IIaa) wnerein R4 and R7 are 4-fluorobenzyl, R22 and R23 a.e 3-acetylbenzyl;
the compound of formula ~IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-butyrylbenzyl;
the compound of formula ~IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-hydroxymethylbenzyl;
the compound of formula ~IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-(CH3C(=N-OH)benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-~H2NC(=NOH)benzyl;
the compound of formula ~IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-(H2NC(=NOH)-4-fluorobenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula ~IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are 4-hydroxymethylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are 3-methoxybenzyl;

2ls~4 WO94/19329 : PCT~S94/01609 the compound of formula (IIaa) wherein R4 and R7 are 3-hydroxybenzyl, R22 and R23 are 3-hydroxybenzyl.
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are 2-naphthylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are 4-hydroxymethylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-hydroxybenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are allyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-(2-hydroxyethoxy)benzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-(2-morpholinylethoxy)benzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-(H2NC(=O)CH~O)benzyl, R22 and R23 are n-butyl;
the compound of fo_mula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 3-hydroxymethylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 4-hydroxymethylbenzyl;

WO34/19329 2 ~S 6 S 9 ~ PCT~S94/01609 the compound of formula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 3-(H2NC(=O))benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 3-(H2NC(=NOH))benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 2-naphthylmethyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 2-naphthylmethyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 2-thienylmethyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 2-thienylmethyl, R22 and R23 are 3-(H2NC(=NOH))benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methylthiobenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are isopropyl, R22 and R23 are n-hexyl;

[17] Also preferred in the present embodiment are compounds of formula (IIb):

Ph W~ Ph ~-~."/

HO
(IIa) wherein:

W i~:

~094/19329 ~ PCT~S94/01609 -N~R22)c(=s)N(R23!-~
-N(R22)C(=N-CN)N(R23)-;

R22 and R23 are independently selected from:
(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2CO)-benzyi, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH30NHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl, (carbomethoxy)pentyl, glyoylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-ben yl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazoiyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl3benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycy.l)amlnoPenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, WO94/19329 PCT~S94/Q1609 ~9~ (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-l-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, 'NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.

[18] Specifically preferred are compounds of formula (IIb):
,CN
N

R22N J~ ~ R23 Ph ~ Ph HO OH
(IIb) or a pharmaceutically acceptable salt form thereof, selected from the group consisting of:
the compound of formula (IIb) wherein R22 is 4-hydroxybenzvl and R23 is 4-hydroxybenzyl;
the compound of formula (IIb) wherein R22 is cyclopentylmethyl ard R23 is cyclopentylmethyl;
the compound of formula (IIb) wherein R22 is n-butyl and R23 is n-butyl;

~094/19329 ~ S 6 ~ ~ PCT~S94l01609 _~9_ :
the compound of formula (IIb) wherein R22 is 3-hydroxybenzyl and R23 is 3-hydroxybenzyl;
the compound of formula (IIb) wherein R22 is 3-aminobenzyl and R23 is 3-aminobenzyl;
the compound of formula (IIb) wherein R22 is cyclohexylmethyl and R23 is cyclohexylmethyl;
the compound of formula (IIb) wherein R22 is cyclobutylmethyl and R23 is cyclobutylmethyl;
the compound of formula (IIb) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-hydroxymethylbenzyl;
the compound of formula (IIb) wherein R22 is 3-formylbenzyl and R23 is 3-formylbenzyl;
the compound of formula ~IIb) wherein R22 is 3-formaldoximebenzyl an~ R23 is 3-formaldoximebenzyl.

[19] Specifically preferred are compounds of formula (Ibb):

S
RZN ~--~ R23 Ph ~ "--Ph HO OH

(Ibb) or a pharmaceutically salt form thereof, selected from the group consisting of:
the compound of formula (Ibb) wherein R22 is benzyl and R23 is hydrogen;
the compound of formula (Ibb) wherein R2~ is cyclopropylmethyl and R23 is cyclopropylmethyl;

WO94/19329 PCT~S94/01609 9~ the compound of formula (Ibb) wherein R22 is benzyl and R23 is benzyl;
the compound of formula (Ibb) wherein R22 is 3-hydroxybenzyl and R23 is 3-hydroxybenzyl;
the compound of formula (Ibb) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-hydroxymethylbenzyl;
the compound of formula (Ibb) wherein R22 is 4-hydroxybenzyl and R23 is 4-hydroxybenzyl;
the compound of formula ~Ibb) wherein R22 is 3-methoxybenzyl and R23 is 3-methoxybenzyl;
the compound of formula (Ibb) wherein R22 is 3-tH2NC(=NOH))benzyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (Ibb) wherein R22 is 3-(H2NC(=NOH))benzyl and R23 is 3-(H2NC(=NOH)~benzyl;
the compound of formula (Ibb) wherein R22 is 3-(H2NC(=NOH))-4-fluorobenzyl and R23 is 3-(H2NC(=NOH))-4-fluorobenzyl.

[20] A fourth embodiment of this invention is a compound of the formula (I):

R4~<~R7A

~ ~ R6a R5 F sa R6 \ ~ n (I) or a pharmaceutically acceptable salt form thereof wherein:

~094/19329 21 ~ ~ S 9 4 PCT~S94/01609 R4 and R7 are independently selected from the following groups:
hydrogen;
Cl-C8 alkyl substituted with 0-3 R11;
C2-Cg alkenyl substituted with 0-3 R11;
C2-C8 alkynyl substituted with 0-3 Rll;
- a C3-C1g carbocyclic ring system substituted with 0-3 R11 or 0_3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocycllc ring system being substituted with 0-2 Rl2;
--oR1 3; --SR1 3; C02R1 3;

R4A and R7A are independently selected from the following groups:
hydrogen;
C1-Cg alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-oR13; -SR13; C02R13;

25 R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

R7 and R7A can alternatively join to form z 5-7 membered carbocyclic ring substituted with 0-2 R12;
n is 0, l, or 2;

R5 is selected from hydrogen; bromine, chlorine, Cl-C6 alkyl substituted with 1-3 R1l, -N(R20)2, -SR20, or 3 5 -N3;

WO94/19329 PCT~S94/01609 , 9 R6 is selected from bromine, chlorine, C1-C6 alkyl C~ substituted with 1-3 Rll, -N(R20)2, -SR20, or -N3;

R5 and R6 can alternatively join to form an aziridine ring; -OC((CH2)3NH2)(CH3)0-; -NHC(=O)NH-;
-OC(=O)NH-; -NHC(=O)O-; -NHCH2O-; -OCH2NH-;
-NHC(=S)O-; -OS(=O)NH-; -NHC(=O)C(=O)O-;
-OC(=O)C(=O)NH-; -NHC(=O)C(=O)NH-; -NH~(CH3)2-;
-OC(CH3)2NH-; or any group that, when administered to a mammalian subject, cleaves to form a diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20, or -oR20;
R6a is selected from: hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20 or _oR21;

R5 znd R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 Rl1;
C3-C6 alkoxyalkyl substituted with 0-3 R11;
Cl-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 R11;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or VO94/19329 21 ~G~g~ PCT~S94/01609 any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sul~hydryl;

~ 5 R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3, -OC (=O) R13, -oRl3, -s (O) mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=o)NR13R14, -NR14C (=O) R13, =NoR14, _NR14C (=O) oR14 1 0 --OC (=O) NR13R14, _NR13C (=O) NR13R14 --NR14So2NRl3Rl4~ --NR14So2Rl3~ --So2NRl3Rl4 -op(o)(oRl3)2~ C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hy~roxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or _c(Rl4)=N(oRl4);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C1o cycloalkyl substituted with 0-2 R12i C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
Cl-C4 alkylcarbonyloxy substituted with 0-2 R12;
- C6-C1o arylcarbonyloxy substituted with 0-2 Rl2;
a Cs-C14 carbocyclic residue substituted with 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently WO94/19329 PCT~S94101609 selected from oxyqen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13BR14B, -NR13BR14B, -CO2H, -OC(=O)(Cl-C3 alkyl), -OH, C2-Cç
alkoxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C1o cycloalkyl, C3-C6 cycloalk~lmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C1o arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, C1-Cg alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-Cs haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(C1-C3 alkyl), a Cs-C14 carbocyclic residue; a 5- to
10-membered heterocyclic rins system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C~-C1o arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, Cl-C4 alkyl substituted with -NR13R14, -NR13R14, C2-C6 VO94/19329 21 ~ 6 ~ 9 ~-¦ PCT~S94101609 alkoxyalkyl optionally substituted with :
-Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, Cl-c4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -s(o)mRl3~ -So2NRl3Rl4 -NHSo2Rl4, -0CH2Co2Rl3~
2-(1-morpholino)ethoxy, -C(R14)=N(oR14); or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, _CH2NR13R14, _NR13R14, C2-C6 alkoxyalkyl~ Cl-C4 haloalkyl, Cl-c4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R19)=N(oR14);

R12A, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-WO94/19329 PCT~S94/Q1609 C1o arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -oR13, C1-C4 alkyl substituted with -NH2, -NH2~ -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3~3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, ~s(o)mMe~ -SO2NH2~
-NHSO2Me, -ocH2co2Rl3~ 2-(1-morpholino)ethoxy, -C(=NOH)NH2; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12A may be a 3- o.r 4- carbon chain attached to adjacent carbons on the rins to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;
R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, -NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2;
R13 is selected from:

VQ94/19329 21 5 6 ~ PCT~S94/01609 -H;
phenyl substituted with 0-3 Rl1A;
benzyl substituted with 0-3 RllA;
C1-C6 alkyl substituted with 0-3 Rl1A;
C2-C4 alkenyl substituted with 0-3 Rl1A;
Cl-C6 alkylcarbonyl substituted with 0-3 Rl1A;
- C1-C6 alkoxycarbonyl substituted with 0-3 R11A;
Cl-C6 alkylaminocarbonyl substituted with 0-3 RllA;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, C1-C6 alkyl substituted with 0-3 groups selected from OH, Cl-C4 alkoxy, halogen, NH2, -NH~C1-C4 alkyl), Cl-Cb alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting ~roup when R14 is bonded to N, a hydroxy protecting group when R1 is bonded to O;

p~13 and R14 can alternatively join to form -(CH2)4-, -(CH2)s-, -cH2cH2N(Rl5)cH2cH2-/ or -cH2cH2ocH2cH2-R13B and R19B are independently selected from H or Cl-C
alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -CH2CH20CH2CH2-;

R15 is H or CH3;

m is 0, 1 or 2;

W is selected from:
-N(R22)c(=z)N(R23)_ --OC (=Z) O--, -N(R22)c(=z)o-~ -_C(~25~(R26)c(=z)c(R27)(R28) WO94/19329 PCT~S94/01609 9~
~ -iO8--N~R22)C(=z)c(R27)(R28)-~
C~ --C (R25) (R26) C (=Z) O-, -N(R22)C(=o)c(=o)N(R23) --C (R25) (R26) C (F2) C (R27) (R23)--_C(R25)(R26lN(cH3)(o)c(R27)(R28) -C(R25)(R26)N(oR29)c(R27)(R28) -C (R25) (R26) C (=Z) S-, -N(R22)S(=o)N(R23)_ wherein:
Z is 0, S, NR24;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-Cg alkenyl substituted with 0-3 R31;
C2-C& alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- 'o 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32; or -OR22a; -N(R22a)(R22b);

R22a and R22b are independently selected from the following:
hydrogen;
C1-Cg alkyl substituted with 0-3 R31;
C2-Cg alkenyl substituted with 0-3 R31;
C2-Cg alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0_5 R31 or 0-5 R32; or VO94/19329 21 S~9 4 PCT~594/01609 a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R24 is selected from: hydrogen; hydroxy; amino; C1-C4 alkyl; C1-C4 alkoxy; mono- or di-(C1-C6 alkyl)amino, cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally subst_tuted with (C1-C6)alkyl;

R25 and R27 are independently selected from the following:
hydrogen;
Cl-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0_5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containins 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR13; -SR13;

R26 and R28 are independently selected from:
hydrogen;
halogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
-oR13; -SR13;

WO94/19329 PCT~S94/01609 R29 is selected from:
hydrogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;

alternatively, R22, R25, or R26, independently, can join with R4 or R4A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R23, R27, or R28, independently, can join with R7 or R7A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R22, R25, R26, R23, R27, R28, R34, or R35 can join with R5 or R6 to form a 0- to 7-membered bridge to form a carbocyclic or heterocyclic ring, said bridge being substituted with 0-2 R12 and said bridge containing 0-3 heteroatoms independently selected from N, S, or O ~i.e., a 0-membered bridge is formed when R22, R25, R26, R23, R27, R28 R34 or R35 are taken together with R5 or R6 to form a direct bond);

alternatively R28 or R23 can join with R7A to form a direct bond;

~1 ~ 6 ~
~094/19329 PCT~S94/01609 alternatively R26 or R22 can join with R4A to form a direct bond;

R31 is selected from one or more of the following:
keto, halogen, cyano, -CH2NR13R14, -NR13R14, -Co2Rl3~ -C (=O) Rll, -OC (=O) R13, -oRl3, C2-C6 alkoxyalkyl, ~S~o)mRl3/ -NHC(=NH)NHR13, -C(=NH)NHR13, _C(=o)NR13R14, _NR14C(=o)R13, --NoR14, -NR14C (=O) oRl4, -OC (=O) NR13R14, _NR13C(=o)NR13R14, -NR13C(=S)NR13R14, _NR14So2NR13R14, --NR14So2Rl3, --sO2NRl3Rl4, Cl--Cg alkyl, C2-C4 alkenyl, C3-C1o cyclcalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-Clo arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, Cl-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, Cl-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-Cg alkylcarbonylamino, -ocH2co2Rl3~ 2-(1-morpholino)ethoxy, azido, _C(Rl4)=N(oRl4); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;

a Cs-C1g carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing l to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said WO~4/19329 PCT~S94101609 ~c ~ he.erocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:

phenethyl, phenoxy, C3-Clo cycloalkyl, C3-C6 cycloalkylmethyl, C7-C1o arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSo2Rl4~
benzyloxy, halogen, 2-(1-morpholino)ethoxy, -Co2Rl3~ hydroxamic acid, -CoNR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, _NR13R14, _C(R14)=N(oR14), -NO2, -oR13, -NR40R41, -SomRl3~ ~SomNRl3Rl4~ ~C (=O) NR13R14, --OC (=O) NR13R14, --C (=O) Rll, --OC (=O) Rll, -oco2Rl3~ phenyl, -C(=o)NRl3-(Cl-C4 alkyl)-NR13R14, -C(=O)NR40R41~ C1-C4 ha10a1kY1, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl; or -C(=O)NR13C(R11)2NR13R14;
-C (=O) NR13C (Rll) 2NR13Co2Rl3;
-C(=O)NR13-(C1-C4 alkyl)- NRl3CO2Rl3;
_C(=O)N (R13)-(C1-C4 alkyl)-R11; or -C (=O) C ~Rll) 2NR13R14;
-C(=O)C~R11)2NR 3CO2P~13; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, -Co2Rl3 _C(=o~NR13R14~ _NR13R14 or OH;
C1-C4 alkyl substituted with 0-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14' =NNR13C(=O)OR13~ or _NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11;

VO94/19329 21 ~ ~ 59 ~ PCT~S94/01609 a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, subst;.tuted with 0-2 R12;
or R32 may be a 3- or 4- c~rbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14;
or, when R32 is attached to a saturated carbon , it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, Ci-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-Cs alkoxyalkyl, C1-C4 haloalkyl, Cl-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, _c~Rl4)=N(oRl4);

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-c(=o)NRl3Rl4;
-C(=O)NR13NR13R14;
-C(=o)c(Rll)2NRl3Rl4;
-C ~=0) C (Rll) 2NR13NR13R14;
-C (=O) C (Rll) 2NR13Co2Rl3;
-C(=O)H;
-C (=O) Rll;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C (=0)- (Cl-C4 alkyl)-NR13CO?R13;

WO94/19329 PCT~S94/01609 ~!~ 1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4, R4A, R7 and R7A are not all hvdrogen;

when W is -OC(=Z)O-, -SC(=Z)-, -C(=Z)-, -P(=o)(R24a)-, -S(=Z')- or -S(=Z')2-, R4 and R7 are not hydrogen.

[21] Also included in the present invention are compounds, or a pharmaceutically acceptable salt form thereof, selected from compounds having the following formulae:

~0 R6 . R5 R R5 , R22 o O

N OJ~N~ P
R4~\ /~ R7R4~ ~ R7 OH~ R4A~ Ph ~
R6 HO ; OH R5 ~O 94/19329 21 S 6 ~ 9 ~ PCTtUS94tO1609 ~ R~ ;

R22- N~O R22- NJ~NR23 R22- N~S
R4~ R7 R4~ R7 R4~ R7 R22 N~ R~ ~ , ~Ph --~C(H)R11 R4 ~~ R
5 R5 R6 Rs R6 R5 RZ O RZ O
Y O R4 N~

R5J~ R7 Rs~ R7 H o H N C~C N

Bn~ ~N~ ~Bn N N

R4--~ R7 R41~R7 WO94/19329 PCT~S94/01609 O

R'2~ ,~_ ,R23 R4~N~ ~ H7 R4_~;;;R7 ~ ,OPh ol O R22-N NR23 R4~R7 R4--(~ R7 wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C3 alkyl substituted with 0-1 R11;

R5 is -oR20;
R6 is hydrogen or -OR21;

R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:

VO94tl9329 21 S 6 ~ 9 4 PCT~S94/01609 H; halogen; -oR13;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substituted with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
aryl substituted with 0-2 R12; or a heterocyclic ring system selected from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
benzyloxy, halogen, methyl, C1-C4 alkoxy, CF3, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(oR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, -NR13R14, hydroxy, hydroxymethyl; or R12, when a substituent on nitrogen, is methyl;

R13 is H, Cl-C4 alkyl, C2-C4 alkenyl, or benzyl;
R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

w is selected from:
35 -N(R22)C(=Z)N(R23)-;

W094/19329 PCTtUS94tO1609 -N(R22)C(=Z)O-;
~9 --c (R25) (R26~ C (=z) C (R27) (R28, -N(R22)S(=z~)N(R23)_;
-N(R22)S(=z~ )2N(R23)_;
-C(R25)(R26)C(R34)(R35)C(R27)(R28)-;
-N=C(R~6)N(R23)-;
--C (=z)_;

Z is 0, S, or N-CN;

Z ' is O;

R22 and R23 are independently selected from the following:
hydrogen;
C1-Cg alkyl substituted with 0-3 R31;
C2-C6 alkenyl substituted with 0-3 R31;
C2-C4 alkynyl substituted with 0-3 R31;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C4 alkyl substituted with 0-3 R31;
C3-C4 alkenyl substituted with 0-3 R31;
R26 and R28 are hydrogen or halogen;

R31 is selected from one or more of the following:
halogen, -oR13, Cl-C4 alkyl, C3-Clo cycloalkyl, _C(R14)=N(oRl4)~ -C02R13, ~S(O)mR13;
aryl substituted with 0-5 R32; or a heterocyclic ring system chosen from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, ~094/19329 21 5 6 ~ 9 ~ PCT~S94/01609 isoquinolinyl, oxazolidinyl, said heterocyclic ring being substituted with 0-2 R32; :

R32, when a substituent on carbon, is selected from one or more of the following:
benzyloxy, halogen, 2-(1-morpholino)ethoxy, -Co2Rl3~ hydroxamic acid, -CoNR13NR13R14, cyano, boronic acid, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(oR14), NO2, -oRl3, -NR40R41, -somRl3~ ~SomNRl3Rl4~
_C(=o~NR13R14, -oc(=o)NRl3Rl4~ -C(=O)R11, -OC(=O)R11, -0Co2Rl3~ phenyl, -C(=o)NRl3-(C1-C4 alkyl)-NR13R14~ -C(=o)NR4 OR4 1 C1_C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C2-C4 haloalkynyl, -C(=o)NR13Rl4i -C (=O) C (Rll) 2NR13P14; -C (=O) C (Rll) 2NR13NR14;
-C(=o)C(R11)2NR13C02R13; -C(=O)-(Cl-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-3 groups selected from: R11, C3-C6 cycloalkyl, -C(=o)NR13R14, _NR13R14, or OH;
C1-C4 alkyl substituted with 0-3 groups selected from R11 =NR14, =NNR13C(=o)NRl3Rl4 or -NR13R14;
C2-C4 alkenyl substituted with 0-3 R11;
C2-C4 alkynyl substituted with 0-3 R11;
a 5- or 6-membered heterocyclic ring containing from l to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;

R32, when a substltuent on nitrogen, is methyl;

m is 0, 1, or 2;
R34 is selected from:

WO94/19329 PCT~S94/01609 hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;

R35 is selected from:
hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;

R36 is selected from: C1-C2 alkyl; CoR37; NR38R39; CN;
CCl3;

R37 is selected from:
hydrogen;
C1-C2 alkyl substituted with 0-1 R11;
hydroxyl;
C1-C2 alkoxy substituted with 0-1 R11;
-NR38R39;

R38 and R39 are independently selected from:
hydrogen;
C1-C2 alkyl substituted with 0-3 R11; or an amine protecting group;

R40 is selected from: H, Cl-C3 alkyl;

R41 is selected from:
-c(=o)NRl3Rl4;
-C(=O)NR13NR13R14;
-C(=o)c(Rll)2NRl3Rl4;
-C (=O) C (Rll) 2NR13NR13Rlg;
-C (=O) C ~Rll) 2NR13Co2Rl3;
-C(=O)H;
_C(=O)Rll;
-C(=O)-(Cl-C4 alkyl)-NR13R14;
-C (=O) - (Cl-C4 alkyl)-NR13C02R13;

21S6~9.i~
'094/19329 ~CT~S94/01609 1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus.

[22] Another aspect of the invention is a process for preparing cyclic compounds of formula (I):

R4 ~ ~R7 R5~15a~R6 ~ n (I) wherein:

W is selected from:
-N(R22)C(=o)N(R23)_;
-N(R22)C(=S)N(R23)-;
-N(R22)S(=o)2N(R23)-;

R22 and R23 are as defined above, provided that at least one of R22 or R23 must be H;
R4, R4A, R7, R7A, R5a, and R6a are as defined above;

n is 0, l, or 2;

R20 and R2l are as defined above and may in addition be selected from a hydroxyl protecting group;

said process comprising the step of reacting an acyclic diamine compound of the formula (III):

WO94/19329 PCT~S94/01609 R4~ R~

R22H N 6a R /n (III) with a suitable cyclizing reagent in a suitable solvent, said solvent optionally comprising a base, thereby to form a compound of formula (I).

For compounds of formula (I) wherein W is -N(R22)C(=o)N(R23)-, the suitable cyclizing reagent may be selected from, but is not limited to, phenyl chloroformate, phenyl tetrazoylformate, urea, phosgene, triphosgene, oxalyl chloride, N,N'-disuccinimidyl carbonate, l,l'-carbonyldiimidazole, trichloromethyl chloroformate, and 2(S),3-pyridinediyl thiocarhonate. A
preferred cyclizing reagent is l,l'-carbonyl diimidazole.

For compounds of formula (I) wherein W is -N(R22)C(=S)N(R23)-, the suitable cyclizing reagent may be selected from, but is not limited to, l,l'-thiocarbonyl diimidazole or carbon disulfide.
Preferably, the cyclizing reagent is l,l'-thiocarbonyldiimidazole.

For compounds of formula (I) wherein W is -N(R22)S(=o)2N(R23)-~ the suitable cyclizing reagent may be selected from, but is not limited to, sulfamide.

A base may optionally be included in the above-described method in order to account for the lability of the R20 and R2l hydroxyl protecting groups _~094/19329 2 ~ ~ 6 ~ g ~ PCT~S94/01609 to the cyclization conditions. The base may be selected from organic bases which include, but are not limited to, pyridine, diisopropylethylamine, and triethylamine.
The base may alternatively be selected from inorganic bases which include but are not limited to sodium hydroxide.

The above-described reaction is carried out in a suitable solvent, for example, in an organic solvent or in a biphasic suspension of water and an organic solvent. Suitable solvents include chlorinated organic solvents which include, but are not limited to, chloroform, methylene chloride, tetrachloroethane, butyl chloride and dichloroethane. A preferrable chlorinated organic solvent is chloroform. The non-chlorinated organic solvents useful in the method of the invention include, but are not limited to tetrahydrofuran, N,N-dimetnylformamide and toluene. A preferrable non-chlorinated organic solvent is toluene.
The reaction can be conducted at a temperature of from about 0C to about the boiling point of the solvent selected, 153C in the case of N,N-dimethylformamide.
Preferably, the temperature of the reaction is about 0C
to about room temperature.
The time required for completion of the reaction can range from about 1 hour to about 5 days, depending on the combination of cyclizing reagent, solvent, base and stereoisomer of compound (III? selected. The reaction can be run under nitrogen or other inert atmosphere, provided that any changes in concentration and integrity of the reagents due to decomposition are compensated for.

As used herein, the term "hydroxyl protecting group" means any group known in the art of organic WO94/19329 PCT~S94/01609 synthesis for the protection of hydroxyl groups. Such protecting groups include those listed in Greene and Wuts, ~Protective Groups in Organic Synthesis", John Wiley & Sons, New York ~l99l), the disclosure of which is hereby incorporated by reference. The hydroxyl protecting groups are base-stable and can include, but are not limlted to acyl types, aromatic carbamate types and alkyl types. Exemplary are methyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, t-butoxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl, t-butyl, triphenylmethyl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, pivaloate or N-phenylcarbamate.

In the present invention it has been discovered that the compounds of formula (I) above are useful as inhibitors of HIV protease and similar retroviral proteases, and for the inhibition of HIV and the treatment of HIV infection and similar retrovirus infections.
The present invention also provides methods for the treatment of HIV infection by administering to a host infected with HIV a pharmaceutically or therapeutically effective or acceptable amount of a compound of formula (I) as described above. By therapeutically effective amount, it is meant an amount of a compound of the present invention effective to inhibit HIV infection or treat the symptoms of HIV infection in a host.

The compounds of formula (I) of the present invention are also useful for the inhibition of HIV in an ex vivo sample containing HIV or expected to be exposed to HIV. Thus, the compGunds of the present invention may be used to inhlblt HIV present in a body _ 094/19329 21 ~ ~ ~ 9 ~1 PCT~S94/01609 fluid sample (for example, a serum or semen sample) which contains or is suspected to contain or be exposed to HIV.
The compounds provided by this invention are also useful as standard or reference compounds for use in tests or assays for determining the ability of an agent to inhibit viral replication and/or HIV protease, for example in a pharmaceutical research program. Thus, the compounds of the present invention may be used as a control or reference compound in such assays and as a quality control standard. The compounds of the present invention may be provided in a commercial kit or container for use as such standard or reference compound.
Since the compounds of the present invention exhibit specificity for HIV protease, the compounds of the present invention may also be useful as diagnostic reagents in diagnostic assays for the detection of HIV
protease. Thus, inhibition of the protease activity in an assay (such as the assays described herein) by a compound of the present invention would be indicative of the presence of HIV protease and HIV virus.

The compounds herein described may have asymmetric centers. All chiral, diastereomeric, and racemic forms are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are cor.templated in the present invention. It will be appreciated that certain compounds of the present invention contain an asymmetrically substituted carbor. atom, and may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, from optically active starting materials.

WO94/19329 PCT~S94/Q1609 ~i Also, it is realized that cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

When any variable (for example, R1 through R41, R4A and R7A, m, n, W, Z, etc.) occurs more than one time in any constituent or in formula (I) or (II), or any other formula here n, its definition on each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-3 R11, then said group may optionally be substituted with up to three R11 and R11 at each occurrence is selected independently from the defined list of possible R11. Also, ror example, in -N(R20)2, each of the R20 substituents may be independently selected from the 1 st of possible R20 groups defined. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. Similarly, by way of example, for the group -C(R11)2-, each of the two R11 substituents on C is independently selected from the defined list of possible R11.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen; "alkoxy" represents an alkyl group of indicated number of carbon atoms 21SS~4 _~094/19329 PCT~S94/01609 -127- -~
attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-,bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and cyclooctyl, and "biycloalkyl"
is intended to include saturated bicyclic ring groups such as [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, and so forth. "Alkenyl" is intended to include hydrocarbon chair.s of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds hhich may occur in any stable point along the chain, such as ethenyl, propenyl, and the like; and "alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable pcint along the chain, such as ethynyl, propynyl and the like.
The terms "-(alkyl)-", "-(alkyenyl)-", "-(phenyl)-", and the like, refer to alkyl, alkenyl, and phenyl group.s, respectively, which are connected by two bonds to the rest of the structure of Formula I. Such groups may alternatively and equivalently be denoted as "alkylene", "alkenylene", "phenylene", and the like, respectively.
"Alkylcarbonyl" is intended to include an alkyl group of an indicated number of carbon atoms attached through a carbonyl group to the residue of the compound at the designated location. "Alkylcarbonylamino" is intended to include an alkyl group of an indicated number of carbon atoms attached through a carbonyl group to an amino bridge, where the bridge is attached to the residue of the compound at the designated location.
"Alkylcarbonyloxy" is intended to include an alkyl group of an indicated number of carbon atoms attached tc a carbonyl group, where the carbonyl group is attached WO94/19329 PCT~S94/01609 ~9~

through an oxygen atom to the residue of the compound at the designated location. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic or tricyclic or an up to 26-membered polycyclic carbon ring, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocyles include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, biphenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). "C7-C1o arylalkyl" is intended to refer to an aryl group attached through a C1-C4 alkyl bridge to the residue of the indicated compound. "(C1-C3 alkyl)aryl" is intended to refer to a C1-C3 alkyl group which is attached through an aryl ring to the residue of the indicated compound. "Aryl(C1-C3 alkyl)" is intended to refer to an aryl group attached through a C1-C3 alkyl group to the residue of the indicated compound.
As used herein, the term "heterocycle" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O
and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene rins. The heterocyclic ring may be attached to its pendant group at any heteroatom _~094/19329 21 ~ ~ ~ 9 1 PCT~S94/01609 or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. Examples of such heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, benzothiophenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl,tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl or octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thiophenyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathiinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-ir,dolyl, lH-indazolyl, purinyl, 4~-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, ~-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenarsazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclldinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl. Also included are fused rinq and spiro compounds containing, for example, the above heterocycles. Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl.

WO94/19329 PCT~S94/01609 ~6~ The term "substituted'-, as used herein, means that an one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.
By "stable compound" or "stable structure" is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

As used herein, the term "any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl" means any group bonded to an O, N, or S atom, respectively, which is cleaved from the O, N, or S atom when the compound is administered to a mammalian subject to provide a compound having a remaining free hydroxyl, amino, or sulfhydryl group, respectively. Examples of groups that, when administered to a mammalian subject, are cleaved to form a free hydroxyl, amino or sulfhydryl, include but are not limited to, phosphate esters, C1-C6 alkyl substituted with 0-3 R11, C3-C6 alkoxyalkyl substituted with 0-3 R11, C1-C6 alkylcarbonyl substituted with 0-3 R11, C1-C6 alkoxycarbonyl substituted with 0-3 R11, C1-C6 alkylaminocarbonyl substituted with 0-3 R11, benzoyl substituted with 0-3 R12, phenoxycarbonyl substituted with 0-3 R12, phenylaminocarbonyl substituted with 0-3 R12, or heteroarylcarbonyl. Examples of groups that, when administered to a mammalian subject, are cleaved to form a free hydroxyl, amino or sulfhydryl, include hydroxy, amine or sulfhydryl protecting groups, respectively.

VO94/19329 PCT~S94/01609 2l~6~9~
As used herein, the term "amine protecting group"
means any group known in the art of organic synthesis for the protection of amine groups. Such amine protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis" John Wiley & Sons, New York (1991) and "The Peptides:
Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981), the disclosure of which is hereby incorporated by reference. Any amine protecting group known in the art can be used. Examples of amine protecting groups include, but are not limited to, the following: 1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyls, l-(p-biphenyl)-l-methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate types such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl, dilsopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5j alkyl types such as triphenylmethyl and benzyl; 6) trialkylsilane such as trimethylsilane; and 7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl.
By a "ketal _ing" or "ketal" group is meant any ketal protecting group which can be hydroyzed to form a carbonyl. Such ketal rings or ketal protecting groups are well known in the art of organic synthesis and typically include, for example, substituted or unsubstituted carbocyclic diethers, dithioethers, or mixed ethers. Such ketal protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis" John Wiley & Sons, New York (1991) The term "amino acid" as used herein means an organic compound containing both a basic amino group and WO94/19329 ~ PCT~S94/01609 6~ 132-an acidic carboxyl group. Included within this term are natural amino acids, modified and unusual amino acids, as well as amino acids which are known to occur biologically in free or combined form but usually do not occur in proteins. Included within this term are modified and unusual amino acids,such as those disclosed in, for example, Roberts and Vellaccio (1983) ~h~
Pe~ti~es, 5: 342-429, the teaching of which is hereby incorporated by reference. Modified or unusual amino acids which can be used to practice the invention include, but are not limited to, D-amino acids, hydroxylysine, 4-hydroxyproline, an N-Cbz-protected amino acid, ornithine, 2,4-diaminobutyric acid, homoarglnine, norleucine, N-methylaminobutyric acid, naphthylalanine, phenylglycine, ~-phenylproline, tert-leucine, 4-aminocyclohexylalanine, N-methyl-norleucine, 3,4-dehydroproline, N,N-dimethylaminoglycine, N-methylaminoglycine, 9-aminopiperidine-4-carboxylic acid, 6-aminocaproic acid, trans-4-(aminomethyl)-cyclohexanecarboxylic acid, 2-, 3-, and 4-(aminomethyl)-benzoic acid, 1-aminocyclopentanecarboxylic acid, 1-aminocyclopropanecarboxylic acid, and 2-benzyl-5-aminopentanoic acid.
The term "amino acid residue" as used herein means that portion of an amino acid (as defined herein) that is present in a peptide.
The term "peptide" as used herein means a compound that consists of two or more amino acids (as defined herein) that are linked by means of a peptide bond. Ihe term "peptide" also includes compounds containing both peptide and non-peptide components, such as pseudopeptide or peptide mimetic residues or other non-amino acid components. Such a compound containing both peptide and non-peptide components may also be referred to as a "peptide analog".

_'094/19329 21 5~S9 ~ PCT~S94/01609 The term "peptide bond" means a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of one amino acid and the amino group of a second amino acid.
- 5 As used herein, ~pharmaceutically acceptable salts"
refer to derivatives of the disclosed compounds wherein - the parent compound of formula (I) is modified by making acid or base salts of the compound of formula (I).
Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
"Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of formula (I) ar~ prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds.
Prodrugs include compounds of formula (I) wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, or benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I); phosphate esters, dimethylglycine esters, aminoalkylbenzyl esters, aminoalkyl esters and carboxyalkyl esters of alcohol and phenol functional groups in the compounds of formula (I); and the like.
The pharmaceutically acceptable salts of the compounds of formula (I) include the conventional non-toxic salts or the quaternary ammonium salts of the compounds of formula (I) formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-_oxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic; lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula (I) which contain a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in ~n organic solvent, or in a mixture of the two; generally~
non~queous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Ph~rm~ceutlc~l Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
As used herein, 'IW'' is not intended to be a symbol for tungsten.
The disclosures of all of the references cited herein are hereby incorporated herein by reference in their entirety.
The description may include matter which exceeds the scope of the claims but is retained herein for the sake of clarity. The disclosure of PCT International Application Publication Number WO 93/07128 is incorporated herein by reference. Specific reference is NO94/19329 2 1~ B j g q PCT~S94/01609 made herein to the disclosure of PCT International Application Publication Number WO 93/07128, including the Schemes and Examples Synthesis The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present inventior. can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art.
Preferred methods include but are not limited to those methods described below.
The compounds of the present invention may be synthesized using the general synthetic procedures described below. Each of the references cited below are hereby incorporated herein by reference.
Compounds of the invention wherein:

W is -N~R22)C~=z)N~R23)- or -N~R22)C~=o)C(=o)N(R23)- or -N(R22)S(=Z')N(R23)- or -N(R22)S~=zr)2N~R23)- or _N~R22)p(=o)~R24a)N(R23) or -N(R22)C(F2)C(=o)N(R23)- or -N(R22)C(F2)S(=o)N(R23)-;

R5 is -oR20 or H;
R~ is -OR21 or H; and n is 1; can be formed from diamines of formula - (III):

WO94/19329 PCT~S94/01609 R22HN > ~ ~7A

~III) The diamines of formula (III) can be synthesized as described in copending commonly assigned patent application Jadhav et al. USSN 07/714,042, filed 5/31/91. Alternative methods which can be used to synthesize the compounds of structure (III) above are described in European Patent Application Publication Number 402646Al, U.S. Patent 4,837,204, and Canadian Patent Application 2,026,832 .

The compounds of formula (III) can be cyclized to form compounds of formula tIV) under conditions normally used to form cyclic ureas, as is known to one skilled in the art. Reagents J-(C=Z)-J', where J and J' are leaving groups, are employed, preferably under relatively dilute conditions (for example, less than about 0.1 M), to effect ring closure to provide compounds of formula (I). Many examples of J and J' are known; preferred are carbonyl diimidazole, thiocarbonyldiimidazole, phosgene, thiophosgene, diphenyl carbonate, or diphenyl thiocarbonate.
Additionally, for compounds wherein W is -N(R22)C(=o)C(=o)N(R23)-, compounds of formula (III) can be reacted with activated derivatives of oxalic acid, preferably oxalyl chloride, under the above conditions to form the diamide.

~094/19329 2 1 ~ 6 S 9 ~ PCT~S94/01609 For compounds of the invention where R20 or R21 is -OH, it is advantageous to protect the free hydroxyl before cyclization. Protecting groups used can nclude any of those listed in Greene and Wuts, Protective Groups ln Or~nic Synthes;s, Chapter 2, Wiley, NY
(1991). The preferred protecting groups are trimethylsilylethoxymethyl (SEM), methoxyethoxymethyl (MEM), or methoxymethyl (MOM).

Cyclization of compounds of formula (III) results in structure (IV) (i.e., structure (I) wherein W is -N(R22)C(=o)C(=o)N(R23)- and n is 1).
R22N ~ R23 R4A ¦ R7 R4~<R7A
Rs R6 (IV) Another, preferred method to form compounds of formula (IV), in cases wherein R22 and R23 are linked to their respective nitrogens by a CH2 residue, is to cyclize a compound of structure (III) where R22 and R23 are hydrogen, and to alkylate the nitrogens using a base, a phase transfer catalyst, and an alkylating agent, using methods well known in the art. The preferred base is sodium hydride, and the preferred alkylating agents are R22Y and R23Y, wherein Y is a halogen, triflate, or mesylate, preferably a bromide or iodide. Preferred conditions are in polar aprotic solvents between 0 and 100 C.

Cleavage of protecting groups, if employed, yields structures of formula (I) wherein R5 and R6 are hydroxyl.

When RS and R6 are other than oR20 and OR21, some chemical manipulation of functional groups may need to be performed in the preparation of the compounds of formula (III) or ~IV), as is appreciated by one of skill in the art of organic synthesis. Described below are examples of such procedures.

Methods for obtaining compounds wherein R5 is OH
and R6 is OR21 ir.clude protection of nitrogen, if necessary, followed by reaction of the diol with one equivalent of base and one equivalent of acyl halide, alkyl halide, alkoxyalkyl halide, alkoxycarbonyl halide, benzoyl halide, diphenyl carbonate or phenylisocyanate, and purification by column chromatography of the unwanted bis-alkylated and unreacted material.

Methods for obtaining compounds wherein R5 is OH
and R6 is H include protection of nitrogen, if necessary, and reduction of the diol to the monool using techniques known in the art (see, for example, Chem. Comm. 1971, 1097; J. Org. Chem.
1969, 3923) . The preferred method is formation of cyclic diol ester and reduction using hydride.
Deprotection of nitrogen, if necessary, results in the desired compound.

Methods for obtaining compounds wherein R5 is OH
and R6 is F include protection of nitrogen, if nec~ssary, followed by formation of mono-protected diol as described above. Reaction with a fluorinating agent, preferably _ ~094/19329 21 S 6 S9 ~ PCT~S94/01609 diethylaminosulfurtrifluoride (DAST) (Re~gents for Org~nic Synthesis, Vol. 13, p. 110, Wiley Interscience, NY, 1988), provides the alkyl fluoride. Deprotection of nitrogen, if necessary, and hydroxyl results in the desired compound.

Methods for obtaining compounds wherein R5 is OH
and R6 is =O include protection of nitrogen, if necessary, and standard conditions for oxidizing glycols to pinacols. The preferred oxidant is one equivalent of pyridinium dichromate in dichloromethane, or one equivalent of NaOCl in HOAc. Deprotection of nitrogen, if necessary, results in the desired compound. Alternatively, a monohydroxy compound described above can be oxidized to the ketone under standard conditions, preferably Swern oxidation using oxalyl chloride, DMSO and Et3N, followed by alpha-hydroxylation of the ketone (see Tet. Lett. 1981, 607; Tet. Lett.
1982, 2917).

Methods for obtaining compounds wherein R5 is OH
and R6 is difluoro include protection of nitrogen, if necessary, and hydroxyl of the above obtained pinacol, followed by reaction of the carbonyl with a fluorinating reagent, such as DAST. Deprotection of hydroxyl and nitrogen, if necessary, results in the desired compound.

Methods for obtaining compounds wherein R5 and R6 join to form an epoxide include protection of nitrogen, if necessar~, followed by standard conditions for the formation of an epoxide from a - glycol (see, for example, J. Org. Chem. 1981, 3361). Preferred is the reaction of the glycol WO94/19329 PCT~S94/01609 5~ with more than 2 equlvalents of base and one equlvalent of an activating group, such as methanesulfonyl chloride. Deprotection if necessary results in the desired compound.

Methods for obtaining compounds wherein R5 is OH
and R6 is C1-C3 alkyl include protection of nitrogen, if necessary, and reac'ion of the epoxide prepared above with C1-C3 alkylmetal reagents.
Preferred is the reaction of lithium dialkyl cuprates in aprotic solvents at low temperatures (-78 to -40 C) (see Carruthers, Some Mo~ern Metho~s in Org~nic Synthes1s, p. 64, Cambridge University Press, 1978).
With a judicious selection of reagents, as is well appreciated to one skilled in the art, these manipulations can be performed in a straightforward manner to yield the claimed combinations of R5 and R6.
Compounds of the invention wherein:

W is -N(R22)C(=Z)N(R23)- or -N(R22)C(=o)C(=o)N(R23)- or -N(R22)S(=Z')N(R23)- or -N(R22)s(=z)2N(R23)- or _N(R22)p(=o)(R24a)N(R23) or -N(R22)C(F2)C(=o)N(R23)- or -N(R22)C(F2)S(=o)N(R23)- or -N(R22)P(-Z)N(R23)-, and n is 0;

can be synthesized from diamines of formula (V):

_ VO94/19329 21 S 6 5 9 ~ PCT~S94/01609 Rs R22HNy~<NHR23 (v) which can in turn be synthesized as described in European Patent Application Publication Number 402 646 Al.

Protection, if necessary, cyclization, and functional group manipulation if desired is performed as described above to obtain compounds of structure (VI):
R22N ~ R23 R4A ¦ R7 R4 ~<R7A

(VI) Compounds of the lnvention whereln:

W is -OC(=O)O- or -C(=Z)- or -C(R25)(R26)p(=o)(R24a)c(R27)(R28)- or -p(=o)(R24a)_ and n is l;

can be formed from diols of structure (VII):

WO94/19329 PCT~S94/01609 HO ~ ~OH

(VII) which can in turn be synthesized as described in copending, commonly assigned U.S. patent application Jadhav et al. USSN 07/71~,042, filed 5/31/91.

Functional group manipulation, if desired, may be performed as described above, followed by cyclization to the carbonate using standard conditions, preferably phosgene or thiophosgene in the presence of 2 equivalents of a base such as potassium hydride, to obtain compounds of structure (I).

Compounds of the invention wherein:

W is -N(R22)C(=Z)O- or N(R22)P(=o)(R24a)c(R27)(R28)- or -C(R25)(R26)P(=o)(R24a)o- and n is li can be formed from aminoalcohol of structure (VIII):

Rs R7A

R22HN ~OH

~094/19329 1~6 j g ~ PCT~S94/01609 (VIII) which can in turn be synthesized as described in a copending, commonly assigned U.S. patent application Jadhav et al. USSN 07/714,042, filed 5/31/91, by employing a single equivalent of azide in the reaction of the diol of formula (VII) to obtain the azidoalcohol, followed by reduction as described in USSN 07/714,042, to form the aminoalcohol.

Protection, if necessary, and functional group manipulation, if desired, is performed as described above, followed by cyclization to the carbamate using standard conditions, preferably phosgene or thiophosgene in the presence of 2 equivalents of a base, such as potassium hydride, to obtain compounds of structure (I).

Compounds of the invention wherein:

W is -OC(=Z)O- and n is 0;

can be formed from the diol of structure (IX):

HO ~ ~OH
~ `C
R4A/ 7~R7A

(IX) which can in turn be synthesized by the reaction of R4CHo with the lithium anion of l,3 dithiane, followed WO94/19329 PCT~S94/01609 21S65 9 ~ -144-by the reactlon of R7CHo with the anion of the product ~see Carruthers, Some Mo~ern Metho~.~ ;n Org~nic Synthesis, p. 45, Cambridge University Press, 1978).
Cleavage of the dithiane with mercuric ion yields the acyclic alpha, alpha' dihydroxyketone.

Functional group manipulation, if desired, is performed as described above, followed by cyclization to the carbonate using standard conditions, preferably phosgene or thiophosgene, in the presence of 2 equivalents of a base such as potassium hydride, to obtain compounds of structure (I).

Compounds of the invention wherein:

W is -N(R22)C(=Z)O- and n is 0;

can be formed from aminoalcohol of structure (X):

R22HN ~\~OH

R R

(x) which can in turn be synthesized by the techniques described in European Patent Application Publication Number 402 646 Al for the synthesis of compounds of structure (V), above; however, in place of azide, in opening the oxirane (shown below), an oxygen nucleophile, such as acetate or hydroxide ion, is ~094/19329 21 ~ 6 S 9 ~ PCT~S94/OlC09 reacted in the presence of a polar aprotic solvent, such as DMSO.

BOC-NH ~ R7 Alternatively, the oxirane is treated with a catalytic amount of a strong acid in water and a cosolvent, if necessary, which technique also removes the BOC protecting group.
Protection, if necessary, and functional group manipulation, if desired, is performed as described above, followed by cyclization to the carbamate using standard conditions, preferably phosgene or thiophosgene in the presence of 2 equivalents of a base such as potassium hydride, to obtain compounds of structure (I).

Compounds of the present invention wherein:

W is -C~R25)(R26)N(CH3)(o)c(R27)(R2~

can be synthesized from aminoalcohols (VIII) and (X) by the following steps: protection of nitrogen, if necessary, preferably with a benzyloxycarbonyl group;
activation of the alcohol to displacement, preferably with a sulfonate derivative, such as mesyl chloride;
removal of the nitrogen protecting group, preferably ~ with hydrogen in the presence of a catalyst, such as palladium on carbon; and heating under dilute conditions - in the presence of a base such as triethylamine to effect cyclization.

WO94/19329 PCT~S94/01609 ~5~ ~ -146-The secondary cyclic amine is then methylated, preferably with formic acid/formaldehyde, and oxidized, preferably with a peracid, such as MCPBA, to form compounds of formula (I), wherein W is -C(R25)(R26)N(CH3)(o)C(R27)(R28)-. The secondary cyclic amine can alternatively be directly oxidized to form structure (I), where W is -C(R25)(R26)N(oR29)c(R27)(R28) Compounds wherein:

W is -C(R25)~R26)C(=Z)C(R27)(R28)- and n is 0;
can be prepared by the alkylation of protected cyclohexanedione (XI) with the required R4-LG and R7-LG, and optionally R4A-LG and R7A-LG groups, wherein LG
represents a leaving group such as halogen or sulfonate ester.

~/
O~ ~O

(XI) _ ~Q94/19329 21~ 6 5 ~ ~I PCT~S94/01609 Reduction of the ketone to the alcohol, preferably with LiAlH4, or manipulation to other values of R5 as described above, is followed by cleavage of the ketal (see Greene and Wuts, Protective Grou~s in Org~nic 5 .~ynthesis, Chapter 2, Wiley, NY, 1991). Protection of the alcohol or other reactive groups, followed by alkylation ketone and deprotection, provides compounds of structure (I), wherein W is -C(R25)(R26)C(=Z)C(R27)(R28)- and n is 0.

Compounds wherein:

W is _C(R25)(R26)c(-z)c(R27)(R28)- and n is 1;
can be prepared from the protected hydroxyketones described immediately above by ring expansion, for example via the Tiffeneau-Demyanov reaction (March, A~v~nce~ Or~nic Chemistry, p. 965, Wiley, NY, 1985), or by treatment with dimethylsulfonium ylide to form the spiro-epoxide, followed by acid-catalyzed ring expansion to the cycloheptanone (l~i~., pp. 871, 966).

The above routes have the advantage of producing a number of stereoiomers which, upon purification, can be evaluated for the best combination of potency, safety and in vivo availability.

Compounds wherein:

W is -c(R25)(R26)c(F2)c(R27)(R28)- and n is 0 or l;
-WO94/19329 PCT~S94/01609 can be obtained from the above-described protected hydroxyketone by treatment with a fluorinating reagent, preferably DAST, as described above.

Compounds wherein:

W is -N(R22)C(=Z)C(R27)(R28)- and n is 0;

can be obtained by cyclization of compound (XII) to the lactam using techniques known in the art (March, A~v~nce~ OrgAnic Chemistry, p. 371, Wiley, NY, 1985).
op R27 H2N~OH

(XII) Compounds of structure (XII) can in turn be obtained as described in European Patent Application Publication Number 434 365 A2, European Patent Application Publication Number 386 611 A2, European Patent Application Publication Number 389 127 Al, and CA
2005337, each of which are hereby incorporated by reference. OP in structure (XII) designates protected oxygen. Hydroxyl can be protected by the use of any of a number of groups as described in Greene and Wuts, Protective Grou~s in Or~Anic Synthesis, Chapter 2, Wiley, NY (1991).

If desired, the resulting lactam ~XIII):

_l094/19329 1 S ~ S~ 1 PCT~S94/01609 ~\~R27 HN

R4/~

OP

(XIII) can be further functionalized, for example by the following techniques: the lactam nitrogen can be alkylated with an R22-LG group, preferably employing sodium hydride in DMF; an R4A, R7 or R7A group can be added by deprotection and oxidation of the alcohol, followed by alkylation of the enolate using R4A-LG, R7-LG or R7A-LG; and reduction of the ketone to hydroxyl or otherwise functionalizing to obtain the R5 group of choice as described above.

Compounds wherein:

W is -N(R22)C(=Z)C(R27)(R28!- and n is l;

can be obtained through techniques known in the art from ketones Gf structure (I) wherein W is _C~R25)(R26)c~=z)c(R27)(R28)- and n is 0, preferably via the Beckmann rearrangement (March, Advanced Or~anic Chemistry, p. 987, Wiley, NY, 1985). Manipulation of the R5 group, if desired, as described above provides R5 and R6-substituted examples of (I), wherein W =
_N(R22)c(=z)c(R27)(R28)- and n = l.

Compounds wherein:
c~' W is -C(R25) (R26)C(=Z)O- and n is 0 or 1;

5 can be obtained from compounds of structure (I), wherein W = -N(R22)C(=Z)C(R27) (R28)_, n = 0 or 1, and R22 = H, for example, by hydrolysis of the lactam, followed by displacement of the primary amine by hydroxyl, and closure to the lactone (March, A-3v~nce~ Org~nic 10 Chemistry, p. 348, Wiley, NY, 1985).

Similarly, compounds wherein:

W is -C(R25) (R26)C(=Z)S- and n is 0 or 1;
can be obtained from compounds of structure (I), wherein W = -N (R22)C(=Z)C(R27) (R28)-, n = 0 or 1, and R22 = H, for example, by hydrolysis of the lactam, followed by conversion of the primary amine to the diazonium salt, 20 displacement by NaSH, and closure to the thiolactone (March, ~dv~nced Organic Chern;stry, p. 601, Wiley, NY, 1985) .

Compounds of structure (I) described above wherein 25 Z = O can be converted to the thio derivatives, Z = S, using standard conditions (March, Adv~nced Org~n;c Chemistry, p. 792, Wiley, NY, 1985); preferred is the use of the disulfide described in Rull. Soc. Chlm.
Relges 1978, 223.
Structures (I) described above wherein Z = O can be converted to the imino derivatives, Z = NR24, using standard conditions. When R24 is OH or O-alkyl, the oximes can be formed and alkylated if desired as 35 described in March, Advanced Ora~nic Chemistry, pp. 359, 2l~6~9~
~094/19329 PCT~S94/01609 805, Wiley, NY, 1985. The hydrazones and imines can be formed similarly (iki~, PP- 533, 797)-The compounds of the formula I where in W =
-N(R22)P(o)(R24a)N(R23)- and n = 1, and R24a is ethyl, can be synthesized by cyclization of diamine III under conditions normally used to form cyclic phosphoric amides, as exemplfied by Patois et al. in Heteroatom.
Chem. 1(5), 369-374, (1990), wherein ethyl phosphorodichloridate in presence of trialkylamine, such as triethylamine, was used to cyclize a diimino derivative. Similarly, other diimines could be cyclized to form cyclic phosphoric amide derivatives.

It is expected th~t the compounds of the invention can also be prepared as shown in Scheme 1 (shown below).
The intra-molecular coupling of the N-substituted or unsubstituted dialdehydes may be achieved by organometal reagents derived from vanadium, titanium, samarium etc.
The dialdehyde precursors can be prepared from the commercially available materials by the methods known to those skilled in the art of organic synthesis, preferably by the techniques disclosed in copending commmonly assigned U.S. Patent Application, Hodge, USSN
07/659,442, filed 2/21/91.

Compounds wherein W is -N(R22)C(=o)N~R23)- and n is 2 can be synthesized as shown in Scheme 2 (below). The eight-membered cyclic urea in Scheme 2 can be protected, if necessary, and manipulated as described above to ; yield the desired compounds.

- Compounds wherein W is -N(R22)C(=o)N(R23)- and n is 1 can likewise be synthesized as shown in Schemes 3, 4, 6, 7 (below). If necessary, intermediates described WO94/19329 PCT~S94/01609 ~* -152-9 herein can be manipulated by methods known to those skilled in the art of organic synthesis to provide compounds within the scope of the invention.

Compounds wherein W is -N(R22)C(=N-oR)N(R23)- or -N(R22)C(=S)N(R23)- and n is l can be synthesized as shown in Scheme 5 (below). If necessary, intermediates described herein can be manipulated by methods known to those skilled in the art of organic synthesis to provide compounds within the scope of the invention.

Compounds wherein W is -N(R22)C(=o)N(R23)- and n is 0 can likewise be synthesized as shown in Scheme 8 (below). If necessary, intermediates described herein can be manipulated by methods known to those skilled in the art of organic synthesis to provide compounds within the scope of the invention.

Compounds wherein W is -N(R22)C(=o)N(R23)-, n is 0 and R23 and R33 are combined to be a direct bond, can be synthesized as shown in Scheme 9. Compounds of (XXXIIa) were treated under strongly ionizing conditions to produce compounds where W is -N(R22)C(=o)N(R23)-, n is 0, and R23 is H, R33 is -O2C-alkyl. Treatment of compound (XXXIIa) with hydrogen and palladium catalyst provided R33 is H, whereas treatment with gaseous hydrogen bromide provided R33 is Br. Another route to these compounds was developed (Scheme lO). If necessary, intermediates described herein can be manipulated by methods known to those skilled in the art of organic synthesis to provide compounds within the scope of the invention.

Compounds wherein W is -N(R22)S(=o)2N(R23)-~ n is l could be synthesized as shown in Scheme ll. Diamines of _~094/19329 21 5 6 ~. 9 ~ PCT~S94/01609 structure (III) were treated with sulfamide to give the cyclic sulfamides. Alkylation using a metal hydride base gave the bisalkylated products. The monoalkylated products could be obtained by selective alkylation using techniques known to one skilled in the art of orgainc synthesis and further described in this invention.

Compounds wherein W is -C(R25)(R26)SC(R27)(R28)--c(R25)(R26)s(=z~)c(R27)(R28)- and -C(R25)(R26)S(=Z~)2C(R27)(R28)-, n is 1, and Z' is defined above can be synthesized as shown in Scheme 12.
Asymmetric epoxidation of muconic acid (Sharpless et al., J. Org. Chem. 57, 2768 (1992)); followed by benzylation (Seebach, D. and Wasmuth, D. Helv. Ch;m.
~ 63, 197 (1980)) provides a secondary diol, which can be converted to primary diol (XXXVIIa) by protection and reduction with lithium aluminum hydride. Further elaboration by the methods of Dugger et al. (Tetr~he~ron Tetters 33, 6763 (1992)) and Trost et al. (Tetrahedron Letters, 22, 1287 (1981)) provide the sulfoxide shown.
Further oxidation using a stronger oxidizing agent such as m-chloroperbenzoic acid would provide the corresponding sulfone (W is -C(R25)(R26)S(=o)2c(R27)(R28)-). The intermediates described therein can be manipulated by methods known to those skilled in the art of organic synthesis to provide compounds within the scope of the invention.

Compounds wherein W is -C(R25)(R26)C(=Z)C(R27)(R28)-, n is 1, and Z is defined above can be synthesized as shown in Scheme 13.
Compound XXXVIIa could be converted to the corresponding dibromide using carbon tetrabromide/ triphenylphosphine.
- Dithiane anion, formed according to the method of Seebach, as reported in Org. Syn., Coll. Vol. 6, 316 WO94/19329 PCT~S94/01609 ;! ~ 154 (1988), could be alkyiated with this dibromide. The seven-membered ring ketone ~Z is O), upon liberation with aqueous mercuric ion, could be alkylated according to methods reported in the literature. Imines (Z is NR24) and thiocarbonyls (Z is S) can be prepared by one skilled in the art of organic synthesis using methods described in the literature.

Compounds wherein W is -C(=Z)-, n is 1, and Z is defined above can be synthesized as shown in Scheme 14.
Secondary diol (VII) could be converted to the dibromide using such as described previously. Dithiane alkylation followed by deprotection with mercury ion would produce the five-membered ring ketone. Alkylation of the alpha-carbons would provide for substitution at R4A and R7A.Thiocarbonyls and imines of the carbonyl could be prepared using methods described in the literature.

Compounds wherein W is -c~R25)(R26)p(=o)(R24a)N(R23)- or _c(R25)(R26)p(=o)(R24a)o- and n is 1, could be prepared as shown in Scheme 15. Aminoalcohol (VIII) could be converted to the corresponding bromide using the method of Morin and Sawaya (Synthesis, 1987, 479) and displaced with lithiophosphinate according to the method of Corey and Kwiatkowski (J. Amer. Chem. Soc., 1966, 88, 5654).
Deprotection of the amine protecting group would be followed by phosphoramide formation according to the method described by Patel et al., ~Tet Tett.~ 1990, 31, 5591). Alkylation with strong base would lead to the compounds where W is _c(R25)(R26)p(=o)(R24a)N(R23)-Similarly, diazotization and nucleophilic displacement with hydroxide would lead to the compounds where W is _C(R25~(R26)p(=o)(R24a)o- after cyclization.

~094/19329 21~ 6 5 9 ~ PCT~S94/01609 Compounds wherein W is -C(R25)(R26)P(=o)(R2~a)C(R27)(R28)- or -P(=o)(R24a)- and n is 1, could be prepared as shown in Scheme 16.
Secondary diol (VII) could be brominated by the method of Morin and Sawaya to give (XXXVIa), which could be elaborated to (XXXVIIIa) via earlier described (XXXVIIa). Grignard coupling with methyl dichlorophosphate using the method of Polniaszek and Foster (J. Or~. Chem., 1991, 56, 3137) would lead to a cyclic phosphinate. Alkylation with strong base based on methods described in the literature (ie., see Polniaszek above) would provide the desired products.

Compounds of formula (I) wherein W is -(R22)N+=C(R36)N(R23)- and -N=C(R36)N(R23)- and n=l can be prepared according to Scheme 17. Intermediate (XXXIXa) can be cyclized under standard amidine reaction conditions, based on method known in the art.
Quaternary salt formation with alkyl halide leads to compounds of the formula (XXXIXd) and (XXXIXe), which can be acid-deprotected according to method described herein.

Synthesis of intermediate (XLa) is described in Scheme 18a, and use thereafter is described in Schemes 18b-18c. N-Cbz-Phenylalaninal (XLb') is prepared from optically-active phenylalanine (XLa') by the route previously described. Compound (XLc') can be prepared by the reaction of (XLb') with an appropriate acetic acid anion equivalent such as a Reformatsky reagent derived from ethyl bromoacetate (prepared from bromoethyl acetate and zinc metal). Other acetic acid anion equivalents are contemplated and are recognized by those possessing skill in the art. Compound (XLd') can be prepared by reacting (XLc') with an acyl anion equivalent such as a dithiane anion (such as that WO94/19329 PCT~S94/01609 3 derived from l,3-dithiane upon reaction with butyllithium). Other acyl anion equivalents are contemplated and are recognized by those possessing skill in the art. The conversion of (XLc') to (XLd') can also incorporate the use of either or both oxygen-protecting groups and nitrogen-protecting groups. A
suitable oxygen-protecting group is the SEM
(trimethylsilylethyloxymethyl) ether and a suitable nitrogen-protecting group is the Cbz (carbobenzyloxy) carbamate. Other protecting groups are contemplated including those described in Protecting Groups in Organic Synthesis, Second Edition by T. W. Greene and P.
G. M. Wuts, John Wiley & Sons Inc., l99l. Compound ~XLa) can be obtained by the hydrolysis of ~XLd') with acid or base.
Alternatively, (XLa) can be obtained as follows:
tXLe') can be prepared by reaction of (XLb') with a pyru~ic acid anion equivalent such as a Reformatsky reagent. Other pyruvic acid anion equivalents are contemplated and are recognized by those possessing skill in the art. (XLf') is prepared by the reaction of (XLe') with an alkyl or aryl derived nucleophile such as a Grignard reagent or an organolithium reagent (such as benzylmagnesium bromide or phenyllithium). Other organometallic species are contemplated and are recognized by those possessing skill in the art.
Intermediate (XLa) can be obtained by reaction of (XLf') under hydrolytic conditions needed to induce ester cleavage and/or conditions necessary to remove any or all protecting groups.
Intermediates (XLa)-(XLk) can be derived from (L)-phenylalanine, for example, although all other naturally-occurring and other unnatural amino acids are also contemplated.
Intermediate (XLb) can be prepared by the reaction of a methylene chloride solution of compound (XLa) with ~094tl9329 21~ 9 i PCT~S94/01609 SEM-Cl (trimethylsilylethyloxymethyl chloride) in the presence of an amine base (such as diisopropylethylamine). Intermediate ~XLc) can be obtained by the reaction of (XLb) with a carboxylic acid activating reagent such as dicyclohexylcarbodiimide (DCC). Other peptide-forming conditions and reagents are contemplated and are recognized by those possessing skill in the art. Intermediate (XLd) can be obtained by the reaction of (XLc) with an appropriately protected (if needed) hydroxymethylbenzyl halide followed by the removal of the SEM protecting groups via reaction with fluoride ion (tetrabutylammonium fluoride) in a suitable solvent (tetrahydrofuran).
Intermediate (XLe) is obtained by the reaction of (XLa) with SEM-Cl under conditions to avoid/suppress bis-alkylation such as limiting molar equivalents of SEM-Cl and/or using lower reaction temperatures.
Intermediate (XLf) can be obtained reaction of (XLe) with phosgene in the presence of a suitable base.
Phosgene equivalents and various amine bases are also contemplated and are recognized by those possessing skill in the art. Compounds of the formula (XLg) can be obtained by the same methodology described above for the preparation of (XLd) from compound (XLc).
Compounds (XLh) can be obtained by reacting (XLb) with Cbz-Cl (carbobenzyloxy chloride) in the presence of a base. Intermediate (XLi) can be obtained by reacting (XLh) with a carboxylic acid activating reagent in the presence of an amine such as ammonia. Other methods are contemplated and are recognized by those possessing skill in the art. Compound (XLj) is obtained by the reaction of (XLi) with a carbon monoxide equivalent such as phosgene in the presence of an amine base as previously described for the conversion of (XLe) to (XLf). Compounds of the formula (XLk) can obtained by W O 94/19329 PCT~US94/01609 N-alkylation and removal of protecting group~s) as described for the conversion of (XLc) to (XLd).
A more detailed description of the general formulas is provided in Scheme 18c.

Compounds such as lactam (XLIm) with an alkoxy substituent could be synthesized as shown in Scheme 19.
The alcohol (XLIh) obtained using the procedure of S.
Thaisrivongs, et al (J. Med. Chem. 1991, 3g, 2344 -2356) can be alkylated with benzyl bromide using standard procedures to give (XLIi). Treatment with catalytic p-toluene-sulfonic acid in methanol cleaves the oxazolidine to give the free alcohol (XLIj) which can be then converted to the acid (XLIk) using the procedure described by S. Thaisrivongs, et al (J. Med. Chem. 1991, 39, 2344-2356) . Protection of the alcohol as the t-butyldimethylsilyl ether and cyclization to the lactam is analogous to that described in Scheme 23.

Compounds such as the cyclohexane fused 7-membered ring lactam (XLIIh) could be synthesized as outlined in Scheme 20. The acid (XLIIa) is obtained following the procedure of J.A. Martin and G.J. Thomas (EP O 512 343 A2). This can be treated with methanol and catalytic p-toluenesulfonic acid to give the free alcohol which can be protected as the t-butyldimethylsilyl ether to give the acid (XLIIc). The cyclization to the fused lactam (XLIIf) followed by an alkylation deprotection sequence can lead to (XLIIh) Compounds of formula (XLIII) can be converted to a variety of cyclic structures and the general outline of useful routes is detailed in Schemes 21, 21a and 21b.
Advanced intermediates (XLIIIh) and (XLIIIn) are known and details of their preparation are described in WO9301166- A (published 21 January 1993), herein 21~i6~9 1 VO 94/19329 PCT~US94/01609 incorporated by reference. The conversion of (XLIIIa) `
via known methodology and that described herein, to a 6-memebered cyclic structure (XLIIIg), wherein P denotes a suitable hydroxyl protecting group (for example 2-(trimethylsilyl)ethoxymethyl (SEM), 2-methoxyethyl (MEM)) and X can be NH, O. R and R' are similar to R4 and R7. Further alkylation of the nitrogens can be performed. Conversion of (XLIIIh) to a 7-membered cyclic structure via known synthetic transformations is described, wherein P denotes a suitable protecting group (for example SEM, MEM) and R and R' are similar to R4 and R7. X and X' can be any nucleophile (nucleophilic carbon, nitrogen, oxygen, sulfur). Conversion of intermediate (XLIIIn) to an 8-membered cyclic structure (XLIIIs) is described. P denotes an appropriate protecting group; R and R' are similar to R4 and R7 and X can be any nucleophile; X' can be NH, O.

Compounds such as the benzo-fused 7-membered ring lactam (XLIVh) can be synthesized as outlined in Scheme 22. The acid ~XLIVa) is obtained following the procedure of M. Hammond and S.W. Kaldor (EP 0 526 009 A1). The free alcohol can be protected as the t-butyldimethylsilyl ether to give the acid (XLIVc). The cyclization to the fused lactam (XLIVf) followed by an alkylation deprotection sequence can generate (XLIVh) by analogy to that described for Scheme 23.

Compounds of Formula (I) wherein, W is N(R22)C(=o)C(R27)(R28), n is 0 and R7 is hydrogen, and R4 and R27 are benzyl can be synthesized according to ~ Scheme 23. Conversion of N-Boc-phenylalanine by an 8 step procedure can give intermediates of the formula (XLVa). Hydrolysis of the lactone, followed by activation of the acid functionality using methods known in peptide chemistry, followed by deprotection of the WO94/19329 PCT~S94/01609 Ga amine protecting g.oup and intramolecular cyclization can give lactam ~XLVe). Standard alkyation and alcohol liberation provide compounds of the formula stated above.

The p eparation of compounds of the formula (XLVId) is shown in Scheme 24. The Wittig product from the first step is reduced to the allylic alcohol using DIBAL-H in methylene chloride at -78C. This alcohol can be epoxidized using m-chloroperbenzoic acid or using Sharpless epoxidation methodology to give the epoxy alcohol (XLVIa). The epoxide can be opened selectively using TMSN3 (Sharpless, K.B. J. Org. Chem (1988) 53 5185) to give the desired 1,2-diol. Exhaustive silylation followed by selective deprotection of the primary silyl ether gives compound (XLVIb). Standard primary tosylate formation followed by displacement with sodium azide can give the diazide (XLVIc). Reduction of the diazide using catalytic hydrogenation and cyclization using carbonyl diimidazole would give the 6-membered cyclic urea. Alkylation as described herein and deprotection would give the final product (XLVId).
The diazide (XLVIc) can be manipulated to give a variety of cyclic structures as previously shown.
Compounds of the formula (I), wherein W =
-R22NC(=o)NR23-, n is 1, R5 is OH or =O and R6 = R6a is fluorine, can be synthesized as shown in Scheme 25.
Compound (XLVIIa) can be o~idized to the corresponding ketone by Jones oxidation (Org. Syn. Coll., Vol. V, 866) followed by reaction of the carbonyl with a fluorinating agent such as DAST. Deprotection, cyclization, alkylation and removal of hydroxyl protecting groups (such as MEM) can give (XLVIIg), which can be further oxidized to (XLVIIh) using the method of Gallina &
Giordano (Synthesis 1989, 466).

~O 94/19329 PCT/US94/01609 -161- 2~ S6~9 1 The preparation of compounds of the formula (XLVIIIc) is shown in Scheme 26. Starting from the known hydroxy ketone (XLVIIIa) (WO 92/00956, published January 23, 1992) the alcohol can be protected and the amine function deprotected to give diamine (XLVIIIb).
Cyclization and introduction of the R22 and R23 can be accomplished as described herein. Reduction of the ketone and deprotection can give the desired diol (XLVIIIc). Hydroxy ketone (XLVIIIa) can be converted to the triol (XLVIIIe). After alcohol protection, a second hydroxyl group can be introduced a to the ketone using standard chemical procedures known to one skilled in the art. After protecting this hydoxyl, the amines can be deprotected to give diamine (XLVIIId).

Using similar chemistry as discussed previously, the triol (XLVIIIe) can be prepared as shown in Scheme 26a. The mono-ol (XLVIIIj) can be prepared starting from the aldehyde (XLVIIIf) and an organometallic reagent (XLVIIIg). Both of these compounds can be prepared from amino acids using standard chemical procedures known to one skilled in the art. The alcohol (XLVIIIh) can be protected and manipulated as discussed previously to give the desired mono-ol (XLVIIIj) .

The cyclic carbonates of the formula (XLIXb) can be prepared, as shown on Scheme 27, starting from commercially available 3,4-O-Isopropylidene-D-mannitol.
Primary tosylate formation and base treatment can provide the diepoxide which can be opened with numerous nucleophiles to give compounds of the formula (XLIXa).
Cyclization and deprotection would give the desired diol (XLIXb).

WO94/19329 PCT~S94/01609 .` -162-~,~Go Compounds wherein W is -N(R22)P~o)tR24a)N(R23) n=1 and R24a is phenoxy or OH, can be synthesized as described earlier and as shown in Scheme 28. Diamine III could be cyclized with phenyldichlorophosphate using the method of Patois et al. (Heteroatom. Chem. 1990, 1, 369) to give the cyclic phosphoric amide. Alkylation with strong base and removal of the protecting groups using methods known to one skilled in the art would give the desired products.
Compounds of the formula (I) wherein W is -N(R22)C(=o)N(R23)-, and R22 and R23 are NH(R22a) and NH(R23a), respectively, can be prepared as shown in Scheme 29. Intermediate (XXIc) can be treated with chloramine to yield dihydrazine (LIa) according to the method of S.R. Sandler and W. Karo (Organic Functional Group Prepara'ions, Vol 1, Academic Press, N.Y., 1983, p.445), herein incorporated by reference. Cyclization using phosgene can give cyclic urea (LIb). Standard procedure for alkylation and deprotection can provide alkylated dihydrazine (LIc). Alterna~ively, (XXIc) can be treated with chloroaminobenzene, according to the method of S.R. Sandler and W. Karo above, to yield dihydrazine (LId). Cyclization using phosgene, followed by alkylation of the product as described previously, can provide compounds of the formula (LIe).

Compounds of the formula (I), wherein W is -N(R22)C(=C(CN)2)N(R23)- and n =1, can be prepared as shown in Scheme 30. Intermediate (XXIc) can be treated with 1,1'-bismethylthio-2,2'biscyanoethylene in acetonitrile, followed by the standard procedure of alkylation and deprotection to give compounds of the formula (LIIa).

'094/19329 215 6 59 ~ PCT~S94/01609 -l63-Compounds of the formula (I), wherein W is -N(R22)C(=S)N(R23)-, R22 and R23 are not hydrogen, and n =l, can be prepared as shown in Scheme 31. Mono-alkylated intermediate (XXVIIb) can be further reacted with a alkyl bromide under refluxing reaction conditions (to facilitate the removal of byproduct methyl bromide) to give dialkylated thiocarbonyl compound (LIIIa), which can be acid-deprotected as described previously.

Compounds of the formula (I), wherein W is -N(R22)C(=o)C(R27)-, n =l, and R28 and R7a are taken to form a bond can be prepared as shown in Scheme 32. The aldehydes required for coupling can be prepared by methods known to one of skill in the art. Acetylation after coupling can provide diacetate (LIVa). Amine protecting group modification can lead to (LIVb), afterwhich liberation of the carbonyl (LIVb) and Wittig olefination using stabilized Wittig can provide (LIVc), after separation of the geometric isomers. Liberation of the amine protecting group can provide (LIVd), which upon modification of the ester for standard amino-acid type coupling (via LIVe) can lead to compounds of formula (LIVf).

WO94/19329 PCT~S94/01609 ~The synthesis of compounds of the invention is C~ described in further detail below.

Procedure 1 Preparation of di-N-CBZ protected 1,4-diamino-2,3-diols (XIX):
ZN NZ

Ph ~ "~,. Ph HO OH
10 (XIX) Detailed experimental procedures for the synthesis of compound (XIX) are described in copending commonly assigned patent application Jadhav et al. USSN
1507/714,042, filed 5/31/91.

Proce~ure 2 Preparation of di-O protected di-N-CBZ 1,4-diamino diols (XXa) and (XXb):
ZN NZ

Ph J~ , Ph OR R

(XXa) R=SEM
25(XXb) R=MOM
(XXc) R=MEM

A. Protection as 2-(trimethylsilyl) ethoxy methyl (SEM) ether (XXa):

094/19329 21 5 G ~ 9 l PCT~S94/01609 Compound (XIX) (60 g, 105 mmol) was dissolved in dry DMF (600 mL). Diisopropylethylamine (75 mL) and SEMCl (66.8 g, 400mmol) were added and the mixture stirred for 16 h at room temperature under N2. The solution was diluted with water (lL) and extracted with hexane (9OOmL). The organic layer was separated and washed with water (2xlOOmL). The aqueous layers were combined and extracted with hexane (2x300mL). The organic layers were combined, washed with water (2xlOOmL), dried over MgS04, filtered and evaporated. The residue was chromatographed on SiO2 and eluted with 10-30% ethyl acetate/hexane to afford a white solid (9lg, 100%). NMR(CDC13~:~7.0-7.4 (m, 20H, Ph), 5,01 (br s, 4H, PhCH2CO), 4.5-4.95 (m, 6H, NH, OCH20), 3.6-4.25 (m, 4H, C~OCH2, C~NH), 3.5 ~s, 4H, OCH2CH2), 2.76 (br d, 4H, PhCH2), 0.8-1.0 (m, 4H, SiCH2). MS: 846 (M+NH4, 100), 695 (M-SEM, 40).

B. Protection as methoxymethyl ~MOM) ether tXXb).

Compound (XIX) (.50 g, 0.88 mmol) was dissolved in dry DMF (lOmL). Diisopropylethylamine (.46 mL, 2.64 mmol) and methoxymethyl bromide (.165 mL, 2.02 mmol) were added and the solution stirred at 40 C under nitrogen for four h. TLC (50/50 ethyl acetate /methylene chloride) showed that the reaction was complete. The mixture was partitioned between methylene chloride (50 mL) and 5% HCl (30 mL). The organic layer was separated, washed with water (5x20 mL), brine (20 mL), dried over MgS04, filtered and evaporated to a light yellow oil.
~ Chromatography on SiO2 and elution with 1-20% ethyl acetate/methylene chloride afforded (XXb) as a clear oil (0.29 g, 53%).
NMR (CDC13):~6.95-7.42 (m, 20H, Ph), 5.1-3.8 (m, complex), 3.35 (s, 6H, OCH3), 2.8-2.95 (m, 4H, PhCH2).

WO94/19329 PCT~S94/01609 MS: 657 ~13, M l), 674 (21, M+NH4), 522 (84), 414 (100), 370 (34).

Procedure 3 Deprotection of amines ~XXa) and (XXb) via hydrogenation to afford (XXIa) and (XXIb):
NH2 l H2 Ph ~ "~ Ph ~R ~R
(XXIa) R=SEM
(XXIb) R=MOM
(XXIc) R=MEM

A. Hydrogenation of SEM ether (XXa).

Compound (XXa) (90 g, 108.5 mmol) was dissolved in absolute ethanol (2.5 L). 5% Pd/C (6.5 g) was added and the solution was stirred under hydrogen for 1.5 h until hydrogen uptake ceased. TLC (20/80 ethyl acetate/hexane) showed that the reaction was complete. The solution was filtered through Celite and evaporated at reduced pressure to give XXIa as a colorless gum (60 g, 99%).
NMR (CDCl3):~7.1-7.35 (m, 10H, Ph), 4.72 (br d, 4H, OCH2O), 3.5-3.9 (m, 6H, NH2, CHOCH2), 3.15 (m, 2H, C~NH2), 2.55-2.95 (m, 4H, PhCH2), 0.95 (m, 4H, SiCH2).

B. Hydrogenation of MOM ether (XXb).

Compound (XXb) (0.29 g, 0.441 mmol) was dlssolved in ethyl acetate (6 mL) and methanol (3 mL). 10% Pd/C
(70 mg) was added and the solution stirred under ~094119329 215 G .~ 9 ~ PCT~S94/01609 hydrogen until H2 uptake ceased. TLC (20/80 methanol/ethyl acetate) showed that the reaction was complete. The solution was filtered through Celite and evaporated at reduced pressure to afford XXIb as a clear oil (.132 g, 77.4%). NMR (CDC13~:~7.1-7.35 ( m, 10H, Ph), 4.58 (s, 4H, OCH2O), 3.75 (br s, 2H, C~OCH2), 3.3-3.5 (m, 2H, C~NH2), 3.23 ~s, 6H, OCH3), 2.85 (br d, 4H, PhCH2). MS: 389 (M+l, 100), 345 (3.7), 280 (1.8), 120 (6.1).
Procedure 4 Eormation of cyclic ureas (XXIIa),(XXIIb) and (XXIIc):
O

HNJ~I\H

Ph - ~,/ "--Ph OR OR

(XXIIa) R=.SEM
(XXIIb) R=MOM
(XXIIc) R=MEM

A. Cyclization of SEM ether (XXIa).

Compound (XXIa) (40 g, 71.3 mmol) was dissolved in methylene chloride (200 mL). Carbonyl diimidazole (13.87 g, 85.6 mmol) was dissolved in methylene chloride (200 mL) in a separate flask. Each solution was then pumped into dry methylene chloride (6 L) at a rate of 90 mL/h.
The mixture was then stirred for 18h at room temperature under nitrogen. TLC (60/40 ethyl acetate/hexane) showed the reaction was complete. The solvent was removed at WO94/19329 PCT~S94/01609 ~3 reduced pressure and residue chromatographed on SiO2 and eluted with 1-50% ethyl acetate/hexane to afford (XXIIa) as a white solid (38.82g, 93%). mp: 75-76C. NMR (CDCl3):
~7.05-7.4 (m, 10II, Ph), 4.6-4.8 (dd, 4H, OCH2O), 4.08 (s, 2H, C~OCH2), 3.5-3.91 (m, 8H, NH, CHNH, OCH2CH2), 2.86, (br d, 4H, PhCH2), 0.8-0.95 (m, 4H, SiCH~). MS: 587 (M+1, 100).

B. Cyclization of MOM ether (XXIb).
Compound (XXIb) (.53 g, 1.364 mmol) was dissolved in dry methylene chloride (20 mL). In a separate flask, carbonyl diimidazole ( 265 g, 1.64 mmol) was dissolved in methylene chloride (20 mL). To a third flask containing pyridine (.22 mL, 2.73 mmol) in methylene chloride (100 mL) at room temperature under nitrogen were added the first two solutions via syringe pump at a rate of 1.7 mL/h. The solution was stirred overnight at room temperature. TLC (50/50 ethyl acetate/methylene chloride) showed that the reaction was complete. The solution was washed with 5% HCl (50 mL), NaHCO3 (50 mL), brine (50 mL), dried over MgSO4, filtered and evaporated. The residue was chromatographed on SiO2 and eluted with 50-75% ethyl acetate/methylene chloride to afford ~XXIIb) as a colorless gum (198 mg, 35%). NMR
(CDCl3):~7.1-7.4 (m, 10H, Ph), 4.65 (q, 4H, OCH2O), 4.13 (s, 2H, NH), 3.89 (t, 2H, CHNH), 3.59 (s, 2H, CHOCH2), 3.18 (s, 6H, OCH3), 2.87 (m, 4H, PhCH2). MS: 415 (M+1, 100), 102 (11).

Synthesis of Dimem DiZ Intermediate (XXc):
DiZ Diol (XIX) 507g(0.89mol) was stirred in 4L of dichloro~.ethane. To the slurry was added N,N-Diisopropylethylamine 780g(6.05mol) in one portion atroom temperature followed by the dropwise addition of 2-Q94/19329 21~ 6 S 9 I PCT~S94/01609 methoxyethoxymethyl choride 500g~4mol) (1 hour addition, -exothermic). Heated the solutlon at reflux for 12 hours. TLC (10:1:10 EtOAc:EtOH:Hexanes, Rf=0.56) indicated a complete reaction. The solution was worked up by quenching with ice water(3L). Washed the dichloromethane extract with water(2x 2L) and dried over magnesium sulfate. The filtrate was taken to dryness.
The resultant semi-solid was dissolved in chlorobutane(lL). Passed the solution through a four inch pad of silica gel to remove most of the intense red color. To the chlorobutane extract was added hexane(2L) to precipitate the desired DiZ Dimem intermediate ~XXc).
Washed the white solid with hexanes(3x 350ml). Dried at room temperature. Recovered the desired DiZ Dimem intermediate as a white solid in a yield of 525g(79%
yield). m.p. 52-54 C, lH NMR(CDC13): 2.80(m, 4H)-cH2Ph~
3.38(s, 6H)-OCH3, 3.58(m, 8H)-OCH2CH20-, 3.80(m, 2H), 4.20(m, 2H), 4.6-5.2 (m, 10H)NH, H2CCO2, -OCH2O-, 7.25(m, 20H)C6Hs Synthesis of Cyclic Urea Intermediate (XXIIc):
DiZ Dimem (XXc) 20g(26.8mmol) was dissolved in 200ml of tetrahydrofuran. To the solution was added 2g of 10% Palladium on Carbon and the suspension stirred for 7 hours under hydrogen(l atm). TLC (10:1:10 EtOAc:EtOH:Hex, Rf=0.05) indicated a complete reaction.
The suspension was filtered through a bed of Celite to remove the catalyst. Washed the Celite bed with 150ml of tetrahydrofuran. Transferred the THF solutiGn to a 500ml round bottom flask. To the THF solution was added 5.5g(33.3mmol) l,l'-Carbonyldiimidazole in several portions as a solid. Stirred at room temperature for 12 hrs. TLC (10:1:10 EtOAc:EtOH:Hex, Rf=0.26) indicated a complete reaction. The mixture was worked up by quenching with ice-cold 0.5N HCl (150ml) and extracting with diethyl ether (2x50ml). The organic extract was WO94119329 PCT~S94/01609 ~ -170--~.~ washed with water ~2xlOOml) and dried over magnesium sulfate. The filtrate was taken to dryness. The residue was purified on silica gel(200g; 1:1 EtOAc:Hex followed by 10:1:10 EtOAc:EtOH:Hex) to provide 10.2g (75.7% yield over two steps) of the desired cyclic urea intermediate (XXIIc) as a colorless oil. lH NMR(CDC13):
2.90(m, 4H)-CH2Ph, 3.36(s, 6H)-OCH3, 3.40(m, 8H)-OCH2CH20-, 3.60(m, 2H), 3.90(t, 2H), 9.10(s, 2H)NH, 4.80(q, 4H)-OCH20-, 7.30(m, 10H)C6Hs Procedure 5 General alkylation/hydrolysis procedure:

Compound (XXIIa) (1 mmol) in dry DMF (5 mL) was added to a flask containing sodium hydride (10 mmol, that had been washed with hexane, 3x20 mL) in DMF (5 mL). The solution was stirred at room temperature under nitrogen for 5 min. Evolution of hydrogen gas was observed. The appropriate alkyl bromide (5 mmol) was added and the solution was stirred at room temperature under nitrogen for lh. Hindered alkyl bromides required heating at 90-70 C for up to 5 h. TLC (90/60 ethyl acetate/hexane) was used to ensure that no starting material remained. The solution was quenched with methanol (1 mL), partitioned between ether (60 mL) and water (50 mL) and the organic layer was removed. The aqueous layer was washed with ether ~50 mL), the organic layers combined and washed with water (4x30 mL), brine (30 mL), dried over MgSO4, filtered and evaporated. In cases where the alkyl bromide contained basic nitrogen, 1 N NaOH was used in place of water.
The crude product was hydrolyzed directly in methanol (10 mL) and 4 N HCl/dioxane (5 mL) for up to 16 h at room temperature. The solution was evaporated and chromatographed directly on SiO2 to afford the bis-V094119329 215 S ~ 9 l PCT~S94/01609 alkylated cycllc ureas. Where nitrogen was present, the solutions were first basified with 1 N NaOH and extracted with ethyl acetate, dried over MgSO , filtered, evaporated and chromatographed. Hydrolysis - 5 can also be carried out using ~aturated hydrogen chloride in methanol with shorter reaction times.
- Hydrolysis of (XXIIb) under the same conditions gave 67% yield of the N,N-unsubstituted cyclic urea Example lA, mp 170-174 C.

WO94/19329 PCT~S94/01609 F.x~mG~e lG

~' O

~NJ~NJ
"" Ph H H

The experimental procedure is similar to the synthesis of Example lE. The isomer, ~2R, 3R, 4R, 5R) -2,5-diamino-1,6-diphenyl-3,4-hexanediol, needed for the synthesis was isolated from the vanadium trichloride coupling reaction, as described in copending commonly assigned patent application Jadhav et al. USSN
07/714,042, filed 5/31/91 (see Procedure 1 above).
Example lG: 13C NMR (CDCl3): (75.48 MHz) 37.387, 51.51, 65.136, 72.779, 118.649, 126.540, 128.409, 129.714, 134.618, 137.757, 162.705.

Synthesis of Mono~lkyl Cyclic Ure~:
The intermediate from previous step 2g(4mmol) was dissolved in 25ml toluene and placed in a 100ml round bottom flask. To the solution was added 85% KOH
0.82g(12mmol) and polyethylene glycol (M.W.=1000) 0.20g. With a Dean Stark trap in place the mixture was refluxed for 4 hours until the theoretical amount of watert0.20ml) was collected. Cooled to room temperature and added (bromomethyl)cyclopropane 1.78g(13.2mmol).
Stirred at 75 C for 17 hours. T~C(10:1:10 EtOAc:EtOH:Hex, Rf=0.52) indicated that the reaction was complete. Worked up by quenching with aqueous ammonium chloride(50ml) and extracting with ethyl acetate 'Q94/19329 PCT~S94/01609 - l7~1~6~1 (2x35ml). Washed the organic layer with water(2x35ml) and dried over magnesium sulfate. The filtrate was taken to dryness. The residue was purified on silica gel(150g, 2:3 EtOAc:Hex) to provide 1.55g(70% yield) of the desired monoalkyl cyclic urea as a colorless oil.
C13 NMR(CDCl3): 3.33i, 4.000, 10.619, 32.877, 34.159, 55.677, 58.294, 58.972, 64.085, 67.361, 67.437, 71.723, 71.753, 76.576, 78.023, 96.347, 96.519, 126.224, 126.316, 128.366, 128.563, 129.400, 129.447, 139.475, 139.555, 161.558. For reactive alkylating agents, e.g.
m-nitrobenzyl chloride, the reactions are carried out lower temperatures, such as room temper~ture.
An alternative procedure to make the monoalkylated cyclic urea involved using the procedure described previously for formation of the dialkylated cyclic urea, however, varying the amount of sodium hydride to 1.5 equivalents and alkylating agent to 1.0 equivalents.
Silica gel chromatography provided the desired product, as well as dialkylated cyclic urea and unreacted starting material.

Synthesis of Cyclic Guanidines Cyclic guanidine compounds of the invention wherein W = NH(C=N-CN)NH, differ from the cyclic urea compounds of the invention wherein W = NH(C=O)NH. Described below are representative methods for the preparation of cyclic quanidine compounds of the invention.

WO94/19329 PCT~S94/01609 ~ SYNTHESIS OF CYCLIC GUANIDINES

c~ N ,CN ~ N V

Ph~,_Ph ~ Ph~) Ph S~mO OS~m SemO OS~m Sem = CH20CH2C H2Si(CH3)3 in Dioxane CN

~NJ~NJ
Ph ~) .",_ Ph HO OH
as23s F.x~m~le 8G (vi~ Alkene Interme~i~te XXIX):

A solution of Example 7Q (150 mg, 0.22 mmol) in DMF
was treated with sodium iodide (160 mg, l.l mmol) and heated at 90C for 2 hrs. The mixture is cooled to room temperature, diluted with water and the precipitate is extracted into CH2Cl2. The extract is washed with water and brine, dried over MgSO4 and evaporated to give a yellow oil. This is HP~C chromatographed on silica gel (50% EtOAc/Hex) to give 50 mg of alkene intermediate ~XXIX) as a white solid. MS:(CI,NH3) 589 ~M+H)+.

21~9~
YO94/19329 PCT~S94/01609 @~--N 1N - ~J
~J -13 OH

Alkene intermediate (XXIX) A solution of alkene intermediate (XXIX) (90 mg, 0.07 mmol) in THF was treated with 20 mg of 10% Pd/C and hydrogenated in a Parr Hydrogenator at 50 psi overnight.
The catalyst was filtered off and the filtrate concentrated. The resulting residue was HPLC
chromatographed on silica gel (70% EtOAc/Hex) to give 10 mg of Example 8G 2S a white solid. MS:(CI,NH3) 591.5 tM+H)+

Method 2 (As outlined in Scheme 10):
A suspension of Example 3U (2.0 g, 0.0033 mol) in methylene chioride was treated at room temperature with 2-acetoxyisobutryl bromide (2.09 g, 0.01 mol) and stirred for 1 hour until the solution became clear. The reaction was quenched with a solution of sat'd sodium bicarbonate and the organic layer was washed with water and brine. The solution was dried over magnesium sulfate, concentrated and chromatographed on silica gel (30% EtOAc/Hexane elution) to give 1.3 g of the correspoilding bromoacetate intermediate as a white solid. MS:(CI,NH3) 713.4 (M+H)+.
A solution of the bromo acetate intermediate (0.45 g, 0.63 mmol) in acetic acid was treated with 1 g of zinc dust and stirred at room temperature until TLC
analysis showed no starting material remained. The mixtured was diluted with ethyl acetate and filtered.

WO94/19329 PCT~S94/01609 ~C~ -176-G~ The flltrate was concentrated and the resulting residue was dissolved in methanol and treated with lN aq. NaOH
and stirred overn ght. The solution was concentrated and the residue was dissolved in methylene chloride, washed with water and brine, dried over magnesium sulfate, and concentrated. The residue was chromatographed on silica gel ~50% EtOAc/Hexane elution) to give 170 mg of Example 8G as a white solid. MS: ~CI,N~3) 591.5 ~M+H)+.

Fxample 8H

Method 1.
A. Synthesis of 6-membered ring cyclic urea ~XXX):

N N
~""~
MEMO

~XXX) The synthesis of the six-membered cyclic urea (XXX) is outlined in Scheme 8. A solution of N-Cbz-D-phenylalanine N,O-dimethylhydroxylamide ~33.5 g , 0.098 mol) in ether was cooled to 0C and treated with 300 mL
of a 1 M solution of vinyl magnesium bromide in THF. The mixture was stirred for 30 mins and then poured into an ice cold solution of 1 N HCl ~500 mL). The mixture was extracted into ether and the extracts washed with water and brine. The organic layer was dried over MgSO4, filtered and concentrated to give the desired vinyl ketone as a thick, light yellow residue which was used without further purification. MS: (CI,NH3) 310 30 (77%, ~M+H) +); 327.1 (100%, ~M+NH4) +) .

~094/19329 215 G a 9 l PCT~S94tO1609 The crude ketone was dissolved in methanol (350 mL) and treated with cerium trichloride heptahydrate ~37.2 g, 0.1 mol) and cooled in an ice bath. While stirring vigorously sodium borohydride (3.78 g 0.1 mol) was added slowly, a small portion at a time, over a period of 30 min. After the addition was complete the mixture was ~ allowed to warm to room temperature and stirred for an additional 1 hr. The solvent was removed under vacuum on a rotorary evaporator and the residue was partitioned between 1 N HCl and methylene chloride. The organic layer was washed with water, brine, and then dried over MgSO4, filtered and concentrated to give the desired allylic alcohol as an off-white solid which was used without further purification.
15A solution of the crude allylic alcohol and diisopropylethylamine (30 g, 0.23 mol) in methylene chloride was cooled in an ice bath and treated dropwise with methanesulfonyl chloride (28 g, 0.24 mol). The solution was stirred for 30 mins, then washed sequent.ally with 1 N HCl, water, brine and dried over MgSO4. The solution was filtered and concentrated to give the crude mesylate as a thick oil. To a flamed-dried flask was added copper cyanide (12 g, 0.144 mol) and 100 mL of THF. The flask was cooled to -78 C under nitrogen atmosphere. A solution of benzylmagnesium chloride (360 mL, 2M in THF, 0.72 mol) was added via syringe and the resulting thick solution was stirred at -60C for 20 mins and at O C for 30 mins. The solution was then cooled to - 78C and a solution of the mesylate in 130 ~L of THF was added via syringe. The solution was stirred at --60C for 45 mins and then poured into a mixture of 1 N HCl/ice. This was extracted into ethyl acetate and the organic layer was washed sequentially with NH4Cl (aq), NH40H, brine, dried over MgS04, filtered and concentrated. The resulting residue is chromatographed on silica gel (hexane, then 10%

WO94/19329 PCT~S94/01609 3 EtOAc/Hex) to give 11.7 g of the desire alkene as a white solid. MS:(CI,NH3) 386.3 (98%, (M+H)+); 403.2 (100%, (M+NHq)+).
A solution of the above alkene (11.0 g, 0.029 mol) 5 in methylene chloride (75 mL) was cooled to 0C in an ice bath and treated with 60% m-chloroperbenzoic acid (14.0 g, 0.049 mol). The solution was stirred 0C for 7 hrs until TLC analysis showed no starting material remained. A precipitate formed during this time. The 10 suspension was diluted with methylene chloride and washed sequentially with 1 N Na2S2O3, 1 N sodium hydroxide, water, brine, dried over MgSO4, filtered and concentrated to give the epoxide as a thick oil which was used without further purification.
To solution of crude epoxide in 80 mL of DMF was added sodium azide (20 g , 0.3 mol), ammonium chloride (2.5 g , 0.047 mol) and 20 mL of water. The mixture was heated at 90 C for 3 hrs and then stirred at rt overnight. The solvent was removed under high vacuum on 20 a rotorary evaporator and the residue was partitioned between water and methylene chloride. the organic layer was washed with water and brine, dried over MgSO4, filtered and concentrated to give a residue. This was then chromatographed on silica gel (20% EtOAc/Hex) to 25 give 7.4 g of the azide alcohol as a white solid.
MS:(CI,NH3) 445.0 (25%, (M+H)+j; 462.2 (100%, (M+NH4-BnOH)+).
A solution of the azide alcohol above (7.2 g, 0.016 mol) in methylene chloride was treated with diisopropylethylamine (4.2 g , 0.032 mol) and MEM-Cl (4.0 g 0.032 mol) and heated to reflux overnight (18 hrs). The mixture was concentrated and the residue chromatographed on silica gel (20% EtOAc/Hex - 35%
EtOAc/Hex) to give 7.7 g of the MEM protected azido alcohol ~s a colorless oil. MS:(CI,NH3) 533.2 (100%, (M+H)+j.

VO 94/19329 21!~ G ~ ~ -1 PCT/US94/01609 To a solution of MEM protected azido alcohol (5.7 g 0.0107 mol) in ethyl acetate was added 2 mL of acetic acid and 1 g of Pearlman's catalyst (10 % Pd(OH) 2 on Carbon) and the solution was hydrogenated at 55 psi for 5 22 hrs. The solution was filtered through Celite and the filtrate was extracted with 1 N HCl ~organic layer turn orange). The acidic aqueous extract was made basic with 50% NaOH (while cooling in an ice bath) and the precipitate is extracted into ethyl acetate. The organic 10 layer is washed with water, brine, dried over MgSO4, filtered and concentrated to give 2.5 g of the MEM
protected diamino alcohol as a colorless oil.
MS:(CI,NH3) 373.1 (100%, (M+H)+).
To a solution of the MEM protected diamino alcohol (2.5 g 0.0067 mol) in THF was added 1,1-carbonyldiimidazole (1.1 g, 0.0067 mol) and stirred over night at room temperature. The solution was concentrated and the residue partitioned between 1 N HCl and CH2Cl2.
The organic layer is washed with brine, dried over MgSO4, filtered and concentrated. The residue is HPLC
chromatographed on silica gel ( 5% MeOH/CHCl3) to give 1.2 g of the MEM protected 6-membered ring cyclic urea (XXX) as a white solid. MS:(CI,NH3) 399.1 (100%, (M+H)+).
B. The MEM protected 6-membered ring cyclic urea (XXX) (100 mg, 0.27 mmol) was alkylated with cyclopropylmethylbromide (250 mg, 1.8 mmol) followed by removal of the MEM group, as described in general procedure 5, to give after chromatography on HPLC
(silica gel, 10~ MeOH/CHCl3) 20 mg of Example 8H as a clear, viscous residue. MS:(CI,NH3) 419.4 (100%, (M+H)+) .

Method 2.
A solution of Example 8A (160 mg, 0.3 mmol) and thiocarbonyldiimidazole (55 mg, 0.3 mmol) in THF was WO94/19329 PCT~S94/01609 -l80-~ heated to reflux for 4 hrs. The mixture was evaporated Co~ and the residue chromatographed on silica gel ~50%
4~ EtOAc/Hex) to give 34 mg (0.05S mmol) of the corresponding thioczrbamate. The thiocarbamate was dissolved in 2 mL of toluene and heated to reflux. To the refluxing solution was added tributyltin hydride (32 mg, 0.l mmol) and 2 mg of AIBN. The mixture was refluxed for l hour, concentrated, and the residue chromatography on HPLC ~silica gel, 65% EtOAc/Hex) to give 20 mg of lG clear colorless oil. The oil was dissolved in MeOH, cooled in an ice bath and gaseous HCl was bubbled through the solution for 30 mins. The solution was then stirred at room temperature overnight, concentrated and the residue chromatography on HPLC (silica gel, 10%
MeOH/CHCl3) to give l0 mg of Example 8H as a clear, viscous residue. MS:(CI,NH3) 419.2 (100%, (M+H)+).

Example 8AA

~N~N
Ph ~J.",~
OH
OH

Compound (XXIIb) (0.85g) was hea~ed with mixture of acetic acid (9.5 mL) and water (0.5 mL) at 85 C for 4h.
After extraction with dichloromethane, followed by washing the organic extract with saturated sodium blcarbonate and brine, a mixture was provided which, on separation by column chromatography, furnished (XXIIb) (TLC l:l0 ethyl acetate/hexane Rf = 0.4; 0.54g), the desired mono-alcohol intermediate ( TLC l:l0 ethyl /094/19329 21~ ~ 5 ~ ~1 PCT~S94/01609 acetate/hexane Rf = 0.1; 0.13g), and overhydrolysed diol (0.05g).

The above mono-alcohol intermediate 0.25g (0.466 mmol), triphenylphosphine 183mg (0.7 mmol), diethylazadicarboxyalte 0.11 mL ~0.7 mmol), and chloroacetic acid 66mg (0.7 mmol) were stirred in 5 mL
anhydrous tetrahydrofuran at 0 C for 15 minutes and then at room temperature for 18 h. The excess reagents were quenched with 0.5 mL methanol and the mixture allowed to stir for 20 minutes. The mixture was purified by silica gel column chromatography to provide the desired chloroacetate intermediate with inversion of configuration. 13C NMR (CDCl3) : (75.48 MHz) -1.373, 14.413, 14.487, 18.253, 25.591, 33.851, 35.741, 40.505, 48.824, 49.962, 57.507, 58.234, 66.589, 67.885,73.179, 77.423, 95.454, 117.296, 118.554, 126.588, 126.887, 128.518, 128.610, 129.117, 129.199, 129.479, 133.686, 134.168, 136.324, 138.285, 155.698, 166.323.
The above chloroacetate intermediate 73mg (0.12 mmol) in 2mL dry methanol was treated with 0.25 mL
(0.5M) sodium methoxide and stirred for 30 minutes at room temperature. The contents were then treated with 0.3 mL (4~ HCl in methanol) and stirred for 4.5h at room temperature. The residue after removal of solvent was purified on silica gel column to provide Example 8AA.
13C NMR (CDCl3): (75.48 MHz) 34.075, 37.672, 48.941, 48.985, 58.071, 60.640, 65.861, 73.212, 177.975, 118.669, 126.535, 126.858, 128.6~3, 128.815, 129.225, 133.605, 134.172, 13?.637, 138.273, 155.497.

Example 8R

A solution of the bromoacetate intermediate from Example 8G (0.10 g, 0.14 mmol) in methaol was treated WO94/19329 PCT~S94101609 dropwise with sodium hydroxide solution ~lN, 1 mL) and stirred at room temperature for 1 hour. The solution was diluted with water, acidified with lN HCl(aq) and extracted into methylene chloride. The extract was washed with water, brine and dried over magnesium sulfate. The solution was filtered and concentrated to give 90 mg of Example 8R as white solid. MS:tCI,NH3) 671.2 (72%, (M+H)+); 669.2 (67%).

T~hle ld R22 N ,11~ N ~R23 ~""'b Ex.No B22 _23 ~ ~ stereo ~i ICgo MS
. 2:3:4:5 (M+H) 7AL 3- OH H RSSR +++ +++
hydroxymethyl benzyl 7AM R22 = 3_ OH H RSSR ++ +++
carbomethoxy R23 = benzyl 7AN benzyl OH H RSSR +++ +++
7AO benzyl OH N3 ++
7AP benzyl OH NH2 Table le R ~NJ~N~R
~".1~3 Y X

/O 94119329 215 6 .~ 9 1PCTAJS94/01609 Ex. ~ ~ Y ~ 9o Ma~s ~Q- Spec (~) 80 3-cyanobenzyl H OH ++ +++ 541.3 8P O H OH +++ +++ 575.3 8Q benzyl/H OH OH ++ ++ 417.0 8R 2-naphthylmethyl Br OH ++ ++/+ 671.2 2 8S 3-hydroxybenzyl/ H OH +++ +++ 417.1 4 8T N-methylamino Br OH ++ +++ 629.2 2 benzyl 8U 3-cyanobenzyl H OH ++ +++ 577.2 2, 3 8V 3-hydroxymethyl Br GH ++ +++ 631.2 2 benzyl 8W N-methylamino H OH +++ +++ 549.3 2 benzyl 8X O - N H OH ++ ++ 763.4 2 CF3~ N ~--8Y 3-carbomethoxy H OH +++ ++ 607.3 2 benzyl 8Z 3-hydroxymethyl H OH +++ +++ 551.4 4 benzyl 8AA allyl OH OH ++
8AR 3-carbomethoxy H H + +++ 623.3 benzyl 8AC 4-hydroxymethyl H H ++ +++ 535.2 benzyl 8AD benzyl H OH ++ +++ 491.2 8AE 3-(H2NC(O)) H OH +++ +++ 577.2 benzyl 8AF 3-(H2NC(=NOH)) H OH +++ +++ 607.3 benzyl (ESI ) 8AG 3-(H2NC(=NOH)) H OH +++ +++ 643.3 3 benzyl ~ESI ) 8AH 3-(H2NC(O)) H OH +++ +++ 613.2 3 benzyl 8AI 3(H2NC(0))-4- H OH +++ ++~ 613.5 fluorobenzyl 8AJ 3-(H2NC(=NOH))-4- H OH +++ +++ 643.2 fluorobenzyl ~ESI ) 8AK 3-(H2NC(O)) H OH +++ +++ 649.2 5 benzyl 8AL 3-(H2NC(=NOH)) H OH +++ +++ 679 5 benzyl 8A~. 3-(3-pyrazolyl)- H OH 623.3 benzyl 8AN 3-cyanobenzyl H OH + + 541.2 6 8Ao 3-(H2NC(=NOH)) H OH ++ + 607.0 6 benzyl WO94/19329 PCT~S94101609 ,C~ -184-CCa-~ 8AP 3-(H2NCtO)) H OH + ~ S77.3 6 benzyl 8A2 3-carbomethoxy H OH + + 607.4 6 benzyl 8AR 3-hydroxymethyl H OH +~ + 551.4 6 benzyl Notes l. As in Scheme 9: CF3COOH opening of aziridine followed by hydrolysis of the diester.
2. As in Scheme lO.
3. The unsubstituted benzyls in the title structure are replaced with p-fluorobenzyls.
4. As in Scheme 9A: Hydrolysis of monoacetate followed by catalytic hydrogenolysis of aziridine ring.
5. The unsubstituted benzyls in the title structure are replaced with 3,4-difluorobenzyls.
6. SSS isomer Pro~rugs For compounds of the present invention with reduced water solubility it has been found to be advantageous to prepare prodrugs to enhance the solubility and bioavailability of these compounds. The addition of ionizable groups by derivatization of free hydroxy groups of compounds of formula (I) with bioreversible esters resulted in greatly improved water solubility.
Solubility studies were performed by mixing an excess of solid compound in water or aqueous medium for at least 4 hours. Solubility was asessed either visually, if a weighed amount clearly dissolved in a measured volume of solvent (method A), or by HPLC assay of filtrates of saturated solutions (method B). Solubility results are summarized in Table A.

~094/19329 21 S 6 ~ ~ I PCT~S94/01609 T~hle A

Ex. Solvent Method Solubility No. (mg/ml) 5U water B 0.01 29A water B 2.25 29B water A >100 29C O.lM citric acid A >20 29D water A >200 For these prodrugs to be useful therapeutic agents (assuming that the intact esters have relatively little inherent pharmacologic activity), the ester must be hydrolyzed after dosing to yield the parent hydroxy compound. Compounds 29A-29E are hydrolyzed to parent compound 5U in biological fluids in vitro. This was shown as follows. Plasma was collected from rats, dogs, or human volunteers, and was used within 24 hours.
Prodrug was added to plasma, which had been warmed to 37 C, at concentrations of 2-10 ~g/ml. After various times of incubation at 37 C, the hydrolysis reaction was quenched with the addition of an organic solvent.
The organic solvent was used for extraction of 5U, and concentrations of 5U in the plasma aliquots were determined using HPLC after extraction. Concentrations of 5U were thus measured vs. time of incubation of the prodrug in plasma at 37 C. Similar studies were performed using a homogenate of rat intestinal tissue (10 ~ w/v) as the hydrolysis medium. Results for in vitro hydrolysis of prodrug 29B in dog plasma and rat intestinal homogenate (10% w/v) are given in Table B.
Results for in vitro hydrol~sis of prodrug 29C in rat, dog and human plasma are given in Table C. Prodrugs - 29B, 29C, and 29E were shown to readily convert to parent 5U when exposed to plasma or intestinal enzymes in vitro. These results indicate that these prodrugs WO94/19329 PCT~S94/01609 ~.~, will convert to 5U in vivo. Other salt forms of these compounds, such as prodrugs 29A and 29D, will be similar to their free acid or free base forms.
T~hle R
lim8 % Converte~ to 5U % Converte~ to 5U
(min) (Dog plasma) (Rat intestine homogenate) 0 3.4 16.0 4.9 16.6 5.5 22.7 9.3 46.0 120 19.9 47.1 T~hle C

% converted to 5U % converte~ to 5U % converte~ to 5U
~min) (rat plasma)(dog plasma)(human plasma) 0 29.4 1.8 6.7 69.0 3.1 12.9 74.6 3.3 12.9 77.6 5.0 81.6 6.7 14.5 90.6 10.1 31.3 120 100 15.7 45.&
240 100 31.0 73.4 360 74.9 Improved water solubility can result in lncreasing the extent of oral bioavailability. Oral bioavailability studies were performed in fasted beagle dogs. Compounds were dosed orally using a solution vehicle or the solid drug powder filled into hard gelatin capsules. Periodic blood samples were taken from each dog and plasma was separated. Plasma drug concentrations were determined using extraction and HPLC
analysis. Generally, after the administration of 5U or its prodrugs 29A-E, the plasma concentrations of 5U were determined, rather than unchanged prodrug concentrations. Oral bioavailability was estimated by '094119329 215 6 S ~ 4 PCT~S94/01609 comparing the dose-normalized area under the plasma 5U
concentration vs. time curve (AUC) after oral dosing with the AUC after intravenous administration of 5U.
Oral bioavailability is expressed as the percentage of - 5 the oral dose absorbed.
Compound 5U has reduced water soluble, and when admlnistered as the solid powder gave reduced oral bioavailability. Therefore, in order to attain increased oral bioavailability, 5U was administered using a solution with polyethylene glycol 400 or propylene glycol as the vehicle. However, as the dose of 5U was increased, oral bloavailability was reduced, due to precipitation of 5U from the glycol vehicle upon mixing with the aqueous contents of the gastrointestinal tract. Improved oral bioavailability was attained when the water soluble prodrugs were administered in the solid form, with no added excipients or solvents. One advantage of these water soluble prodrugs is that they can be formulated in conventional solid oral dosage forms, whereas 5U gave reduced oral bioavailability when dosed in solid form. The advantage of the water soluble prodrugs is especially clear at high doses. Both prodrugs 29B and 29D yielded good oral bioavailability at relatively high doses, whereas the administration of a similar dose of 5U in a non-aqueous vehicle resulted in reduced oral bioavailability.
Prodrug 29E resulted in lower bioavailability then prodrugs 29B-D. Additional assay of the plasma samples for intact ester (total of mono and bis ester) was performed by treating plasma with NaOH to hydrolyze any intact esters. Samples were then extracted again and assayed for 5U concentration. The AUC of intact esters was approximately 2 fold greater than that of 5U. Thus, plasma levels of both intact prodrug and hydrolysis product can be attained using these water soluble prodrugs. The results of the comparison of the oral WO94/19329 PCT~S94/01609 bloavailability in dogs of 5U and its water soluble prodrugs are shown in Table D.
T~hle D

Ex .F.xc~Di ents ~Q&~ % OrAl ~Q- (mg/kg, 5U eq.) Rlo~v~ h;lity of (Mean iSE) 5U glycol 10-15 50+20 5U glycol 40 5+2 29B none 8 29i2 28B none 27 27+6 29D none 31 40+12 29E none 8 12+2 Ut;lity The compounds of this invention possess retroviral protease inhibitory activity, in particular, HIV
inhibitory efficacy, as evidenced by their activity in the assays, as described below. The compounds of formula (I) possess HIV protease inhibitory activity and are therefore useful as antiviral agents for the treatment of HIV infection and associated diseases. The compounds of formula (I) possess HIV protease inhibitory activity and are effective as inhibitors of HIV growth.
The protease inhibitory activity of the compounds of the present invention is demonstrated using standard assays of protease activity, for example, using the assay described below for assaying inhibitors of HIV
protease activity. The ability of the compounds of the present invention to inhibit viral growth or infectivity is demonstrated in standard assay of viral growth or infectlvity, for example, using the assays described below. The compounds of the present invention inhibit HIV-protease activity in vivc as demonstrated using the animal models for HIV protease inhibition described Q94/19329 215 6 39 ~ PCT~S94/01609 below. The compounds of the present invention demonstrate in vivo HIV inhibitory activity, as shown in the animal models described below. The HIV inhibitory activity in the animal models described below indicates that the presently claims compounds are useful for the treatment of HIV infection in humans.
As discussed above, the compounds provided by this invention are also useful as standards and reagents for use in tests or assays for determining the ability of a potential pharmaceutical to inhibit HIV protease andtor HIV growth, such as the assays described herein below.
Thus, the compounds of the present invention may be provided in commercial kits or containers comprising a compound of this invention, for use pharmaceutical research.
Since the compounds of the present invention inhibit HIV growth and infectivity, they may be used as HIV antivirals for the inhibition of HIV in a biological sample which contains HIV or is suspected to contain HIV
or to be exposed to HIV.
As used herein "~g" denotes microgram, "mg" denotes milligram, "g" denotes gram, ~L~ denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, "~M" denotes micromolar, "mM" denotes millimolar, "M" denotes molar and "nm" denotes nanometer. "Sigma" stands for the Sigma-Aldrich Corp.
of St. Louis, MO.
A compound is considered to be active if it has an IC50 or Ki value of less than about l mM for the inhibition of HIV protease or HIV viral growth or infectivity.

HIV Protease Inhibition Assay- Spectroscopic Method Materials:

WO94/19329 PCT~S94/01609 ~ Protease: Inclusion bodies of E. coli harboring G~ plasmid containing HIV protease under the control of an inducible T7 promoter were prepared according to Cheng et. al (1990) Gene 87: 243. Inclusion bodies were solubilized in 8 M urea, 50 mM tris pH 8Ø Protease activity was recovered by dilution 20-fold into buffer containing 50 mM sodium acetate pH 5.5, 1 mM EDTA, 10%
glycerol and 5% ethyiene glycol. Enzyme was used at a final concentration of 1.0-10 ug/ml.
Substrate: Peptide of sequence: Ala-Thr-His-Gln-Val-Tyr-Phe(NO2)-Val-Arg-Lys-Ala, containing p-nitrophenylalanine (Phe(NO2)), was prepared by solid phase peptide synthesis as previously described by Cheng et al. (1990) Proc. Natl. Acad. Sci. USA 87: 9660.
Stock solutions of 10 mM were prepared in DMSO.
Inhibitory compounds were dissolved in sufficient DMSO to make 2.5 or 25 mM stock solutions. All further dilutions were done in DMSO.

Reactions:
Compound (1-5 uL) and HIV protease were mixed in buffer containing 50 mM MES, pH 6.5, 1 M NaCl, 1 mM
EDTA, 1 mM dithiothreitol, 10% glycerol. Reactions were initiated by the addition of peptide substrate to a final concentration of 240 uM, and absorbance at 300 nM
monitored for 10 min. Values of Ki for inhibitor binding were determined from percent activity measurements in the presence and absence of known concentration of inhibitor, using a value of 0.07 mM for the Km of the substrate (Cheng et al. ~1990) Proc. Natl.
Acad. Sci. USA 87: 9660).
The HIV-1 protease inhibitory activity of representative compounds of the invention is shown in Table 1 and 2.

21~6S94 ~094/19329 PCT~S94/01609 HIV Prote~se Inh;hit;on Ass~y- HPTC Metho~

M~teri~ls:
Protease: Incluslon bodies of E. coli harboring - 5 plasmid containing plasmid T1718R with a synthetic gene coding for a single-chain tethered dimer of HIV protease were prepared as described in Cheng et al. ~Proc. Natl.
Acad. Sci. USA, 87, 9660-9664, l990). Active protease was prepared as described therein by extraction with 67%
acetic acid, dilution 33-fold with water, dialysis against water and then against a "refolding buffer"
consisting of 20 mM MES, 1 mM dithiothreitol and 10%
glycerol. Protease was stored as a stock preparation at 10 uM in refolding buffer.
Substrate: Peptide of sequence: aminobenzoyl-Ala-Thr-His-Gln-Val-Tyr-Phe(NO2)-Val-Arg-Lys-Ala containing p-nitrophenylalanine, was prepared by solid phase synthesis as previously described Cheng et al., op.cit.
Stock solutions of 2 mM substrate were prepared in DMSO.
Inhibitory compounds were dissolved in sufficient DMSO to make 3 mM stock solutions. All further dilutions were prepared in "assay buffer": 1 M NaCl, 50 mM MES, pH
5.5, 1 mM EDTA, lmM DTT, 20% glycerol.

Reactions:
Enzyme reaction: In a 2 ml screw-cap centrifuge tube were added 50ul protease (final concentration 0.25 nM) and 0.1 ml inhibitory compound (final concentration 0.1-12,500). After 15 min preincubation at room temperature, the reaction was started with the addition of .05 ml substrate (final concentration 5 uM).
Incubation was carried out at 30 C. for 1 hr. The reaction was stopped with 1 ml 0.1 M ammonium hydroxide.
HPLC measurement of product formation: The product (aminobenzoyl-Ala-Thr-His-Gln-Val-Tyr) was separated from substrate on a Pharmacia Mor.oQ anion exchange WO94/19329 PCT~S94/01609 ~C~ column. The injection volume was 0.2 ml. The mobile f_~
Ga phases were: A (20 mM trisHCl, pH 9.0, 0.02~
sodium Azide, lO~ acetonitrile), B (20 mM tris HCl, pH
9.0, 0.02% sodium azide, 0.5 M ammonium formate, 10 acetonitrile). The mobile phases were pumped at 1 ml/min, with a gradient from 0 to 30% B in 5 min, 100 %
B for 4 min to wash the column, and a xe-equilibration for 4 min. The retention time of the product was 3.6 min. Detection with a Shimadzu model RF535 fluorescence monitor was at 330 nm (excitation) and 430 ~emission).
The Ki was calculated from the formula Ki = I/(((Km+S-FA*S)/(FA*Km))-1) where I = inhibitory concentration, S
= substrate concentration, FA = fractional activity = cm peak height with inhibitor/cm peak height without inhibitor, and Km = Michaelis constant = 20 uM.

HIV RNA Assay DNA Plasmids and in vitro RNA transcripts:
Plasmid pDAB 72 containing both gag and pol sequences of BH10 (bp 113-1816) cloned into PTZ l9R was prepared according to Erickson-Viitanen et al. AIDS
Research and Human Retroviruses 1989, 5, 577. The plasmid was linearized with Bam HI prior to the generation of in vitro RNA transcripts using the Riboprobe Gemini system II kit (Promega) with T7 RNA
polymerase. Synthesized RNA was purified by treatment with RNase free DNAse (Promega), phenol-chloroform extraction, and ethanol precipitation. RNA transcripts were dissolved in water, and stored at -70C. The concentration of RNA was determined from the A260.

Probes:
Biotinylated capture probes were purified by HPLC
after synthesis on an Applied Biasystems. (Foster City, CA) DNA synthesiz~r by addition of biotin to the 5' Q94/19329 21 S 6 ~ PCT~S94/01609 terminal end of the oligonucleotide, using the biotin-phosphoramidite reagent of Cocuzza, Tet. Lett. 1989, 30, 6287. The gag biotinylated capture probe ~5-biotin-CTAGCTCCCTGCTTGCCCATACTA 3') was complementary to nucleotides 889-912 OL HXB2 and the pol biotinylated capture probe ~5'-biotin -CCCTATCATTTTTGGTTTCCAT 3' ) was complementary to nucleotides 2374-2395 of HXB2.
Alkaline phosphatase conjugated oligonucleotides used as reporter probes were prepared by Syngene (San Diego, CA.). The pol reporter probe (5' CTGTCTTACTTTGATAAAACCTC 3') was complementary to nucleotides 2403-2425 of HXB2. The gag reporter probe (5' CCCAGTATTTGTCTACAGCCTTCT 3') was complementary to nucleotides 950-973 of HXB2. All nucleotide positions are those of the GenBank Genetic Sequence Data Bank as accessed through the Genetics Computer Group Sequence Analysis Software Package (Devereau Nucleic Acids ~esearch 1984, 12, 387). The reporter probes were prepared as 0.5 ~M stocks in 2 x SSC (0.3 M NaCl, 0.03 M
sodium citrate), 0.05 M Tris pH 8.8, 1 mg/mL BSA. The biotinylated capture probes were prepared as 100 ~M
stocks in water.

Streptavidin coated plates:
Nunc-immunomodule microtiter plate strips were coated by addition of 200 ~L of streptavidin (30 ~g/mL, Scripps, La Jolla, CA) in freshly prepared 10 mM sodium carbonate (pH 9.6). Plates were incubated overnight at 4C. Streptavidin solution was aspirated from the wells and a blocking buffer composed of phosphate buffered saline (PBS), 20 mg/mL bovine serum albumin (crystalline, nuclease and protease free, Calbiochem) and 100 mg/mL lactose (Sigma) was added to the plates for 3 hrs at room temperature. Blocking buffer was removed from the wells, which were allowed to dry overnight at room temperature and subsequently stored at WO94/19329 PCT~S94/01609 ,~ -194-4C in zip lock bags with desiccant. For the majority of the compound evaluation experiments, streptavidin coated plates were obtained from Du Pont Biotechnology Systems (Boston, MA).

Cells and virus stocks:
MT-2, CEM, and H9 cells were maintained in RPMI
1640 supplemented with 5% fetal calf serum ~FCS), 2 mM
L-glutamine and 50 ~g/mL gentamycin, all from Gibco.
Laboratory strains of HIV-l (RF, MN and IIIB) were propagated in H9 cells in the same medium. Virus stocks were prepared approximately 1 month after acute infection of H9 cells by clarification of the tissue culture medium and storage of aliquots at -70C.
Infectious titers of HIV-l(RF) stocks were 1-3 x 107 PFU
(plaque forming units)/mL as measured by plaque assay on MT-2 cells (see below). Each aliquot of virus stock used for infection was thawed only once. In some cases, infected H9 cells were shifted to Dulbecco's modified Eagle's medium 3-10 days before collection of virus in order to generate virus stocks in medium with low biotin content. Clinical isolates of HIV that had been passaged once in MT-2 cells were used to infect fresh MT-2 cells in RPMI medium. Three days after infection, cells were peileted, resuspended and culture continued in Dulbecco's modified Eagle's medium as above. Virus stocks of clinical isolates were prepared 10-15 days after infection when cytopathic effects were apparent in the culture.
For evaluation of antiviral efficacy, cells to be infected were subcultured one day prior to infection.
On the day of infection, cells were resuspended at 5 x 105 cells/mL in RPMI 1640, 5% FCS for bulk infections or at 2 x 106/m~ in either Dulbecco's modified Eagles medium, or RPMI 1640 medium minus biotin (Gibco, custom formulation) with 5% FCS for infection in microtiter /094/19329 2 1 ~ 6 ~, 3 ~ PCT~S94/01609 plates. Virus was added and culture continued for 3 days at 37C. In some experiments, virus was removed after an initial adsorption period.

preparat;on of ~IV-l infected cell lysates:
HIV-l infected cells were pelleted by centrifugation. After removal of the supernatant the cells were resuspended at a concentration of l x 107 cells/mL in 5 M guanidinium isothiocyanate solution (GED: 5 M guanidinium isothiocyanate ~Sigma), 0.1 M
EDTA, 10~ dextran sulfate). Alternately, cells grown in biotin free tissue culture medium were mixed with 5 M
GED to a final concentration of 3 M guanidinium isothiocyanate, 0.06 M EDTA and 6% dextran sulfate.
HIV RNA assay:
Cell lysates or purified RNA in 3 M or 5 M GED were mixed with 5 M GED and capture probe to a final guan dinium isothiocyanate concentration of 3 M and a final biotin oligonucleotide concentration of 30 nM.
Hybridization was carried out in sealed microfuge tubes or in sealed U bottom 96 well tissue culture plates (Nunc or Costar) for 16-20 hours at 37C. RNA
hybridization reactions were diluted three-fold with deionized water to a final guanidinium isothiocyanate concentration of 1 M and aliquots (150 ~L) were transferred to streptavidin coated microtiter plates wells. Binding of capture probe and capture probe-RNA
hybrid to the immobilized streptavidin was allowed to proceed for 2 hours at room temperature, after which the plates were washed 6 times with DuPont ELISA plate wash buffer (phosphate buffered saline(PBS), 0.05% Tween 20.) A second hybridization of reporter probe to the immobilized complex of capture probe and hybridized target RNA was carried out in the washed streptavidin coated well by addition of 120 ~l of a hybridization WO94/19329 PCT~S94/01609 ~ cocktail containing 4 X SSC, 0.66% Triton X 100, 6.66%
C~ deionized formamide, 1 mg/mL BSA and 5 nM reporter probe. After hybridization for one hour at 37 C, the plate was again washed 6 times. Immobilized alkaline phosphatase activity was detected by addition of 100 ~L
of 0.2 mM 4-methylumbelliferyl phosphate (MUBP, JBL
Scientific) in buffer~ ~2.5 M diethanolamine pH 8.9 (JB~
Scientific), 10 mM MgCl2, 5 mM zinc acetate dihydrate and 5 mM N-hydroxyethyl-ethylene-diamine-triacetic acid). The plates were incubated at 37C. Fluorescence at 450 nM was measured using a microplate fluorometer (Dynateck) exciting at 365 nM.

Microplate based compound evaluation in HIV-1 infected MT-2 cells:
Compounds to be evaluated were dissolved in DMSO
and diluted in culture medium to twice the highest concentration to be tested and a maximum DMSO
concentration of 2%. Further three-fold serial dilutions of the compound in culture medium were performed directly in U bottom microtiter plates (Nunc).
After compound dilution, MT-2 cells (50 ~L) were added to a final concentration of 5 x 105 per mL (1 x 105 per well). Cells were incubated with compounds for 30 minutes at 37C in a CO2 incubator. For evaluation of antiviral potency, an appropriate dilution of HIV-1 (RF) virus stock (50 ~L) was added to culture wells containing cells and dilutions of the test compounds.
The final volume in each well was 200 ~L. Eight wells per plate were left uninfected with 50 ~L of medium added in place of virus, while eight wells were infected in the absence of any antiviral compound. For evaluation of compound toxicity, parallel plates were cultured without virus infection.
After 3 days of culture at 37C in a humidified chamber inside a CO2 incubator, all but 25 ~L of 'Q94/19329 21~ 6 ~ 91 PCT~S94/01609 -l97-medium/well was removed from the HIV infected plates.
Thirty seven ~L of 5 M GED containing biotinylated capture probe was added to the settled cells and remaining medium in each well to a final concentration of 3 M GED and 30 nM capture probe. Hybridization of the capture probe to HIV RNA in the cell lysate was carried out in the same microplate well used for virus culture by sealing the plate with a plate sealer (Costar), and incubating for 16-20 hrs in a 37C
incubator. Distilled water was then added to each well to dilute the hybridization reaction three-fold and 150 ~L of this diluted mixture was transferred to a streptavidin coated microtiter plate. HIV RNA was quantitated as described above. A standard curve, prepared by adding known amounts of pDAB 72 in vitro RNA
transcript to wells containing lysed uninfected cells, was run on each microtiter plate in order to determine the amount of viral RNA made during the infection.
In order to standardize the virus inoculum used in the evaluation of compounds for antiviral activity, dilutions of virus were selected which resulted in an ICgo value (concentration of compound required to reduce the HIV RNA level by 90%) for dideoxycytidine (ddC) of 0.2 ~g/mL. ICgo values of other antiviral compounds, both more and less potent than ddC, were reproducible using several stocks of HIV-l (RF) when this procedure was followed. This concentration of virus corresponded to ~3 x 105 PFU (measured by plaque assay on MT-2 cells) per assay well and typically produced approximately 75%
of the maximum viral RNA level achievable at any virus inoculum. For the HIV RNA assay, ICgo values were determined from the percent reduction of net signal (signal from infected cell samples minus signal from uninfected cell samples) in the RNA assay relative to the net signal from infected, untreated cells on the same culture plate (average of eight wells). Valid WO94119329 PCT~S94/01609 -l98-performance of individual infection and RNA assay tests ~ was judged according to three criteria. It was required Co~ that the virus infection should result in an RNA assay signal equal to or greater than the signal generated from 2 ng of pDAB 72 in vitro RNA transcript. The ICgo for ddC, determined in each assay run, should be between O.l and 0.3 ~g/mL. Finally, the plateau level of viral RNA produced by an effective protease inhibitor should be less than 10% of the level achieved in an uninhibited infection.
For antiviral potency tests, all manipulations in microtiter plates, following the initial addition of 2X
concentrated compound solution to a single row of wells, were performed using a Perkin Elmer/Cetus ProPette.
The HIV inhibitory activity of representative compounds of the present invention in the RNA assay described above is shown in TP~LE 3. The ICgo values in TABLE 3 were determined using the assay conditions described above under HIV RNA Assay. The ICgo values are indicated as follows: +++ = <lO ug/mL; +~ = lO to lO0 ug/mL; + = >lO0 ug/mL. The ++/+ is used in the cases where an ICgo was determined to be >50 ug/mL.

HIV Yield Reduction Cell Assay Materials: MT-2, a human T-cell line, was cultured in RPMI medium supplemented with 5% (v/v) heat inactivated fetal calf serum (FCS), L-glutamine and gentamycin. Human immunodeficiency virus strains, HIV
(3B) and HIV(RF) were propagated in H-9 cells in RPMI
with 5~ FCS. Poly-L-lysine (Sigma) coated cell culture plates were prepared according to the method of Harada et al. (1985) Science 229: 563-566. MTT, 3-(4,5-dimethyl-thiazol-2yl)-2,5-diphenyltetrazolium bromide, was obtained from Sigma.

'O 94/19329 21~ 6 ~ ~ 4 PCT/US94/01609 Method: Test compounds we-e dissolved in dimethylsulfoxide to 5 mg/mL and serlally diluted into RPMI medium to ten times the desired final concentration. MT-2 cells (5 x 105/mL) in 2.3 mL were 5 mixed with 0.3 ml of the appropriate test compound solution and allowed to sit for 30 minutes at room temperature. HIV (3B) or HIV (RF) (-5 x 105 plaque forming units/mL) in 0.375 ml was added to the cell and compound mixtures and incubated for one hour at 36C.
The mixtures were centrifuged at 1000 rpm for 10 minutes and the supernatants containing unattached virus were discarded. The cell pellets were suspended in fresh RPMI
containing the appropriate concentrations of test compound and placed in a 36C, 4% CO2 incubator. Virus was allowed to replicate for 3 days. Cultures were centrifuged for 10 minutes at 1000 rpm and the supernatants containing cell free progeny virus were removed for plaque assay.
The virus titers of the progeny virus produced in the presence or absence of test compounds were determined by plaque assay. Progeny virus suspensions were serially diluted in RPMI and 1.0 mL of each dilution was added to 9 ml of MT-2 cells in RPMI. Cells and virus were incubated for 3 hours at 36C to allow for efficient attachment of the virus to cells. Each virus and cell mixture was aliquoted equally to two wells of a six well poly-L-lysine coated culture plate and incubated overnight at 36C, 4% CO2. Liquid and una.tached cells were removed prior to the addition of 1.5 mL of RPMI with 0.75% (w/v) Seaplaque agarose (FMC
Corp.) and 5% FCS. Plates were incubated for 3 days and a second RPMI/agarose overlay was added. After an additional 3 days at 36C, 4% CO2, a final overlay of phosphate-buffered saline with 0.75% Seaplaque agarose and 1 mg MTT/mL was added. The plates were incubated overnight at 36C. Clear plaques on a purple background WO94/19329 PCT~S94/01609 were counted and the number of plaque forming units of virus was calculated for each sample. The antiviral activity of test compounds was determined by the percent reduction in the virus titer with respect to virus grown S in the absence of any inhibitors.

HIV T.ow Multiplicity Assay Materials: MT-2, a human T-cell line, was cultured lO in RPMI medium supplemented with 5% ~v/v) heat inactivated fetal calf serum (FCS), ~-glutamine and gentamycin (GIBCO). Human immunodeficiency virus strains HIV (3B) and HIV (RF) were propagated in H-9 cells in RPMI with 5% FCS. XTT, benzene-sulfonic acid, 15 3,3'-[l-[(phenyl-amino)carbonyl]-3,9-tetrazolium]bis(9-methoxy-6-nitro)-, sodium salt, was obtained from Starks Associates, Inc.
Method: Test compounds were dissolved in dimethyl-sulfoxide to 5 mg/ml and serially diluted into RPMI
20 medium to ten times the desired final concentration.
MT-2 cells ~5 x 104/O.l mL) were added to each well of a 96 well culture plate and 0.02 m~ of the appropriate test compound solution was added to the cells such that each compound concentration was present in two wells.
25 The cells and compounds were allowed to sit for 30 minutes at room temperature. HIV(3B) or HIV(RF) (~5 x 105 plaque forming units/mL) was diluted in medium and added to the cell and compound mixtures to give a multiplicity of infection of 0.01 plaque forming 30 unit/cell. The mixtures were incubated for 7 days at 36C, during which time the virus replicated and caused the death of unprotected cells. The percentage of cells protected from virus induced cell death was determined by the degree of metabolism of the tetrazolium dye, XTT.
35 In living cells, XTT was metabolized to a colored formazan product which was quantitated l094/19329 21 ~ 6 5 ~ ~ PCT~S94/01609 spectrophotometrically at 450 nm. The amount of colored -formazan was proportional to the number of cells protected from virus by the test compound. The concentration of compound protecting either 50% (IC50) or 90% (ICgo) with respect to an uninfected cell culture was determined.

The HIV inhibitory activity of representative compounds of the present invention in the whole cell infectivity assay described above is shown in Table E.

Table E

Example Number I~go lC +++
lX +++
1 Z +++
lAC +++
lAF +++
lAH +++
lAQ +++

The ICgo values in Table 2 are indicated as: +++ =
<lO ug/mL.
In the Tables herein the Ki values were determined using the assay conditions described above under HIV
Protease Inhibtion Assay. The Ki values are indicated as follows: +++ = <lO nM; ++ = lO nM to l ~M; + = >l ~M.
In the Tables herein the ICgo values were determined using the assay conditions described above under HIV RNA Assay. The ICgo values are indicated as follows: +++ = ~lO ~g/mL; ++ = lO to lO0 ~g/mL; + = >100 ~g/mL. The ++/+ is used in the cases where an ICgO was determined to be >50 ~g/mL.

WO94/19329 PCT~S94/01609 HIV-1/CEM Mouse Xenotransplant Animal Model The HIV inhibitory activity of the presently claimed compounds in an animal was demonstrated in an animal model wherein HIV-l infected human CEM lymphcyte cells were xenotransplanted in nude mice and the growth of HIV in vivo in such xenotr~nsplanted CEM cells was monitored. The in vivo assay using this model consisted of testing compound in a prophylactic manner, whereby the daily dose of agent was administered to a group of mice one day prior to HIV challenge. The test and control animals were followed with drug for a period of 25 days. Upon the experiment termination and animal sacrifice, serum p24 antigen levels, and relative percent indirect immunofluorescence assay (IFA) positive cell numbers were determined as the experimental endpoint (as described below).

Cell Line and HIV Culture: CCRF-CEM or CEM, a well characterized tumorigenic and HIV permissive cell line, was obtained from the American Type Culture Collection, Rockville, MD. (AYCC CC~ 119) and maintained in RPMI
1640 medium with 15% heat inactivated fetal calf serum and 50 ~g/ml gentamicin as described by Wetherall (In:
Schellekens and Horzinek, eds., ~nimal Models in AIDS, Elsevier, Amsterdam, 1990, pp 291-302). The cells were propagated at 37C in a humid 5% CO2 atmosphere. Stocks of the HIV-1 isolate HTLV-IIIB were acquired from Dr. Neal T. Wetherall, Vanderbilt University, and were harvested from cultures of chronically-infected CCRF-CEM
(CEM) cells obtained from the American Type Culture Collection. For routine propagation, virus containing culture fluids were clarified of cells by low speed 2156.~1 i~O 94/19329 PCTtUS94/01609 _ centrifugation and passed through 0.45 ~m filters.
Infectious virions were quantitated on MT-2 cells in microculture using cytopathic effect ~CPE) as the end point for infection.(Scudiero et al., Cancer Res. 1988, 48, 4827-4833). The 50% tissue culture infectious dose (TCIDso) was calculated by the method of Reed and Muench (Amer J. Hygiene, 1938, 27, 493-497). CCRF-CEM cells used for virus xenotransplantation were acutely infected with a stock dilution of HIV-1 at a MOI (input multiplicity of infection) of 0.01 followed by adsorption for 1 h at 37 C.

Anim~ls ~nd Cell/HIV Tr~nsl~lant~tion: Sprague Dawley 21+2 day old female nude (nu/nu) mice were exposed to 450 Rad's of 137Cs irradiation. Twenty-four hours later, the drug dosing was started. CEM cell cultures, both HIV infected or uninfected, were harvested and washed with serum free media and reharvested. Cells of a specified number were suspended in 0.2 ml media and injected subcutaneously (s.c.) into the intrascapular region of the mice, 24 h after drug dosing commenced.
The mice were observed the following day and at least three times a week for the duration of the experiment.
At each of these time points the animal group weight is determined, and the inoculation site is gently palpated to determine the date of gross tumor onset. At the termination of an experiment, the animals were anesthesized and euthanized by exsanguination.

p29 Fnzyme Immunoass~y: The p24 enzyme immunoassay ~EIA) used was the unmodified procedure commercially available from Coulter Corporation (Hialeah, Fl), which uses a murine monoclonal antibody to the HIV core - protein coated onto microwell strips. The assay detects 35 p24 gag antigen in culture supernatants, plasma, and W094/19329 PCT~S94tO1609 ~ -204-c~ serum. ~on-specific cross reactions with mouse serum ~ J--~
~ are not seen with this assay.

C~ In~irect Immunofluorescence A~s~y (IFA): HIV-1 antigen-expressing cells are detected by IFA using the method described by Montefiori and Mitchell (Virology 1986, 155, 726-731). Slides were prepared by air drying and fixing in a 50:50 mixture of acetone/methanol for 30 minutes, followed by adding a 1:200 dilution in PBS-BSA
(phosphate buffered saline containing 0.1% globin-free bovine serum albumin) of high-titer serum from pooled HIV-l positive individuals (positive by Western immunoblot for all HIV-1 antigens).
Anti-HIV IgG then will be detected using a 1:200 dilution of fluorescein-conjugated, IgG fraction of goat anti-human IgG (heavy and light chains specific, Cappel) containing Evan's blue counter stain. Slides were mounted using 50% glycerol and cells examined for fluorescence using a Zeiss KF-2 Epi-fluorescence microscope.

PreD~r~tion ~nd A~min;str~t;on of Com~oun~s: Compounds were mixed with 0.25% (wt/v) methylcellulose solution, warmed to 37 C, and homogenized. One drop of Tween 80 was added to the stock suspension (1 drop/10-20 ml) and mixed by vortexing. Dilutions of the stock suspension were made in methylcellulose/Tween 80 and stored at 4 ,C
for no more than one week. The suspensions were gently warmed and vortexed after removal from the refrigerator and prior to injection to ensure proper suspension. The compounds were administered BID, i.p. at doses of 30, 100, and 300 mg/kg or 60, 200, and 600 mg/kg/day.
.

The HIV inhibitory activity in vivo in the HIV/CEM
mouse xenotransplant animal model for a representative compound of the invention is shown in Table F below.

2~ S9~
_ 094/19329 PCT~S94/01609 Data in the p24 EIA and IFA is expressed as a percent of the control untreated levels.

Table F

Compound pQ~ p24 FIA IE~

Ex. 5I 300 mg/kg bid 37.8 51.5 ip Ex. 5I 100 mg/kg bid 76.4 111.3 ip Ex. 5I 30 mg/kg bid 61.5 116.7 ip HIV-1 Protease Transgenic Mouse Model The in vivo HIV protease inhibitory activity of t-he presently claimed compounds was also demonstrated using a transgenic animal model system wherein the HIV-l protease protein was expressed in the mouse lens using a transgene where the HIV-1 protease coding sequence was placed under the transcriptional control of the mouse alpha A-crystallin promoter. Such transgenic animals were found to display a HIV protease-mediated cataract phenotype. The HIV protease inhibitory activity of the presently claimed compounds was measured in this animal system as a delay or prevention of the onset of cataract appearance in the test animals.
Plasmid Constructlon: The mammalian expression vector pMSG (Pharmacia) was modified by replacing the MMTV LTR promoter with the a12-bp Bgl II-BamHI mouse alpha A-crystallin promoter fragment (Chépelinsky et al.
Proc. Natl. Acad. Sci. USA, 1985, 82, 2334-2338). The SV40 early splice and polyadenylation signals were retained and this plasmid was renamed pCSV 19. A single W094/19329 PCT~S94/01609 c~ chain, tethered dimeric form of the active HIV-1 ~r~ protease gene (BAA; Cheng et al., Proc. Natl. Acad. Sci.
~ USA, 1990, 87, 9660-9664 and Cheng et al., Gene, 1990, C~ 87, 243-248) was modified for mammalian cell expression by replacing nucleotides 7 to 90 with CGTAATAGAAGGAGATATAACCATGGAG. The gene was cut with EcoRI and Hind III and after blunt-end repair cloned into the Sma I site of the pCSV 19 , thus producing pCSV 19-BAA. The mutant form of the construct (BA*A*) was produced by site directed mutagenesis (GAT to GGT) resulting in the change of aspartic acid (25th residue) to glycine in both monomers resulting in an inactive form of the protease.
Construction of Tr~ns~enic M;ce: 2.5 kb Hind III
fragments from the pCSV 19-BAA and pCSV 19-BA*A*
plasmids were isolated (modified from Sambrook at al., Molecul~r Clon;ng, A T~hor~tory M~nu~l, 2nd Ed., 1989, Cold Spring Harbor Laboratory) and used for the construction of transgenic mice using the pronuclei injection method (Hogan et al., M~nlpul~t;ng the Mouse Fmhryo. A T~hor~tory M~nu~l, 1986, Cold Spring Harbor Laboratory). Mice were screened for the HIV-1 protease transgene by either Southern blot or Polymerase Chain Reaction (PCR) methods. Mice of the FVB/N strain (Taketo et al., Proc. Natl. Acad. Sci. USA, 1991, 88, 2065-2069) were used for the construction and breeding of these transgenic mice, and were originally obtained from Dr. Carl Hansen (NIH) and bred in our facility.
Subsequently, the mice were purchased from Charles River Laboratory (Portage, MI).
I~entific~tion of Tr~nsgenic Mice: Southern blot analysis (Sambrook et al. vide supra) was performed on DNA purified from tail biopsies (Hogan et al. vide supra) using the 2.5 kb Hind III fragment from pCSV 19-BAA as the probe (32p labeled). DNA for PCR wasprepared from tail biopsies by overnight digestion with ~O 94/19329 21~ ~ S 9 ~ PCT/US94/01609 0 . 5 mg of Proteinase K (Boehringer-Manheim GmbH) in 100 111 of water and 0. 025% SDS. PCR primers specific for the mouse c-fos gene and and the transgene's SV40 segment were used as an internal control in some 5 samples. Each PCR reaction contained 1-2 ~11 of tail digest, 60 llg of each primer, 200 llM of Perkin Elmer Cetus dATP, dCTP, dGTP,TTP (buffered at pH 8.8) and up to 5 units of Perkin Elmer Cetus Ampli/Taq polymerase.
The reactions were run on a Perkin Elmer DNA Thermal Cycler as follows: 1 min at 94 C, 3 min at 67 C (2 sec extension/cycle) for 35 cycles. The PCR products were analyzed by gel electrophoresis (1% agarose,0. 5 ~g/ml of ethidium bromide), and tail samples with a 625 PCR
fragment (SV40 specific) were considered positive for the transgene. Mice bearing the active HIV-1 protease transgene were also identified by their cataract phenotype. Progeny of homozygous parent(s) were 100%
positive for the transgene and did not require Southern/PCR analysis.
Dosing Regimen: Compounds to be tested were pulverized by manual grinding with mortar and pestle.
Just prior to dosing of mice, the compound was suspended in 0. 25% methylcellulose/Tween 80 solution, homogenized in a manual Dounce homogenizer and sonicated for 10 min in a sonicating water bath. The volume of suspension was adjusted so that the amount of compound required for dosing one mouse was 0.1-0. 2 mL. In order to maintain the required mg/kg dose, an average mouse weight for each group was determined twice a week and the amount of compound adjusted accordingly. Intraperitoneal (ip) and oral (po) dosing was performed using 25 G 5/8 in.
injection and 20 G 1-1/2 in. feeding needles, respectively. The dosing was performed twice a day (bid) and the doses were administered 6-8 h apart. Eyes 35 of control and dosed animals were examined daily by up to 3 individuals, and the day when cataracts became WO94/19329 PCT~S94/01609 c~ -208-~r3 visible to the naked eye was recorded as the ~ experimental end point (days after birth). Because C~ cataracts do not always develop in both eyes of individual mice on the same day, each eye was scored as 5 an independent observation. Results from individual eyes were used to calculate the average (mean) day of cataract development and its standard deviation for each group.
~ye Histology: Eyes were dissected from euthanized lO mice and fixed with 10% neutral buffered formalin. Eye histology was performed at the Experimental Pathology Laboratories (EPL), Inc., Sterling, VA.

Ch~r~cteriz~tion of HIV-l Prote~se Tr~nsgenic Mlce:
Gross ~ppe~r~nce: Three lines of mice with the active (BAA) and three lines with the mutant (BA*A*) form of HIV-l protease gene were established. The eyes of mice with the mutant gene appear identical to those 20 of normal mice (Fig. lA), but bilateral cataracts develop in the eyes of mice with the active gene. This phenotype is easily detected even by an untrained observer because the inside of cataract eye is opaque and white/gray in color (Fig. lB). Cataracts appear 25 similar in all transgenic lines.
Time of c~t~r~ct ~evelopment: The time when cataract develops varies among the three transgenic lines bearing the active HIV-l protease gene (BAA, Appendix 2). Mice of the Tg 61 line develop the 30 phenotype prenatally (dayl8 in utero). Mice of the remaining two lines (Tg 62, and 72) develop the cataracts postnatally (at 29-30 days). Among the mice of each individual line, the time difference in cataract development is less than one week. None of the mice 35 bearing the mutant form of the gene (BA*A*) have developed cataract. Based on this _~094/19329 21~ ~ ~ 3 4 PCT~S94/01609 genetic evidence that cataracts develop only in transgenic mice with the active but not inactive form of HIV-1 protease we conclude this phenotype is caused by the protease's enzymatic activity.
~ethod:
A single homozygous male mouse (Tg 72-110) was mated - with three non-transgenic FVB/N females. From each litter, 4-5 mice were used as controls, i.e., were dosed with vehicle only (ip or po route). The remaining mice of each litter (5-7) were dosed (ip or po) with test compound. When mice were 15 days old, dosing began in two groups of 5 mice each with ip injections of 100 mg/kg/BID. The compound was administered ip to the mice in the first group until all had bilateral cataracts.
For the second group, the compound was administered ip for 5 days only and from day 20 via the po route until cataracts appeared. A third group (7 mice) was dosed ip starting on day 15 but with 400 mg/kg/bid. On day 41, when no cataracts had yet developed in this last group, three were removed from treatment, and the remaining four were dosed until day 52. All mice were observed daily for cataract formation.

The results for representative compounds of the present invention in the above HIV-1 transgenic mouse model are shown in Table G below. The results show that the representative compounds of the present invention effectively inhibit HIV protease activity in vivo.

Table G

F.X. No- Dose/Route Mouse Cataract Delay in Density Cataract ~i of control) (relative tc control~

W O 94/19329 PCTrUS94/01609 lAQ 60 mg/kg ip Tq 61 46.6 preg days 11-18 lAQ 85 mg/kg ip Tq 61 20.6 preg days 11-18;

lX 15 mg/kg ip Tq 61 28.8 preg days 11-18 lX 5 mg/kg ip Tq 61 39.8 preg days 11-18 5I 80 mg/kg bid Tq72 6 days ip days 15-19/
po days 20 & ff 5I 50 mg/kg bid Tq 72 3.6 days ip days 15-20/
po days 21 & ff 5U 100 mg/kg bid ip Tg 72 5 days 5U 400 mg/kg bid ip Tq 72 days 15-42 _/094/19329 215 6 ~ 9 4 PCT~S94/01609 Dos~e ~n~ Form~ tlon The antiviral compounds of this invention can be administered as treatment for retroviral infections by any means that produces contact of the active agent with the agent's site of action, the retroviral protease, in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The compounds of the present invention can be administered in oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
The compounds of the present invention may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed for the inhibition of HIV and the treatment of HIV
infection.
The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired.

WO94/19329 PCT~S94/01609 ~ -212-,c~ By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses may range from about 1 to about 10 mg/kg/minute during a constant rate infusion.
Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
The compounds for the present invention may also be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches wall known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittant throughout the dosage regimen.
In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol 094119329 215 6 ~ 1 PCT~S94/01609 and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamallar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, WO94/19329 PCT~S94/01609 ~9 polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
Dosage forms (compositions suitable for administration contain from about l milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95%
by weight based on the total weight of the composition.
The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch,cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours.
Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium 21~;G ~91 -~,094/19329 PCT~S94/01609 bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
Also used are citric acid and its salts and sodium EDTA.
In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciénces, Mack Publishing Company, a standard reference text in this field.
~seful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Gelatin Capsules A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.

Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 - milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose,
11 milligrams of starch and 98.8 milligrams of lactose.

WO94119329 PCT~S94/01609 Appropriate coatings may be applied to increase palatability or delay absorption.

Inject~hle A parenteral composition suitable for administration by injection is prepared by stirring l.5%
by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.
Suspension:
An aqueous suspension is prepared for oral adminlstration so that each 5 mL contain lO0 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, l.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

The compounds of formula ~I) of the present invention may be administered in combination with a second therapeutic agent, such as a second HIV
inhibitory agent or other therapeutic agent for treatment of HIV associated disease conditions. The compound of formula (I) and such second therapeutic agent can be administered separately or as a physical combination in a single dosage unit, in any dosage form and by various routes of admir.istration, as described above. The compound of formula (I) may be formulated together with the second therapeutic agent in a single dosage unit (that is, combined together in one capsule, tablet, powder, or liquid, etc.). When the compound of formula (I) and the second therapeutic agent are not formulated together in a single dosage unit, the compound of formula (I) and the second therapeutic agent may be administered essentially at the same time, or in any order; for example the compound of formula (I) may be administered first, followed by administration of the 21~ 6 ~ g ~
_/094/19329 PCT~S94/01609 second agent. When not administered at the same time, preferably the administration of the compound of formula (I) and the second therapeutic agent occurs less than about one hour apart, more preferably less than about 5 to 30 minutes apart.

The present invention also includes pharmaceutical kits useful, for example, for the treatment of HIV
infection, which comprise one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I. Such kits may further ir.clude, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Printed instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.
In the present disclosure it should be understood that the specified materials and conditions are important in practicing the invention but that unspecified materials and conditions are not excluded so long as they do not prevent the benefits of the invention from being realized.

The Tables below provide representative compounds of formula ~I) of the present invention. Specifically incorporated herein by reference is the disclosure of PCT International Application Publication Number Wo 93/07128.

WO94/19329 PCT~S94/01609 -~
., The structures of the Examples below are shown in Table 2d through 2u and set forth representative compounds of the present invention.

Example 9R

A solution of Example 90 (50 mg, 0.066 ~mol) in methanol (2 ml) was treated with sodium borohydride ~25 mg, 0.66 mmol). After the reactions was completed, the mixture was washed with hydrochlcric acid(2N), water and dried with magnesium sulfate. Concentration gave a residue which was purified to give a good yield of the desired product: MS 629.2015 for C31H3gN2OrBr; 1H NMR
(CD30D); ~7.42-7.01 (m, 18H), 4.79-9.60 (m, 3H), 3.65-3.58 (m, 4H), 3.08-2.78 (m, 6H), 1.40-1.37 (m, 3H);
13CNMR (CD3OD): ~ 163.73, 148.11, 142.08, 141.19, 139.26, 133.64, 131.75, 131.45, 130.61, 129.62, 129.57, 129.19, 129.15, 127.61, 127.49, 127.17, 126.05, 123.46, 72.06, 71.92, 70.59, 68.20, 6.27, 57.12, 57.0g, 53.68, 25.55.

Example 9S

Prepared according to the general alkylation and deprotection procedures (see Procedure 5) MS: 603.2163 (M+H+), 100~); HR Mass Spec: 603.2163 for C3sH37N2O3Cl2 (M+H); 1HNMP~ (CD30D) ~7.3S,-7.02 (m, 18H), 4.68 (d,J=14.3 H2, 2H), 4.55 (S, 4H!, 3.65-3.59 (m,4H), 3.09-3.04 (m, 2H), 3.00 (d,J=14.3 H2, 2H), 2.93-2.84 (m, 2H), 13HNMR (CD3OD, ppm): 162.26, 139.74, 138.47, 138.16, 129.35, 129.16, 128.82, 128.48, 128.09, 127.38, 125.97, 70.47, 66.14, 55.69, 45.19, 32.20.

Example 15XC

21~6~j3 1 ~094/19329 PCT~S94/Q1609 A solution of Example 9S (100 mg., 0.166 mmol) in tetrahydrofuran (1 ml) was treated with methyl amine (90% in H2O, 1 ml) and the resulting solution was stirred at room temperature overnight. After the solution was concentrated on a rotary evaporator, the residue was obtained and was purified on Prep. T.L.C. to give a good yield of a neutral product which was acidified with 4M HCl in ether to give the desired product. MS: 593 (M+H+, 100%); HRMS: 593.2483 for C37HgsN4O3; 1H NMR (CD30D) ~ 7.38-7.07 (m, 18H), 4.69 (d, J=14.3 Hz,2H), 3.93 (S, 4H), 3.66-3.64 (m, 4H), 3.09-3.02 (m, 4H), 2.90-2.81 (m, 2H), 2.52 (S, 6H);
13CNMR (CD30D, ppm) 163.75,141.30, 140.85, 139.58, 130.70, 130.64, 129.79, 129.51, 129.32, 128.85, 127.41, 71.91, 67.55, 57.22, 56.21, 35.50, 33.63.

Example 15XE

To a suspension of NaH (240 mg, 60% in mineral oil, 6 mmol) in DMF ~4mL) was added MEM-protected Example llN
(694 mg. 0.98 mmol), and 3-chloromethylpyridine (492 mg., 3 mmol); and the resulting mixture was stirred at room temperature overnight. After the reaction mixture was filtered through Buchner funnel, the filtrate was treated with 4M HCl in dioxane(15 ml) for 16 hours and then was neutralized with sat. NaHCO3, to pH=7. After general workup, the resulting crude was purified on T.L.C. plate using ethyl acetate to give the product in a good yield. MS: 538 (M+H~, 100%); HRMS 538.2693 for C33H36O4N3 13C NMR (CD30D) ppml63.67, 151.07, 149.16, 141.11, 139.33, 135.91, 130.59, 130.51, 130.48, 129.62, 128.53, 138.24, 127.51, 127.47, 135.28, 71.96. 71.80, 68.68, 66.98, 64.81, 56.71, 55.10, 33.73, 33.66.
-Example 15XF

WO94119329 PCT~S94/01609 To a solution of Exampie 9S (100 mg, 0.166 mmol) in DMF t2 ml) was added K2C03 ~138 mg, 1.0 mmol) and diethylamine hydrochloride (80 mg, 1.0 mmol) and the ~ resulting mixture was stirred for 24 hrs.- The mixture was diluted with EtOAc and washed with water. After the organic layer was dried over MgSO4, the solution was concentrated under vacuum to give 70 mg. of the product.
MS: 677 (M+H, 100%); HRMS: 677.4444 for C43Hs7N4O3; 1H
NMR(CDC13): ~ 7.26-6.96 (m, 18H), 4.84 (d,J=14.3 Hz, 2H), 3.50-3.46 (m, 4H), 3.35 (s, 4H), 2.97-2.78 (m, 6H), 2.36 (q, J=6.9 Hz, 4H), 0.90 (t, J=6.9 Hz, 6H), 13C NMR
(CDCl3,) ~161.98, 139.52, 138.52, 138.17, 129.99, 129.46, 128.46, 128.25, 128.84, 127.84, 126.30, 71.09, 64.23, 56.98, 55.54, 46.~2, 32.62, 11.31.
Example 15XG

The experimental procedure is similar as preparation of Example 15XF. MS: 667. (MtH, 100~);
HRMS: 667.3394 for C41H43N6O3; 13C NMR (CD30D, ppm):
163.76, 141.27, 141.21, 138.82, 130.62, 130.28, 129.70, 129.56, 127.88, 127.45, 71.93, 67.37, 57.11, 51.36, 33.75; 1H NMR (CD30D): ~ 7.69, (s, 2H), 7.35-6.92 (m, 22H), 5.19 (s, 4H), 4.62 (d,J=14.3 Hz, 2H), 3.52-3.50 (m, 4H), 3.03-2.70 (m, 6H).

Example 15XH

To a solution of MEM-protected Example 4P (366 mg, 0.5 mmol) in THF (15 mL) at -78C was dropwise added tBuli (1.7 M, 2.59 ml, 4.4 mmol), and the resulting solution was allowed to warm to room temperature. The mixture was diluted with ether washed with saturated NH4Cl, water, and dried ever MgSO4. After concentrated 3~ on a rotary evaporator, a residue was o~tained and was purified on T.L.C. plate with 10% EtOAc in CH2Cl2 to 21~91 ~094/19329 PCT~S94/01609 give a good yield of the product; MS: 675.5 (M+H), 100%); HRMS: 675.3805 for C43Hs1N2Os; lH NMR (CDC13): ~
7.56-7.54 (m, 2H), 7.43 (s,2H), 7.33-7.25 (s,lOH), 7.08-7.06 (m, 4H), 4.88 (d,J=14.3 Hz, 2H, 3.64-3.53 (m,4H), 3.09-2.87 (m, 6H), 1.29 (s, 18H); 13C NMR (CDC13): ~
209.24, 161.87, 139.35, 139.05, 138.23, 131.66, 129.43, 128.70, 128.36, 126.96, 126.62, 71.58, 64.76, 55.80, 44.21, 32.89, 27.94.

Example 15XI

To a solution of trifluoromethyl trimethylsilane (312 mg. 2.2 mmol), in THF (3 ml) in an ice-water bath was added a solution of MEM-protected Example 5V (400 mg, 0.55 mmol) in THF (2 mL); and then to the resulting solution was added tetrabutylammonium fluoride catalyst (TBAF, 3 mg, 0.011 mmol. After the reaction mixture was stirred at 0C for 40 min., the cooling bath was removed and the reaction mixture was brought io room temperature and was continued for an additional hour. The reaction mixture was then treated with 4M HCl in dioxane (5 mL) overnight. General worl-up and purification on TLC plate with 20% EtOAc in CH2C12 to furnish a quantitative yield of Example 15XI: MS: 703 (M+H, 100%); HRMS: 703.2611 for C37H37N2OsF6; 13C NMR (CDC13, ppm) 162.40, 139.70, 138.02, 135.76, 129.61, 129.18, 128.30, 128.14, 126.74, 126.58, 126.03, 71.39 (q, J=32.4 Hz), 70.55, 65.88 (d, J=6.2 Hz), 55.66, 32.12; 19F NMR (CDC13) 79.72 (q.J=6.0 H2); 1H NMR (CDC13): ~7.83-7.04 (m, 18H), 5.01-4.98 (m, 2H), 4.72 (d,J=14.2 Hz, 2H), 3.67-3.58 (m, 4H), 3.09-2.92 (m, 6H).

Example 15XJ

To a solution of N-SEM protected imidazole (552 mg., 2.78 mmol) in THF (10 ml) at -78C was added n-Buli WO94/19329 RCT~S94/01609 ~r~ (1. 6M, 2.5 mL, 4 mmol) dropwise and the resulting solution was allowed to warm to -20C over one hour.
After a solution of MEM-protected 5V(510 mg., 0.697 mmol) in THF (10 mL) was added, the reaction mixture was allowed to warm to room tempera~ure and was stirred for an additional hour. Workup by general procedure and purification on T.L.C. plate with 50% ether in CH2Cl2 gave an oily intermediate (160 mg., 21.3% of yield), which was deprotected with 4M HCl in dioxane to give the 10 product in good yield: MS: 695 (M+H, '00%); HRMS:
695.2977 for C41H3gN6Os, 13C NMR (CD30D, ppm): 183.16, 164.07, 146.27, 141.34, 139.59, 137.92, 135.08, 133.06, 130.70, 130.53, 120.74, 120.57, 127.45, 71.92, 66.93, 56.72, 33.72; lH NMR (CD30D): ~ 8.50 (s, 2H), 8.29-8.27 15 (m, 2H), 7.61-7.21 (m, 18H), 4.94 (d, J=14.3 Hz, 2H), 3.77-3.72 (m, 4H), 3.20-3.09 (m, 6H).

Example 15XK

A solution of Example 15XE in MeOH was acidified with 4M HCl in dioxane to give the product: lH NMR
(CD30D): ~ 8.58 (d,J=l.l Hz, 2H), 8.42 (dd,J,=l.l Hz, J=4.0 Hz, lH), 7.78 (bs, lH), 7.30-7.00 (m, 12H), 6.78 (d,J=6.4 Hz, 2H), 4.61 (d,J=14.2 Hz, lH), 9.32 (dd, 25 J=39.8Hz, J=14.2Hz, 2H), 4.03-3.99 (m, lH), 3.71-3.62 (m, 4H), 3.21 (d,J=13.2 Hz, lH), 3.02-2.90 (m, 4H), 2.72-2.66 (m, lH), 13C NMR (CD30D, ppm) 163.80, 148.66, 143.75, 142.32, 141.38, 140.85; 140.44, 137.59, 130.46, 129.60, 129.54, 128.43, 128.2C, ~27.66, 127.53, 71.54, 30 70.84, 68.41, 67.56, 64.67, 56.67, 54.02, 34.36, 33.05.

Example 15XL
-The experimental procedures is similar as preparations Example 9N: MS: 632 (M+N14, 100%); HRMS:
615.2853 for C3gH3gN2Os; lH NMR (CD30D): ~7.32-6.99 (M, ~094/19329 215 6 ~ 9 -i PCT~S94101609 18H), 4.82 (d,J=1.3 Hz, 2H), 4.65 (d,J=13.9 Hz, 2H), 4.37 (s, 2H), 3.31-3.30 (m, 4H); 3.08-3.04 (m, 2H), 3.98 (d,J=13.9 Hz, 2H), 2.89-2.84 (m, 2H).

Example 15XM

To a solution of MEM-protected-m-i~dobenzyl cyclic urea (980 mg., 1.07 mmol) in THF (10 ml) at -78C was added t-BuLi (1.7M in hexane, 2.64 mL, 4.5 mmol) and the resulting solution was stirred for another 30 mins. The N,N-dimethyl trifluoroacetamide (560 mg., 4 mmol) was added and the mixture was stirred for 2.5 hours. The mixture was diluted with ether and acidified with 2N HCl to pH=1. The ether layer was neutralized and washed with water, brine, and dried over MgSO4. The solution was concentrated to give a residue which was purified on silica gel column with gradient solvents (0-20% ethyl acetate in CH2Cl2) to give an oily intermediate (350 mg).
The oil was dissolved in CH2C12 (5 ml) and was treated with 4M HCl in dioxane overnight. General workup and purification on Prep. T.L.C. plate with 40%
EtOAc in CH2Cl2 gave the the product (300 mg) in 40.2%
yield. MS: 699.4 (M+H, 100%); HRMS: 699.2286 for C37H33N2OsF6; 1H NMR (CD3COCD3): ~ 7.97 (bs, 4H), 7.73-7.59 (m, 4H), 7.14-6.96 (m, 10H), 4.75 (d,J=13.9 Hz, 2H), 3.72-3.63 (m, 4H), 3.32 (d,J=14.3 Hz, 2H), 3.18-3.13 (m, 2H), 2.95-2.79 (m, 4H); 19FNMR (CD3COCD3): ~
72.54; 13C NMR (CD3COCD3) 180.&3 (q,J=34.3 Hz), 162.39, 141.27, 141.06, 137.90, 131.60, 130.43, 130.35, 130.23, 129.73, 129.16, 127.C5, 117.62 (q,J=291.4 Hz), 71.83, 67.40, 56.55, 33.59.

Example 15XN

WQ94/19329 PCT~S94/01609 To ~ solution of MEM-protected 4P ~750 mg, 1.02 mmol) in THF (20 mL) was added ethyl magnesium bromide (2M in Et2O, 4 mL) and the resulting mixture was allowea to reflux for 2 hours. After removing all solvents on rotary evaporator, the resulting residue was dissolved in MeOH (15 mL) and was treated with 4M HCl in dioxane overnight. After general workup and purification on T.L.C. plate with 40% EtOAc in CH2Cl2. Example 15XN was obtained (600 mg) in 95.2% yield. MS: 636 (M+N H4, 100%); HRMS: 619.3181 for C3gH43N2Os; 1H NMR (CDCl3):
7.77-7.71 (m, 4H), 7.39-7.22 (m, 10H), 7.06-7.03 !m, 4H), 4.83 (d,J=14.3 Hz, 2H), 3.75 (bs,2H) 3.64-3.60 (m,2H), 3.53 (S, 2H), 3.14 (d,J=14.31 Hz, 2H), 3.10 (d,J=11.6 Hz, 2H), 2.95-2.86 (m, 2H), 2.87 (q,J=7.3 Hz, 4H), 1.12 (t,J=7.3 Hz, 6H); 13C NMR (CDC13, ppm) 200.85.
161.88, 139.36, 138.72, 136.92, 133.70, 129.31, 128.75, 128.66, 128.54, 127.09, 126.50, 71.28, 65.28, 55.84, 32.70, 31.70, 8.04.

Example 15XP

The experimental procedure of Note 5, Table 2D was followed: MS: 649 (M+H+, 100%); 1H NMR (CD3OD): ~ 7.62-7.08 (m, 18H), 4.76 (d,J=13.9Hz, 2H), 3.63-3.60 (m, 4H), 3.10-2.91 (m, 4H), 2.97 (d,J=13.9 Hz, 2H), 2.78 (q,J=7.7 Hz, 4H), 1.06 (t,J=7.7 Hz, 6H); 13C NMR(CD3OD, ppm) 162.46, 158.95, 139.71, 138.00, 136.45, 129.31, 129.17, 128.29, 128.11, 126.8i, 126.02, 125.09, 70.53, 65.63, 55.57, 32.17, 18.67, 9.88.
Example 15XQ

To a solution of MEM-protected-m-iodobenzyl cyclic urea (lg, 1.07 mmol) in THF (15 mL) at -78C was dropwise added t-Buli (1.7M in hexane, 2.5 mL) and the resulting solution was stirred for another 30 minutes.

21~5~91 ~094/19329 PCT~S94101609 Sulfur dioxide gas was introduced into the basic solution at the same temperature for 15 mins. Iihe mixture was allowed to warm to R.T. over 2 hours and then was cooled to -78C again. Sulfuryl chloride 5 (0.72g., 5.35 mmol) was added and the resulting mixture was allowed to warm to R.T. and stirred overnight.
After all volatile reagents and sol~ents were removed under vacuum, the r~sidue was dissolved in THF tl0 mL) at -60C and was treated with excess ammonia gas for 10 minutes. The final mixture ~as diluted with EtOAc and washed with water, brine and dried over anhydrous MgSO4 followed by filtration. The solvents were removed on a rotary evaporator and the residue was deprotected by general procedure. Finally, the crude was purified on T.L.C. plate and further purified on HPLC to gi~e the desired product in moderated yield. MS: 682 (M+NH4, 10%); HRMS: 665.2103 for C33H37N4O7S2; 13C NMR (CD3CCD3, ppm) 162.33, 145.25, 141.16, 140.81, 133.59, 130.38, 129.86, 129.21, 127.77, 126.95, 125.85, 71.87, 67.52, 56.78, 33.56; lH NMR (CD30D): ~ 8.19-7.32 (m, 18H), 5.06 (d,=14.3 Hz, 2H), 4.08-3.95 (m, 4H), 3.49-3.16 (m, 6H) Example 15XR

The experimental procedure in Note 5 of Table 2d was followed. MS: 745 (M~18, 100%); HRMS: 729.2500 for C37H3sN4OsN6; lH NMR (CD30D): ~ 7.47-7.39 (m, 6H), 7.29-7.24 (m, 8H), 7.06-7.03 (m, 4H), 4.71 (d,J=13.9 Hz, 2H), 3.66 (S, 2H), 3.62 (d,J=11.7 Hz, 2H), 3.08 (d,J=12.5 Hz, 30 2H), 2.98 (d,J=14.2 Hz, 2H), 2.95-2.89 (m, 2H), 13C NMR
(CD30D, ppm) 163.87, 141.26, 139.71, 132.08, 131.04, 130.64, 129.75, '29.56, 128.95, 128.92, 127.45, 122.57 (q,J=273.1 Hz), 72.02, 67.42, 57.02, 33.67; 19F
NMR(CD30D) 67.75.
Example 15XS

-PCT~S94/01609 The experimental procedure of Note 5, Table 2D was followed. The obtained product was further purified on chiral-HPLC to give the product: MS: 621 (M+H+, 100%);
5 1H NMR [CDCl3+CD30D(1:1)]: ~7.26-6.76 (m, 18H), 4.47 ~d,J=14.3 Hz, 2H), 3.24-3.03 ~m, 4H), 2.76-2.56 ~m, 6H,) 1.86 ~s, 6H); 13C NMR [CDC13+CD30D(1:1), ppm] 163.28, 155.56, 190.48, 138.78, 138.18, 130.34, 130.09, 129.22, 129.12, 127.62, 127.04, 125.84, 71.45, 66.00, 56.42, 33.15, 12.25;

Example 15YG

To a stirred mixture of cyclic urea Example 5I (300mg, 0.56 mmol) and anhydrous cesium carbonate (912 mg, 2.8 mmol) in dioxane, free base of N-(2-chloroethyl) morpholine (2.5g, 16.8 mmol) was added (prepared by dissolving 3.lg of the hydrochloride in 5 mL of water and 5 mL of sat'd NaHCO3, extracting with 100 mL of Hexane, drying over MgSO4, and concentrating) (Thompson;
et al. J. Med. Chem. 1992, 35, 1698) and heated up to 80C for 2 days. The mixture was filtered, rinsed with chloroform and purified on silica gel (1:5 Methanol :
Chloroform) to give 339 mg (79%) pure product. M. P.
25 110-112C. M. S. 765(M+1, 100%).

Example 15YH

The intermediate was prepared by alkylating the appropriate monoalkylated compound with m-cyanobenzyl chloride. Lithium aluminum hydride (158 mg, 4.18 mmol) was added to AlCl3 (180 mg, 1.39 mmol) in ether at 0C.
The mixture was warmed up to RT and stirred for 15 min..
Then a solution of the above intermediate (950 mg, 1.16 mmol) in ether was added dropwise. The mixture was stirred at RT for lh, quenched with 1 mL of H2O, 1 mL Gf 2 1 ~ 9 ~
~094/19329 PCT~S94/01609 5% NaOH and washed with H2O, sat'd NaCl and dried over MgSO4. Following the same hydrolysis procedure, the product was isolated (70 mg) in 10% yield. M. P. 132-134C. M.S. 566 (M+1, 100%).

Example 15YI

To the mixture of 1 mL of DMF and 4 mL CH2C12, oxalyl chloride ~0.72 mL, 2M in CH2C12) was added dropwise at -20C under N2. After 20 min, 500 mg (0.65 mmol) of bis(N-m-benzoic acid) cyclic urea Example 6A (Table 2c) and 0.14 mL (2 mmol) of N-methyl-morpholine were added.
The mixture was stirred at -20C for 20 min. N-methylhydroxylamine hydrochloride (217 mg, 4 mmol) and an additional 0.56 mL (8 mmol) of N-methylmorpholine were added. The reaction mixture was diluted with ethyl acetate, washed with cold 5% HCl, sat'd NaHCO3, H2O, brine and purified on silica gel (1:95 Methanol :
chloroform). Following the same hydrolysis procedure, the product (80 mg) was isolated in 20% yield. M. P.
223-224C.

Example 15YJ
Using an analogous procedure to that reported by Paul Unangst, et al. (in J. Med. Chem. 1992, 35, 3691-3698) the title compound can be prepared from the hydroxyamidine. To a stirred solution Gf hydroxyamidine analog (150 mg, 0.19 mmol) containing triethylamine (0.13 mL, 0.95 mmol), ethyl chloroformate in 10 mL
chloroform was added dropwise at 0C. The mixture was stirred at RT for 2h and washed with water, brine and dried over MgSO4. The residue was purified on silica gel (1:1 ethyl acetate: methylene chloride). The product (137 mg, 76% yield) was isolated as ester intermediate.

WO94tl9329 PCT~S94/01609 ~

To the above ester intermediate, toluene was added and the solution was heated up to 110C for 48h. The solvent was removed on rotary evaporator. Following the same hydrolysis procedure. The product(45 mg) was isolated in 35% yield. M. P. 223-224C (decomp.).

Example 15YF

A solution of bis~N-m-benzaldehyde) cyclic urea Example 5V (Table 2c)(120 mg, 0.21 mmol) containing small amount of 3A molecular sieves was treated with toluenesulfonyl-hydrazide dropwise at 0C under N2. The mixture was stirred at RT for overnight. The solvent was removed on rotary evaporator and purified on silica gel (1:4 ethyl acetate : methylene chloride) to give 92 mg (52%) pure product. M. P. 169-171C.

Example 15YK

To a solution of N-SEM-imidazole (396 mg, 2 mmol) in THF (10 mL) at -78 C was added n-BuLi (5 mmol, 3.1 mL) dropwise and the resultant mixture was stirred for 30 minutes, and to this was added a solution of zinc chloride (410 mg, 3 mmol) in THF (5 mL~. After the resulting solution was allowed to warm to room temperature, a solution of m-iodobenzyl cyclic urea (466 mg, 0.5 mmol) in THF (2 mL) and Pd(PPh3)4 (77 mg, 0.07 mmol) were added under nitrogen and resultant mixture was allowed to reflux overnight. Work-up and deprotection by general procedure, followed by purification on TLC plate with 50% EtO~c in CH2Cl2 gave Example 15YK as a solid. 1H NMR (CD30D) ~ 7.74-7.09 (m, 22 H), 5.34 (s, 2H), 4.84 (d, J = 13.3 Hz, lH), 4.68 (d, J = 14.3 Hz, lH), 3.76-3.69 (m, 4H), 3.60 (t, J = 8.0 ~094/19329 21~ S ~ 9 ~ PCT~S94/01609 Hz, 2H), 3.18-3.03 (m, 4H), 2.96-2.88 (m, 2H), 0.90 (t, J = 8.0 Hz, 2H), 0 00 (s, 9H); 13C NMR (CD30D): ppm 164.91, 150.71, 143.28, 142.52, 142.43, 141.37, 141.11, 139.14, 135.08, 135.06, 134.43, 134.33, 133.13, 132.84, 132.72, 132.34, 131.96, 131.38, 131.35, 131.22, 131.03, 130.94, 130.91, 130.84, 129.79, 128.84, 128.80, 124.79, 96.36, 77.82, 73.27, 73.24, 69.49, 68.97, 68.84, 58.54, 58.32, 35.16, 34.91, 19.94, 0.00.

Example 15YL

To a solution of N-SEM protected pyrazole (1.98 g., 10 mmol) in THF (40 mL) at -78C was added n-BuLi (1.6 M, 7.5 mL, 12 mmol) dropwise and the resulting solution was stirred for an additional half hour, and then triisopropylborate (9.4 g, 50 mmol) was added. After being allowed to warm to room temperature over 2 hours, the reaction mixture was acidified with 2 N HCl, extracted with ether, washed with water and brine, and dried over MgSO4. Filtration and concentration gave N-SEM-3-hydroxyboric-pyrazole (2.4 g, 100 %) as a solid.1H
NMR (CD30D) ~ 7.57 (S, lH), 6.80 (s, lH), 5.70 (s, 2H), 3.57 (t, J = 7.8 Hz, 2H), 0.89 (t, J = 8.0 Hz, 2H), 0.00 25 (s, 9H); 13C NMR (CD30D): ppm 138.54, 115.65, 78.98, 65.98, 17.31, -2.30.
To a solution of m-iodobenzyl cyclic urea (932 mg, 1 mmol) in THF (5 mL) was added N-SEM-3-hydroxyboric-pyrazole (968 mg, 4 mmol), Pd(PPh3)4 (57.8 mg, 5 %) and 30 Na2CO3 (1.7 g in H2O (4 mL) under nitrogen and the resultant mixture was allowed to reflux over 48 hours.
The organic layer was concentrated on rotary evaporatior to give a residue, which was deprotected by the general procedure, followed by purification on TLC plate with 35 20~ EtOH in hexane to give Example 15YL (560 mg, 87.8%) as a solid. MS 639 (M+~+, 100 %); HRMS calcd for WO94/19329 PCT~S94/01609 ~
~, C3gH3gN6O3 639.3084, Found 639.3081; lH NMR (CD30D) 7.76-7.69 (m, 6H), 7.45-7.15 (m, 14H), 6.66 (s, 2H), 4.87 (d, J = 14.3 Hz, 2H), 3.77 (b, 4H), 3.19-2.98 (m, 6H); 13C NMR (CD30D) ppm 162.82, 140.19, 139.01, 129.67, 129.22, 128.96, 128.59, 127.06, 126.49, 125.03, 102.41, 71.02, 66.69, 56.37, 32.65.

Example 15YM
A solution of Example 15YL (200 mg) in methanol (5 mL) was treated with HCl gas for 2 seconds and the solvent was removed under full vacuum to give Example 15YM as a solid. 1H NMR (CD30D) ~ 8.34-8.32 (m, 2H), 7.76-7.74 (m, 2H), 7.73-7.66 (m, 2H), 7.55-7.50 (m, 4H), 7.15-7.09 (m, 8 H), 6.89-6.86 (m, 4H), 4.58 (d, J = 13.9 Hz, 2H), 3.88-3.78 (m, 4H), 3.32 (d, J = 13.9 Hz, 2H), 3.08-3.04 (m, 2H), 2.78-2.69 (m, 2H); 13C NMR (CD30D) ppm 161.86, 147.23, 139.72, 139.50, 135.07, 132.00, 129.53, 129.04, 128.00, 127.92, 126.03, 125.97, 125.74, 104.78, 70.21, 67.75, 56.28, 32.27.

Example 15YN
To a solution of N-SEM protected pyrazole (780 mg., .3.9 mmol) in THF (40 mL) at -78C was added t-BuLi (1.7 M, 2.8 mL, 4.7 mmol) dropwise and the resulting solution was stirred for an additional 30 minutes. The solution was transferred to another solution of MEM-protected m-cyanobenzyl cyclic urea (732 mg., 1 mmol) in THF (10 m~) at -78C and the resulting reaction mixture was allowed to warm to room temperature and was stirred overnight.
After evaporation of all volatiles, the residue was diluted with methanol (20 mL) and then treated with 4M
HCl in dioxane ~20 mL) overnight. Workup by general 2 156S, ~.~
~094/19329 PCT~S94/01609 procedure and purification on reverse phase T.L.C. plate with 70~ MeOH in H2O gave Example 15YN in good yield:
MS: 695 ~M~H, 100%); HRMS calcd for C41H39N6Os 695.2983, Found 695.2967; 13C NMR (CD30D): ppm 183.16, 164.07, 146.27, 141.34, 139.59, 137.92, 135.08, 133.06, 130.70, 130.53, 120.74, 120.57, 127.45, 71.92, 66.93, 56.72, 33.72; 1H NMR ~CD30D) ~8.50 (s, 2H), 8.29-8.27 (m, 2H), 7.61-7.21 (m, 18H), 9.94 (d, J=14.3 Hz, 2H), 3.77-3.72 (m, 4H), 3.20-3.09 (m, 6H).
Example 15BI

A solution of MEM-protected compound 12J (0.94 g, 1.0 mmol) was treated with n-BuLi (1.6 M, 1.6 mL) at -78 C for 20 minutes, followed by quenching with N-methoxy-N-methyl benzyloxyacetamide (1.35 g, 6 mmol), prepared by a reaction of benzyloxyacetyl chloride with N-methoxy-N-methylamine in pyridine and CH2C12 at room temperature. Removal of MEM-groups by general hydrolysis procedure followed by purification by preparative T.L.C.gave compound 153I in moderate yield.
H NMR (CDCl3) ~7.72-7.66 (m, 4H), 7.42-7.00 (m, 24H), 4.79 (d, J = 14.6 Hz, 2H), 4.64 (s, 2H), 4.57 (d, J =
2.5 Hz, 2H), 3.71-2.82 (m, 14 H); 13C NMR (CDCl3) ~
196.08, 161.84, 139.30, 138.95, 136.89, 134.40, 129.45, 129.40, 129.29, 128.92, 128.58, 128.48, 128.02, 127.96, 126.97, 126.54, 73.26, 72.29, 71.12, 65.40, 55.82, 32.72; HRMS: calcd. for CslHslN2O7 803.3696; found 803.3693.
Example 15BJ

To a solution of SEM protected imidazole (2 g) in THF (20 mL) was added t-BuLi (1.7 M, 6.9 mL) at -78 C
and the mixture was stirred for 20 minutes. After addition of TMSCl (1.25 g), the resulting mixture was WO94/19329 PCT~S94/01609 ~~

allowed to warm to 0 C over 2 hours, and then cooled to -78 C again. The mixture was treated with t-BuLi (1.7 ~ M, 6.9 mL), stirred for 20 minutes, followed by addition C~ of B(OMe)3 (10.4 g). The reaction mixture was warmed to room temperature and stirred overnight.The reaction was poured into EtOAc/H2O and the organic layer was washed to PH 7, dried with NaSO4, and purified on column with MeOH to give pure N-SEM-5-borono-imidazole (2.3 g 95 %) as a solid. lH NMR (CD30D) ~7.63 (d, J = O.74 Hz, lH), 10 6.87 (d, J = 1.1 Hz, lH), 5.47 (s, 2H), 3.55 (t, J = 8.4 Hz, 2H), 0.93 (t, J = 8.4 Hz, 2H), 0.00 (s, 9H); 13C
NMR (CD3OD) ~138.97, 134.54, 77.89, 68.00, 20.19, 0.00.
A solution of the borono-imidazole prepared above (1.3 g, 5.37 mmol), MEM-protected cpd 12J (0.937 g, 1.01 mmol), Pd(Ph3P)4 (0.18 g, 0.16 mmol) and K2CO3 (7.5 g) in THF (20 mL) and H2O (20 mL) was degassed, znd then was heated to reflux under N2 overnight. The reaction mixture was cooled to room temperature and partitioned between EtOAc/H2O. The organic layer was dried over MgSO4 and concentrated to give a residue, which was deprotected by general hydrolysis procedures and purified on T.L.C. plate with 5 % MeOH in EtOAc to give the coupling product, 15BJ (0.4 g, 37.2 %). lH NMR
(CD30D) ~ 7.97 (s, 2H), 7.61-7.11 (m, 20H), 5.37 (s, 25 4H), 4.83 (d, J = 13.9 Hz, 2H), 3.78-3.73 (m, 4H), 3.59 (t, J = 8.0 Hz, 4H), 3.18-2.97 (m, 6H), 0.90 (t. J = 8.0 Hz, 4H), 0.00 (s, 18H).

Example 15BK
Compound 15BJ was treated with 4M HCl in dioxane under reflux overnight. After the solvent was removed under full vacuum, the residue was purified on reverse phase T.L.C. plate to give the desired compound as a 35 solid in moderate yield. lH NMR (CD30D) ~7.71 (sb, 2H), 7.61 (d, J = 7.7 Hz, 2H), 7.52 ~s, 2H), 7.35-7.19 (m, 2156~9`~
~094/19329 PCT~S94/01609 10H), 7.10-7.08 (m, 6H), 9.78 (d, J = 13.9 Hz, 2H), 3.71-3.65 (m, 4H), 3.32-3.00 (m, 4H), 2.96-2.87 (m, 2H);
3C NMR (CD3OD) ~163.80, 141.26, 139.94, 137.20, 134.78, 130.67, 130.11, 129.5~, 128.88, 127.40, 127.08, 125.22, 72.00, 67.72, 57.38, 33.60; HRMS: calcd. for C3gH3gN6O3: 639.3084; found 639.3089.

Example 15BL

Compound 15BK in MeOH was treated with 4M HCl in dioxane and the resulting solvents ware evaporated under full vacuum to give the hydrochloride salt. 1H NMR
~CD30D) ~.02 ~d, J = 1.1 Hz, 2H), 7.87 ~d, J = 1.1 Hz, 2H), 7.65-7.38 (m, 8H), 7.19-7.17 (m, 6H), 6.93-6.90 (m, 4H), 4.65 (d, J = 14.3 Hz, 2H), 3.78-3.72 (m, 4H), 3.25 (d, J = 14.3, 2H), 3.06-3.02 (m, 2H), 2.81-2.7 (m, 2H); 13C NMR (CD30D)~163.41, 141.11, 141.04, 135.91, 134.97, 131.95, 130.89, 130.51, 129.47, 128.16, 128.10, 127.43, 126.09, 116.38, 71.80, 69.21, 57.87, 33.73.

Example 15BM

2-Trimethyltin-N-dimethylsulfamoyl-imidazole was prepared in situ by lithiation of N-dimethylsulfamoyl-imidazole (1.75 g, 10 mmol) in THF (30 mL) at -78 C with n-BuLi (1.6M, 7.5 mL), followed by quenching with trimethyltin chloride (2.19 g, 11 mmol). A coupling reaction of the tin reagent (1.2 g, crude) and MEM-protected compound 12J (0.8 g, 0.86 mmol) in thepresence of Pd(Ph3P)4 (0.18 g, 0.16 mmol) was carried out under reflux overnight. After being cooled to room temperature, the reaction mixture was poured into EtOAc/H2O. The organic iayer was dried over MgSO4 and concentrated on a rotary evaporator. The residue was dissolved in MeOH, saturated with HCl (gas) at 0 C for 5 WO94/19329 PCT~S94/01609 --minutes and then stirred at that temperature for 1 hour.
~c~ The resulting mixture was worked up and purified on G~ column with EtOAc to give compound 15BM as a solid~450 mg, 61 %). lH NMR (CD30D) ~ 7.61-7.11 (m, 22H), 4.86 (d, J = 14.3 Hz, 2H), 3.61-3.59 (m, 4H), 3.10-2.92 (m, 6H), 2.54 (s, 6H); 13C NMR (CD3OD) ~ 163.98, 148.97, lgl.21, 139.37, 132.57, 132.17, 131.55, 130.98, 130.69, 129.63, 129.50, 128.30, 127.53, 123.61, 71.92, 66.99, 56.66, 38.23, 33.74. HRMS: calcd. for C43H4gNgO7S2: 853.3166;
found 853.3163.

Example 15 BN

A solution of 4-iodopyrazole (1.54 g, 8 mmol) in THF (20 mL), was treated with NaH (4.3 g, 10.6 mmol), followed by quenching with dimethylsulfamoyl chloride (1.38 g, 9.6 mmol) to form the N-protected pyrazole (2.4 g, 92 ~). This intermediate (1.5 g, 5 mmol) was reacted with hexamethylditin (1.8 g, 5.5 mmol) in the presence of Pd(Ph3P)4 (0.055 g, 0.01 mmol) in THF (25 mL) at 78 C overnight .o give crude 4-trimethyltin-N-dimethylsulfamoyl-pyrazole.
The crude tin compound was reacted with MEM-protected cpd 12J (0.932 g, 1.0 mmol) in the presence of Pd(Ph3P)4 (0.18 g, 0.16 mmol) under reflux to form the coupled product, which was deprotected by general hydrolysis procedure, followed by purification on reverse phase TLC plate with 85 ~ MeOH in water to give compound 15BN as a solid. 1H NMR (CD30D) ~ 7.77-7.12 (m, 4H), 7.38-6.95 (m, 18H), 4.72 (d, J = 14.3 Hz, 2H), 3.59-3.55 (m, 4H), 3.02-2.88 (m, 6H); 13C NMR (cD3oD) 163.36, 140.63, 139.40, 133.75, 130.19, 129.83, 129.18, 127.87, 127.38, 127.12, 125.47, 122.79, 71.64, 66.4~, 56.76, 33.23;
Example 15BP

7.-~94/19329 21~ 6 S ~ l PCT~S94/01609 MEM-protected mono-m-bromobenzyl cyclic urea was made by general procedure for preparation of - monoalkylated cyclic ureas. The monoalkyated intermediate (2.4 g, 3.56 mmol) was dissolved in DMF (15 - mL) and treated with NaH (0.43 g, 10.75 mmol), followed by addition of methyl mtbromomethylbenzoate (1.63 g, 7.1 mmol) to give pure desired asymmetric cyclic urea (1.6 g, 55 ~)-This asymmetric urea (1.6 g, 2 mmol) was coupled with 5-borono-N-SEM-pyrazole (0.48 g, 2 mmol) by the same procedure described for example 15BJ above to provide pure coupled product, which was further deprotected by general hydrolysis procedure to form 15 compound 15BP (0.9 g, 73.2 % for the two steps). 1H NMR
(CD30D) ~7.85-7.82 (m, 2H.), 7.66-7.57 (m, 4H), 7.35-7.01 (m, 13H), 6.56 (s, lH), 9.76 (d, J = 14.3 Hz, lH), 4.69 (d, J = 14.3 Hz, lH), 3.77 (s, 3H), 3.72-3.58 (m, 4H), 3.11-3.02 (m, 4H), 2.94-2.84 (m, 2H); 13C NMR (CD30D) 20 166.79, 162.24, 139.69. 139.59, 138.56, 138.50, 133.63, 130.09, 129.16, 128.78, 128.61, 128.46, 128.29, 128.16, 126.59, 126.08, 124.60, 102.00, 70.50, 66.36, 66.31, 55.99, 55.63, 51.32, 32.23, 32.15; LRMS: 631.4 (M~1, 100 %); HRMS: calcd. for C3gH3gN4Os 631.2920; found 25 631.2916.

Example 15BQ

To a solution of compound 15BP (63 mg, 0.1 mmol) in THF (1 mL) was added LiBH4 (2M in THF, 0.3 mL) and MeOH
(57.6 mg, 1.8 mmol) and the resulting mixture was stirred at room temperature overnight. The mixture was acidified to pH 1 with 2N HCl and extracted with EtOAc.
The organic layer was washed with H2O, brine, dried over MgSO4, and concentrated. The residue was purified on TLC
plate with EtOAc to give the desired compound (46 mg, WO94/19329 PCT~S94/01609 76.3 %). lH NMR ~CD3OD)~ 7.78-7.60 (m, 4H), 7.50-7.07 (m, 15H), 6.68 (d, J = 2.2 Hz, lH), 4.90-4.81 (m, 2H), ~ 4.66 (bs, 2H), 3.79-3.63 (m, 4H), 3.18-3.0C (m, 6H);
P~ 13C NMR (CD3OD) ~163.92, 143.24, 141.32, 141.23, 139.41, 130.67, 130.17, 129.93, 129.69, 129.57, 129.53, 129.30, 129.04, 128.04, 127.45, 127.41, 127.25, 126.01, 103.33, 72.02, 71.96, 67.04, 64.97, 57.30, 57.07, 33.63, 33.57;
LRMS: 603.2 (M+1, 100 %); HRMS: calcd. for C37H3gN4O4 603.291; found 603.2968.
Example 15BR

N-dimethylsulfamoyl-imidaz-2-yl zinc chloride was prepared in situ by lithiation of N-dimethylsulfamoylimidazole (0.97 g, 5.5 mmol) in THF (20 mL) with t-BuLi (1.7M, 6.7 m~), followed by quenching with zinc chloride (1.87 g, 13.75 mmol).
A coupling reaction of the zinc reagent (crude) and MEM-protected cpd 12J (0.932 g, 1.0 mmol) in the presence of Pd(Ph3P)4 (0.12 g, 0.1 mmol) was carried out under reflux overnight. After cooling to room temperature, the reaction mixture was poured into EtOAc/H2O. The organic layer was dried over MgSO4 and concentrated on a rotary evaporator. The residue was dissolved in MeOH, and treated with 4M HCl in dioxane under reflux for 2 hours. The resulting mixture was worked up and purified on a reverse phase TLC plate with 75 % MeOH in water to give compound 15BR as a solid. 1H
NMR (CD30D) ~ 7.75-7.70 (m, 4H), 7.42-7.33 (m, 2H), 7.28-7.12 (m, 12H), 7.00-6.94 (m, 4H), 4.73 (d, J = 14.3 Hz, 2H), 3.71 (bs, 4H), 3.14 (d, J = 13.9 Hz, 2H), 3.04-2.99 (m, 2H), 2.85-2.77 (m, 2H); 13C NMR (CD30D) ~
162.00, 146.27, 139.58, 138.87, 130.23, 129.36, 129.11, 128.80, 128.00, 126.20, 125.89, 124.36, 122.64, 70.39, 67.14, 56.29, 32.22i HRMS: calcd. for C3gH3gN6O3 639.3089; found 639.3069.

VO94tl9329 ~ 1 i & ~ 9 4 PCT~S94/01609 Example 15BS

Compound 15BR was dissolved in MeOH, and treated with 4M HCl in dioxane at r.t. for 1 minute. The resulting mixture was concentrated in vacuo to give the solid dihydrochloride salt. lH NMR (CD30D) ~ 7.81-7.79 ~m, 2H), 7.73 (s, 2H), 7.65 (s, 4H), 7.61-7.57 (m, 4H), 7.13-7.11 (m, 6H), 6.86-6.84 (m, 4H), 4.59 (d, J = 13.9 Hz, 2H), 3.84 (s, 2H), 3.76 (d, J = 11.7 Hz, 2H), 3.45 ~d, J = 14.1 Hz, 2H), 3.06 (d, J = 12.2 Hz, 2H), 2.75-2.68 (m, 2H); 13C NMR (CD30D) ~ 163.39, 145.94, 141.63, 140.94, 134.79, 131.28, 130,46, 129.44, 129.13, 127.38, 127.14, 124.31, 121.37, 71.58, 69.54, 57.82, 33.84.
Exampe 15BT

To compound 15BP (63 mg, 0.1 mmol) was added 4-(2-aminoethyl)morpholine (0.13 g, 1 mmol) and the resulting mixture was stirred at 110 C overnight. The mixture was evaporated in vacuo to remove the excess 4-(2-aminoethyl)morpholine, and the residue was purified on TLC plate with 10 % MeOH in EtOAc to give pure product (44 mg, 60.4 ~ H NMR ~CD30D) ~ 8.04 (s, lH), 7.73-6.99 (m, 18H), 6.59 (d, J = 2.2 Hz, lH), 4.72 (d, J =
14.4 Hz, 2H), 3.69-3.64 (m, 8H), 3.36 (t, J = 6.6 Hz, 2H), 3.14 (J = 14.2 Hz, 2H), 3.08-2.85 (m, 4H), 2.54 (t, J = 6.6 Hz, 2H), 2.51-2.45 (m, 4H); 13C NMR (CD30D) ~
169.84, 163.68, 141.25, 141.12, 140.09, 136.07, 133.65, 130.63, 129.87, 129.56, 129.51, 128.02, 127.44, 103.31, 71.98, 71,91, 68.26, 67.75, 58.62, 58.37, 58.45, 5g.68, 37.76, 35.76, 33.69, 33.62; HRMS: calcd. for C43H4gN6Os 729.3764; found 729.3753.

Example 15BU

WO94/19329 PCT~S94/01609 MEM-protected mono-m-bromobenzyl cyclic urea was ~, made by general procedure for preparation of monoalkylated cyclic ureas. The mono cyclic urea ~2.4 g, 3.56 mmol) in DMF (15 mL) was coupled with 5-borono-N-SEM-pyrazole by the same procedure used to make compound 20AX to provide pure coupled product, MEM-protected mono m-(N-SEM-pyraz-5-yl)benzyl cyclic urea.
This intermediate (0.2 g, 0.25 mmol) in DMF (5 mL) was treated with NaH (0.04 g, 1.0 mmol), followed by quenching with m-picolyl chloride hydrochloride (0.123 g, 0.75 mmol) to give desired asymmetric cyclic urea, which was further deprotected by general hydrolysis procedure to form compound 15BU. lH NMR (CD30D) ~ 8.51-8.46 (m, 2H), 7.83-7.63 (m, 4H), 7.48-7.03 (m, 13H), 15 6.68 (d, J = 2.2 Hz, lH), 4.84 (d, J = 14.3 Hz, lH), 4.66 (d, J = 14.3 Hz, lH), 3.85-3.76 (m, 4H), 3.20-2.83 (m, 6H); 13C NMR (CD30D) ~ 163.63, 151.12, 149.22, 141.12, 141.07, 139.41, 135.98, 130.60, 130.55, 130.24, 129.63, 129.60, 128.04, 127.54, 126.08, 125.34, 103.35, 20 71.94, 71.81, 68.72, 55.13, 33.75, 33.S1; HRMS: calcd.
for C3sH36NsO3 574.2818; found 574.2811.

Example 15BV

The MEM-protected mono m-(N-SEM-pyraz-5-yl)-benzyl cyclic urea (788 mg, 1 mmol), described in procedure of example 15U was dissolved in DMF (8 mL) and treated with NaH (0.16 g, 4.0 mmol, 60 % in mineral oil), followed by quenching with ~-bromo-m-tolunitrile (0.392 g, 2.0 mmol) to give desired asymmetric cyclic urea, which was further deprotected by general hydrolysis procedure to form compound 15BV. lH NMR (CD30D) ~ 7.9S-7.07 (m, l9H), 6.68 (bs, lH), 4.70 (d, J = 13.9 Hz, lH), 4.64 (d, J =
13.9 Hz, lH), 3.93-3.70 (m, 4H), 3.21-2.83 (m, 6H); 13C
NMR (CD3OD) ~ 163.82, 141.40, 141.24, 141.14, 135.42, 134.42, 133.90, 132.52, 130.85, 130.67, 130.15, 130.03;

2~!56.~9~
~094/19329 PCT~S94/01609 129.82, 129.71, 128.16, 127.66, 119.67, 113.62, 103.40, 71.42, 71.87, 68.67, 57.14, 33.79, 33.62; HRMS: calcd.
for C37H36NsO3 598.2818; found 598.2813.

Example 15BW

To a solution of compound 15BV (50 mg, 0.084 mmol) in pyridine (3 mL) was added hydroxylamine hydrochloride (36 mg, 5.2 mmol) and the resulting mixture was refluxed overnight. After being cooled to room temperature, the mixture was evaporated in vacuo to remove pyridine. The resulting residue was worked up and purified on TLC
plate with EtOAc to give pure amidoxime (32 mg, 60.6 %).
1H NMR (CD30D) ~ 7.96-7.05 (m, l9H), 6.59 (d, J = 2.2 Hz, lH), 4.78 (d, J = 14.3 Hz, lH), 4.75 (d, J = 14.3 Hz, lH), 3.70-3.59 (m, 4H), 3.11-3.03 (m, 4H), 2.96-2.88 (m, 2H); 13C NMR (CD3OD) ~ 163.82, 141.25, 141.14, 140.02, 139.77, 134.52, 134.00, 131.68, 130.62, 130.18, 129.93, 129.69, 129.56, 129.54, 128.04, 127.44, 126.01, 103.32, 71.97, 67.65, 67.58, 57.31, 56.97, 33.67, 33.56.

Example 15BX

Mono-m-(N-SEM-pyraz-5-yl)-benzyl cyclic urea prepared above in procdure of Example 15BU was deprotected by general hydrolysis procedure to give compound XS618. 1H NMR (CD30D)~ 7.67-7.05 (M, 15H), 6.58 (d, J = 4.0 Hz, lH), 4.80 (d, J = 14.7 Hz, lH), 3.86-3.82 (m, lH), 3.71-3.62 (m, 2H), 3.51-3.48 (m, lH), 3.18-2.99 (m, 4H), 2.80-2.72 (m, lH); 13C NMR (CD30D) 163.90, 141.47, 140.89, 130.63, 130.49, 130.09, 130.01, 129.64, 129.49, 129.27, 127.52, 127.25, 125.85, 103.33, 72.99, 72.55, 66.50, 66.47, 55.27, 35.13, 34.32;
HRMS: calcd. for C2gH31N4O3 483.2400; found 483.2401.
Example 15BY

WQ94/19329 PCT~S94/01609 MEM-protected mono m-(N-SEM-pyraz-5-yl)benzyl cyclic urea described above (220 mg, 0.28 m~ol) was dissolved in DMF (3 mL) and treated with NaH (0.095 g, 1.12 mmol, 60% in mineral oil), followed by quenching with p-benzyloxybenzyl chloride (0.13 g, 0.56 mmol) to give the desired asymmetric cyclic urea, which was deprotected by general hydrolysis procedure to give compound 15BY. lH NMR (CD30D) ~7.68-6.91 (m, 24H), 6.58 (d, J = 2.2 Hz, lH), 5.02 (s, 2H), 4.78 (d, J = 13.9 Hz, lH), 9.66 (d, J = 13.9 Hz, lH), 3.67-3.54 (m, 4H), 3.08-2.88 (m, 6H); 13C NMR (CD30D) ~ 163.88, 159.84, 141.29, 138.63, 131.73, 131.58, 130.69, 130.69, 130.15, 129.56, 129.49, 129.4~, 128.82, 128.50, 128.03, 127.46, 127.37, 125.99, 116.07, 103.32, 72.05, 72.02, 66.81, 56.45, 33.62, 33.59; HRMS: calcd. for C43H43N404 6779.3284;
found 679.3284.

Example 15BZ
To compound 15BP (45 mg, 0.071 mmol) was added 3-~aminomethyl)pyridine (0.077 g, 0.71 mmol) and the resulting mixture was stirred at 110 C overnight. The mixture was evaporated in vacuo to remove the excess 3-(aminomethyl)-pyridine. The residue was purified on TLC
plate with 15% MeOH in EtOAc to give pure product (37 mg, 73.8 %). 1H NMR (CD30D) ~7.80-6.95 (m, 23 H), 6.59 (d, J = 2.2 Hz, lH), 4.77-4.72 (m, lH), 4.68 (d, J =
14.3Hz, lH), 4.58 (d, J = 2.2 Hz, 2H), 3.66-3.64 (m, 4H), 3.15 (d, J = 14.3 Hz, lH), 3.06-2.82 (m, 5H); 13C
NMR (CD30D) ~ 170.09, 163.83, 152.96, 149.63, 141.32, 141.23, 140.30, 137.40, 136.94, 135.80, 134.04, 130.71, 130.29, 130.09, 129.75, 129.66, 128.12, 127.67, 127.54, 126.14, 125.34, 125.19, 103.38, 72.00, 71.93, 68.47, 57.56, 42.02, 33.62.

~094tl9329 2 I 5 6 ~ 9 ~ PCT~S94/01609 Example 15AC

Hydrogenation of compound 15BY in MeOH in the presence of catalytic amount of 10% Pd/C produced the hydroxymethyl compound in good yield. lH NMR (CD30D) ~
7.68-7.58 (m, 3H), 7.39-7.05 (m, 12H), 6.98 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.4 Hz, 2H~, 6.58 (d, J = 2.2 Hz, lH), 4.78 (d, J = 14.3 Hz, lH), 4.66 (d, J = 13.9 Hz, lH), 3.68-3.50 (m, 4H), 3.08-2.83 tm, 6H); 13C NMR
(CD3OD)~ 163.94, 158.15, 141.31, 140.11, 131.73, 130.69, 130.65, 130.16, 129.96, 129.56, 129.48, 128.04, 127.96, 127.35, 125.98, 116.39, 103.32, 72.10, 72.02, 66.42, 57.22, 56.37, 33.56; HRMS: calcd. for C36H37N4O4 589.2815; found 589.2811.

Example 15BC

To compound 15BP (44 mg, 0.07 mmol) was added 2-(aminomethyl)pyridine (0.077 g, 0.71 mmol) and the resulting mixture was stirred at 110 C overnight. The mixture was evaporated in vacuo to remove the excess 2-(aminomethyl)pyridine. The residue was purified on a TLC
plate with 20% MeOH in EtOAc to give pure product (35 mg, 71 ~ H NMR (CD30D) ~ 8.95 (d, J = 4.8 Hz, lH), 7.80-6.98 (m, 22H), 6.58 (d, J = 1.5 Hz, lH), 4.77 (d, J
= 14.3 Hz, lH), 4.71 (d, J = 14.3 Hz, lH), 4.66 (d, J =
4.8 Hz, 2H), 3.68-3.65 (m, 4H), 3.17-2.82 (m, 6H); 13C
NMR (CD3OD) ~ 169.99, 163.71, 159.28, 149.75, 141.25, 141.14, 140.17, 139.98, 138.80, 135.79, 133.94, 130.63, 130.18, 129.96, 129.92, 129.57, 128.03, 127.64, 127.45, 126.03, 123.72, 122.76, 103.32, 71.99, 71.92, 68.32, 67.72, 57.50, 57.30, 45.92, 33.69, 33.65; HRMS: calcd.
for C43H43N6O4 707.33g6; found 707.3344.

Example 15CC

WO94/19329 PCT~S94/01609 ~ -242-Co MEM-protected monc m-(N-SEM-pyraz-5-yl)benzyl cyclic urea (200 mg, 0.254 mmol) was dissolved in DMF (5 mL) and treated with NaH (0.041 g, 1.02 mmol, 60% in mineral oil), followed by quenching with m,p-dibenzyloxybenzyl chloride (0.172 g, 0.51 mmol) to give the desired asymmetric cyclic urea. After deprotection by general hydrolysis procedure, the urea was hydrogenated to give the dihydroxy compound. lH NMR
(CD30D) ~ 7.83-7.07 (m, 15H), 6.81-6.71 (m, 3H), 6.53 (s, lH), 4.86 (d, J = 13.9 Hz, lH), 4.72 (d, J = 13.6 Hz, lH), 3.80-3.66 (m, 4H), 3.19-2.82 (m, 6H); 13C NMR
(CD3OD) ~ 164.10, 149.97, 146.56, 146.12, 141.43, 141.32, 140.29, 134.53, 133.55, 130.82, 130.71, 130.67, 130.29, 129.64, 129.53, 128.23, 127.51, 127.42, 126.14, 122.22, 117.49, 116.39, 103.59, 72.13, 72.01, 67.77, 65.89, 57.28, 56.35, 33.61, 33.45; HRMS: calcd. for C36H37N4Os 605.2764; found 605.2750.

Example 15CD
MEM-protected mono m-(N-SEM-pyraz-5-yl)-benzyl cyclic urea (560 mg, 0.71 mmol) was dissolved in DMF
(10 mk) was treated with NaH (0.114 g, 2.84 mmol, 60 %
in mineral oil), followed by quenching of m-nitrobenzyl chloride (0.360 g, 2.13 mmol) to give desired asymmetric cyclic urea. After deprotection by general de-MEM
procedure, the urea was purified on TkC plate with EtOAc to give pure product. 1H NMR (CD30D) ~ 8.11-8.06 (m, 2H), 7.69-7.15 (m, 13H), 7.06-6.95 (m, 4H), 6.59 (d, J =
2.2 Hz, lH), 4.76 (d, J = 13.9 Hz, lH), 4.61 (d, J =
14.3 Hz, lH), 3.78-3.56 (m, 4H), 3.15-2.79 (m, 6H); 13C
NMR (CD30D) ~ 163.75, 149.67, 141.75, 141.12, 140.97, 136.71, 130.78, 130.53, 130.21, 129.93, 129.73, 129.57, 128.04, 127.53, 127.43, 126.07, 125.37, 123.51, 103.33, 71.84, 68.28, 57.31, 56.86, 33.85, 33.58; HRMS: calcd.
for C36H36NsOs 618.2716; found 618.2703.

~094119329 215 6 ~ 9 ~ PCT~S94/01609 Example 15CE

Hydrogenation of compound 15CD (210 mg, o.34 mmol) in MeOH (5 mL) and lN HCl (1 mL) in the presence of 10%
Pd/C was carried out at roo~ temperature overnight. The catalyst was removed by filtration, and the filtrate was concentrated. The residue was purified on TLC plate with EtOAc to aive the amino compound (140 mg, 61 %). 1H NMR
(CD30D) ~ 8.31 (s, lH), 7.81-6.88 (m, l9H), 4.60 (d, J =
13.6 Hz, 2H), 3.80-3.57 (m, 4H), 3.16-2.68 (m, 6H); 13C
NMR (CD3OD) ~ 163.99, 149.09, 141.38, 141.23, 140.01, 130.73, 130.65, 130.35, 130.15, 129.93, 129.55, 129.46, 128.04, 127.42, 127.35, 125.97, 120.06, 117.33, 115.81, 103.32, 72.11, 71.99, 66.39, 57.28, 56.97, 33.66, 33.53;
HRMS: calcd. for C36H3gNsO3 588.2975; found 588.2983.

Example 15CF

MEM-protected mono m-~N-SEM-pyraz-5-yl)-benzyl cyclic urea (240 mg, 0.3 mmol) was dissolved in DMF (5 mL~ and treated with NaH (0.049 g, 1.2 mmol, 60% in mineral oil), followed by addition of m-cyano-p-fluorobenzyl bromide (0.128 g, 0.6 mmol) to give desired asymmetric cyclic urea. After deprotection by general hydrolysis procedure, the urea was purified on T1C plate with EtOAc to give pure compound 15CF (72 mg, 39%). 1H
NMR (CD30D) ~7.68-6.86 (m, 18H), 6.57 (d, J = 0.7 Hz, lH), 4.72 (d, J = 14.1 Hz, lH), 4.36 (d, J = 13.8 Hz, lH), 3.82-3.55 (m, 4H), 3.16-2.69 (m, 6H); HRMS: calcd.
for C37H3sNsO3F: 616.2713; found 616.2710.

Example 15CG
..
A solution of compound 15BX in MeOH was treated with 4M HCl in dioxane, and the resulting solution was WO94/19329 PCT~S94/01609 ~t -244-evaporated to dryness in vacuo to give the hydrochloride ~CQ salt. lH NMR (CD30D) ~8.31 (d, J = 2.6 Hz, lH), 7.72-7.06 (m, 15H), 4.68 (d, J = 15 Hz, lH), 3.83-3.75 (m, 3H), 3.73-3.60 (m, lH), 3.59-3.41 (m, lH), 3.23-3.03 (m, 3H), 2.69-2.65 (m, lH); 13C NMR (CD30D) ~163.52, 198.75, 141.15, 140.30, 136.47. 132.50, 130.88, 130.49, 130.35, 129.62, 129.46, 128.~32, 127.53, 127.35, 127.04, 106.27, 73.14, 72.49, 67.06,~`"58.97, 55.16, 35.61, 34.93.

10 Example 15GH

A solution of the compound of Example 9P (0.11 g, 0.2 mmol) and hydroxylamine hydrochloride (0.014 mg, 0.2 mmol) in pyridine (2mL) was refluxed overnight. Workup 15 and purification using HPLC with a solvent gradient from 10% hexane in EtOH to 100% of EtOH pro~ided compound 15GH (28 mg). lH NMR (CD30D) ~7.89-7.86 ~m, lH), 7.81 (s, lH), 7.54 (d, J = 4.0 Hz, lH), 7.45-7.00 (m, 15H), 4.73 (d, J = 14.1 Hz, lH), 4.71 (d, J = 14.2 Hz, lH), 3.62-3.55 (m, 4H), 3.17 (d, J = 14.2 Hz, lH), 3.08-3.05 (m, 2H), 2.98 (d, J = 14.1 Hz, lH), 2.96-2.83 (m, 2H), 2.54 (s, 3H), 2.16 (s, 3H); 13C NMR (CD3OD) ~200.03, 163.85, 155.42, 141.19, 141.16, 140.19, 139.40, 139.00, 138.63, 135.31, 130.77, 130.62, 130.59, 130.48, 130.07, 25 129.71, 129.60, 129.57, 128.71, 128.11, 127.50, 126.35, 71.99, 71.93, 67.81, 67.24, 57.15, 57.09, 33.65, 26.72, 11.94; HRMS: calcd. for C37H40N3Os 606.2968; found 606.2971.

Examples 15CI and 15CJ

Bis-m-cyano-p-fluorobenzyl cyclic urea was prepared using general alkylation and deprotection procedures.
The urea (0.47 g, 0.79 mmol) in THF (20 mL) was treated with MeMgBr (3M, 2.5 mL, .5 mmol) under reflux for 3 hours. General workup and purification on TLC plate with _ ~094119329 2 I 5 6 ~ 9 ~ PCT~Sg4/01609 40% EtOAc in CH2Cl2, followed by further purification on HPLC with 85% hexane in EtOH gave compound 15CI (40 mg) and compound 15CJ (80 mg).
Example 15CI: lH NMR (CDCl3) ~7.64 (dd, J = 7.0 Hz, J = 2.2 Hz, 2H), 7.40-7.00 (m, 14H), 4.72 (dd, J =
14.6 Hz, 2H), 3.75 (s, 2H), 3.55 (d, J = 11.4 Hz, 2H), 3.22 (d, J = 14.6 Hz, 2H), 3.08 (dd, J = 13.6 Hz, J =
2.6 Hz, 2H), 2.83 (dd, J = 13.2 Hz, J = 11.0 Hz, 2H), 2.59 (d, J = 4.8 Hz, 6H), 2.51 (b, 2H); 13C NMR (CDC13) ~196.31 (d, J = 3.1 Hz), 161.7i, 161.46 (d, J = 255.6 Hz), 139.39, 135.78 (d, J = 9.2 Hz), 134.74, 130.82 (d, J = 2.3 Hz), 129.31, 128.60, 126.48, 125.38 (d, J = 13.0 Hz), 116.97 (d, J = 14.9 Hz), 70.89, 65.58, 55.08, 32.78, 31.26 (d, J = 7.6 Hz); HRMS: calcd. for C37H37N2OsF2 627.2671; found 62.2670.
Example 15CJ: lH NMR (CDC13) 7.74 (dd, J = 7.0 Hz, J = 2.2 Hz, 2H), 7.57-7.00 (m, 14H), 4.80 (d, J =
14.3 Hz, lH), 4.62 (d, J = 14.3 Hz, lH), 3.90 (bs, 2H), 3.71-3.61 (m, 2H), 3.53 (d, J = 14.6 Hz, lH), 3.29 (d, J
= 14.3 Hz, lH), 3.25-3.17 (m, 4H), 2.93-2.82 (m, 2H), 2.68 (s, 3H), 2.66 (s, 3H); 13C NMR (CDCl3) ~196.48 (d, J = 2.3 Hz), 162.37 ~d, J = 259.4 Hz), 161.75, 161.58 (d, J = 255.6 Hz), 139.21, 139.15, 136.02 (d, J = 8.4 Hz), 135.85 (d, J = 8.4 Hz), 135.34 (d, J = 3.8 Hz), 134.62 (d, J = 3.0 Hz), 134.31, 130.76, 129.24, 128.68, 128.62, 126.63, 126.59, 125.42 (d, J = 13.0 Hz), 117.03 (d, J = 14.4 Hz), 116.41 (d, J = 19.9 Hz), 113.67, 101.28 (d, J = 15.3 Hz), 70.85, 65.96, 65.75, 55.09, 54.95, 32.96, 32.79, 31.25 (d, J = 6.9 Hz); HRMS:
calcd. for C36H34N3O4F2 610.2517; found 610.2534.

Example 15CK

In the synthesis of compound 9Q, compound 15CK was a minor stereoisomer and was isolated on HPLC with 80%
hexane in EtOH. lH NMR (CD30D) ~ 7.55-7.53 (m, 2H), 7.48 WO94/19329 PCT~S94/01609 ~ 9 -296-Ga~ (s, 2H), 7.33-7.19 (m, lOH), 7.10-7.07 (m, 4H), 4.75 (d, ,~ J= 14.6 Hz, 2H), 3.61-3.58 (m, 4H), 3.08-3.04 (m, 2H), C~ 2.99 (d, J =14.3 Hz, 2H), 2.96-2.90 tm, 2H), 2.17 (s, 6H); 13C NMR (CD3OD) ~163.94, 155.49, 141.22, 139.43, 138.96, 130.76, 130.63, 129.68, 129.56, 128.09, 127.46, 126.30, 72.00, 67.09, 57.03, 33.59, 11.97; HRMS: calcd.
for C37H41N4Os 621.3077; found 620.3091.

Example 15CL

By the same procedure used to make Example 9Q , compound 15CL was obtained from compound 15CI in good yield. 1H NMR (CD30D) ~7.31-7.02 (m, 16H), 4.63 (d, J=
13.9 Hz, 2H), 3.62-3.56 (m, 4H), 3.09-2.99 (m, 4H), 2.90-2.82 (m, 2H), 2.16 (d, J= 2.2 Hz, 6H); 13C NMR
(CD30D)~163.76, 161.28 (d, J = 248.7 Hz), 153.70, 141.18, 135.44 (d, J = 3.8 Hz), 132.57 (d, J = 8.4 Hz), 131.86 (d, J = 3.8 Hz), 130.60, 129.59, 127.49, 127.13 (d, J= 13.7 Hz), 117.21 (d, J= 22.9 Hz), 71.90, 67.41, 56.34, 33.66, 14.8 (d, J= 4.6 Hz); HRMS: calcd. for C37H3gN4OsF2 657.2889; found 657.2874.

Example 15CM

Compound 15CM was obtained from compound XS534 by the same procedure used to make Example 9Q. 1H NMR
(CD3GD) ~ 7.34-7.02 (m, 16H~, 4.66 (d, J= 14.2 Hz, lH), 4.64 (d, J= 14.2 Hz, lH), 3.64-3.54 (m, 4H), 3.09-2.83 (m, 6H), 2.15 (d, J= 2.4 Hz, 3H); 13C NMR (CD30D) 163.83, 161.29 (d, J = 248.0 Hz), 161.08 (d, J= 250.3 Hz), 153.67, 151.69, 141.21, 141.16, 13i.44, 133.40 (d, J= 9.2 Hz), 132.58 (d, J = 8.4 Hz), 132.20, 131.98 (d, J=3.8 Hz), 130.61, 129.63, 127.49, 127.14 (d, J= 13.7 Hz), 122.37 ~d,J= 13.77 Hz), 117.43 (d, J= 22.9 Hz), 117.20 (d, J = 22.9 Hz), 71.84, 67.41, 66.99, 56.38, 21~i6~9 1 _~094/19329 PCT~S94/01609 -2q7-56.98, 33.74, 33.58, 14.78 (d, J = 5.3 Hz); HRMS:
calcd. for C36H3gNsOsF2 658.2841; found 658.2838.

Example 15FN

- To a stirred solution of 3.66 g(10 mmol) of compound XXVIIIf ir, 15 mL of DMF and 7 mL of THF, cooled to 0 C, was added 1.2 g(40 mmol) of an 80% dispersion of sodium hydride in mineral oil. The mixture was stirred 5 min., and 4.66 g(40 mmol) of 3-furylmethylchloride was added. The mixture was warmed to ambient temperature over 30 min. and then recooled to 0C. The reaction was quenched by the addition of 0.4 N HCl, and the resulting mixture was extracted with Et2O. The organic extract was washed with sat'd aq. NaHCO3, then brine, dried (MgSO4), and concentrated under reduced pressure to afford 4.92 g(93~) of alkylated intermediate. lH NMR
(CDCl3) ~ 7.11-7.42(m, 7H); 6.32(s, lH); 4.72(d, lH);
3.88(s, lH); 3.82(m, lH); 3.03(d, lH); 2.79-2.97(m, 2H);
1.40(s, 6H).
To 0.20 g(0.38 mmol) of acetonide protected bis(N-3-furylmethyl cyclic urea above was added 8 mL of MeOH
and 1 mL of conc. aq. HCl. The solution was stirred 1 h at ambient temperature and poured into water. The white colloidal suspension was extracted with 1:1 Et2O-EtOAc, and the organic extract was washed with sat'd aq.
NaHCO3, brine, dried (MgSO4), and concentrated under reduced pressure to afford an off-white solid. This material was dissolved in 7 mL of EtOAc and warmed to boiling. Hexane, 20 mL, was introduced, and the - solution was concentrated to -6 mL. The product was triturated with 3 mL of hexanes and allowed to cool.
Solvent was removed by pipette, and the white crystalline solid was washed with 9:1 hexanes-EtOAc.
The diol 15FN, following removal of residual solvent at WQ94/19329 PCT~S94/01609 ~ -248-C`~ vacuum pump pressure, weighed lllmg (60% of theoretical).
~t' Example 15FO

To 0.22 mL (2.3 mmol) of stirred, cooled POC13 was added 0.20 mL (2.5 mmol) of DMF. The solution was stirred 5 min., and a solution of 530 mg (1.0 mmol) of acetonide protected bis(N-3-furylmethyl)cyclic urea, described in example 15FN above, in 0.5 mL of THF and O.5 mL of DMF was introduced. The solution was warmed to ambient temperature with stirring over 25 min., whereupon an additional 0.10 mL of POC13 was introduced.
The reaction was heated to reflux for 30 min., cooled, and poured into water. The resulting colloidal solid was extracted with l:l Et2O-EtOAc, and the organic extract was washed with sat'd aq. NaHCO3, water, then brine. Drying (MgSO4), and concentration under reduced pressure afforded a brown oil. Chromatography on silica gel (gradient elution with 3:1 to 1:1 hexanes-EtOAc) afforded 120 mg (22~) of monoaldehyde intermediate as an oil. lH NMR (CDC13) ~ 9.41(s, lH, CHO); 7.52(s, lH, furyl); 7.00-7.38(m, 12H, aryl); 6.59(s, lH, furyl);
6.31(s, lH, furyl); 4.80(d, lH, J = 14.6 Hz, one of NCH2); 4.69(d, lH, J = 14.6 Hz, NCH2); 3.77-4.03(m, 5H, 2xHa, one of NCH2, CHOC(CH3)2OCH); 2.68-302(m, 5H, one of NCH2, 4xH~); 1.44(s, 3H, CH3); 1.42(s, 3H, CH3).
To a stirred solution of 100 mg (0.18 mmol) of the monoaldehyde intermediate in 10 mL of MeOH and 1 mL of water was added 0.5 mL of conc. aq. HCl. The solution was stirred for 1 h at ambient temperature, poured into water, and extracted with l:i Et2O-EtOAc. The organic extract was washed with brine, dried (MgSO4), and concentrated under reduced pressure to afford diol 15FO
as an oil. 1H NMR (CDC13) ~ 9.43(s, lH); 7.51(s, lH);
6.98-7.36(m, 12H); 6.64(s, lH); 6.32(s, lH); 4.73(d, lH, 2156a9~
~094/19329 PCT~S94/01609 J = 15 HZ)i 4.64(d, lH, J = 15 Hz); 3.55-3.78(m, 5H);
2.62-3.14(m, 6H).

Example 15FP

To a stirred solution of 530 mg (1.00 mmol) of acetonide protected bis(N-3-furylmethyl cyclic urea, described in example 15FN above, in 8 mL of THF, cooled to -78 C, was added 1.6 mL (2.5 mmol) of a 1.6 M
solution of n-BuLi in THF. The solution was stirred 20 min. at -78 C, and DMF was added. The reaction was stirred 1 h at -78 C, whereupon it was quenched with lN
HCl. The mixture was extracted with Et2O, and the organic extract was washed with brine, dried(MgSO4), and concentrated under reduced pressure. Chromatography on silica gel ~elution with 1:1 EtOAc-hexanes) afforded, after removal of solvent, 310 mg (53%) of dialdehyde intermediate as an oil. 1H NMR (CDC13) ~ 9.42(s, lH);
7.52(d, lH, J = 2 Hz); 7.20-7.36(m, 5H); 6.58(d, lH, J =
2H)i 4.18(ABq, 2H, JAB = 13 Hz, ~v = 330 Hz); 4.00(br.
s, lH)i 3.90(d, lH, J = 11 Hz); 2.84(ABx, 2H, JAB = 13.5 Hz, JAX = 1-7 Hz, JBX = 11.3 Hz, ~v = 78 Hz); 1.45(s, 6H).
To a stirred, cooled (-78C) solution of 120 mg (0.21 mmol) of the dialdehyde intermediate in 4 mL of Et2O was added 2 mL (2 mmol) of 1 M diisobutylaluminum hydride in CH2Cl2. The solution was stirred 15 min at -78 C, the dry ice bath was removed, and the reaction was quenched with saturated aqueous sodium potassium tartrate. The mixture was diluted with Et2O, and the two phases were stirred together for 30 min. The phases were separated, and the organic phase was dried (MgSO4), concentrated, and chromatographed on silica gel. The product was eluted with EtOAc, concentrated, and re-dissolved in 8 mL of MeOH. This solution was treatedwith 0.4 mL of con. aq. HCl, stirred lh, and poured into WO94/19329 ~CT~S94/01609 water. The colloidal suspension was extracted with EtOAc, and the organic extract was washed with brine, - dried (MgSO4), and concentrated under reduced pressure.
Chromatography on silica gel ~elution with EtOAc) afforded a glass which was lyophilized from benzene-acetonitrile to give 62 mg (57%) of tetraol 15FP as a powder. lH NMR (CD30D) ~ 7.43(d, lH, J = 2 Hz); 7.20-7.37(m, 3H); 7.11(dd, 2H, J = 8.1, 1.1 Hz); 6.37(d, lH, J = 2H); 4.22(ABq, 2H, JA8 = 13.3 Hz, ~v = 33 Hz);
3.76(ABq, 2H, J = 14.6 Hz, ~v = 460 Hz); 3.65(br. s, lH); 3.56(br. d, lH, J = 11 Hz); 2.98(ABx, 2H, JAB s 13.3 Hz, JAX = 1.8 Hz, JBX = 12.1 Hz, ~v = 54 Hz). Mass spec.(NH3-CI/DDIP): 529((M+H-H20)+, 100%).

Example 15FQ

To a stirred solution of 55 mg (0.1 mmol) of monoaldehyde intermediate prepared in example 15FO in 2 mL of EtOH and 1 mL of water was added 35 mg (0.5 mmol) of hydroxylamine hydrochloride. The solution was stirred 25 h at ambient temperature, poured into water, and extracted with EtOAc. The organic extract was washed with brine, dried (MgSO4), and concentrated under reduced pressure to afford 33 mg (58%) of oxime 15FQ as an amorphous solid. Mass Spec.(NH3-CI/DDIP):
530((M+H)+, 8%); 512((M+H-H20)+, 100%). lH NMR (CDC13) 7.76(s, lH); 7.01-7.38(m, 13H); 6.47(s, lH); 6.32(s, lH); 4.59-4.76(m, 2H); 3.55-3.84(m, 4H); 3.25(d, lH, J =
15 Hz); 2.75-3.09(m, 5H).
Example 15FR

c.) To a stirred solution of 50 mg (0.097 mmol) of compound of example 15FO in 6 mL of EtOH was added 20 mg (excess) sodium borohydride. The solution was stirred 3h at ambient temperature, kept Gt -23C for 15h, and 215G~94 ~094/19329 PCT~S94101609 -rewarmed to ambient temperature with stirring over 6h.
The reaction was quenched with 10% aq. HOAc, stirred for 30 min., and extracted with EtOAc. The organic extract was washed with brine, dried ~MgSO4), and concentrated under reduced pressure. Chromatography on silica gel (elution with EtOAc) followed by lyophilization afforded 45 mg (90%) of triol 15FR as a white powder. 1H NMR
(CDCl3) ~ 7.05-7.38(m, llH); 6.85(s, lH); 6.82(s, lH);
6.30(s, 2H); 4.51-4.61(m, 2H); 4.31(d, lH, J = 13 Hz);
3.93(dd, J = 14, 5 Hz); 3.65-3.77(m, 2H)3.51-3.60~m, lH); 2.74-3.12(m, 6H). Mass Spec.(NH3-CI/DDIP):
517((M+NH4-H20)+, 7%); 499((M+H-H20)+, 100%).

Example 15FS and 15FT
A flask was charged with lithium chloride (1.02 g, 24.0 mmol, 1.2 equiv.) and flame dried in vacuo. A
nitrogen atmosphere was introduced and dry dimethylformamide (12.0 ml) was added. The flask was cooled to 0 C and the starting alcohol, 2-furylmethanol (1.7 ml, 20.0 mmol) was added via syringe. The reagents, 2,6-lutidine (3.5 ml, 30.0 mmol, 1.5 equiv., distilled from calcium hydride) and methanesulfonyl chloride (1.7 ml, 22.0 mmol, 1.1 equiv.), were added and stirring continued for one hour. The reaction was poured onto ice and extracted with ether. The ethereal layer was washed with a saturated aqueous solution of sodium carbonate, whereupon a precipitate formed. The precipitate was removed by filtration and the layers sepa ated. The organic layer was dried with anhydrous sodium carbonate.
The product was isolated by filtration and removal of solvent on an ice cooled rotary evaporator. When the volume neared 20 ml, the flask was removed from the rotary evaporator, flushed with nitrogen and diluted with dry dimethylformamide (20.0 ml). This solution WQ94/19329 PCT~S94/01609 ~.~

containing 2-chloromethylfuran was used without characterization in the next reaction.
The cyclic urea acetonide XXVIIIf (1.02 g, 2.79 mmol) was added to the solution of 2-chloromethylfuran.
Sodium hydride (490 mg, 16.3 mmol, 5.9 equiv., 80% oil dispersion) was added and stirring continued for one hour. The reaction was then quenched by the addition of water and extracted with ethyl acetate-hexanes (1:1).
The organic phase was washed twice with water, once with brine, and dried over anhydrous magnesium sulfate.
Filtration and evaporation gave the crude product which was purified by flash column chromatography (30% ethyl acetate-70% hexanes). The column provided two major fractions: a nonpolar fraction containing the significantly contaminated bis-alkylated product and a polar fraction containir.g adequately pure mono-alkylated cyclic urea intermediate (343 mg). lH-NMR (300 MHz, CDCl3) ~ 7.28(llH, m), 6.27(lH, t), 6.05(lH, d), 5.07(1H, d), 4.83(1H, d), 4.22(1H, dd), 3.88(2H, m), 3.48(1H, m), 3.15-2.88(4H, m), 2.70(1H, t), 1.48(3H, s), 1.46(3H, s). HRMS(NH3 CI) Calculated for C27H31N24 (M+H): 447.2284; observed : 447.2277. The nonpolar fraction was further purified by flash column chromatography (15% ethyl acetate - 85% hexanes) to give pure bis-alkylated intermediate (73.4 mg, 5%). lH-NME~
(300 MHz, CDCl3) ~ 7.37-7.09(11EI, m), 6.27(2H, dd), 6.08(2H, d), 4.94(2H, d), 3.90(2H, s), 3.82(2H, b), 3.03(2H, d), 2.90(4H, m), 1.41(6H, s). 13C NMR (75.4 MHz, CDC13) ~ 160.74, 151.93, 142.19, 138.86, 129.45, 128.57, 126.46, 110.21, 108.71, 75.26, 61.49, 48.45, 32.87, 26.7i. MS(NH3 CI) m/e 527 (M+H).
Tne monoalkylated cyclic urea acetonide above (33.5 mg, 0.075 mmol) was dissolved in methanol (3.0 ml). p-Toluenesulfonic acid monohydrate (2.9 mg) was added and stirring continued for four hours. The reaction was quenched by the addition of saturated aqueous sodium '094/19329 ~ 1 ~ 6 ~ 9 ~ PCT~S94/01609 carbonate. The solvent was removed on a rotary evaporator and the residue applied to a flash silica gel column. The column was eluted with initially 50% ethyl acetate-50% hexanes and finally 100% ethyl acetate. This provided 15FS (27.8 mg, 91%) in excellent yield. lH-NMR
(300 MHz, CD30D) ~ 7.43(lH, s), 7.34-7.12(lOH, m), 6.31(1H, m), 6.10(1H, d), 4.75(1H, d), 3.86(1H, dd), 3.65(2H, m), 3.39(lH, m), 3.11(2H, m), 3.01(lH, dd), 2.88(lH, d), 2.77(lH, dd). 13C NMR ~75.4 MHz, CD30D) ~
162.17, 151.45, 142.30, 139.79, 139.74, 129.10, 129.06, 128.08, 127.91, 125.96, 125.64, 109.80, 108.15, 70.90, 70.53, 65.28, 58.73, 32.70, 31.94. HRMS(NH3 CI) Calculated for C24H27N2O4 (M+H): 407.1971; Observed :
407.1961.
The bisalkylated acetonide was deprotected using the same procedure. Flash sllica gel chromatography using 50% ethyl acetate-50% hexanes gave 15FT in 83%
yield. 1H-NMR (400 MHz, CD3OD) ~ 7.44(2H, dd), 7.32-7.13(10H, m), 6.33(2H, dd), 6.15(2H, d), 4.75(2H, d), 3.64(2H, bd), 3.60(2H, s), 3.05-2.89(6H, m). 13C NMR
(100.6 MHz, CD30D) ~ 163.11, 153.01, 143.93, 130.63, 129.47, 127.38, 111.36, 110.01, 71.75, 67.24, 48.88, 32.99. HRMS(NH3 CI): Calculated for C29H31N25 (M+H) :
487.2233; Observed: 487.2226.
Example 15FU

The starting 3-carbomethoxy-2,5-dihydrothiophene was prepared from 1,4-dithiane-2,5-diol, trimethylphosphonoacrylate and triethylamine as described in the literature [J. Org. Chem. 43 (23) 4431 (1978)]. The resulting ester (1.03 g, 7.15 mmol) was dissolved in dry methylene chloride (16.0 ml) and cooled to -78 C under a nitrogen atmosphere. A solution of diisobutylaluminum hydride (11.9 ml, 17.88 mmol, 2.5 equiv., 1.5 M in toluene) was added and stirring WO94/19329 PCT~S94/01609 ~ -254-.9 continued for two hours. The reaction was then briefly Gô warmed to room temperature then recooled to -78 C.
Excess reagent was then quenched with methanol t5.0 ml) and the reaction was allowed to warm to room temperature. The reaction was diluted with ether and treated with a saturated solution of sodium potassium tartrate. The clarified aqueous phase was extracted with two additional portions of ether. The combined organic layers were dried with magnesium sulfate, filtered and evaporated. Purification was accomplished by flash silica gel chromatography (5% methanol 95% methylene chloride). The resulting 3-hydroxymethyl-2,5-dihydrothiophene was isolated in 91% yield ~753.7 mg).
1H-NMR (300MHz, CDCl3) ~ 5.77(lH, bs), 4.22(2H, d), 15 3.74(4H, m), 2.09(lH, t). 13C NMR (75.4 MHz, CDC131 ~
142.77, 124.13, 61.39, 38.45, 38.21. MS(CH4 CI) m/e 117 (M+H).
Ths alcohol (663.0 mg, 5.72 mmol) was dissolved in dry methylene chloride (20 ml) under a nitrogen atmosphere. Dry triethylamine (1.2 ml, 8.57 mmol, 1.5 equiv.) was added and the reaction cooled to 0 C.
Methanesulfonic anhydride (1.2 g, 6.86 mmol, 1.2 equiv.) was added and reaction continued for 0.5 hours. The reaction was diluted with methylene chloride and washed with dilute hydrochloric acid and brine. Drying over magnesium sulfate, filtration and evaporation gave the crude mesylate which was used without purification.
The residue was dissolved in dry dimethylformamide (5.0 ml) and the cyclic urea acetonide XXVIIIf (524.5 mg, 1.43 mmol) was added. Sodium hydride (172 mg, 5.72 mmol, circa 4 equiv., 80% oil dispersion) was added and stirring continued overnight. The reaction was quenched by the careful addition of water and extracted with 50%
ethyl acetate-50~ hexanes. The organic phase was washed twice with water, once with brine, and dried over magnesium sulfate. Filtration and evaporation gave the _ ~094/19329 21 S 6 ~ 9 ~ PCT~S94/01609 crude product which was purified by flash silica gel chromatography (15% ethyl acetate-85% hexanes). The desired bisalkylated product was obtained in excellent yield (720.1 mg, 90%). lH-NMR (300MHz, CDC13) ~
7.29(6H, m), 7.14(4H, d), 5.40(2H, s), 4.32(2H, d), 4.08(2H, s), 3.83(2H, d), 3.78-3.49(8H, m), 3.06(2H, dd), 2.87(2H, d), 2.83(2H, dd), 1.31~6H, s). HRMS(NH3 CI) Calculated for C32H3gN2O3S2 (M+H)+: 563.2402;
Observed: 563.2394.
Removal of the acetonide protecting group using the hydrolysis procedure described in the procedure of example 15FS gave compound 15FU. (34.1 mg, 78%). 1H-NMR
(300 MHz, CDCl3) ~ 7.36-7.11(lOH, m), 5.45(2H, bs), 4.27(2H, d), 3.93(2H, bs), 3.82-3.49(10H, m), 3.16(2H, dd), 2.87(2H, dd), 2.84(2H, d), 2.62(2H, bs). 13C-NMR
(75.43 MHz, CDCl3) ~ 162.14, 139.66, 139.10, 129.36, 128.66, 128.51, 126.70, 71.81, 63.01, 50.97, 39.70, 38.31, 32.91. HRMS(NH3 CI) Calculated for C29H35N2O3S2 (M+H): 523.2089; Observed: 523.2071.
Example FW
Compound 15FU, protected as the acetonide, (53.2 mg, 0.0947 mmol) was dissolved in dry methylene chloride (2.0 ml) under a nitrogen atmosphere. The reaction was cooled to 0 C and solid m-chloroperoxybenzoic acid (83.7 mg, 0.388 mmol, 4.1 equiv., circa 80% active) was added and stirring continued for three hours with gradual warming to room temperature. The reaction was then diluted with methylene chloride and washed successively with saturated sodium bisulfite, saturated sodium carbonate, and brine. The organic phase was dried with magnesium sulfate, filtered and evaporated. The crude product was purified by flash silica gel chromatography (50% ethyl acetate-50% hexanes) to give 3S the bis-sulfone acetonide (61.5 mg; slightly more than theoretical). This material was of sufficient purity for W094/19329 PCT~S94/01609 G~ the subsequent transformations. lH-NMR (300 MHz, CDCl3) 7.39-6.95(lOH, m), 5.60(2H, bs), 4.22(2H, d), 4.06(2H, s), 3.83-3.47(lOH, m), 3.13(2H, d), 2.99(2H, d), 2.73(2H, dd), 1.31(6H, s). MS(NH3 CI) m/e 563(M+H-S02), 499(M+H-2S02).
Removal of the acetonide protecting group using the hydrolysis procedure described in the procedure of example 15FS gave compound 15FV (17.4 mg, 65%). 1H-NMR
(300 MHz, CDCl3) ~ 7.28(6H, m), 7.11(4H, d), 5.57(2H, bs), 4.16(2H, d), 3.92(2H, s), 3.83-3.45(10H, m), 3.23(2H, d), 2.92(2H, d), 2.74(2H, t). 13C-NMR (100.6 MHz, CDCl3) ~ 161.99, 139.00, 135.52, 129.32, 128.84, 127.04, 123.28, 71.09, 63.84, 56.53, 53.07, 33.14.
HRMS(FAB (glycerol/TFA)): Calculated for C29H35N207S2 tM+H): 587.1886; Observed: 587.1889.

Example 15FW

Compound 15FU, protected as the acetonide, (46.6 mg, 0.0829 mmol) was dissolved in dry 1,2-dichloroethane (2.0 ml). Addition of 2,3-dichloro-5,6-dicyanobenzoquinone (41.4 mg, 0.182 mmol, 2.2 equiv.) resulted in an instantaneous conversion to product. The reaction was applied to a flash silica gel column and eluted with first methylene chloride then 5% methanol-95% methylene chlorlde. The desired bis-thiophene intermediate was isolated in 92% yield (42.4 mg). 1H-NMR (300 MHz, CDCl3) ~ 7.37-7.20(8H, m), 7.10(4H, d), 6.98(2H, d), 6.95(2H, b), 4.88(2H, d), 3.83(2H, bs), 3.80(2H, bd(obscured)), 3.16(2H, d), 2.92(2H, dd), 2.82(2H, dd), 1.37(6H, s). 13C-NMR (75.4 MHz, CDCl3) ~
161.29, 139.01, 138.84, 129.43, 128.71, 127.74, 126.53, 126.37, 123.87, 110.19, 75.59, 60.89, 51.00, 33.58, 26.79.
MS(NH3 CI) m/e 559 (M+H).

2156~9 i VO94/19329 PCT~S94/01609 After deprotection of the acetonide as descirbed -~
for example 15FS, the resulting residue was applied to a preparative silica gel plate (0.25 mm) and eluted with 50% ethyl acetate-50% hexanes. Isolation of the appropriate fractions gave compound 15FW (12.9 mg, 61%).
1H-NMR (300 MHz, CDCl3) ~ 7.38~8H, m), 7.12~4H, d), 7.00(2H, dd), 6.97(2H, bd), 4.82(2H, d), 3.64(2H, s), 3.58(2H, bd), 3.16(2H, d), 3.04(2H, dd), 2.89(2H, dd), 2.34~2H, bs). 13C-NMR (75.4 MHz, CDC13) ~ 161.69, 139.4, 138.92, 129.46, 128.68, 127.98, 126.58, 126.43, 124.07, 71.77, 64.04, 50.20, 32.81. MS(NH3 CI) m/e 519(M+H).

Example 15FX

Compound 15FV, protected as the acetonide, (15.5 mg, 0.024 mmol) was dissolved in dry toluene (5.0 ml) under nitrogen. The reaction was heated at reflux for seven hours then allow to cool overnight. The solvent was removed under reduced pressure and the residue applied to a preparative silica gel plate (0.25 mm) and eluted with 25% ethyl acetate-75% hexanes. The bis-diene intermediate was isolated in 61% yield (7.5 mg). lH-NMR
(300 MHz, CDC13) ~ 7.37-7.17(10H, m), 6.31(2H, dd), 5.35(2H, d), 5.14(2H, s), 5.13(2H, d), 4.83(2H, d), 25 4.70(2H, d), 3.88(2H, s), 3.85(2H, m), 2.89(4H, m), 2.6g(2H, d), 1.44(6H, s) 13C-NMR (100.6 MHz, CDCl3) ~
161.68, 142.93, 139.49, 136.85, 129.39, 128.64, 126.49, 120.23, 115.46, 110.22, 75.76, 59.19, 52.81, 33.40, 26.90. MS(NH3 CI) m/e 499(M+H).
After deprotection of the acetonide as described for example 15FS, the resulting residue was applied to a preparative silica gel plate (0.25 mm) and eluted with 50% ethyl acetate-50% hexanes. Isolation of the appropriate fractions gave compound 15FX (2.9 mg, 42%).
1H-NMR (400 MHz, CDCl3) ~ 7.37-7.16(10H, m), 6.31(2H, dd), 5.34(2H, d), 5.17(2H, s), 5.12(2H, d), 4.79(2H, s), WO94/19329 PCT~S94/01609 9.74(2H, d), 3.76(2H, s), 3.64(2H, d), 3.06-2.88(4H, m), 2.67(2H, d), 2.28(2H, s). 13C-NMR (100.6 MHz, CDC13) ~
162.02, 143.05, 139.93, 136.88, 129.48, 128.68, 126.97, 120.08, 115.61, 71.89, 63.06, 52.42, 32.68. HRMS(NH3 CI): Calculated for C2gH3sN2O3 (M+H): 459.2648;
Observed: 459.2653.

21~6~9 ~:
Z ~D r r r ~ o a V~ S. _ ~ ~ ~ ~
_ + Z u~ o r r -- u~ r O CD -O N O O

O + + + +
~ + + + +
~ + + + +
~ + + + +

~r . T 3 + + + +
Z ~ O
~ .' I~ r~J ~/ O ~ I _I ~ S I I ~ I
T t~ ~ 1 ~ ~ N r~ ~ ~o-) S

-- -- O ~ -- O ~ -- 3 ~ ~ ~ U ~

T C) S ,~ S ~ S
~ I I S
~ :r s. s. r ~ s. S ~ s.
S ~ ~.) Z ~ S. Z ~ ~ Z
-- ~ -- O

~ :~ Z
X q U~

~,~

r r r r r r ~ . . a~
_I r a~ r ~ ~o U) ~ o r ~ ~ u~ ~r r o r- ~ o r~ o o + +
+ + + +

+ + + + + +
+ + + + + + + +
o Z I
~, ~ o Z V o Z 5 ~ ~ V ' V
.? v, ~5, 55 ", ~ V Z I ~ ~ ~1 V 5~
-- Z V ~ ~ ~ 5 ~~ z o ~ ~ 5 ~ 1 5, Z ~
~ t~ ~ ~~ Z I ~ Z O ~ v ~r E U _ E3 ~ ~ B ~ O L Fl U ~n r F~ 5. 5 F~ 5 5 1 1 1 5. Z

5 N ~ c~ z I ~ ~ U ~ ~
~~ 5' ~ 5 ~ ~ 5~ ~ r- 5z o ~ I 5, ~ 1 5 Z ~
-- O ~N ~ O C ) !r Z I Z O !-e ~ ~ 5 ~, 5 ~) ~ 5 5 ~: m 215~
~lO 94119329 PCTIUS94/01609 - ~ 0 CJ ~ 0 ~ ~ ~ N ~ ~J

_ S ~ ~ r ~ + 2 ~ o ~ ~ ~7 ~ cn ~
_ o U7 --'~

+ + + + + + +
+ + + + + + + + +
+ + + + + + + + +

+ + + +
+ + + + + + + + +
o cJ~, -- ~D N
V
I . _ I O I
N N
S -- S S S 5 ~ N
~1 S C~--~ S O .~ S I ~D

o _ N N N N N N
S -- _ O o ( ~ S
:r: oo o o o o o g ~ ~ g C,~,,~

O _I O

a~ r ~ r r r o~ ~ r ut ~
C~ N r a~

+ + + +
+ + + +
+ + + + + + + + +
+ + + + + + + + +

+ + + +
+ + + + + + +
+ + + + + + + + +
o N ~
S, S N ¦ N
,~ V O I S S S' I
~ S. S, S. ^ O I N _ U'1 O (,) O O Z --~ S
-- 11 , S, N
' I S S S I ~ ~ N
-- NC ) I~_) U
Iq 1'1 y ~1 N t'l '1 N S~ ~1 r-N
ô ~ S

S, -- _ ~ ,~
S S S l S S ~ N
~ S S S N

S S. ~ ~.) ~.) I O ~.) S. S. S. S, ~Z g ~ g~ g ~ ~

~O 94/19329 PCT/US94/01609 215S.~9~

r r ~ ~ 0 ~ u~ a~ r err W ~ 1~ N U~ r u~

+ + + + + + +
+ + + + + + ++ + +

+ + + + + +
++ + + + + + + + +

~ I I N O :r ~ ~
11 ~
U7 U') ~ -- -- ~ C~

S S U U I U~ U U U =

_ -- _ ~ o I
-- ^ ^ ^ OO O Z
_ _ _ ~ ~ r~ ~) 2 O :C O O O

@ 3 WO 94/lg32g PCT/US94/0160g ~"
~3 r ~ ~ a~ o cr~

o ~ ~
r ~D o a~ 0 u~ r ~D ~o ~ ~ ~ o r ~ o ~o r ~ r a~ r r CD o ~D ~D

+ + + + + + + +
+ + + + + + + +
+ + + + + + + + +

+ + + + + + +
+ + + + + + + +
+ + + + + + + + +
U

O O O I _ o ~ V ~ ~ ~Z 5 o 5 (~ 5~ Z ~ N I
S ~ S ~ S ~ S

O I I ~ ~ _ N ~ Z~ 5 C ~ ~ ~ 0, ~ 5~
Z o ~ S ~ S ~ S ~ S ~ S ~ S
5. 5. ~ _ 5.
53' æ æ æ 3 ~0 94/19329 PCT/US94/01609 _ -265 -215S~

_ C~o 0 ~ 0 r ~ ~ 0 o ~r r ~ ~ ~ ~ ul r o ~ ~ ~

+ + + + + + + + +
+ + + + + + + + +
+ + + + + + + + +

+ + + + + + + + +
+ + + + + + + + +
o -~ 1 _ _ -- I 5~ ~ I S
c z ~ z ~ = I ~ . o 8 -- -- ~ -- ~ C ~, ~ O C.
m u U, 5 U U U U o ~ o ~ o Z
S ~ O ~ O ~ O , O , ~ ~ S ~ S
e~ E- e- e- 6- CLCJ e c~ ~ e o~

, ~0 N

~ r 0 r 0 ~
~r o o ~ ~ o~ In ~ U~ ~1 ~1 ~D 0 U~ 0 U~

0 o ~ I ~ I O
0 _~ ~1 0 0 I ~ 0 ~ ~ a~ ~

+ + + + + + + +
+ + + + + + + + +
+ + + + + + + + +

+ + + + + + + +
+ + + + + + + + +
+ + + + + + + + +

I I _ ~ r O .r ~ I I ~ ~

S ~r S ~ = ~, Z ~ ~ z ~_ S C, ~ -- 3 -- 5 -- ~ -- 7 e ~ e ~ e ~ e - ~ e ~ e ~

~ ~ I ~

_~ S I S I ~ ~,~ ô ¦ C~ I S, _ r S, ~ S. C~ V S
~ I ~o I ~ I ~ I
c~ e S. e ~ e c, e - CL- ~ e ~ e 3 3 3 ~ x x x VO 94/19329 PCTtUS94tO1609 21~C~9 1 ~ r ~ ~D
o ,~ 0 ~D ~ ~ 0 ~ 0 0 ~ r u~
r o a~

+ + + + + + + + +
+ + + + + + + + +
+ + + + + + + + +

+ + + + + + + +
+ + + + + + + + +
+ + + + + + + + +
o N
~ S ~ I ~ N
N 5~-- S~
a -- ~ ~ ~D o o ~r _ o o ~ S N Z N .~~') S C~ S ~ ) S ~) S ~ S
~ o ~ m ~ o ~ o E I ~ ~ r z r ~ ~ -- s.
~ ~ e ~ E EE C~ E t E - ~) D. t, E t~ E

~ S ~ I ~ N ,.~ _ _ C Sl w O O ~ q~ C ~ O
0 N 5 ~'1~ S ~'1 S C. O t~ N O N

E C_ E E C E t. E- ~ ~ s. E ~_ E

X X ~ x ~ ~ X x X

,, o ~ o ., ~
0 o o o r ~
~ o o ~r O-- r-- ~D ~ 0 o o + + + + + ~ +
+ + + + + + + +

+ + + + + + + +
+ + + + + + + +
C
o ~ 3 r~ _ I z ~ 5 Z ~

N ~ ~ Y 5 ~ 3. ~ O
3~7 3 ~ 3 1 ~ 3~ ~3 ~ a) C' 0 3 I 5- 1 ~D 1 5 1 5.
t ~ L C_ O ~ t_ O O CL C, ~ ,.~1 ô , c~ ~ ~

5 ~ I 0 3 1 ~cn 5~ 1 5~ r _ ~ -- Z ~ ~ -- z 5 ~ ~ t.) S ~ ~ 5 ~ 5~ S ~ 5 ~ 5 N ~ -- 5 ~ o ~ o o -- I
Z O D~
X X X X X X X X

21S~9-~

D ~ N r r~ ~ ~ u7 ~r r ~ ~ ~ ~D O ~ CD
~ N ~ r ~ ~
.
u7 u~ r ,~ u~ r ,~
r a~
r r u~
~ ~ o ~o U7 o o ~ ~ o r~ r~
a~ I I
o ,~ r I ~ o o o ,~ ~ r o ,~

+ + + + +
+ + + + +
+ + + + + + +

+ + + + +
+ + + + + + +
I~ + + + + + + +
C
o ~c~I I r~ 5 ~
t-~ ~ r~ _ r _ , _ ._r _ v --~ I _ I _ I _ ~ ~ I _ ~D 5 ~' ~l -~ O ~l O ~~ O ~~ O ~-- O _ w 11 l ll l 11 1 11 ~r I 11 r~ C, -~
~LZ~ C~ Z _ C~ Z _ C~ Z~ _ C~ _ ~' Z 1 ~ I Z ~ S, I Z ~ S. I Z ~ S. I ~-- , r~ Z ~ Si I ~ -- O ---- , ~ - Z s ~ ~ Z s ~ _ æ :r ~ ' Z s ~ --L Z 3 -- ~` 11 r-l O -- ~-11 1 V r1 cJ I .r l ~ I V r l ~ I . r I ~ I r-l r~ I . r~ r-l r' N.1 ~ V ~ ~ C~ N ~ V
C 5~ ~ C 5~ ~ C 5~ ~ rj 5 C ~ C ~0 r 5 ~ Si C 'I C 11) I ~r V w I V ~ - V ~:) I - V ~ (J) L V ~ I ~ V ~ Z I ~IJ ~ V E
~c. ~ ~c. ~ ~c ~ ~c. ~-~- e~c ~
C C r' _ I _ I V V V
r~ _ t~
I _ ~ -- E E E~i -- O -- O ,~
Z -- Z
~_ C~ ~ `_ C~
Z i S. ~, Z ' Si C, 5~ -- r I ~ V w I - V ~ 5j Si S
1 C~ ~ ' O t_ V C~ C~ , c) :~ x ~ m c~
X X X X X
r~ r~

~S6 '~) ~ ~

T~hle ?~ (cont .) ~o 15YD cyclopropylmeth m-~(3-pyridyl)- +++ 115-117 605.311364 yl methylNHC(=O))-15YE cyclopropylmeth m-((2-pyridyl)-yl methylNHC(=O))-15YF m-(p-toluyl m-(p-toluyl ++ +++ 169-171 sulfonylhydra- sulfonyhydra-zone-)C6H~CH2 zone)C6H4CH2 15YG m-(N-morpholino m-(N-morpholino ++ +++ 110-112 765 ethoxy)C6H4CH2~ ethoxy~C6H4CH2~

15YH p-HOCH2C6H4CH2 p-H2NCH2C6H4CH2 ++ ++ 132-134 566 o 15YI m-(CH3NHOC=O)- m-(CH3NHOC=O)- +~+ +++ 223-224 15YJ m-(1,2,4-oxadia m-(1,2,4-oxadia +++ 202(dec) zolidinon-3- zolidinon-3-yl)-- yl)-15YK m-~2- m-(N-SEM-2- ++ +++ 769 imidazole)- imidazole)-C6H4CH2- C6H4CH2- u r -o '~O 94/19329 PCT/US94/01609 -2 7 l -2151~ .S9~

~ ~ r ~ ~ ~ ~ ~r o ~
r o t-- C~ U
~ 0 0 u~ 0 Ln o ~r ~
O O~ O O t-- ~D 0 + + + + + + + + +
+ + + + + + + + +
+ + + + + + + + +

+ + + + _ _ + + +
+ + + + _ _ + + +
~ + + + + _ _ + + +
C _ C ~ '' a c a, z ~ 'r N ~1 ~ _ -- 1 5 5 C~ C C t~ ~ 5~ 0 5 N ~ O N 5 S 1~ 5~ L 5 L, ~ ) z 5 -- 5 -- 5~ -- -- -- O -- 5~ ~ 5 ~ -- O ~;

a, a~ a 5z ~
S' ` 5 ~D 5 ~ ~ S 5 5, 5 5 .~ 5~ ~_ 5, -- _ -- O 5 ~-- 5~
e ~ e ~
Z

WQ 94~ ~ PCTIUS94/01609 C~

0 o ~ ~r ~ u~ Ino a~ 0_I u7 o a~ a~o N O
~ 0 o r ~ a~
--I N
0 U~0 ~r ~--IO l_ N a~
I ~I N _1 + + + + ++ + +
+ + + + + + +

+ + + + +
JJ + + + + + + +
C _1 S " >, I, o I G .C
æ ~ N, co)~ N æ
S
. . S I ' .S S
I I ~I S. I

G O N
S o ~ S ~ ~ _ S
O

S .,. S~ S N Z N

e~ z ' ~ ' ~ S. ~ ~, Y ~

21~S9-~

r ~D ~r u~
r ~ r r ~
~) ~r r ~ CD
S,~
r o ~ In o r ~ ~

+ + + + +
+ + ++ + +
+ + + + +

+ + + + +
+ + + + + +
+ + + ++ + + +
O _ _ ~."
2. ~ 2 ~ 2 S~ æ,a . ~ 1 1 ~ _ S N ~ C
,~ S~ C ~
N

2' ~ E2.

z a Z 2 N z N ~ I ~ 2 2 2 .) ~. i _ 2. ~ ~ 2, n~ I Z 2 Z 2' Z 2 1 Q, 2 ~ 2 ~ 2 O ~ O -- S -- ~ -- :L
I ~ 2, E `~ ~ E ~ ~ E t e ~ E t.

o ~ a $6S9 4 D r~ a~ ,~ r ~ ~ ~ r~
U~ O O~ ,r~ O ~D
u~ r r ~D r ~D ~ r ~
~ r o r a~ r1 Q) ~ ~D ~
r'l ~ 'O N r1 -1 0 u~ r ~ r r o ,~ o r ~ u~ ~1 r~ N ~ ~ '~ ~

+ + + +
+ + + +
+ + + +

+ ++ + + + +
J~ + + + + + + +
I
,~ r~ O Z
C~~ O c ,,~
~` V V V '` I ~ ,~
' '- N '~ 2' z I r I ~- ~c I " ~
-~ 2 j2 2' ~ 2"~ c' c L -- C 7 -- ~ -- S -- ~ -- ~ ~ :~ --''I --''I
E D ~_ E .-` ~ E CE ~_ E L C_ 'r C_ E ~ E
-- _ 2. --~ ~ 20 Z ~ ~ '~
2. ~ Z 11 l ~ ~r O r~ "
C-~ V r~
Il , ,~r 0 I 21 I C ~ I ~, V ~ ' ~ ' ~ 2z ~ r ~
Z 2 1 ~ 2. r 2' C'.- N ~ N er V :~ V ~ N ~ ~ _ N ~ --E ~ E . ! ~ e _~ ~ E ~J e vE L ~ U E ~ u g~ m ~ ~ m 'O 94/19329 2 15 6 5 9 4 PCT/US94/01609 . .

~; ~^` `. ~.

U~ U7 r ~ ~ ~o.
~ O O~ ~ U7 0 0U~ 0 ~ ,A U~
0 ~D r _~ o 0 1 U~
r ~ u7 r + + + + + + +

+ + + + + + + +
O --~
"

X I I I I _ _ ~' ~ C 5 ~ 5~ ~ 2 ' ~ C' ,~ Z :~ ` G
~ ~ 5~ -- 7 _ E I ~ C. E t_ E ~ E
~. . _ r , _I
X

N ~ "A C~ 5 ~ ; N
Ei ~ C_ E te~ ' C_ ~ ; Aj ~ 1~ X
m m m m m m m m T~hle 2 i (cont . ) 15BN m-(4-pyrazole)- m-(4-pyrazole)- +++ +++
C6H4CH2---HCl C6H4CH2--HCl ~ ~' 15BP m-carbomethoxy-m-(3-pyrazole)- +++ +++ 127-130 631.4 15BQ m-hydroxymethyl-m-(3-pyrazole)- +++ +++ 603.2 15BR m-(2- m-(2- +++ +++ 178-180 639.4 imidazoyl)- imidazoyl)-15BS m-(2- m-(2- +++ +++ 191-194 imidazoyl)- imidazoyl)-C6H4CH2--HCl C6H4CH2--HCl 15BT m-((2-morpholinom-(3-pyrazole)- +++ +++ 729.5 ethyl)amino C6H4CH
carbonyl)-C6H4CH2 15BU 3-pyridinylmethyl m-(3-pyrazole)- +++ +++ 133-136 574.2 15BV m-cyano-C6H4CH2- m-(3-pyrazole)- ++++++ 598.2 15BW m-(H2NC(=NOH))- m-(3-pyrazole)- +++ +++ u C6H4CH2- C6H4CH2- r o ~'0 94/19329 PG~t~JS94tO1609 - -277- S6~)g~

~ rJ r cr~ r ~ ~ u~ ~o a~ r o c~ o ~ ~ o ~r ~D r ul r o ~o u~ rr + + + + + + + ++
+ + + + + + + ++
+ + + + + + + ++

+ + + + + + + ++
+ + + + + + + ++
C + + + + ++

â â â ~ â ~c 7; _ _ _ _ __ _ --h ~ C _C O
L 5 L ~ L 5 CL 7 L T L 5 L ~- L 5 L 5 ~ _ 7 _ _ 7_ ~ _ "
E t E ~ E ~ E ~E ~E ~ E 'E ~_E ~.

x o c ~ ~ s ~
--I ~ E ^ ~ ~ 'L
~ rl 5 )J 1 5 ~ :r ~ ~ ~ ~ ~ CL :C C
S, CL ~ E E g E E ~, E ~ E
x ~ m c~ c~
m m m W~ 94/19329 PCT/US94/01609 ~

Z Z
U~ , o ~
~ _I N --I
U~ ~ O ~

++ + +

+ + +
+ + +
O
C.) ~ N ~ N

S Z ~ o~ oo L o L

E h ~ X

s I I rI N>, --S, ~ ~ V
~ ~ z z ~DzO ~

v ~ 2 _2 --~ , S , ,, , s ~ ~e ~ E CLE ~ ~ ~`I
~ 2 ~ '~ ~~, ~ o , ~o U~
O
_, _, fJ~ ~ a) t~
o ~ ~ ~
~ ~ _Iu~ o o n _I o ~ a~
~ r~ A ~ ~`J N --~

+ + + +
+ + + + + + +
+ + + + + + +

+ + + +
+ + + + + + + +
+ + + + + + + +
,f"
~1 ~1 I L
--I O O
r~ O
r ~ f` ~- X I
Q ` ' ~ o ~
~, C ,~
C " ~ C ~
h ~ ~. Ll ~ ` Ll C L' ~ N l Ll Il') ' , ~ ~ V.-: ' V':) V -- C -~ V ~
~ `~ I au au . ~ L a) I

~ o o 1~U~ O r I
,, ~ O
~, ; ~ In ", C C~J N I _ . I ,' . I V -- f~ ~
D ¦ Q A ~ I

~ X
C~ O ~ U O O ~ O

TAhle 7rl (cont . ~

15CY 6-indazolylmethyl 6-indazolylmethyl +++ +++ 170-175 15CZ ~3-methyl-2-oxo- (3-methyl-2-oxo- +++ +++ 192-200 5-benzimidazolyl) 5-benzimidazolyl .
-methyl -methyl 15DA 5-isatinylmethyl 5-isatinylmethyl +++ +++ 196-200 15DB (3-hydroxyimino-5-3-hydroxyimino-5- +++ +++ 242-245 oxindolyl)methyl oxindolylmethyl 15DC (2-oxo-5-benz (2-oxo-5-benz +++ +++ 181-185 oxazolin-2-yl)- oxazolin-2-yl)-methyl methyl 15DD 5-oxindolylmethyl 5-oxindolylmethyl +++ +++ 170-175 15DE 5-indolylmethyl 5-indolylmethyl +++ +++ 170(dec) 15DF (3-amino-5- (3-amino-5- +++ +++ 180-184 indazolyl)methyl indazolyl)methyl -15DG (3-amino-5- (3-amino-5- +++ +++ 153-158 c benzisoxazolyl) benzisoxazolyl) u methyl methyl '~D

~0 94/19329 PCT/US94/01609 -28 l -215659~

r c) ~ ~ N O O ~ O
r ~ r u~ ~
~ r~ ~ r~ ~ ,t r l o co o r 0 c~
r o~ In u~ r ~ o ~n r~ ~ ~1 ~1 ~ r~ ~ r~ r~

+ + + + + +
+ + + + + +
+ + + + + +
+ $ ++ $ ++ $ ++ ++
+ + + + + + + +
o I ~.1 ,.1 ,., I . ,~ ~-1 r~ r~
v r ~ o c o o o ~1r~ a r .r .r .r _ rl O rl rl _ ~ _ L, L L
C ~ J ~ _ _ L -~ C _ ~ _ h . ~ C ~ I
-- - ------ - -- . ~ --~ E U7 u~
~ ,~
~ .c ~ r'l .c . ~
V
6 ~ 6 '- e o _ ~1; r l _ r~ r~ r.~ r~ ~r l r~ :
r~
' 6 --U7 6 :~ ' N .

Z O
a a a a a a a a a 0 ~ u~

U~ O (D U~
--~ N
I

+ + + + + + + + +
+ + + + + + + + +

+ + + + + + +
+ + + + + + + +
+ + + + + + + +

C~ O O O ~
n ~ s o :; s ~L L L ; L ô ~ ~, ~ 5 _ 5 E~ ~ S,) Sv S ~ V ~'~ ~ 5~ S

~ _ L ~.r h I --I ~ ~ S
S o ~, L ~ ' ~ ~I S O
_ ~ r .c ~ Z ~ S

Q. ~ E t. ~ ~ E ~ E ~ E ~ ~ O C, g ~ a a ~ ~ 3i x ,~ 21S6,59~
, ,.

~¦ CA ~
. . _, ~ o O~D ~D -o ~~ ,1~ ~ c o U~ U7~ ~ ~ U~ o ~

+ ++ + + + + +
+ ++ + ++ ++ + ++ $ +

+ + + + + + +
+ ++ + + + + + +
+ ++ + + + + + +

3 ~ ~ I N ~1N ^ 3 ~1 N ^ 3 3 3 3 ~ 3 3.
~1 3~ r O 3 `~
~ ~ 3~ ~ 3 Z `~ Z `~

S _~ I . 3 3 3 z 7 , o-- 3 ~ ~ L
N N '1 N
E-1 _ ., _ ~ ~r'1 ~ 3 ~3 -- '- -- 3 --~ _ 3C 3~ ~ 3 -- . ~ -- ~ --~ --E ~ e ~ e ~ e ~
OA I I ~ N
N '>1 N~ S S ~' 3 04 3' 3' S
"I ''I~ O ~ `~ lZI C- ' O
N sN sN z -~ ,t7 z _ ~ Z

SA~ O ~O ~ ~ e ~ e fS a C~ a ~ ~ ~ s a ~ 3 w T~hl e 2-3 (cont . ) ~9 3 15EI p-methylC6H4CH2- p-hydroxymethyl- +++ 174-175 SSl 15EJ 5-hydroxy-5- 5-hydroxy-S- ++ ++ S55 methylhexyl methylhexyl 15EK 5-~methylamino S-(methylamino ~+ ++ 613 carbonyloxy) carbonyloxy) pentyl pentyl 15EL 7-~1,1,4,4-tetra 7-~1,1,4,4-tetra + ++/+ 727 methyl-1,2,3,4- methyl-1,2,3,4-tetrahydro tetrahydro naphthyl)methyl naphthyl)methyl 15EM 5-azidopentyl 5-azidopentyl ++ .+++ 549 ~566) 15EN S-~methylsulfonyl 5-(methylsulfonyl ++ ++/+ (670) amino)-pentyl amino)-pentyl lSEO S-(p-methylphenyl S-~p-methylphenyl ++ ++t+ ~822) sulfonyl)pentyl sulfonyl)pentyl 15EP 5-aminopentyl S-aminopentyl + ++/+ 497 NO 94/19329 PCTfUS94/01609 21$6~9~

, . .

o a _~ ~ G r ~ r r ~ r ~
-- ~D-- -- r ~O r ~ r + + + + + + +
+ +
+ + + + + + + + +
+
+ + + + + + + + +
+ + + + + + + + +
O ~, _I r~ ~ ~ _ ~ r ,~_ r _ ~ .- O
_ I ~_ rl, r l r1 ~ rl ~ C
' E
., _ __ ~ ~ C
r~ ~1 r' ~1 -- L ~ CL ~ ~ r ,~ v ~ ô E ~
E . ~ --. c -- G ~ ~ O _. V -- ~--- C -- -- . -~ -- ~r ~ ~ -r ~~ ' ' C
," ul CJ CL u7 CLu~ CL u~ CL u~, CL
,~ I
~1 r~

r l ~ . rl -- -- -- ' E
CL ~ ~ --~

It~ ul CL u ~ ~, CL u~ CL U) u~ CL IJ-), CL

a a~ 3 X :~

~9 q~

_ a~ r ~ ~ ,~ o ,~
o ~ 0 u~ u~ r ~-- N
r t~-- r-- ~-- t~

+ + + + + +
+ +
+ + + + + + + + +
+ + + + + + + + +
-C;
O ~ . .
O ~ T
T _I _ I _ C _I ~
O ~ O
C~ C --~ -- ~ C' I -- C
a~ ~a c_l CL '. ~ ~ ~ _I ~ T

-- --- -- ~ ~t C -- C ) -- J~ '-- C~ C. J~
u)u7 CL u~, CL u-) ~ CL ~ CL u~, I CL ~ Q

~, T _I _ _ _ C --I --I -- ' --r~ O O -, ~ ~ 0 _~ C, I ~ C~ C~ -- ~ C' -- C
,I E E. ~ - E
f C' '~ Aa Aa ~ Aa '~ Aa C _I
A~ CL ' ~ ~ ~t ~ --I '` - ~ ', ~ Il~ _~ S:
O ~ ~ ~ C >~ ~1 0 ~1 ~ ~ '' --I
C CA ~ C S C ~ ~ V
u~ Ia u7 CL ~n, CL ~ ~ CL 'r u~ _ Aa Y CL u-) J CL CA Q
N ~: m ~O 94/19329 PCT/US94/01609 2ls6s9~

.
` .

fJ~ f~

U~
~f~
_I _1 0 +
+ + +

+ +
+ + +
~ + + + + + + +
,~f,, ~f,) I _ ~1 --I C

, L ~ ~

r ~ r V
~ ~ -- C' ~ C ~ C ~ C ~ I
4 ~ f~ 10 _4 U') fL ~7 --~1 --^ ~ --I C r . S
f S _ L
r j I ~ r _~
~ 1 4 ~ ~ f' ~ Ll .. ~
-- ~- '' C' -- ~ -- -- ,f~ 1 W
f4 ~ C4 U~ _4 ~ ~ --~ Z O D~

C~
CC~
Lr~
~2 U~

+ + + ++ + ,++ +

O ~ . l ~ v h Ial C ID~ C
I E ~ c v L E ~1 0-- E ~ E

~ E v _ E ~ ~7 _ ~ ~

O ~ V N
L . e - I ~L, L, C---' ~ Ll C. ~ ~ ~ C' ,C . L~ ) LC ~ ;` a ~ ~
J LC I _I -rl L, I
-- e ~ --~ ~--~ ~ ~ ~ N .
a ~ 3 X

~094/19329 PCT~S94/01609 Notes (for Table 2d): -289- 215 6 5 9 4 ~
~2) Monoalkylated compounds were prepared by following ~`
the procedure 5 under the title of synthesis of :~
monoalkyl cyclic urea. Further functional group elaboration is similar to the corresponding dialkylated cyclic ureas described herein.
(4) Isolated as the side product due to incomplete reaction.
(17) Prepared from Example 15J using the conditions described for Example 6ZI in Table 2C.

(18) Prepared from the compound of Table 2C, Example 6ZI
using methanesulfonic anhydride.

(19) Prepared from Example 6ZI using isocyanic acid.

(20) A solution (60ml) of borane in tetrahydrofuran (THF, 2M) was added dropwise into a cooled solution (0C) of bis-formamide 6ZM (9.18g, 15.5 mmoles) in anhydrous THF (200ml). The mixture was stirred for 16 hours at room temperature, followed by dropwise addition of methanol (50ml). When the effervescence had subsided, hydrochloric acid (conc., 35ml) was added.
The residue was stirred for 30 minutes, evaporated to dryness, and partitioned between ethyl acetate and sodium hyd~oxide (1 N). The organic layer was washed with brine, dried over magnesium sulfate, filtered and evaporated to give 8.65g of the product.

(21) Prepared from Example 6ZI using benzyl chloroformate.

(22) Prepared from Example 15D using the conditions described of 6ZM.

~a~, (23) Prepared from Example 15H using the conditions L~ described for Example 6ZI.

e~2 (24) Prepared from Example 15F using the procedure described for Example 15D.

(25) Prepared form Example 6ZI using methyl isocyanate.

(26) The formamide of Example 15A was prepared by the procedure Example 6ZM, followed by reduction described for Example 15D.

(27) The amide bond is formed between an amlno acid and aminobenzyl cyclic urea using dicyclohexylcarbodiimide/
catalytic 1-hydroxybenzotriazole in N,N-dimethylformamide in the proper proportions. When the desired product is to be a primary or secondary amine, the N-terminus of the aminG acid was first suitably protected, based on the compatability with later reactions (see T.W. Greene and P.G.M. Wuts, "Protecting Groups in Organic Synthesis", 2nd edition, Wiley (1991)) and then later removed.

(28) Cyclic urea XXIIc was alkylated with sodium hydride (2.5 equiv) and THPO(CH2)5Br (prepared in 2 steps from HO(CH2)sOH) (4 equiv) in DMF to give the monoalkylated product. Where upon further treatment with sodium hydride and a second bromo-alkylating agent provided an intermediate which was deprotected using methanolic HCl in dioxane to provide the product.

(29) Prepared by acidic deprotection of the monoalkyated intermediate.

V094/19329 215 6 ~ 9 4 PCT~S94/01609 -(30) Prepared from intermediate (XXII) by treatment with phenyllithium, boron trifluoride and l,2-epoxybutane, followed by acidic deprotection.

.
(31) Prepared from intermediate (XXII) by treatment with phenyllithium, boron trifluoride and 1,2-epoxyhexane, followed by acidic deprotection.

(32) Prepared by pyridinium chlorochromate oxidation of the corresponding alcohol.

~33) Prepared from Example 15VQ using hydroxylamine hydrochloride.

(34) See preparation of Example 15VW using excess reagents.

(35) Prepared by selective monoalkylation of the dialkylated diol using sodium hydride/ methyl iodide.
(36) Prepared by substituting CH3CH(OTHP)(CH2)4Br in the procedure described for Example 15VE. Bromide is prepared from CH3CH(OH)(CH2)40H by the following sequence: (1) Ac20; (2) THP, H+; (3) NaOH; (4) CBr4, Ph3P.

(37) Prepared by substituting Ph2C=N(CH2)2Br in the procedure described for Example 15VE. Bromide is prepared from H2N(CH2)20H by the following sequence: (1) Ph2CO; (2) CBr4, Ph3P.

(38) See note 7, Table 2d.

(39) See note 3, Table 2d.
(40) See note 2, Table 2d.

WO94/19329 PCT~S94/01609 ~ (41) The intermediate was prepared by following $ Procedure 5 under the title of synthesis of monoalkyl cyclic urea. This was followed by alkylation with Bromo-m-tolunitrile. This intermediate (670 mg, 0.82 mmol) was treated with potassium hydroxide (0.4g, 7.13 mmol) in ethylene glycol at 140C overnight. The solution was acidified with pre cooled hydrochloric acid (lN) and extracted with ethyl acetate. The organic phase was concentrated to give 415 mg (61%) of M~EM-protected diol. Procedure for hydrolysis of this product is covered under procedure 5.

(42) The intermediate was prepared by following Procedure 5 under the title of synthesis of monoalkyl cyclic urea followed by alkylation with Bromo-m-tolunitrile. This intermediate ~210 mg, 0.26 mmol) was treated with DIBAL-H (0.19 mL, 1.5M in toluene, 0.286 mmol) at -78C under nitrogen, stirred at -78C for 1 hour and RT for 3 hours. The reaction was quenched w,th cooled hydrochloric acid ~lN) and worked up in the usual manner to give 180 mg ~87%) of the MEM-protected product. Hydrolysis of this product is covered under procedure 5.
(43) N,N-dimethylformamide dimethyl acetal (2.lml, 15.9 mmol) was added to a solution of ketone 9P (940 mg, 1.59 mmol) in ethanol. The mixture was heated at reflux overnight, and the solvent was removed on a rotary evaporator. The residue was purified on silica gel ( 15%
methanol/chloroform) to provide the product (940 mg, 8q%) .

(44) The intermediate was prepared by following procedure 5 under the title of synthesis of monoal~yl cyclic urea. The monoalkylation product was further VO94tl9329 215 6 ~ 9 ~ PCT~S94/01609 alkylated with bromo-m-tolunitrile. This intermediate (185mg, 0.24 mmol) was treated with hydroxylamine HCl -(25 mg, 0.37 mmol), and triethylamine (0.05 ml, 0.37 -mml) in refluxing ethanol for 16 h. The resulting solution was partitioned between ethyl acetate/water.
The organic layer was washed twice with water and concentrated to give MEM-protected product which can be further hydrolyzed as described above to yield 90 mg (58%) product 9C.
(45) Guanidine carbonate (7.2g, 40.23 mmol) was added to Ex 15AE in xylene. The mixture was heated at 130 C until no starting material was left. The solution was partitioned between ethyl acetate/water and the organic layer washed with water twice. The organic residue was purified on silica gel (10% methanol/ ethyl acetate) to provide the pure product(347 mg, 37%).

(46) To a solution of MEM-protected formaldoxime 6C ( 0.5 g, 0.65 mol) in DMF was added 1/3 of N-chlorosuccinimide (173 mg, 1.3 mmol) . The mixture was stirred for 10 min followed by 2 min of heating at 40-50 C. After stirring for another 10 min, the rest of NCS
was added. The mixture was stirred at room temperature for overnight. The solution was then partitioned between ethyl acetate/water. The organic layer was washed with water and dried over MgSO4. Treatment of the hydroximoyl chloride with 3 equivalents of o-phenylenediamine in ethanol gave a single product which can be further hydrolyzed to the product (126 mg, 43%).

(g7) To a solution of aniline 3K (146 mg, 0.27 mmol) in methylene chloride, was added isonicotinoyl chloride hydrochloride (110 mg, 0.59 mmol) followed by potassium carbonate ( 187 mg, 1.35 mmol) at 0 C. The mixture was stirred for 2 h and then slowly warmed up to room WO94/19329 PCT~S94/01609 temperature overnight. The mixture was partitioned between ethyl acetate/water. The organic layer was washed twice with water and dried over MgSO4. The residue was purified on silica gel (5% methanol/ethyl acetate) to gave the product (52 mg, 26%).

(48) The benzoyl chloride intermediate (0.51g, 0.72 mmol)was prepared by following procedure (41) & (7) without removing MEM-protecting group. To the residue, 20 ml methylene chloride was added, followed by pyridine (0.11 ml, 1.44 mmol) and tert-butyl carbazate (190 mg, 1.44 mmol). The mixture was stirred at room temperature overnight. The mixture was washed with water ~ dried over MgSO4. The residue was purified on silica gel (10%
ethyl acetate/methylene chloride). Following the hydrolysis procedure dexcribed above, the product (182 mg) was isolated in 47% yield.

(49) To the MEM-protected hydrazide lOM ( 450 mg, 0.72 mmol) in dioxane was added 165 mg (1.5 mmol) of CNBr followed by a solution of 125 mg (1.5 mmol) of sodium bicarbonate in 10 ml water. The resulting mixture was stirred 2 h at room temperature. The solution was concentrated to 1/2 volume in vacuo. The mixture was diluted with 10 ml of water and the resulting solid isolated by filtration and purified on silica gel (15%
methanol/chloroform) to provide (38.4 mg, 8%).

(50) t-Butyl carbazate (264 mg, 2 mmol) was added to aldehyde 5V(450 mg, 0.8 mmol) in ethanol. The mixture was stirred at room temperature for 2 h and heated at reflux overnight. The residue was purified on silica gel (20% ethyl acetate/methylene chloride) to provide the product (179 mg, 28%).

~094/19329 21~ 6 5 9 4 PCT~S94/01609 (51) To a solution of aniline 3K(160 mg, 0.3 mmol) in THF, chloroacetyl isocyanate was added dropwise at 0 C.
The mixture was stirred for 0.5 h and then slowly warmed up to room temperature overnight. The solution was partitioned between ethyl acetate/water. Tne organic phase was washed with water and dried over MgSO4. The residue was purified on silica gel (5%
methanol/chloroform) to gave 217 mg in 93% yield.

(53) To a solution of 333 mg ( 6.16 mmol) of anhydrous NaOCH3 in 20 ml of anhydrous methanol at 0C was added 855 mg (6.16 mmol) of aminoguanidine carbonate followed by 2 ml methanol. The resulting mixture was treated dropwise with 500 mg (0.77 mmol) of ethyl ester llF
which was made by following procedure (10) in 5 ml of methanol. The mixture was heated at reflux overnight, then poured into ice water, brought to PH 7 with 5%
aqueous HCl, filtered, and purified on silica gel (10%
methanol.chloroform) to give 20 mg (4%) product.
(54) A solution of MEM-protected cyclic urea wherein R22 and R23 are (H2NC(=NOH))benzyl (210 mg, 0.26 mmol) and Et3N (0.18 ml, 1.3 mmol) was treated dropwise with a solution of chloroacetyl chloride ( 0.046 ml, 0.57 mmol) in CHCl3. The mixture was stirred at room temperature for 2 days and then evaporated, and the residue was redissolved in ethyl acetate. The solution was washed with water, brine,dried over Na2SO4. The residue was purified on silica gel (10% ethyl aceta~e/methylene chloride) to provide 140 mg (59~) intermediate. The intermediate was dissolved in DMF and treated with excess dimethylamine gas. The mixture was stirred overnight, then poured into ice water, and extracted with ethyl acetate. The extracts were washed with water, dried over MgSO4. Following the usual hydrolysis WO94/19329 PCT~S94/01609 ~ -296-C~ procedure, the product (15.6 mg) was isolated in 10%
yield.

Listed below are a representative list of data for compounds listed in Table 2d:

Example 15VA: NMR (CDCl3): ~ 7.19-7.40 (m, lOH) 4.66 (d, lH) 3.99-4.12 (m, 2H) 3.59-3.69 (m, 2H) 3.37-3.49 (m, 2H) 3.10-3.21 (m, 2H) 2.25-2.38 (m, 3H) 1.90-2.00 10 (m, 2H) 0.85-0.92 (m, 8H).

Example 15VB: NMR (CD30D): ~7.50-7.70 (m, lH) 7.10-7.35 (m, 9H) 3.95 (m, 2H) 3.53-3.70 (m, 2H) 3.40-3.50 (m, 2H) 3.00-3.20 (m, 3H) 2.75 (t, lH) 2.30 (m, lH) 1.60-2.10 15 (m, 7H) 1.28 (m, 2H) 0.81-1.10 (m, 2H).

Example 15VC: NMR (CDCl3): ~ 7.15-7.90 (m, lOH) 4.70 (d, lH) 4.05 (m, 2H) 3.50-3.70 (m, 3H) 3.57 (m, lH) 3.20 (m, lH) 3.07 (s, 3H) 3.05 (s, 3H) 2.75 (t, lH) 2.59 (s, 2H) 2.93 (m, 2H) 1.40-1.55 (m, 5H) 1.17-1.32 (m, 2H) 1.00-1.15 (m, 2H).

Example 15VD: NMR (CDCl3): ~ 7.05-7.30 (m, lOH), 5.55 (br s, 2H), 3.93 (s, 2H), 3.66- 3.80 (m, 4H), 3.53 (d, 25 2H), 3.09 (d, 2H), 2.85-2.92 (m, 2H), 2.81 (d, 6H), 1.98-2.26 (m, 6H), 0.96-1.52 (br m, 12H).

Example 15VE: NMR (CDCl3): ~ 7.17-7.34 (m, lOH), 3.99 (s, 2H), 3.5S-3.73 (m, 4H), 3.43-3.53 (m, 4H)~ 3.05-3.13 30 (m, 2H), 2.90-3.00 (m, 2H), 2.58 (br d, 2H), 2.15- 2.28 (m, 2H), 1.12-1.80 (br m, 17H).

Example 15VF: NMR (CDCl3): ~ 7.17-7.34 (m, lOH), 4.57 (br s, lH), 4.08 (t, 2H), 3.99 (s, 2H), 3.60-3.72 (m, 35 2H), 3.59 (t, 2H), 3.46-3.54 (m, 2H), 3.05-3.13 (m, 2H), 2156~94 V094/19329 PCT~S94/01609 2.89-3.00 (m, 2H), 2.78 (d, 3H), 2.70 (br s, 2H), 2.14-2.24 (m, 2H), 1.12-1.80 (br m, 17H).

Example 15VG: NMR (CDCl3): ~ 7.10-7.37 (m, lOH), 4.80 (d, lH), 3.92 (s, 2H), 3.20-3.70 ~br m, 6H), 3.00-3.19 (m, 4H), 3.61-3.77 (m, lH), 2.21 (br s, lH), 1.10-1.50 -(br m, 7H).

Example 15VH: NMR (CDC13): ~ 7.64-7.84 (m, 3H), 7.05-7.57 (m, 14H), 4.96 (d, lH), 3.92 (m, lH), 3.38-3.80 (m, 6H), 3.21 (d, lH), 2.99-3.18 (m, 3H), 2.75-2.98 (m, 2H) !
2.43 (br s, lH), 2.20-2.35 (m, lH), 1.10-1.88 (br m, 7H).

Example 15VI: NMR (CDCl3): ~ 7.04-7.40 (m, 15H), 4.80 (d, lH), 3.94 (m, lH), 3.42-3.80 (m, 7H), 2.83-3.17 (m, 6H), 2.64 (br s, lH), 2.19-2.31 (m, lH), 1.16-1.50 (br m, 6H).

Example 15VJ: NMR (CDCl3): ~ 7.11-7.35 (m, lOH), 3.99 (s, 2H), 3.43-3.69 (m, 6H), 3.10 (m, 2H), 2.95 (m, 3H), 2.80 (s, lH), 2.38 (t, 2H), 2.20 (m, 2H), 2.02 (s, 3H), 1.18-1.56 (br m, 13H).

Example 15VK: NMR (CDCl3): ~ 7.05-7.40 (m, 14H), 4.79 (d, lH), 4.58-4.70 (m, 2H), 4.50 (d, lH), 3.91 (m, lH), 3.40-3.75 (m, 6H), 2.98-3.14 (m, 4H), 2.81-2.95 (m, 2H), 2.72 (s, lH), 2.25 (m, lH), 2.07 (br s, lH), 1.16-1.50 (br m, 6H).

Example 15VL: NMR (CDCl3): ~ 7.18-7.36 (lOH, m) 4.53 (lH,s) 3.95 (2H,s) 3.79 (lH,m) 3.51 (lH,m) 3.33 (2H,m) 3.13 (6H,m) 2.72 (lH,t) 2.60 (lH,s) 1.33 (2H,m) 0.84 (3H,t).

W094/19329 PCT~S94/01609 Example 15VM: NMR (CDC13): ~ 7.20-7.34 tlOH,m) 4.57 (lH,s) 3.94 ~2H,s) 3.79 (lH,m) 3.52 (lH,m) 3.38 (lH,m) ~ 3.33 (lH,d) 3.13 (5H,m) 2.94 (2H,.bs) 2.72 (lH,t) 1.26 C~ (6H~m) 0.86 (3H,t).

Example 15VQ: NMR (CDC13): ~ 7.14-7.35 (lOH, m) 4.63 (2H,d) 4.41 (2H,s) 3.49 (2H,d) 3.34 (2H,m) 3.14 (2H,m) 2.85 (2H,d) 2.45 (2H,s) 2.10-2.32 (4H,m) 0.99 (6H,t).

Example 15VP: NMR(CDC13): ~ 8.81 (2H,s) 7.23 (lOH, m) 4.80 (2H,d) 4.14 (4H, m) 3.68 (2H, m) 3.14 (2H, m) 2.60 (2H.d) 2.44 (2H,m) 2.03 (2H,m) 0.98 (6H,t).

Example 15VQ: NMR (CDC13): ~ 7.64-7.82 (m, 3H), 7.07-7.53 (m, 14H), 4.96 (d, lH), 3.88-3.96 (m, lH), 3.44-3.80 (m, 7H), 3.21 (d, lH), 2.99-3.16 (m, 3H), 2.84-2.98 (m, lH), 2.70 (s, lH), 2.19-2.33 (m, 2H), 1.08-1.56 (br m, 8H).
Example 15VR: NMR (Acetone-d6): ~ 8.38 (s, lH), 7.02-7.40 (m, llH), 6.70 (m, 2H), 6.52 (d, lH), 4.73 (d, lH), 4.34 (s, 2H), 3.84-3.96 (m, lH), 3.38-3.76 (br m, 7H), 2.80-3.21 (br m, 5H), 2.07-2.19 (m, lH), 1.16-1.52 (br m, 6H).

Example 15VS: NMR (CDC13): ~ 7.15-7.33 (m, lOH), 4.00 (s, 2H), 3.44-3.69 (m, 5H), 3.10 (d, 2H), 2.88-2.98 (m, 3H), 2.85 (s, 3H), 2.56-2.76 (m, 2H), 2.17-2.35 (m, 2H), 1.18-1.80 (m, 15H).

Example 15 W : NMR (CDC13): ~ 7.10-7.36 (m, lOH), 4.04 (m, 2H), 3.39-3.79 (br m, 7H), 2.78-3.22 (br m, 6H), 2.17-2.29 (m, lH), 2.03 (m, lH), 1.15-1.52 (br m, 6H), 0.91 (m, lH), 0.41 (m, 2H), 0.06 (m, 2H).

V094/19329 2 ~ 5 6 ~ 9 ~ PCT~S94/01609 Example 15 W : NMR (CDCl3): ~ 7.15-7.33 (m, lOH), 3.99 (s, 2H), 3.65 (m, 2H), 3.49 (d, 2H), 3.25 (s, 6H), 3.21-3.33 (m, 4H), 3.04-3.14 (m, 2H), 2.89-3.00 (m, 2H), 2.63 (s, 2H), 2.18 (m, 2H), 1.72 (br s, 2H), 1.15-1.52 (br m, lOH).

Example 15VW: NMR (CDCl3): ~ 7.13-7.33 (m, lOH), 3.99 (s, 2H), 3.45-3.71 (br m, 6H), 3.24 (s, 3H), 3.20-3.33 (m, 3H), 3.10 (d, 3H), 2.89-3.00 (m, 2H), 2.10-2.28 (m, 2H), 1.85 (br d, 2H), 1.15-1.53 (br m, llH).

Example 15VX: NMR ~CDC13): ~ 7.13-7.57 (br m, llH), 6.98 (d, 3H), 4.68 (d, lH), 3.98 (m, lH), 3.74-3.83 (m, 2H), 3.46-3.69 (m, 3H), 3.22 (d, lH), 3.01-3.18 (m, 3H), 2.81-2.93 (m, 3H), 2.66 (br d, 2H), 2.23 (m, lH), 1.18-1.56 (br m, 6H).

Example 15VY: NMR (CDCl3): ~ 7.91 (m, lH), 7.83 (s, lH), 7.17-7.39 (m, lOH), 7.09 (d, 2H), 4.84 (d, lH), 4.31 (q, 2H), 3.95 (dd, lH), 3.62-3.72 (m, 2H), 3.48-3.60 (m, 4H), 2.86-3.16 (br m, 5H), 2.57 (br s, lH), 2.39 (br s, lH), 2.29 (m, lH), 1.05-1.52 (br m, lOH).

Example 15VZ: NMR (CDCl3): ~ 7.17-7.32 (lOH,m) 3.99 (2H,s) 3.68 (4H,m) 3.50 (2H,d) 3.09 (2H,dd) 2.94 (2H,t) 2.62 (2H,s) 2.23 (2H,m) 1.33 (14H,m) 1.12 (6H,d).

Example 15WB: NMR (CDCl3): ~ 7.13-7.33 (m, lOH), 4.02 (s, 2H), 3.61 (m, 2H), 3.50 (d, 2H), 3.10 (dd, 2H), 2.85-2.97 (m, 2H), 2.82 (s, 2H), 2.33 (t, 4H), 2.18 (m, 2H), 2.06 (s, 6H), 1.18-1.50 (br m, 8H).

Example 15WC: NMR (DMSO-d6): ~ 10.17, 10.09 (2 singlets, 2H - 3:1 mixture of isomers), 7.08-7.32 (m, lOH), 5.21 (s, 2H), 3.70 (s, 2H), 3.48 (m, 2H), 3.38 (d, WO94/19329 PCT~S94/01609 ~C~ 2H), 3.03 (d, 2H), 2.81 (m, 2H), 1.91-2.19 (br m, 6H), ~ 1.61-1.71 (m, 6H), 1.15-1.39 (m, 8H).

Example 15WD: NMR (DMSO-d6): ~ 6.91-7.40 (br m, 14H), 5.01-5.22 (m, lH), 4.61 (m, lH), 4.42-4.50 (m, lH), 3.66 (m, lH), 3.12-3.54 (br m, 7H), 3.06 (d, lH), 2.75-2.99 (m, 4H), 2.32-2.57 (m, 4H), 1.94-2.07 ~m, lH), 1.05-1.38 (br m, 8H).

Example 15WE: NMR (CDC13): ~ 7.18-7.38 (m, lOH), 7.33 (s, lH), 7.06 (m, 3H), 4.80 (d, lH), 4.60 (d, 2H), 3.94 (m, lH), 3.46-3.75 (m, 7H), 2.80-3.15 (m, 7H), 2.23-2.42 (m, 2H), 1.18-1.50 (br m, 6H).

15BC; MS (DCI): 514 (M+H+, 100%). lH NMR (CD3OD, 300MHz) ~ 0.1 (m, 2H), 0.4 (m, 2H), 0.8 (m, lH), 1.9 (m, lH), 3.0 (m, 4H), 3.3 (d, lH), 3.4 (m, 2H), 3.6 (m, lH), 3.75 (m,lH), 4.0 ( m, lH), 4.4 (d,lH), 6.8-7.4 (m,13H).
15AA lH NMR (CD30D, 300MHz) ~ 3.00(m, 6H), 3.6 (m, 4H), 4.4 (s, 4H), 4.7 (d, 2H), 6.9-7.5 (m, 18H).

15AM MS (DCI): 661 (M+H,100%). lH NMR (CD30D, 300MHz) ~
1.2 (t, 3H), 3.0 (m, 6H), 3.6 (m, 4H), 4.3 (q, 2H), 4.8 (d,2H), 7.0-7.4 (m, 18), 7.8-8.0 ( m, 3H).

15AQ: MS (DCI): 548 (M+H, 100%). lH MNR (CD30D, 300MHz) 3.0 (m, 6H), 3.6 (m, 4H), 4.8 (m, 2H), 6.8-7.8 (m, 18H).
15AR: MS (DCI): 533 (M+H, 100%). lH NMR (CD30D, 300MHz) 3.0 (m, 6H), 3.7 (m, 4H), 4.7 (d, 2H), 4.8 (d, lH), 7.0-8.4 (m, 18H).
15AO: lH NMR (CD30D, 300MHz) ~ 2.4 (s, 12H), 3.0 (m, 6H), 3.6 (s,4H), 3.9 (s, 4H), 4.8 (d, J=15Hz,2H), 7.05-7.50(m, 14H) 7.96(d, J=7.5Hz, 2H), 8.0(s, 2H).

DENIANDES OU BREVETS VOLUMINEUX

LA PRESENTE PARTIE DE CETTE DENIANDE OU CE BREVET
COMPREND PLUS D'UN TOME.

CECI EST LE TOME I DE ;~

NOTE: Pour Ies tomes additionels, veuillez c~ntacter le Bureau canadign des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE
THAN ONE VOLUME

THIS IS VOLUME -L OF

NC)TE: For additianal v~lumes please c~ntac~ the Canadian Patent Offic~

Claims (23)

WHAT IS CLAIMED IS:
1. A compound of the formula (I):

(I) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C8 alkyl substituted with 0-3 R11;
C2-C8 alkenyl substituted with 0-3 R11;
C2-C8 alkynyl substituted with 0-3 R11;
a C3-C14 carbocyclic ring system substituted with 0-3 R11 or 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;
-OR13; -SR13; CO2R13;

R4A and R7A are independently selected from the following groups:
hydrogen;

C1-C4 alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13; CO2R13;

R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;

R5 is selected from H; halogen; C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR20, or -N3;

R6 is independently selected from: hydrogen, halogen, C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR21, or -N3;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -OCH2SCH2O-; -OC(=O)O-; -OCH2O-;
-OC(=S)O-; -OC(=O)C(=O)O-; -OC(CH3)2O-;
-OC((CH2)3NH2)(CH3)O-; -OC(OCH3)(CH2CH2CH3)O-;
-OS(=O)O-; -NHC(=O)NH-; -OC(=O)NH-; -NHC(=O)O-;
-NHCH2O-; -OCH2NH-; -NHC(=S)O-; -OS(=O)NH-;
-NHC(=O)C(=O)O-; -OC(=O)C(=O)NH-; -NHC(=O)C(=O)NH-;
-NHC(CH3)2O-; -OC(CH3)2NH- or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl or diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20, or -OR20;

R6a is selected from: hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20 or -OR21;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 R11;
C3-C6 alkoxyalkyl substituted with 0-3 R11;
C1-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 R11;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC(=O)R13, -OR13, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C (=O) R13, =NOR14, -NR14C (=O) OR14, -OC(=O)NR13R14, -NR13C(=O)NR13R14, -NR14SO2NR13R14, -NR14SO2R13, -SO2NR13R14, -OP(O)(OR13)2, C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or -C(R14)=N(OR14);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12;
C6-C10 arylcarbonyloxy substituted with 0-2 R12;
a C5-C14 carbocyclic residue substituted with 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:
H, keto, halogen, cyano, -CH2N(R13B)(R14B), N(R13B)(R14B), -CO2H, -OC(=O)(C1-C3 alkyl), -OH, C2-C6 alkoxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C9 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(C1-C3 alkyl), a C5-C14 carbocyclic residue;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mR13, -SO2NR13R14, -NHSO2R14, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(R14)=N(OR14); or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R12A, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyzno, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NH2, -NH2, -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mMe, -SO2NH2, -NHSO2Me, -OCH2Co2R13, 2-(1-morpholino)ethoxy, -C(=NOH)NH2; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy,-NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, -NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2;

R13 is selected from:
H;
phenyl substituted with 0-3 R11A;
benzyl substituted with 0-3 R11A;
C1-C6 alkyl substituted with 0-3 R11A;
C2-C4 alkenyl substituted with 0-3 R11A;
C1-C6 alkylcarbonyl substituted with 0-3 R11A;
C1-C6 alkoxycarbonyl substituted with 0-3 R11A;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, CF3, C1-C6 alkyl substituted with 0-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R13B and R14B are independently selected from H or C1-C6 alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

m is 0, 1 or 2;

W is selected from:
-N(R22)C(=S)C(=S)N(R23)-;
-N(R22)C(=NR24)C(=NR24)N(R23)-;
-N(R22)S(=Z')N(R23)-;
-N(R22)S(=Z')2N(R23)-;
-N(R22)P(=O)(R24a)N(R23)-;
-C(R25)(R26)S(=Z')C(R27)(R28)-;
-C(R25)(R26)S(=Z')2C(R27)(R28)-;
-C(R25)(R26)P(=O)(R24a)C(R27)(R28)-;
-C(R25)(R26)S(=Z')N(R23)-;
-C(R25)(R26)S(=Z')2N(R23)-;
-C(R25)(R26)S(=O)2O-;
-C(R25)(R26)P(=O)(R24a)N(R23)-;
-C(R25)(R26)P(=O)(R24a)O-;
-C(R25)C(F2)C(=O)N(R23)-;
-C(R25)C(F2)S(=O)2N(R23)-;

-SC (=Z)-;
-C(R25) (R26) C(R34) (R35) C(R27) (R28)-;
-N(R22) C(R34) (R35) N(R23)-;
-N=C(R36) N(R23)-;
-N+(R22) =C(R36) N(R23)-;
-N (R22) P(R24a) N(R23)-;
-C(=Z)-;
-P(=O) (R24a)-;
-S(=Z')-;
-S(=Z')2-;
-N(R22) C(=C(R36a) (R36b)) N(R23)--N(R22) C(=Z)N(R23) C(=Z)-wherein:

Z is O, S, NR24;

Z' is O or NR24;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR22a; -N(R22a) (R22b);

R22a and R22b are independently selected from the following:

hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R24 is selected from: hydrogen; hydroxy; amino; C1-C4 alkyl; C1-C4 alkoxy; mono- or di-(C1-C6 alkyl)amino; cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally substituted with (C1-C6)alkyl;

R24a is selected from: hydroxy; amino; C1-C4 alkyl;
C1-C4 alkoxy; mono- or di-(C1-C6 alkyl)amino;
cyano; nitro; benzyloxy; or phenoxy;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR13; -SR13;

R26 and R28 are independently selected from:
hydrogen;
halogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13;

R29 is selected from:
hydrogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;

alternatively, R22, R25, or R26, independently, can join with R4 or R4A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R23, R27, or R28, independently, can join with R7 or R7A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R22, R25, R26, R23, R27, R28, R34 or R35 can join with R5 or R6 to form a 0- to 7-membered bridge to form a carbocyclic or heterocyclic ring, said bridge being substituted with 0-2 R12 and said bridge containing 0-3 heteroatoms independently selected from N, S, or O (i.e., a 0-membered bridge is formed when R22, R25, R26, R23, R27, R28, R34, or R35 are taken together with R5 or R6 to form a direct bond);

alternatively R28 or R23 can join with R7A to form a direct bond;

alternatively R26 or R22 can join with R4A to form a direct bond;

R31 is selected from one or more of the following:

keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -C(=O)R11, -OC(=O)R13, -OR13, C2-C6 alkoxyalkyl, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14 -NR14C(=O)OR14, -OC(=O)NR13R14, -NR13C(=O)NR13R14, -NR13C(=S)NR13R14, -NR14SO2NR13R14, -NR14SO2R13, -SO2NR13R14, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2R13, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(OR14); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;

a C5-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
phenethyl, phenoxy, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSO2R14, benzyloxy, halogen, 2-(1-morpholino)ethoxy, -CO2R13 hydroxamic acid, -CONR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), -NO2, -OR13, -NR40R41, -SomR13, -SomNR13R14, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl, -C(=O)NR13C(R11)2NR13R14;
-C(=O)NR13C(R11)2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl)-R11;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;

C1-C4 alkyl substituted with 0-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14 =NNR13C(=O)OR13, or -NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;

or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R32 is attached to a saturated carbon, it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R34 is selected from:
hydrogen;
OR13;
SR13;
halogen;
N(R38)(R39) C1-C6 alkyl substituted with 0-3 R11;
C1-C6 alkoxy substituted with 0-3 R11;
C1-C6 thioalkyl substituted with 0-3 R11;

R35 is selected from:
hydrogen;
OR13;
SR13;
halogen;
N(R38)(R39) C1-C6 alkyl substituted with 0-3 R11;
C1-C6 alkoxy substituted with 0-3 R11;
C1-C6 thloalkyl substituted with 0-3 R11;

R34 and R35 can be taken together to form a ketal ring, a 3- to 8-membered carbocyclic ring, or a 5- or 6-membered heterocyclic ring containing 1-3 heteroatoms independently selected from the group 0, N, or S, said ring substituted with 0-5 R11;

R36 is selected from:
H
C1-C6 alkyl substituted with 0-3 R11;
-COR37;
-NR38R39;
-CN;

R37 is selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 R11;
hydroxyl;
C1-C6 alkoxy substituted with 0-3 R11;
-NR38R39;

R38 and R39 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 R11; or an amine protecting group;

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C(=O)NR3R14;
-C(=O)NR13NR13R14;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13NR13R14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)H;
-C(=O)R11;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13C02R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4, R4A, R7 and R7A are not all hydrogen;

when W is -OC(=Z)O-, -SC(=Z)-, -C(=Z)-, -P(=O)(R24a)-, -S(=Z')- or -S(=Z')2-, R4 and R7 are not hydrogen.
2. A compound of Claim 1, of formula (II):

(II) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-3 R11;
C3-C4 alkenyl substituted with 0-3 R11;

R5 is -OR20;

R6 is hydrogen or -OR21;

R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:
H, keto, halogen, -CH2NR13R14, -NR13R14, -OR13, C2-C4 alkoxyalkyl, C2-C4 alkenyl, ;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substituted with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, C1-C4 alkyl, C7-C10 arylalkyl, C1-C4 alkoxy, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(OR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, methylenedioxy, C1-C4 haloalkyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

R12, when a substituent on nitrogen, is selected from benzyl or methyl;

R13 is H, C1-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

W is selected from:
-N(R22)C(=Z)O-;
-N(R22)C(=O)C(=O)N(R23)-;
-C(R25)(R26)C(=Z)S-;
-N(R22)S(=Z')N(R23)-;
-N(R22)S(=Z')2N(R23)-;
-N(R22)P(=O)(R24a) (N(R23)-;
-C(R25)(R26)S(=Z')C(R27)(R28)-;
-C(R25)(R26)S(=Z')2C(R27)(R28)-;

-C(R25)(R26)P(=O)(R24a)C(R27)(R28)-;
-C(R25)(R26)S(=Z')N(R23)-;
-C(R25)(R26)S(=Z')2N(R23)-;
-C(R25)C(F2)C(=O)N(R23)-;
-C(R25)C(F2)S(=O)2N(R23)-;
-C(=Z)-;
-P(=O)(R24a)-;
-S(=Z')-;
-S(=Z')2-;

wherein:

Z is O, S, or N-CN;

Z' is O;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-2 R31;
C2-C6 alkenyl substituted with 0-1 R31;
C2-C4 alkynyl substituted with 0-1 R31;

R24a is selected from -OH, C1-C4 alkoxy, mono- or di-(C1-C6 alkyl) amino;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C4 alkyl substituted with 0-3 R31;
C2-C4 alkenyl substituted with 0-3 R31;

R26 and R28 are hydrogen or halogen;

R31 is selected from one or more of the following:

keto, halogen, -CH2NR13R14, -NR13R14, -OR13, C2-C4 alkoxyalkyl, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, -C(R14)=N(OR14), -CO2R13, -S(O)mR13;
aryl substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
phenethyl, phenoxy, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSO2R14, benzyloxy, halogen, 2-(1-morpholino)ethoxy, -CO2R13, hydroxamic acid, -CONR13NR13R14, cyano, boronic acid, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), NO2, -OR13, -NR40R41, -SOmR13, -SOmNR13R14, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41 C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C2-C4 haloalkynyl, or -C(=O)C(R11)2NR13R14; -C(=O)C(R11)2NR13CO2R13;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-3 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13 -C(=O)NR13R14, -NR13R14 or OH;

C1-C4 alkyl substituted with 0-3 groups selected from R11, =NR14, =NNR13C(=O)NR13R14 or -NR13R14;
C2-C4 alkenyl substituted with 0-3 R11;
C2-C4 alkynyl substituted with 0-3 R11;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-3R12;

R32, when a substituent on nitrogen, is selected from benzyl or methyl;

m is 0, 1, or 2;

R34 is selected from:
hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;

R35 is selected from:
hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;

R34 and R35 can be taken together to form a ketal ring, a 3- to 8-membered carbocyclic ring, or a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms independently selected from the group O, N, or S;

R36 is selected from: C1-C2 alkyl; COR37; NR38R39; CN;
CCl3;

R37 is selected from:

hydrogen; C1-C2 alkyl substituted with 0-1 R11;
hydroxyl; C1-C2 alkoxy substituted with 0-1 R11;
NR38R39;

R38 and R39 are independently selected from:
hydrogen; C1-C2 alkyl substituted with 0-3 R11; or an amine protecting group;

R40 is selected from: H, C1-C3 alkyl;

R91 is selected from:
-C (=O)NR13R14;
-C (=O)NR13NR14;
-C (=O)C(R11)2NR13R14;
-C (=O)C(R11)2NR13NR14;
-C (=O)C(R11)2NR13C2R13;
-C (=O)H;
-C (=O)R11;
-C (=O)-(C1-C4 alkyl)-NR13R14;
-C (=O)-(C1-C4 alkyl)-NR13O2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4 and R7 are not both hydrogen;

when W is -C(=Z)-, -P(=O)(R24a)-, -S(=Z')- or -S(=Z')2-, R4 and R7 are not hydrogen;

when R4 is hydrogen, at least one of the following is not hydrogen: R22, R25, R26 and R28.
3. A compound of Claim 2, or a pharmaceutically acceptable salt form thereof, wherein:

R4 and R7 are selected from benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R5 is -OH;

R6 is hydrogen or -OH;

R13 is H, C1-C4 alkyl, C2-C4 alkenyl, or benzyl;

R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

W is selected from:
-N(R22)S(=O)2N(R23)-;
-C(=O)-;
-C(=N-CN)-;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-2 R31;
C2-C6 alkenyl substituted with 0-2 R31;
C2-C4 alkynyl substituted with 0-2 R31;

R31 is selected from one or more of the following:
halogen, -OR13, C1-C4 alkyl, C3-C10 cycloalkyl, -C(R14)=N(OR14), -CO2R13, -S(O)mR13;
aryl substituted with 0-5 R32; or a heterocyclic ring system chosen from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, benzimidazolyl, benzotriazolyl, indazolyl, benzoxazolinyl, benzoxazolyl, said heterocyclic ring being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
-CONH2, -CO2H, -CHO, -CH2NHOH, -CH2NR13R14, -NR13R14, hydroxy, hydroxymethyl, -C(R14)=N(R14), halogen, methoxy, methyl, nitro, cyano, allyloxy, -CO2CH3, -NHCHO, -NHCOCH3, -OCO2CH3, -CH=NCH2CH2OH, -OCONHCH2C6H5, -OCONHCH3, oxazolidinyl, -C=C-CH2OH, -COCH3, hydroxyethyl, C1-C3 alkyl (said alkyl substituted with 0-4 halogen, or OH), tetrazolyl, -OCH2CONH2, -CONHNH2, -CH=NNHCONH2, -CONHOCH3, -CH2CH(OH)CH2OH, adamantamido, hydroxyethoxy, dihydroxyethyl, -C(NH2)=NH, -CONHCH3, -B(OH)2, benzyloxy, -CONHCH2CH3, -CON(CH2CH3)2, methylthio, -SO2CH3, -NHCONH2, -NHCONHCH3, -NHCOCH2N(CH3)2, -NHCOCH2NHCH3, -NHCOCH2NHCO2CH2C6H5, -NHCOCH2NH2, -NHCOCH(CH3)NHCO2CH2C6H5, -NHCOCH(CH2C6H5)NHCO2CH2C6H5, -NHCOCH(CH3)NH2, -NHCOCH(CH2C6H5)NH2, -CO2CH2CH3, -CONHCH2CH2CH3, -CONHCH(CH3)2, -CH2-imidazole, -COC(CH3)3, -CH(OH)CF3, -CO-imidazole, -CO-pyrazolyl, oxadiazolidinonyl, -COCF3, -COCH2CH3, -COCH2CH2CH3, pyrazolyl, -SO2NH2, -C(CH2CH3)=N(OH) or -C(CF3)=N(OH), phenyl, acetoxy, hydroxyamino, -N(CH3)(CHO), cyclopropylmethoxy, -CONR13R14, -CONHOH, (diethylaminoethyl)aminocarbonyl, (N-ethyl,N-methylaminoethyl)aminocarbonyl, (4-methylpiperazinylethyl)aminocarbonyl, (pyrrolidinylethyl)aminocarbonyl, (piperidinylethyl)aminocarbonyl, -NHCOCH2NHCH3, N-(2-(4-morpholino)ethyl)aminocarbonyl, or N-(2-(N,N-dimethylamino)ethyl)aminocarbonyl;

R32, when a substituent on nitrogen, is methyl.
4. A compound of claim 1 of formula (IId) (IId) or a pharmaceutically acceptable salt form thereof, wherein:

R4 and R7 are independently selected from: benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R22 and R23 are independently selected from the group consisting of:

hydrogen, allyl, methyl, ethyl, propyl, cyclopropylmethyl, n-butyl, i-butyl, CH2CH=C(CH3)2, pyridinylmethyl, methallyl, n-pentyl, i-pentyl, hexyl, benzyl, isoprenyl, propargyl, picolinyl, methoxyethyl, cyclohexylmethyl, dimethyl-butyl, ethoxyethyl, methyl-oxazolinylmethyl, naphthylmethyl, methyloxazolinylmethyl, vinyloxyethyl, pentafluorobenzyl, quinolinylmethyl, carboxybenzyl, chloro-thienyl, benzyloxybenzyl, phenylbenzyl, adamantylethyl, cyclopropylmethoxybenzyl, methoxybenzyl, methylbenzyl, ethoxybenzyl, hydroxybenzyl, hydroxymethylbenzyl, aminobenzyl, formylbenzyl, cyanobenzyl, cinnamyl, allyloxybenzyl, fluorobenzyl, difluorobenzyl, chlorobenzyl, chloromethylbenzyl, fluoromethylbenzyl, iodobenzyl, bromobenzyl, cyclobutylmethyl, formaldoximebenzyl, cyclopentylmethyl, nitrobenzyl, (H2NC(=O))-benzyl, carbomethoxybenzyl, carboethoxybenzyl, tetrazolylbenzyl, and dimethylallyl, aminomethylbenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2CO)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, N-methylaminobenzyl, N-ethylaminobenzyl, N-ethylaminomethylbenzyl, acetylbenzyl, acetoxybenzyl, N-hydroxylaminobenzyl, phenylmethyl-boronic acid, N-hydroxylaminomethylbenzyl, (hydroxyl)ethylbenzyl, (CH3C(=NOH))-benzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH3ONHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl (oxazolidinyl)-benzyl, (hydroxyl)hexyl, hexenyl, (hydroxy)octyl, (hydroxyl)pentyl, (carboxy)pentyl, (carbomethoxy)pentyl, (methylthio)benzyl, (methylsulfonyl)benzyl, N,N-dimethylaminomethylbenzyl, N-methylaminomethylbenzyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, (oxadiazolidinonyl)benzyl, trifluoroacetylbenzyl, (pyrazolyl)benzyl, (H2NSO2)-benzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, methoxypentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (CH3CH2C(=NOH))-benzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl, benzimidazolylmethyl, benzotriazolylmethyl, indazolylmethyl, benzoxazolinylmethyl, benzisoxazolylmethyl, thienylmethyl, furylmethyl.
5. A compound of Claim 1 of formula (IId):

(IId) or a pharmaceutically acceptable salt form thereof, selected from the group consisting of:

the compound of formula (IId) wherein R22 is 4-hydroxymethylbenzyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (IId) wherein R22 is 3-hydroxybenzyl and R23 is 3-hydroxybenzyl;

the compound of formula (IId) wherein R22 is cyclopropylmethyl and R23 is cyclopropylmethyl;
the compound of formula (IId) wherein R22 is 2-naphthylmethyl and R23 is 2-naphthylmethyl;
the compound of formula (IId) wherein R22 is 4-hydroxybenzyl and R23 is 4-hydroxybenzyl;
the compound of formula (IId) wherein R22 is 3-aminobenzyl and R23 is 3-aminobenzyl;
the compound of formula (IId) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-hydroxymethylbenzyl;
the compound of formula (IId) wherein R22 is 3-(Me2NCH2C(=O)NH)-benzyl and R23 is 3-(Me2NCH2C(=O)NH)-benzyl;
the compound of formula (IId) wherein R22 is 3-formaldoximebenzyl and R23 is 3-formaldoximebenzyl;
the compound of formula (IId) wherein R22 is 3-(CH3C(=N-OH))-benzyl and R23 is 3-(CH3C(=N-OH))-benzyl;
the compound of formula (IId) wherein R22 is 3-(2-amino-4-thienyl)benzyl and R23 is 3-(2-amino-4-thienyl)benzyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 5-hydroxypentyl;
the compound of formula (IId) wherein R22 is 6-hydroxypentyl and R23 is 6-hydroxypentyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 2-naphthylmethyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (IId) wherein R22 is 5-hydroxypentyl and R23 is 3-hydroxymethylbenzyl.
6. A compound of the formula (I) :

(I) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
C1-C8 alkyl substituted with 1-3 R11B;
C2-C8 alkenyl substituted with 1-3 R11B;
C2-C8 alkynyl substituted with 1-3 R11B;
-OR13; -SR13; CO2R13;

R4A and R7A are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13; CO2R13;

R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;

R5 is selected from H; halogen; C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR20, or -N3;

R6 is independently selected from: hydrogen, halogen, C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR21, or -N3;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -OCH2SCH2O-; -OC(=O)O-; -OCH2O-;
-OC(=S)O-; -OC(=O)C(=O)O-; -OC(CH3)2O-;
-OC((CH2)3NH2)(CH3)O-; -OC(OCH3)(CH2CH2CH3)O-;
-OS(=O)O-; -NHC(=O)NH-; -OC(=O)NH-; -NHC(=O)O-;
-NHCH2O-; -OCH2NH-; -NHC(=S)O-; -OS(=O)NH-;
-NHC(=O)C(=O)O-; -OC(=O)C(=O)NH-; -NHC(=O)C(=O)NH-;
-NHC(CH3)2O-; -OC(CH3)2NH- or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl or diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20, or -OR20;

R6a is selected from: hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20 or -OR21;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 R11;

C3-C6 alkoxyalkyl substituted with 0-3 R11;
C1-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 R11;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC(=O)R13, -OR13, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14, -NR14C(=O)OR14 -OC(=O)NR13R14, -NR13C(=O)NR13R14, -NR14SO2NR13R14, -NR14SO2R13, -SO2NR13R14, -OC(O)(OR13)2, C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(OR14);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;

aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12;
C6-C10 arylcarbonyloxy substituted with 0-2 R12;
a C5-C14 carbocyclic residue substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13BR14B, -NR13BR14B, -CO2H, -OC(=O)(C1-C3 alkyl), -OH, C2-C6 alkoxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(C1-C3 alkyl), a C5-C14 carbocyclic residue; a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R11B is selected from one or more of the following:
-CH2NR13AR14, -NR13AR14, -CO2R13A, -OC(=O)R13A, -OR13A, -S(O)mR13A, -NHC(=NH)NHR13A, -C(=NH)NHR13A, -C(=O)NR13AR14, -NR14C(=O)R13A, -OC(=O)NR13AR14, -NR13AC(=O)NR13AR14, -NR14SO2NR13AR14, -NR14SO2R13A, -SO2NR13AR14, -CH2NR13R14A, -NR13R14A, -C(=O)NR13R14A, -NR14AC(=O)R13, =NOR14A, -NR14C(=O)OR14A, -OC(=O)NR13R14A, -NR13C(=O)NR13R14A, -NR14ASO2NR13R14A, -NR14ASO2R13, -SO2NR13R14A, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, C2-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(OR14), -OP(O)(OR13)2;
C7-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 1-2 R12;
aryl(C1-C3 alkyl) substituted with 1-2 R12;
C2-C6 alkoxyalkyl, substituted with 1-2 R12;
C1-C4 alkylcarbonyloxy substituted with 1-2 R12;
C6-C10 arylcarbonyloxy substituted with 1-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mR13, -SO2NR13R14, -NHSO2R14, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(R14)=N(OR14);
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R12A, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NH2, -NH2, -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mMe, -SO2NH2, -NHSO2Me, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(=NOH)NH2;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, -NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2;

R13 is selected from:
H;
phenyl substituted with 0-3 R11A;

benzyl substituted with 0-3 R11A;
C1-C6 alkyl substituted with 0-3 R11A;
C2-C4 alkenyl substituted with 0-3 R11A;
C1-C6 alkylcarbonyl substituted with 0-3 R11A;
C1-C6 alkoxycarbonyl substituted with 0-3 R11A;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R13A is selected from:
phenyl substituted with 1-3 R11;
benzyl substituted with 1-3 R11;
C1-C6 alkyl substituted with 1-3 R11;
C2-C4 alkenyl substituted with 1-3 R11;
C1-C6 alkylcarbonyl substituted with 1-3 R11;
C1-C6 alkoxycarbonyl substituted with 1-3 R11;
C1-C6 alk.ylaminocarbonyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R11;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, CF3, C1-C6 alkyl substituted with 0-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R14A is C1-C6 alkyl substituted with 1-3 groups selected frGm OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R13B and R14B are independently selected from H or C1-C5 alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)s-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

m is 0, 1 or 2;

W is selected from:
-N(R22)C(=Z)N(R23)-, -OC(=Z)O-, -N(R22)C(=Z)O-, -C(R25)(R26)C(=Z)C(R27)(R23)-, -N(R22)C(=Z)C(R27)(R28)-, -C(R25)(R26)C(=Z)O-, -N(R22)C(=O)C(=O)N(R23)-, _C(R25)(R26)c(F2)c(R27)(R23) -C(R25)(R26)N(CH3)(O)C(R27)(R28)-, -C(R25)(R26)N(OR29)C(R27)(R28)-, -C(R25)(R26)C(=Z)S-, -N(R22)S(=O)N(R23)-;
wherein:

Z iS 0, S, NR24;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;

a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR22a; -N (R22a) (R22b);

R22a and R22b are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R24 is selected from: hydrogen; hydroxy; amino; C1-C4 alkyl; C1-C4 alkoxy; mono- or di-(C1-C6 alkyl)amino; cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally substituted with (C1-C6)alkyl;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;

a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR13; -SR13;

R26 and R28 are independently selected from:
hydrogen;
halogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13;

R29 is selected from:
hydrogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;

alternatively, R22, R25, or R26, independently, can join with R4 or R4A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R23, R27, or R28, independently, can join with R7 or R7A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R22, R25, R26, R23, R27, R28, R34 or R35 can join with R5 or R6 to form a 0- to 7-membered bridge to form a carbocyclic or heterocyclic ring, said bridge being substituted with 0-2 R12 and said bridge containing 0-3 heteroatoms independently selected from N, S, or O (i.e., a 0-membered bridge is formed when R22, R25, R26, R23, R27, R28, R34, or R35 are taken together with R5 or R6 to form a direct bond);

alternatively R28 or R23 can join with R7A to form a direct bond;

alternatively R26 or R22 can join with R4A to form a direct bond;

R31 is selected from one or more of the following:
keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -C(=O)R11, -OC(=O)R13, -OR13, C2-C6 alkoxyalkyl, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14, -NR14C(=O)OR14, -OC(=O)NR13R14, -NR13C(=O)NR13R14, NR13C(=S)NR13R14, -NR14SO2NR13R14, -NR14SO2R13, -SO2NR13R14, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2R13, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(OR14); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
a C5-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
phenethyl, phenoxy, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSO2R14, benzyloxy, halogen, 2-(1-morpholino)ethoxy, -CO2R13, hydroxamic acid, -CONR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), -NO2, -OR13, -NR40R41, -SOmR13, -SOmNR13R14, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl.:
-C(=O)NR13C(R11)2NR13R14;
-C(=O)NR13C(R1)2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;

-C(=O)N(R13)-(C1-C4 alkyl)-R11; or -C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
C1-C4 alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;
C1-C4 alkyl substituted with 0-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14, =NNR13C(=O)OR13, or -NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;
or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R32 is attached to a saturated carbon , it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C(=O)NR13R14;
-C(=O)NR13NR14;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13NR14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)H;
-C(=O)R11;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus.
7. A compound of Claim 6, of formula (II):

(II) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 1-3 R11;
C3-C4 alkenyl substituted with 1-3 R11;

R5 is selected from -OR20;
R6 is hydrogen or -OR21;

R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC(=O)R13, -OR13, -S(O)mR13, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, -C(R14)=N(OR14);
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12, C6-C10 arylcarbonyloxy substituted with 0-2 R12, aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

R11B is selected from one or more of the following:
CH2NR13AR14, -NR13AR14, -CO2R13A, -OC(=O)R13A, -OR13A, -S(O)mR13A, -CH2NR13R14A, -NR13R14A, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, -C(R14)=N(OR14);
C7-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 1-2 R12;
aryl(C1-C3 alkyl) substituted with 1-2 R12;
C2-C6 alkoxyalkyl, substituted with 1-2 R12;
C1-C4 alkylcarbonyloxy substituted with 1-2 R12;
C6-C10 arylcarbonyloxy substituted with 1-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, C1-C4 alkyl, C7-C10 arylalkyl, C1-C4 alkoxy, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(OR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, methylenedioxy, C1-C4 haloalkyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

R12, when a substituent on nitrogen, is selected from benzyl or methyl;

R13 is H, C1-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R13A is selected from:
phenyl substituted with 1-3 R11;

benzyl substituted with 1-3 R11;
C1-C6 alkyl substituted with 1-3 R11;
C2-C4 alkenyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R11;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R14A is C1-C6 alkyl substituted with 1-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

W is selected from:
-N(R22)C(=Z)N(R23)-;
-N(R22)C(=Z)O-;
-N(R22)C(=Z)C(R27)(R28)-;
-N(R22)C(=O)C(=O)N(R23)-;

wherein:

Z is O, S, N-CN

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-2 R31;
C2-C6 alkenyl substituted with 0-1 R31;
C2-C4 alkynyl substituted with 0-1 R31;

R27 is selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C3-C8 alkynyl substituted with 0-3 R31;
R28 is hydrogen or halogen;

R31 is selected from one or more of the following:
keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -C(=O)R11, -OC(=O)R13, -OR13, C2-C6 alkoxyalkyl, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14, -NR14C(=O)OR14, -OC(=O)NR13R14, -NR13C(=O)NR13R14, -NR13C(=S)NR13R14, -NR19SO2NR13R14, -NR14SO2R13, -SO2NR13R14, C-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2R13, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(OR14); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
a C5-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
phenethyl, phenoxy, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSO2R14, benzyloxy, halogen, 2-(1-morpholino)ethoxy, -CO2R13, hydroxamic acid, -CONR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), -NO2, -OR13, -NR40R41, -SOmR13, -SOmNR13R14, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl, -C(=O)NR13C(R11)2NR13R14;
-C(=O)NR13C(R11)2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl)-R11; or -C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
C1-C4 alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;
C1-C4 alkyl substituted with 0-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14, =NNR13C(=O)OR13, or -NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11;

a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;
or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NR13R14; or, when R32 is attached to a saturated carbon , it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

m is 0, 1, or 2;

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C(=O)NR13R14;
-C(=O)NR13NR14;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13NR14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)H;
-C(=O)R11;

-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus.
8. A compound of the formula (I):

(I) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C8 alkyl substituted with 0-3 R11;
C2-C8 alkenyl substituted with 0-3 R11;
C2-C8 alkynyl substituted with 0-3 R11;
a C3-C14 carbocyclic ring system substituted with 0-3 R11 or 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;
-OR13; -SR13; CO2R13;

R4A and R7A are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13; CO2R13;

R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;

R5 is selected from H; halogen; C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR20, or -N3;

R6 is independently selected from: hydrogen, halogen, C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR21, or -N3;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -OCH2SCH2O-; -OC(=O)O-; -OCH2O-;
-OC(=S)O-; -OC(=O)C(=O)O-; -OC(CH3)2O-;
-OC((CH2)3NH2)(CH3)O-; -OC(OCH3)(CH2CH2CH3)O-;
-OS(=O)O-; -NHC(=O)NH-; -OC(=O)NH-; -NHC(=O)O-;
-NHCH2O-; -OCH2NH-; -NHC(=S)O-; -OS(=O)NH-;
-NHC(=O)C(=O)O-; -OC(=O)C(=O)NH-; -NHC(=O)C(=O)NH-;
-NHC(CH3)2O-; -OC(CH3)2NH- or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl or diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20, or -OR20;

R6a is selected from: hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20 or -OR21;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 R11;
C3-C6 alkoxyalkyl substituted with 0-3 R11;
C1-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 R11;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC(=O)R13, -OR13, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14, -NR14C(=O)OR14, -OC(=O)NR13R14, -NR13C(=O)NR13R14, -NR14SO2NR13R14, -NR14SO2R13, -SO2NR13R14, -OP(O)(OR13)2, C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(OR14);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12;
C6-C10 arylcarbonyloxy substituted with 0-2 R12;
a C5-C14 carbocyclic residue substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13BR14B, -NR13BR14B, -CO2H, -OC(=O)(C1-C3 alkyl), -OH, C2-C6 alkoxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(C1-C3 alkyl), a C5-C14 carbocyclic residue;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mR13, -SO2NR13R14, -NHSO2R14, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(R14)=N(OR14); or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur; or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R12A, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NH2, -NH2, -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mMe, -SO2NH2, -NHSO2Me, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(=NOH)NH2; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur; or R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, -NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2;

R13 is selected from:
H;
phenyl substituted with 0-3 R11A;
benzyl substituted with 0-3 R11A;
C1-C6 alkyl substituted with 0-3 R11A;
C2-C4 alkenyl substituted with 0-3 R11A;
C1-C6 alkylcarbonyl substituted with 0-3 R11A;
C1-C6 alkoxycarbonyl substituted with 0-3 R11A;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;

a hydroxy protecting group when R13 is bonded to O;

R13A is selected from:
phenyl substituted with 1-3 R11;
benzyl substituted with 1-3 R11;
C1-C6 alkyl substituted with 1-3 R11;
C2-C4 alkenyl substituted with 1-3 R11;
C1-C6 alkylcarbonyl substituted with 1-3 R11;
C1-C6 alkoxycarbonyl substituted with 1-3 R11;
C1-C6 alkylaminocarbonyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R11;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, C1-C6 alkyl substituted with 0-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R14A is C1-C6 alkyl substituted with 1-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R13B and R14B are independently selected from H or C1-C6 alkyl or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

m is 0, 1 or 2;

W is selected from:
-N(R22)C(=Z)N(R23)-, -OC(=Z)O-, -N(R22)C(=Z)O-, -N(R22)C(=Z)C(R27)(R28)-, -N(R22)C(=O)C(=O)N(R23)-, -N(R22)S(=O)N(R23)-;

wherein:

Z is O, S, NR24;

R22 and R23 are independently selected from the following:
C1-C8 alkyl substituted with 1-3 R31;
C2-C8 alkenyl substituted with 1-3 R31;
C2-C8 alkynyl substituted with 1-3 R31;
a C3-C14 carbocyclic ring system substituted with 1-5 R31 or 1-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;
-OR22a; -N(R22a)(R22b);

R22a and R22b are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;

a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
R24 is selected from: hydrogen; hydroxy; amino; C1-C4 alkyl; C1-C4 alkoxy; mono- or di-(C1-C6 alkyl)amino; cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally substituted with (C1-C6)alkyl;
R31 is selected from one or more of the following:
-CH2NR13AR14, -NR13AR14, -CO2R13A, -OC(=O)R13A, -OR13A, -S(O)mR13A, -NHC(=NH)NHR13A, -C(=NH)NHR13A, -C(=O)NR13AR14, -NR14C(=O)R13A, -OC(=O)NR13AR14, -NR13AC(=O)NR13AR14, -NR14SO2NR13AR14, -NR14SO2R13A, -SO2NR13AR14, -CH2NR13R14A, -NR13R14A, -C(=O)NR13R14A, -NR14AC(=O)R13, =NOR14A, -NR14C(=O)OR14A, -OC(=O)NR13R14A, -NR13C(=O)NR13R14A, -NR14ASO2NR13R14A, -NR14ASO2R13, -SO2NR13R14A, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, C2-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkylcarbonyl, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or -C(R14)=N(OR14A);
aryl substituted with 1-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
C7-C10 cycloalkyl, NHRSO2R14A, -CO2R13A, NR13AR14, NR13R14A, -C(R14)=N(OR14A), -CONR13NR13R14, -NR40R41, -SOmR13A, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, OR13A, -C(=O)NR40R41, C2-C4 haloalkenyl, C1-C4 haloalkynyl, or -C(=O)NR13C(R11)2NR13R14;
-C(=O)NR13C(R11)2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl)-R11; or -C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 1-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;
C1-C4 alkyl substituted with 1-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14, =NNR13C(=O)OR13, or -NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 1-2 R12; when R32 is attached to a saturated carbon, it may be =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:

-CH2NR13AR14, -NR13AR14, -CH2NR13R14A, -NR13R14A,-C(R14)=N(OR14A);

R40 is selected from: H, C1-C3 alkyl R41 is selected from:
-C(=O)NR13R14;
-C(=O)NR13NR13R14;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13NR13R14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)H;
-C(=O)R11;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4, R4A, R7 and R7A are not all hydrogen.
9. A compound of Claim 8, or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-3 R11;
C3-C4 alkenyl substituted with 0-3 R11;
C3-C4 alkynyl substituted with 0-3 R11;

R4A and R7A are hydrogen;
n is 0, 1, or 2;

R5 is selected from fluoro or -OR20;
R6 is independently selected from: hydrogen, fluoro or -OR21;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -OCH2SCH2O-; -OS(=O)O-; -OC(=O)O-;
-OCH2O-; -OC(=S)O-; -OC(=O)C(=O)O-; -OC(CH3)2O-;
-OC(OCH3)(CH2CH2CH3)O-; or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl;
R5a is selected from hydrogen or fluoro;
R6a is selected from: hydrogen or fluoro;
R5 and R5a can alternatively join to form =O, =S, or a ketal ring;
R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkylcarbonyl;
C1-C6 alkoxycarbonyl;
benzoyl; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC(=O)R13, -OR13, -S(O)mR13, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, -C(R14)=N(OR14);
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;

aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12, C6-C10 arylcarbonyloxy substituted with 0-2 R12, aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, C1-C4 alkyl, C7-C10 arylalkyl, C1-C4 alkoxy, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(OR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, methylenedioxyl C1-C4 haloalkyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

R12, when a substituent on nitrogen, is selected from benzyl or methyl;

R13 is H, C1-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R13A is selected from:
phenyl substituted with 1-3 R11;
benzyl substituted with 1-3 R11;

C1-C6 alkyl substituted with 1-3 R11;
C2-C4 alkenyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R11;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is OH, H, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R14A is C1-C6 alkyl substituted with 1-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

W is selected from:
-N(R22)C(=Z)N(R23)-;
-N(R22)C(=Z)O-;
-N(R22)C(=Z)C(R27)(R28)-;
-N(R22)C(=O)C(=O)N(R23)-;

wherein:

Z is O, S, N-CN, N-OH, N-OCH3;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 1-2 R31;
C2-C6 alkenyl substituted with one R31;
C2-C4 alkynyl substituted with one R31;

R27 is selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C3-C8 alkynyl substituted with 0-3 R31;
R28 is hydrogen or halogen;
R31 is selected from one or more of the following:
-CH2NR13AR14, -NR13AR14, -CO2R13A, -OC(=O)R13A, -OR13A, -S(O)mR13A, -NHC(=NH)NHR13A, -C(=NH)NHR13A, -C(=O)NR13AR14, -NR14C(=O)R13A, -OC(=O)NR13AR14, -NR13AC(=O)NR13AR14, -NR14SO2NR13AR14, -NR14SO2R13A, -SO2NR13AR14, -CH2NR13R14A, -NR13R14A, -C(=O)NR13R14A, -NR14AC(=O)R13, =NOR14A, -NR14C(=O)OR14A, -OC(=O)NR13R14A, -NR13C(=O)NR13R14A, -NR14ASO2NR13R14A, -NR14ASO2R13, -SO2NR13R14A, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, C2-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkylcarbonyl, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or -C(R14)=N(OR14A);
aryl substituted with 1-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
C7-C10 cycloalkyl, NHRSO2R14A, -CO2R13A, NR13AR14, NR13R14A, -C(R14)=N(OR14A), -CONR13NR13R14, -NR40R41, -SOmR13A, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, OR13A, -C(=O)NR40R41, C2-C4 haloalkenyl, C1-C4 haloalkynyl, or -C(=O)NR13C(R11)2NR13R14;
-C(=O)NR13C(R11)2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl)-R11; or -C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 1-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;
C1-C4 alkyl substituted with 1-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14, =NNR13C(=O)OR13, or -NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 1-2 R12; when R32 is attached to a saturated carbon, it may be =NOH; or when R32 attached to sulfur it may be =O;

m is 0, 1, or 2;

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C(=O)NR13R14;
-C(=O)NR13NR14;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13NR14;

-C(=O)C(R11)2NR13CO2R13;
-C(=O)H;
-C(=O)R11;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4 and R7 are not both hydrogen;

when R4 is hydrogen, at least one of the following is not hydrogen: R22 and R28.
10. A compound of Claim 8, of formula (II):

(II) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C4 alkyl substituted with 0-3 R11;
C3-C4 alkenyl substituted with 0-3 R11;

R5 is selected from -OR20;

R6 is hydrogen or -OR21;

R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC(=O)R13, -OR13, -S(O)mR13, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, nitro, hydrazide, boronic acid, formyl, C3-C6 cycloalkoxy, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, -C(R14)=N(OR14);
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12, C6-C10 arylcarbonyloxy substituted with 0-2 R12, aryl substituted with 0-3 R12; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, C1-C4 alkyl, C7-C10 arylalkyl, C1-C4 alkoxy, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(OR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, methylenedioxy, C1-C4 haloalkyl, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, hydroxy, hydroxymethyl; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

R12, when a substituent on nitrogen, is selected from benzyl or methyl;

R13 is H, C1-C4 alkyl, C3-C6 alkoxyalkyl, C2-C4 alkenyl, or benzyl;

R13A is selected from:
phenyl substituted with 1-3 R11;
benzyl substituted with 1-3 R11;
C1-C6 alkyl substituted with 1-3 R11;
C2-C4 alkenyl substituted with 1-3 R11;
C3-C6 alkoxyalkyl substituted with 1-3 R11;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is OH, H, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R14A is C1-C6 alkyl substituted with 1-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

W is selected from:
-N(R22)C(=Z)N(R23)-;
-N(R22)C(=Z)O-;
-N(R22)C(=Z)C(R27)(R28)-;
-N(R22)C(=O)C(=O)N(R23)-;

wherein:

Z is O, S, N-CN

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 1-2 R31;
C2-C6 alkenyl substituted with one R31;
C2-C4 alkynyl substituted with one R31;

R27 is selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C3-C8 alkynyl substituted with 0-3 R31;
R28 is hydrogen or halogen;

R31 is selected from one or more of the following:
-CH2NR13AR14, -NR13AR14, -CO2R13A, -OR13A, -S(O)mR13A, -CH2NR13R14A, -NR13R14A, or -C(R14)=N(OR14);
aryl substituted with 1-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 1-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
C7-C10 cycloalkyl, NHRSO2R14A, -CO2R13A, NR13AR14, NR13R14A, -C(R14)=N(OR14A), -CONR13NR13R14, -NR40R41, -SOmR13A, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, OR13A, -C(=O)NR40R41, C2-C4 haloalkenyl, C1-C4 haloalkynyl, or -C(=O)NR13C(R11)2NR13R14;
-C(=O)NR13C(R11)2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl)-R11; or -C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 1-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;
C1-C4 alkyl substituted with 1-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14, =NNR13C(=O)OR13, or -NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 1-2 R12; when R32 is attached to a saturated carbon, it may be =NOH; or when R32 attached to sulfur it may be =O;

m is 0, 1, or 2;

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
_C(=O)NR13R14;
-C(=O)NR13NR14;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13NR14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)H;
-C(=O)R11;
-C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4 and R7 are not both hydrogen;

when R4 is hydrogen, at least one of the following is not hydrogen: R22 and R28.
11. A compound of Claim 10, or a pharmaceutically acceptable salt form thereof, wherein:

R4 and R7 are selected from benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R5 is -OH;

R6 is hydrogen or -OH;

R13 is H, C1-C4 alkyl, C2-C4 alkenyl, or benzyl;

R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

W is selected from:
-N(R22)C(=O)N(R23)-;
-N(R22)C(=N-CN)N(R23)-;
-N(R22)C(=S)N(R23)-;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 1-2 R31;
C2-C6 alkenyl substituted with 1-2 R31;
C2-C4 alkynyl substituted with 1-2 R31;

R31 is selected from one or more of the following:
halogen, -OR13A, -C(R14)=N(OR14), -CO2R13A, -S(O)mR13A;
aryl substituted with 1-5 R32; or a heterocyclic ring system chosen from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, said heterocyclic ring being substituted with 1-2 R32, or benzimidazolyl, benzotriazolyl, indazolyl, benzoxazolinyl, benzoxazolyl, optionally substituted with 0-2 R32;

R32, when a substituènt on carbon, is selected from one or more of the following:
-CH2NR13AR14, -NR13AR14, -CH2NR13R14A, -NR13R14A, -C(R14)=N(OR14A), allyloxy, -CO2CH3, -NHCHO, -OCO2CH3, -CH=NCH2CH2OH, -OCONHCH2C6H5, -OCONHCH3, -C=C-CH2OH, -OCH2CONH2, -CH=NNHCONH2, -CONHOCH3, -CH2CH(OH)CH2OH, adamantamido, hydroxyethoxy, dihydroxyethyl, -C(NH2)=NH, -CONHCH3, -CONHCH2CH3, -CON(CH2CH3)2, -NHCONH2, -NHCONHCH3, -NHCOCH2N(CH3)2, -NHCOCH2NHCH3, -NHCOCH2NHCO2CH2C6H5, -NHCOCH2NH2, -NHCOCH(CH3)NHCO2CH2C6H5, -NHCOCH(CH2C6H5)NHCO2CH2C6H5, -NHCOCH(CH3)NH2, -NHCOCH(CH2C6H5)NH2, -CO2CH2CH3, -CONHCH2CH2CH3, -CONHCH(CH3)2, -CH2-imidazole, -COC(CH3)3, -CH(OH)CF3, -CO-imidazole, -CO-pyrazolyl, -COCF3, -C(CF3)=N(OH), acetoxy, -N(CH3)(CHO), -CONR13R14, -CONHOH, (diethylaminoethyl)aminocarbonyl, (N-ethyl,N-methylaminoethyl)aminocarbonyl, (4-methylpiperazinylethyl)aminocarbonyl, (pyrrolidinylethyl)aminocarbonyl, (piperidinylethyl)aminocarbonyl, -NHCOCH2NHCH3, N-(2-(4-morpholino)ethyl)aminocarbonyl, or N-(2-(N,N-dimethylamino)ethyl)aminocarbonyl.
12. A compound of Claim 8, or a pharmaceutically acceptable salt form thereof, of the formula:

wherein:

W is -N(R22)C(=O)N(R23)-;

-N(R22)C(=S)N(R23)-;
-N(R22)C(=N-CN)N(R23)-;

R4 and R7 are independently selected from: benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl or aminobenzyl, thienylmethyl, hydroxybenzyl, pyridylmethyl, naphthylmethyl;

R22 and R23 are independently selected from the group consisting of:
(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2CO)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH3ONHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl, (carbomethoxy)pentyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.
13. A compound of Claim 8 of formula (IIa):

(IIa) or a pharmaceutically acceptable salt form thereof, wherein:

R22 and R23 are independently selected from the group consisting of:

(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2CO)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH3ONHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl, (carbomethoxy)pentyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.
14. A compound of Claim 8 of formula (IIa):

(IIa) or a pharmaceutically acceptable salt form thereof, selected from the group consisting of:
the compound of formula (IIa) wherein R22 is 1-cinnamyl and R23 is 1-cinnamyl;
the compound of formula (IIa) wherein R22 is vinylbenzyl and R23 is vinylbenzyl;
the compound of formula (IIa) wherein R22 is 3-(NHCHO)benzyl and R23 is 3-(NHCHO)benzyl;
the compound of formula (IIa) wherein R22 is 3-(NHCOCH3)benzyl and R23 is 3-(NHCOCH3)benzyl;
the compound of formula (IIa) wherein R22 is 3-formaldoximebenzyl and R23 is 3-(N-hydroxy)aminomethylbenzyl;
the compound of formula (IIa) wherein R22 is 3-(CH3OC(=O)O-)benzyl and R23 is 3-(CH3OC(=O)O-)benzyl;

the compound of formula (IIa) wherein R22 is 3-(HOCH2CH2N=CH)benzyl and R23 is 3-(HOCH2CH2N=CH)benzyl;
the compound of formula (IIa) wherein R22 is 3-(HOCH2CH2N=CH)benzyl and R23 is 3-(2-oxazolidinyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(C6H5CH2NHC(=O)O)benzyl and R23 is 3-(C6H5CH2NHC(=O)O)benzyl;
the compound of formula (IIa) wherein R22 is 3-(CH3NHC(=O)O)benzyl and R23 is 3-(CH3NHC(=O)O)benzyl;
the compound of formula (IIa) wherein R22 is 3-(HOCH2CC)benzyl and R23 is 3-bromobenzyl;
the compound of formula (IIa) wherein R22 is 3-aminocarbonylbenzyl and R23 is 3-aminocarbonylbenzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NCOCH2O)benzyl and R23 is 3-(H2NCOCH2O)benzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NNHC(=O))-benzyl and R23 is 3-(H2NNHC(=O))-benzyl;
the compound of formula (IIa) wherein R22 is 4-(H2NNHC(=O))-benzyl and R23 is 4-(H2NNHC(=O))-benzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NC(=O)NHN=CH)-benzyl and R23 is 3-(H2NC(=O)NHN=CH)-benzyl;
the compound of formula (IIa) wherein R22 is 3-[(N-methoxy)aminocarbonyl]-benzyl and R23 is 3-[(N-methoxy)aminocarbonyl]-benzyl;
the compound of formula (IIa) wherein R22 is 4-[(N-methoxy)aminocarbonyl]-benzyl and R23 is 4-[(N-methoxy)aminocarbonyl]-benzyl;

the compound of formula (IIa) wherein R22 is 3-(HOCH2CH(OH)CH2O)benzyl and R23 is 3-(HOCH2CH(OH)CH2O)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2-hydroxyethoxy)benzyl and R23 is 3-(2-hydroxyethoxy)benzyl;
the compound of formula (IIa) wherein R22 is 3-(1,2-dihydroxyethyl)benzyl and R23 is 4-(1,2-dihydroxyethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-aminocarbonylbenzyl and R23 is 3-(H2NC(=NH))benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N-methylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(1,2-dihydroxyethyl)benzyl and R23 is 3-(1,2-dihydroxyethyl)benzyl;
the compound of formula (IIa) wherein R22 is 4-(1,2-dihydroxyethyl)benzyl and R23 is 4-(1,2-dihydroxyethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N-methylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(N-ethylaminocarbonyl)benzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
(H2NC(=O)NH)benzyl and R23 is 3-(H2NC(=O)NH)benzyl;

the compound of formula (IIa) wherein R22 is 3-aminobenzyl and R23 is 3-(CH3NHC(=O)NH)benzyl;
the compound of formula (IIa) wherein R22 is 3-(CH3NHC(=O)NH)benzyl and R23 is 3-(CH3NHC(=O)NH)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N,N-dimethylaminoglycyl)amino)benzyl and R23 is 3-((N,N-dimethylaminoglycyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N-methylaminoglycyl)amino)benzyl and R23 is 3-((N-methylaminoglycyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N,N-dimethylaminoglycyl)amino)benzyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (IIa) wherein R22 is 3-((N-phenylmethoxycarbonylaminoglycyl)amino)benzyl and R23 is 3-((N-phenylmethoxycarbonylaminoglycyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-(glycylamino)benzyl and R23 is 3-(glycylamino)benzyl;
the compound of formula (IIa) wherein R22 is 3-(glycylamino)benzyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (IIa) wherein R22 is 3-((N-phenylmethoxycarbonylamino-L-alanyl)amino)benzyl and R23 is 3-((N-phenylmethoxycarbonylamino-L-alanyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-((N-phenylmethoxycarbonylamino-L-phenylalanyl)amino)benzyl and R23 is 3-((N-phenylmethoxycarbonylamino-L-phenylalanyl)amino)benzyl;

the compound of formula (IIa) wherein R22 is 3-L-alanyl)amino)benzyl and R23 is 3-(L-alanyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 3-(L-phenylalanyl)amino)benzyl and R23 is 3-(L-phenylalanyl)amino)benzyl;
the compound of formula (IIa) wherein R22 is 5-hydroxy-1-pentyl and R23 is 3-carboethoxybenzyl;
the compound of formula (IIa) wherein R22 is 4-oxime-1-hexyl and R23 is 4-oxime-1-hexyl;
the compound of formula (IIa) wherein R22 is 3-(N,N-diethylaminocarbonyl)benzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-carbomethoxybenzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N,N-diethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(N-propylaminocarbonyl)benzyl and R23 is 3-(N-propylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(HO2C)benzyl and R23 is 3-(N-isopropylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(HO2C)benzyl and R23 is 3-(N-propylaminocarbonyl)benzyl;

hydroxymethylbenzyl and R23 is 3-aminocarbonylbenzyl;
the compound of formula (IIa) wherein R22 is cyclopropylmethyl and R23 is 3-aminocarbonylbenzyl;
the compound of formula (IIa) wherein R22 is 3-aminocarbonylbenzyl and R23 is hydrogen;
the compound of formula (IIa) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-(N-ethylaminocarbonyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(N-imidazolylmethyl)benzyl and R23 is 3-(N-imidazolylmethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2,2-dimethyl-1-propionyl)benzyl and R23 is 3-(2,2-dimethyl-1-propionyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2,2,2-trifluoro-1-hydroxyethyl)benzyl and R23 is 3-(2,2,2-trifluoro-1-hydroxyethyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2-imidazolyl-C(=O))benzyl and R23 is 3-(2-imidazolyl-C(=O))benzyl;
the compound of formula (IIa) wherein R22 is 3-(3-hydroxy-1-propyn-1-yl)benzyl and R23 is 3-(3-hydroxy-1-propyn-1-yl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(2,2,2-trifluoroacetyl)benzyl and R23 is 3-(2,2,2-trifluoroacetyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-propionylbenzyl and R23 is 3-propionylbenzyl;
the compound of formula (IIa) wherein R22 is 3-(CH3CH2C(=-N-OH))benzyl and R23 is 3-(CH3CH2C(=N-OH))benzyl;

the compound of formula (IIa) wherein R22 is 3-(CF3CH2C(=N-OH))benzyl and R23 is 3-(CF3CH2C(=N-OH))benzyl;
the compound of formula (IIa) wherein R22 is 3-(5-methyl-1,2,3-oxadiazolyl)benzyl and R23 is 3-(5-methyl-1,2,3-oxadiazolyl)benzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NC(=NOH)benzyl and R23 is 3-(H2NC(=NOH)benzyl;
the compound of formula (IIa) wherein R22 is 3-(H2NC(=NOH)-4-fluorobenzyl and R23 is 3-(H2NC(=NOH)-4-fluorobenzyl;
the compound of formula (IIa) wherein R22 is 3-chloro-5-indazolylmethyl and R23 is 3-chloro-5-indazolylmethyl;
the compound of formula (IIa) wherein R22 is 3-methylamino-5-indazolylmethyl and R23 is 3-methylamino-5-indazolylmethyl;
the compound of formula (IIa) wherein R22 is 3-ethylamino-5-indazolylmethyl and R23 is 3-ethylamino-5-indazolylmethyl;
the compound of formula (IIa) wherein R22 is 3-amino-5-benzisoxazolylmethyl and R23 is 3-amino-5-benzisoxazolylmethyl.
15. A compound of Claim 8 of formula (IIaa):

(IIaa) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from: benzyl, fluorobenzyl, pyrrolylmethyl, methoxybenzyl, isobutyl, nitrobenzyl aminobenzyl, hydroxybenzyl, 4-pyridylmethyl, or thienylmethyl;
R22 and R23 are independently selected from:
(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2CO)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonylbenzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH3ONHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl, (carbomethoxy)pentyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.
16. A compound of formula (IIaa):

(IIaa) or a pharmaceutically acceptable salt form thereof, selected from the group consisting of:
the compound of formula (IIaa) wherein R4 and R7 are isobutyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are isobutyl, R22 and R23 are allyl;

the compound of formula (IIaa) wherein R4 is 4-nitrobenzyl, R7 is 2-nitrobenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-nitrobenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 is 4-nitrobenzyl, R7 is 2-nitrobenzyl, R22 and R23 are n-butyl;
the compound of formula (IIaa) wherein R4 is 4-aminobenzyl, R7 is 2-aminobenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-hydroxybenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 4-hydroxymethylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-aminocarbonylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-acetylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-butyrylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-hydroxymethylbenzyl;

the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-(CH3C(=N-OH)benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-(H2NC(=NOH)benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-fluorobenzyl, R22 and R23 are 3-(H2NC(=NOH)-4-fluorobenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are 4-hydroxymethylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-methoxybenzyl, R22 and R23 are 3-methoxybenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-hydroxybenzyl, R22 and R23 are 3-hydroxybenzyl.
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are 2-naphthylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are 4-hydroxymethylbenzyl;

the compound of formula (IIaa) wherein R4 and R7 are 4-hydroxybenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methoxybenzyl, R22 and R23 are allyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-(2-hydroxyethoxy)benzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-(2-morpholinylethoxy)benzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3-(H2NC(=O)CH2O)benzyl, R22 and R23 are n-butyl;
the compound of formula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 3-hydroxymethylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 4-hydroxymethylbenzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 3-(H2NC(=O))benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 3,4-difluorobenzyl, R22 and R23 are 3-(H2NC(=NOH))benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 2-naphthylmethyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 2-naphthylmethyl, R22 and R23 are cyclopropylmethyl;
the compound of formula (IIaa) wherein R4 and R7 are 2-thienylmethyl, R22 and R23 are cyclopropylmethyl;

the compound of formula (IIaa) wherein R4 and R7 are 2-thienylmethyl, R22 and R23 are 3-(H2NC(=NOH))benzyl;
the compound of formula (IIaa) wherein R4 and R7 are 4-methylthiobenzyl, R22 and R23 are benzyl;
the compound of formula (IIaa) wherein R4 and R7 are isopropyl, R22 and R23 are n-hexyl;
17. A compound of formula (IIa):

(IIa) wherein:

W is:
-N(R22)C(=S)N(R23)--N(R22)C(=N-CN)N(R23)-;

R22 and R23 are independently selected from:
(H2NC(=O))-benzyl, carboethoxybenzyl, (O-benzyl-formaldoxime)benzyl, (O-methyl-formaldoxime)benzyl, (CH3O2CO)-benzyl, (HOCH2CH2N=CH)-benzyl, N-benzylaminocarbonyibenzyl, (H2NNHC(=O))-benzyl, (H2NC(=O)NHN=CH)-benzyl, (CH3ONHC(=O))-benzyl, (HONHC(=O))-benzyl, (CH3NHC(=O))-benzyl, N,N-dimethylaminocarbonylbenzyl, (HOCH2CH(OH)CH2O)-benzyl, hydroxyethoxybenzyl, (carbomethoxy)pentyl, glycylaminobenzyl, N,N-dimethylglycylaminobenzyl, alanylaminobenzyl, (N-phenylmethoxycarbonyl)-alanylaminobenzyl, phenylalanylaminobenzyl, (N-phenylmethoxycarbonyl) phenylalanylaminobenzyl, (CH3CH2NHC(=O))-benzyl, N,N-diethylaminocarbonylbenzyl, N-ethylaminocarbonylbenzyl, N-propylaminocarbonylbenzyl, N,N-diisopropylaminocarbonylbenzyl, N, N-di-n-propylaminocarbonylbenzyl, (hydroxypropynyl)benzyl, (imidazolyl-C(=O))-benzyl, (pyrazolyl-C(=O))-benzyl, (pyridylmethylaminocarbonyl)benzyl, trifluoroacetylbenzyl, dihydroxyethylbenzyl, (MeHNC(=O)NH)-benzyl, (H2NC(=O)NH)-benzyl, (HC(=O)NH)-benzyl, methanesulfonylpentyl, N-formyl-N-methylaminobenzyl, acetylaminobenzyl, propionylbenzyl, butyrylbenzyl, (trifluorohydroxyethyl)benzyl, (CF3C(=NOH))-benzyl, (N-methylglycyl)aminobenzyl, ((4-morpholino)ethyl)aminocarbonylbenzyl, (N,N-dimethylaminoethyl)aminocarbonylbenzyl, (N,N-diethylaminoethyl)aminocarbonylbenzyl, (4-methylpiperazin-1-ylethyl)aminocarbonylbenzyl, (benzyl-NHC(=O)O)benzyl, (CH3NHC(=O)O)benzyl, (NH2C(=O)CH2O)benzyl, (NH2C(=NH))benzyl, ((N-phenylmethoxycarbonyl)glycylamino)benzyl, (imidazolylmethyl)benzyl, ((CH3)3C-C(=O))benzyl, (N-methyl-N-ethylaminoethyl)aminocarbonylbenzyl, (pyrrolidinylethyl)aminocarbonylbenzyl, (piperidinylethyl)aminocarbonylbenzyl, (H2NC(=NOH))benzyl, (H2NC(=NOH))fluorobenzyl.
18. A compound of Claim 16 of formula (IIb):

(IIb) or a pharmaceutically acceptable salt form thereof, selected from the group consisting of:
the compound of formula (IIb) wherein R22 is 4-hydroxybenzyl and R23 is 4-hydroxybenzyl;
the compound of formula (IIb) wherein R22 is cyclopentylmethyl and R23 is cyclopentylmethyl;
the compound of formula (IIb) wherein R22 is n-butyl and R23 is n-butyl;
the compound of formula (IIb) wherein R22 is 3-hydroxybenzyl and R23 is 3-hydroxybenzyl;
the compound of formula (IIb) wherein R22 is 3-aminobenzyl and R23 is 3-aminobenzyl;
the compound of formula (IIb) wherein R22 is cyclohexylmethyl and R23 is cyclohexylmethyl;
the compound of formula (IIb) wherein R22 is cyclobutylmethyl and R23 is cyclobutylmethyl;
the compound of formula (IIb) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-hydroxymethylbenzyl;
the compound of formula (IIb) wherein R22 is 3-formylbenzyl and R23 is 3-formylbenzyl;
the compound of formula (IIb) wherein R22 is 3-formaldoximebenzyl and R23 is 3-formaldoximebenzyl.
19. A compound of Claim 18 of formula (Ibb):

(Ibb) or a pharmaceutically salt form thereof, selected from the group consisting of:
the compound of formula (Ibb) wherein R22 is benzyl and R23 is hydrogen;
the compound of formula (Ibb) wherein R22 is cyclopropylmethyl and R23 is cyclopropylmethyl;
the compound of formula (Ibb) wherein R22 is benzyl and R23 is benzyl;
the compound of formula (Ibb) wherein R22 is 3-hydroxybenzyl and R23 is 3-hydroxybenzyl;
the compound of formula (Ibb) wherein R22 is 3-hydroxymethylbenzyl and R23 is 3-hydroxymethylbenzyl;
the compound of formula (Ibb) wherein R22 is 4-hydroxybenzyl and R23 is 4-hydroxybenzyl;
the compound of formula (Ibb) wherein R22 is 3-methoxybenzyl and R23 is 3-methoxybenzyl;
the compound of formula (Ibb) wherein R22 is 3-(H2NC(=NOH)benzyl and R23 is 4-hydroxymethylbenzyl;
the compound of formula (Ibb) wherein R22 is 3-(H2NC(=NOH))benzyl and R23 is 3-(H2NC(=NOH))benzyl;

the compound of formula (Ibb) wherein R22 is 3-(H2NC (=NOH)) -4-fluorobenzyl and R23 is 3-(H2NC (=NOH)) -4-fluorobenzyl.
20. A compound of the formula (I):

(I) or a pharmaceutically acceptable salt form thereof wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C8 alkyl substituted with 0-3 R11;
C2-C8 alkenyl substituted with 0-3 R11;
C2-C8 alkynyl substituted with 0-3 R11;
a C3-C14 carbocyclic ring system substituted with 0-3 R11 or 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;
-OR13; -SR13; CO2R13;

R4A and R7A are independently selected from the following groups:
hydrogen;

C1-C4 alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13; CO2R13;

R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;

R5 is selected from hydrogen; bromine, chlorine, C1-C6 alkyl substituted with 1-3 R11, -N(R20)2, -SR20, or -N3;

R6 is selected from bromine, chlorine, C1-C6 alkyl substituted with 1-3 R11, -N(R20)2, -SR20, or -N3;

R5 and R6 can alternatively join to form an aziridine ring; -OC((CH2)3NH2)(CH3)O-; -NHC(=O)NH-;
-OC(=O)NH-; -NHC(=O)O-; -NHCH2O-; -OCH2NH-;
-NHC(=S)O-; -OS(=O)NH-; -NHC(=O)C(=O)O-;
-OC(=O)C(=O)NH-; -NHC(=O)C(=O)NH-; -NHC(CH3)2O-;
-OC(CH3)2NH-; or any group that, when administered to a mammalian subject, cleaves to form a diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20, or -OR20;

R6a is selected from: hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20 or -OR21;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:
hydrogen;
C1-C6 alkyl substituted with 0-3 R11;
C3-C6 alkoxyalkyl substituted with 0-3 R11;
C1-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 R11;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;

R11 is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC (=O) R13, -OR13, -S (=O) mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14, -NR14c(=OR14, -OC (=O) NR13R14, -NR13C (=O) NR13R14, -NR14SO2NR13R14, -NR14SO2R13, -SO2NR13R14, -OP(O)(OR13)2, C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or -C(R14)=N(OR14);
1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substitued with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
C2-C6 alkoxyalkyl, substituted with 0-2 R12;
C1-C4 alkylcarbonyloxy substituted with 0-2 R12;
C6-C10 arylcarbonyloxy substituted with 0-2 R12;
a C5-C14 carbocyclic residue substituted with 0-3 R12;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:
H, keto, halogen, cyano, -CH2NR13BR14B, -NR13BR14B, -CO2H, -OC(=O)(C1-C3 alkyl), -OH, C2-C6 alkoxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(C1-C3 alkyl), a C5-C14 carbocyclic residue; a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R12, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mR13, -SO2NR13R14, -NHSO2R14, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(R14)=N(OR14); or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;
or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R12A, when a substituent on carbon, is selected from one or more of the following:
phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NH2, -NH2, -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mMe, -SO2NH2, -NHSO2Me, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(=NOH)NH2; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

or R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12A, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, -NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2;

R13 is selected from:
H;
phenyl substituted with 0-3 R11A;
benzyl substituted with 0-3 R11A;
C1-C6 alkyl substituted with 0-3 R11A;
C2-C4 alkenyl substituted with 0-3 R11A;
C1-C6 alkylcarbonyl substituted with 0-3 R11A;
C1-C6 alkoxycarbonyl substituted with 0-3 R11A;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, C1-C6 alkyl substituted with 0-3 groups selected from OH, C1-C4 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R13B and R14B are independently selected from H or C1-C6 alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

m is 0, 1 or 2;

W is selected from:
-N(R22)C(=Z)N(R23)--OC(=Z)O-, -N(R22)C(=Z)O-, -C(R25) (R26) C(=Z) C(R27) (R28)-, -N(R22)C(=Z)C(R27)(R28)-, -C(R25) (R26) C(=Z)O-, -N(R22)C(=O)C(=O)N(R23)-, -C(R25) (R26) C(F2) C(R27) (R28)-, -C(R25)(R26) N(CH3)(O)C(R27)(R28)-, -C(R25)(R26) N(OR29) C(R27)(R28)-, -C(R25) (R26)C(=Z)S-, -N(R22) S(=O) N(R23)-, wherein:

Z is O, S, NR24;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32; or -OR22a; -N(R22a)(R22b);

R22a and R22b are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R24 is selected from: hydrogen; hydroxy; amino; C1-C4 alkyl; C1-C4 alkoxy; mono- or di-(C1-C6 alkyl)amino; cyano; nitro; benzyloxy; -NHSO2aryl, aryl being optionally substituted with (C1-C6)alkyl;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;
a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;
-OR13; -SR13;

R26 and R28 are independently selected from:
hydrogen;
halogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13;

R29 is selected from:
hydrogen;
C1-C4 alkyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-3 halogen or 0-3 C1-C2 alkoxy;

alternatively, R22, R25, or R26, independently, can join with R4 or R4A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R23, R27, or R28, independently, can join with R7 or R7A to form a 5- or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O;
or alternatively, R22, R25, R26, R23, R27, R28, R34, or R35 can join with R5 or R6 to form a 0- to 7-membered bridge to form a carbocyclic or heterocyclic ring, said bridge being substituted with 0-2 R12 and said bridge containing 0-3 heteroatoms independently selected from N, S, or O (i.e., a 0-membered bridge is formed when R22, R25, R26, R23, R27, R28 R34 or R35 are taken together with R5 or R6 to form a direct bond);

alternatively R28 or R23 can join with R7A to form a direct bond;

alternatively R26 or R22 can join with R4A to form a direct bond;

R31 is selected from one or more of the following:
keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -C (=O) R11, -OC (=O) R13, -OR13, C2-C6 alkoxyalkyl, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13 =NOR14, -NR14C (=O) OR14, -OC (=O) NR13R14, -NR13C (=O) NR13R14, -NR13C (=S) NR13R14, NR14SO2NR13R14, -NR14SO2R13, -SO2NR13R14, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2R13, 2-(1-morpholino)ethoxy, azido, -C(R14)=N (OR14); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;

a C5-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:

phenethyl, phenoxy, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSO2R14, benzyloxy, halogen, 2-(1-morpholino)ethoxy, -CO2R13, hydroxamic acid, -CONR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), -NO2, -OR13, -NR40R41, -SOmR13, -SOmNR13R14, -C(=O)NR13R14, -OC(=O) NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl; or -C(=O)NR13C(R11)2NR13R14;
-C(=O)NR13C(R11)2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl)-R11; or -C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;
C1-C4 alkyl substituted with 0-4 groups selected from R11, =NR14, =NNR13C(=O)NR13R14, =NNR13C(=O)OR13, or -NR13R14;
C2-C4 alkenyl substituted with 0-4 R11;
C2-C4 alkynyl substituted with 0-4 R11;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;
or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14;
or, when R32 is attached to a saturated carbon , it may be =O, =S, =NOH; or when R32 attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:
phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C (R14) =N (OR14);

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C (=O) NR13R14;
-C (=O) NR13NR13R14;
-C (=O) C (R11) 2NR13R14;
-C (=O) C (R11) 2NR13NR13R14;
-C (=O) C (R11) 2NR13CO2R13;
-C(=O)H;
-C (=O) R11;
-C(=O)-(C1-C9 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

provided that:

R4, R4A, R7 and R7A are not all hydrogen;

when W is -OC(=Z)O-, -SC(=Z)-, -C(=Z)-, -P(=O)(R24a)-, -S(=Z')- or -S(=Z') 2-, R4 and R7 are not hydrogen.
21. A compound, or a pharmaceutically acceptable salt form thereof, selected from the following formulae:

; ; ;

; ; ;

; ; ;

; ; ;

; ; ;

; ;

; ;

; ; ;

; ;

; ;

wherein:

R4 and R7 are independently selected from the following groups:
hydrogen;
C1-C3 alkyl substituted with 0-1 R11;
R5 is -OR20;
R6 is hydrogen or -OR21;

R20 and R21 are independently hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;
R11 is selected from one or more of the following:
H; halogen; -OR13;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substituted with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
aryl substituted with 0-2 R12; or a heterocyclic ring system selected from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:
benzyloxy, halogen, methyl, C1-C4 alkoxy, CF3, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(OR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, -NR13R14, hydroxy, hydroxymethyl; or R12, when a substituent on nitrogen, is methyl;
R13 is H, C1-C4 alkyl, C2-C4 alkenyl, or benzyl;

R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;
R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;
R15 is H or CH3;
W is selected from:
-N(R22)C(=Z)N(R23)-;
-N(R22)C(=Z)O-;
-C(R25) (R26) C(=Z) C(R27)(R28)-;
-N(R22)S(=Z')N(R23)-;
-N(R22)S(=Z')2N(R23)-;
-C(R25)(R26)C(R34)(R35)C(R27)(R28)-;
-N=C(R36)N(R23)-;
-C(=Z)-;
Z is O, S, or N-CN;
Z' is O;

R22 and R23 are independently selected from the following:
hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C6 alkenyl substituted with 0-3 R31;
C2-C4 alkynyl substituted with 0-3 R31;

R25 and R27 are independently selected from the following:
hydrogen;
C1-C4 alkyl substituted with 0-3 R31;
C3-C4 alkenyl substituted with 0-3 R31;

R26 and R28 are hydrogen or halogen;
R31 is selected from one or more of the following:
halogen, -OR13, C1-C4 alkyl, C3-C10 cycloalkyl, -C(R14)=N(OR14), -CO2R13, -S(O)mR13;
aryl substituted with 0-5 R32; or a heterocyclic ring system chosen from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, said heterocyclic ring being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:
benzyloxy, halogen, 2- (1-morpholino)ethoxy, -CO2R13, hydroxamic acid, -CONR13NR13R14, cyano, boronic acid, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), NO2, -OR13, -NR40R41, -SOmR13, -SOmNR13R14, -C(=O)NR13R14, -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C2-C4 haloalkynyl, -C(=O)NR13R14;
-C(=O)C(R11)2NR13R14; -C(=O)C(R11)2NR13NR14;
-C(=O)C(R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14; -C(=O)-(C1-C4 alkyl) -NR13CO2R13; or C1-C4 alkoxy substituted with 0-3 groups selected from: R11, C3-C6 cycloalkyl, -C(=O)NR13R14, -NR13R14, or OH;
C1-C4 alkyl substituted with 0-3 groups selected from R11, =NR14, =NNR13C(=O)NR13R14 or -NR13R14;
C2-C4 alkenyl substituted with 0-3 R11;

C2-C4 alkynyl substituted with 0-3 R11;
a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;

R32, when a substituent on nitrogen, is methyl;
m is 0, 1, or 2;
R34 is selected from:
hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;
R35 is selected from:
hydrogen;
C1-C2 alkyl;
C1-C2 alkoxy;
R36 is selected from: C1-C2 alkyl; COR37; NR38R39; CN;
CCl3;
R37 is selected from:
hydrogen;
C1-C2 alkyl substituted with 0-1 R11;
hydroxyl;
C1-C2 alkoxy substituted with 0-1 R11;
-NR38R39;
R38 and R39 are independently selected from:
hydrogen;
C1-C2 alkyl substituted with 0-3 R11; or an amine protecting group;
R40 is selected from: H, C1-C3 alkyl;
R41 is selected from:
-C (=O) NR13R14;
-C (=O) NR13NR13R14;
-C (=O) C (R11) 2NR13R14;
-C (=O) C (R11) 2NR13NR13R14;
-C (=O) C (R11) 2NR13CO2R13;
-C(=O)H;
-C (=O) R11;

-C (=O) - (C1-C4 alkyl)-NR13R14;
-C (=O) - (C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus.
22. A process for preparing cyclic compounds of formula (I):

(I) wherein:

R4 and R7 are independently selected from the following groups:

hydrogen;
C1-C8 alkyl substituted with 0-3 R11;
C2-C8 alkenyl substituted with 0-3 R11;
C2-C8 alkynyl substituted with 0-3 R11;
a C3-C14 carbocyclic ring system substituted with 0-3 R11 or 0-3 R12;

a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R12;

-OR13; -SR13; CO2R13;

R4A and R7A are independently selected from the following groups:

hydrogen;
C1-C4 alkyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
benzyl substituted with 0-6 halogen or 0-3 C1-C2 alkoxy;
-OR13; -SR13; CO2R13;

R4 and R4A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

R7 and R7A can alternatively join to form a 5-7 membered carbocyclic ring substituted with 0-2 R12;

n is 0, 1, or 2;

R5 is selected from H; halogen; C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR20, or -N3;

R6 is independently selected from: hydrogen, halogen, C1-C6 alkyl substituted with 0-3 R11, -N(R20)2, -SR20, -OR21, or -N3;

R5 and R6 can alternatively join to form an epoxide or aziridine ring; -OCH2SCH2O-; -OC(=O)O-; -OCH2O-;
-OC(=S)O-; -OC(=O)C(=O)O-; -OC(CH3)2O-;
-OC((CH2)3NH2)(CH3)O-; -OC(OCH3)(CH2CH2CH3)O-;
-OS(=O)O-; -NHC(=O)NH-; -OC(=O)NH-; -NHC(=O)O-;
-NHCH2O-; -OCH2NH-; -NHC(=S)O-; -OS(=O)NH-;
-NHC(=O)C(=O)O-; -OC(=O)C(=O)NH-; -NHC(=O)C(=O)NH-;
-NHC(CH3)2O-; -OC(CH3)2NH- or any group that, when administered to a mammalian subject, cleaves to form a free dihydroxyl or diamino or hydroxyl and amino;

R5a is selected from hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20, or -OR20;

R6a is selected from: hydrogen, halogen, C1-C6 alkyl, -N(R20)2, -SR20 or -OR21;

R5 and R5a can alternatively join to form =O, =S, or a ketal ring;

R6 and R6a can alternatively join to form =O, =S, or a ketal ring;

R20 and R21 are independently selected from:

hydrogen;
C1-C6 alkyl substituted with 0-3 R11;
C3-C6 alkoxyalkyl substituted with 0-3 R11;
C1-C6 alkylcarbonyl substituted with 0-3 R11;
C1-C6 alkoxycarbonyl substituted with 0-3 R11;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11;
benzoyl substituted with 0-3 R12;
phenoxycarbonyl substituted with 0-3 R12;
phenylaminocarbonyl substituted with 0-3 R12; or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino or sulfhydryl;

R11 is selected from one or more of the following:

H, keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -OC (=O) R13, -OR13, -S(O) mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14, -NR14C(=O)OR14, -OC(=O)NR13R14, -NR13C(=O)NR13R14, -NR14SO2NR13R14 -NR14S2R13, -SO2NR13R14, -OP(O)(OR13)2, C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, pyridylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, or -C(R14)=N(OR14);

1-3 amino acids linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;

C3-C10 cycloalkyl substituted with 0-2 R12;

C1-C4 alkyl substitued with 0-2 R12;

aryl(C1-C3 alkyl) substituted with 0-2 R12;

C2-C6 alkoxyalkyl, substituted with 0-2 R12;

C1-C4 alkylcarbonyloxy substituted with 0-2 R12;

C6-C10 arylcarbonyloxy substituted with 0-2 R12;

a C5-C14 carbocyclic residue substituted with 0-3 R12;

a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-3 R12;

R11A is selected from one or more of the following:

H, keto, halogen, cyano, -CH2N(R13B)(R14B), -N(R13B)(R14B), -CO2H, -OC(=O)(C1-C3 alkyl), -OH, C2-C6 alkoxyalkyl, -C(=O)NH2, -OC(=O)NH2, -NHC(=O)NH2, -SO2NH2, C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, boronic acid, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NH2, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2H, 2-(1-morpholino)ethoxy, azido, aryl(C1-C3 alkyl), a C5-C14 carbocyclic residue; a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system substituted with 0-3 R12A;

R12, when a substituent on carbon, is selected from one or more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NR13R14, -NR13R14, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mR13, -SO2NR13R14, -NHSO2R14, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(R14)=N(OR14); or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

or R12 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14; or, when R12 is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12, when a substituent on nitrogen, is selected from one or more of the following:

phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R12A, when a substituent on carbon, is selected from one or more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C4 alkoxy, -CO2H, hydroxamic acid, hydrazide, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, -OR13, C1-C4 alkyl substituted with -NH2, -NH2, -NHMe, C2-C6 alkoxyalkyl optionally substituted with -Si(CH3)3, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -S(O)mMe, -SO2NH2, -NHSO2Me, -OCH2CO2R13, 2-(1-morpholino)ethoxy, -C(=NOH)NH2; or a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur;

or R12A may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NH2; or, when R12A is attached to a saturated carbon atom, it may be =O or =S; or when R12 is attached to sulfur it may be =O;

R12A, when a substituent on nitrogen, is selected from one or more of the following:

phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NH2, -NH2, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(=NOH)NH2;

R13 is selected from:
H;
phenyl substituted with 0-3 R11A;

benzyl substituted with 0-3 R11A;
C1-C6 alkyl substituted with 0-3 R11A;
C2-C4 alkenyl substituted with 0-3 R11A;
C1-C6 alkylcarbonyl substituted with 0-3 R11A;
C1-C6 alkoxycarbonyl substituted with 0-3 R11A;
C1-C6 alkylaminocarbonyl substituted with 0-3 R11A;
C3-C6 alkoxyalkyl substituted with 0-3 R11A;
an amine protecting group when R13 is bonded to N;
a hydroxy protecting group when R13 is bonded to O;

R14 is hydrogen, hydroxy, CF3, C1-C6 alkyl substituted with 0-3 groups selected from OH, C1-C9 alkoxy, halogen, NH2, -NH(C1-C4 alkyl), C1-C6 alkoxy, C2-C6 alkenyl, phenyl, benzyl, an amine protecting group when R14 is bonded to N, a hydroxy protecting group when R14 is bonded to O;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R13B and R14B are independently selected from H or C1-C6 alkyl, or R13B and R14B can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

m is 0, 1 or 2;

w is selected from:
-N(R22)C(=O)N(R23)-;
-N(R22)C(=S)N(R23)-;
-N(R22)S(=O)2N(R23)-;

R22 and R23 are independently selected from the following:

hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or R32;

a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

-OR22a; -N (R22a) (R22b);

provided that at least one of R22 or R23 must be H;

R22a and R22b are independently selected from the following:

hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C8 alkenyl substituted with 0-3 R31;
C2-C8 alkynyl substituted with 0-3 R31;
a C3-C14 carbocyclic ring system substituted with 0-5 R31 or 0-5 R32;

a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

alternatively, R22 can join with R4 or R4A to form a 5-or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O; or alternatively, R23 can join with R7 or R7A to form a 5-or 6-membered fused heterocyclic ring or carbocyclic ring substituted with 0-2 R12, said heterocyclic ring containing 1-3 heteroatoms independently selected from N, S, or O; or R31 is selected from one or more of the following:

keto, halogen, cyano, -CH2NR13R14, -NR13R14, -CO2R13, -C (=O) R11, -OC (=O) R13, -OR13, C2-C6 alkoxyalkyl, -S(O)mR13, -NHC(=NH)NHR13, -C(=NH)NHR13, -C(=O)NR13R14, -NR14C(=O)R13, =NOR14 -NR14C (=O) OR14, -OC (=O) NR13R14, -NR13C (=O) NR13R14, -NR13C (=S) NR13R14, -NR14SO2NR13R14, -NR14SO2R13 , -SO2NR13R14, C1-C4 alkyl, C2-c4 alkenyl, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, benzyl, phenethyl, phenoxy, benzyloxy, nitro, C7-C10 arylalkyl, hydroxamic acid, hydrazide, oxime, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, C1-C4 hydroxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH2CO2R13, 2-(1-morpholino)ethoxy, azido, -C(R14)=N(OR14); or 1-3 amino acids, linked together via amide bonds, said amino acid being linked via the amine or carboxylate terminus;

a C5-C14 carbocyclic residue substituted with 0-5 R32; or a 5- to 10-membered heterocyclic ring system containing 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, said heterocyclic ring system being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:

phenethyl, phenoxy, C3-C10 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, hydrazide, oxime, boronic acid, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 alkylcarbonyloxy, -NHSO2R14, benzyloxy, halogen, 2-(1-morpholino)ethoxy, -CO2R13, hydroxamic acid, -CONR13NR13R14, cyano, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), -NO2, -OR13, -NR40R41, -SOmR13, -SOmNR13R14, -C (=O) NR13R14, -OC (=O) NR13R14, -C (=O) R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl; or -C(=O)NR13C(R11)2NR13R14;
-C (=O) NR13C (R11) 2NR13CO2R13;
-C(=O)NR13-(C1-C4 alkyl)-NR13CO2R13;
-C(=O)N(R13)-(C1-C4 alkyl)-R11; or -C (=O) C (R11) 2NR13R14;
-C(= O) C (R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-4 groups selected from: R11, C3-C6 cycloalkyl, -CO2R13, -C(=O)NR13R14, -NR13R14 or OH;

C1-C4 alkyl substituted with 0-4 groups selected from: R11 =NR14, =NNR13C(=O)NR13R14, =NNR13C(=O)OR13, or -NR13R14;

C2-C4 alkenyl substituted with 0-4 R11;

C2-C4 alkynyl substituted with 0-4 R11;

a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;

or R32 may be a 3- or 4- carbon chain attached to adjacent carbons on the ring to form a fused 5- or 6-membered ring, said 5- or 6- membered ring being optionally substituted on the aliphatic carbons with halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, or -NR13R14; or, when R32 is attached to a saturated carbon atom, it may be =O, =S, =NOH; or when R32 is attached to sulfur it may be =O;

R32, when a substituent on nitrogen, is selected from one or more of the following:

phenyl, benzyl, phenethyl, hydroxy, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, -CH2NR13R14, -NR13R14, C2-C6 alkoxyalkyl, C1-C4 haloalkyl, C1-C4 alkoxycarbonyl, -CO2H, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, -C(R14)=N(OR14);

R34 is selected from:

hydrogen;
OR13;
SR13;
halogen;
N(R38)(R39) C1-C6 alkyl substituted with 0-3 R11;
C1-C6 alkoxy substituted with 0-3 R11;
C1-C6 thioalkyl substituted with 0-3 R11;

R35 is selected from:
hydrogen;
OR13;
SR13;
halogen;
N(R38)(R39);
C1-C6 alkyl substituted with 0-3 R11;
C1-C6 alkoxy substituted with 0-3 R11;
C1-C6 thioalkyl substituted with 0-3 R11;

R34 and R35 can be taken together to form a ketal ring, a 3- to 8-membered carbocyclic ring, or a 5- or 6-membered heterocyclic ring containing 1-3 heteroatoms independently selected from the group O, N, or S, said ring substituted with 0-5 R11;

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C(=O)NR13R14;
-C(=O)NR13NR13R14;
-C(=O)C(R11)2NR13R14;
-C(=O)C(R11)2NR13NR13R14;
-C(=O)C(R11)2NR13CO2R13;
-C(=O)H;
-C(=O)R11;
-C(=O)-(C1-C4 alkyl)-NR13R14;

-C(=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus;

said process comprising the step of reacting an acyclic diamine compound of the formula (III):

(III) with a suitable cyclizing reagent in a suitable solvent, said solvent optionally comprising a base, thereby to form a compound of formula (I).
23. A process of Claim 22 wherein:

R4 and R7 are independently selected from the following groups:

hydrogen;
C1-C3 alkyl substituted with 0-1 R11;

R5 is -OR20;

R6 is hydrogen or -OR21;

R20 and R21 are independently selected from hydrogen or any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl;

R11 is selected from one or more of the following:

H; halogen; -OR13;
C3-C10 cycloalkyl substituted with 0-2 R12;
C1-C4 alkyl substituted with 0-2 R12;
aryl(C1-C3 alkyl) substituted with 0-2 R12;
aryl substituted with 0-2 R12; or a heterocyclic ring system selected from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, said heterocyclic ring system being substituted with 0-2 R12;

R12, when a substituent on carbon, is selected from one or more of the following:

benzyloxy, halogen, methyl, C1-C4 alkoxy, CF3, 2-(1-morpholino)ethoxy, -CO2H, hydroxamic acid, hydrazide, -C(R14)=N(OR14), cyano, boronic acid, sulfonamide, formyl, C3-C6 cycloalkoxy, C1-C4 alkyl substituted with -NR13R14, -NR13R14, hydroxy, hydroxymethyl; or R12, when a substituent on nitrogen, is methyl;

R13 is H, C1-C4 alkyl, C2-C4 alkenyl, or benzyl;

R14 is OH, H, CF3, C1-C4 alkyl, C1-C4 alkoxy, NH2, C2-C4 alkenyl, or benzyl;

R13 and R14 can alternatively join to form -(CH2)4-, -(CH2)5-, -CH2CH2N(R15)CH2CH2-, or -CH2CH2OCH2CH2-;

R15 is H or CH3;

R22 and R23 are independently selected from the following:

hydrogen;
C1-C8 alkyl substituted with 0-3 R31;
C2-C6 alkenyl substituted with 0-3 R31;
C2-C4 alkynyl substituted with 0-3 R31;

R31 is selected from one or more of the following:

halogen, -OR13, C1-C4 alkyl, C3-C10 cycloalkyl, -C(R14)=N(OR14), -CO2R13, -S(O)mR13;

aryl substituted with 0-5 R32; or a heterocyclic ring system chosen from pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, oxazolidinyl, said heterocyclic ring being substituted with 0-2 R32;

R32, when a substituent on carbon, is selected from one or more of the following:

benzyloxy, halogen, 2-(1-morpholino)ethoxy, -CO2R13, hydroxamic acid, -CONR13NR13R14, cyano, boronic acid, sulfonamide, -CHO, C3-C6 cycloalkoxy, -NR13R14, -C(R14)=N(OR14), NO2, -OR13, -NR40R41, -SOmR13, -SOmNR13R14, -C(=O)NR13R14 -OC(=O)NR13R14, -C(=O)R11, -OC(=O)R11, -OCO2R13, phenyl, -C(=O)NR13-(C1-C4 alkyl)-NR13R14, -C(=O)NR40R41, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C4 haloalkenyl, C1-C4 haloalkynyl, -C(=O)NR13R14;
-C(=O)C(R11)2NR13R14; -C(=O)C(R11)2NR13NR14;
-C(=O)C(R11)2NR13CO2R13; -C(=O)-(C1-C4 alkyl)-NR13R14;
-C(=O)-(C1-C4 alkyl)-NR13CO2R13; or C1-C4 alkoxy substituted with 0-3 groups selected from: R11, C3-C6 cycloalkyl, -C(=O)NR13R14, -NR13R14 or OH;

C1-C4 alkyl substituted with 0-3 groups selected from: R11, =NR14, =NNR13C(=O)NR13R14 or -NR13R14;

C2-C4 alkenyl substituted with 0-3 R11;

C2-C4 alkynyl substituted with 0-3 R11;

a 5- or 6-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from oxygen, nitrogen or sulfur, substituted with 0-2 R12;

R32, when a substituent on nitrogen, is methyl;

m is 0, 1, or 2;

R36 is selected from: C1-C2 alkyl; COR37; NR38R39; CN;
CC13;

R37 is selected from:
hydrogen;
C1-C2 alkyl substituted with 0-1 R11;
hydroxyl;
C1-C2 alkoxy substituted with 0-1 R11;
-NR38R39;

R38 and R39 are independently selected from:

hydrogen;
C1-C2 alkyl substituted with 0-3 R11; or an amine protecting group;

R40 is selected from: H, C1-C3 alkyl;

R41 is selected from:
-C (=O) NR13R14;
-C (=O)NR13NR13R14;
-C (=O) C (R11) 2NR13R14;
-C (=O) C (R11) 2NR13NR13R14;
-C (=O) C (R11) 2NR13CO2R13;
-C (=O)H;
-C (=O)R11;
-C (=O)-(C1-C4 alkyl)-NR13R14;
-C (=O)-(C1-C4 alkyl)-NR13CO2R13;
1-3 amino acids linked together via amide bonds, and linked to the N atom via the carboxylate terminus.
CA 2156594 1993-02-16 1994-02-23 Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors Abandoned CA2156594A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19763093A 1993-02-16 1993-02-16
US2343993A 1993-02-26 1993-02-26
US4733093A 1993-04-15 1993-04-15
US08/023,439 1994-02-16
US08/197,630 1994-02-16
US08/047,330 1994-02-16

Publications (1)

Publication Number Publication Date
CA2156594A1 true CA2156594A1 (en) 1994-09-01

Family

ID=27362086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2156594 Abandoned CA2156594A1 (en) 1993-02-16 1994-02-23 Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors

Country Status (1)

Country Link
CA (1) CA2156594A1 (en)

Similar Documents

Publication Publication Date Title
EP0858999A1 (en) Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
EP0607334B1 (en) Cyclic ureas and analogues useful as retroviral protease inhibitiors
EP0973767A1 (en) Indazoles of cyclic ureas useful as hiv protease inhibitors
US5683999A (en) Cyclic urea HIV protease inhibitors
EP0830349B1 (en) Method for preparing n, n&#39;-disubstitued cyclic ureas
WO1997008150A1 (en) Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
WO2000000478A1 (en) Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US5877170A (en) Substitute caprolactams and derivatives thereof useful for treatment of HIV disease
JPH11506779A (en) Process for producing N-monosubstituted and N, N&#39;-disubstituted asymmetric cyclic ureas
US5763469A (en) Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
WO1996029329A1 (en) Cyclic urea hiv protease inhibitors
CA2156594A1 (en) Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
USRE37781E1 (en) Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
AU703962B2 (en) Substituted cyclic carbonyls and derivatives
US5543517A (en) Substituted bicyclic phosphoramides and derivatives thereof
US6313110B1 (en) Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor
WO1998020008A1 (en) 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
WO2002078628A2 (en) Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazapines as hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead